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Preface to ”Monoclonal Antibodies”
Monoclonal antibodies are established in clinical practice for the treatment of various diseases
including cancer, autoimmunity, metabolic and infectious diseases. Over the last 20 years, monoclonal
antibodies have established themselves as therapeutics and various so-called ”blockbuster” drugs are in
fact antibodies. Currently, ca. 80 monoclonal antibodies have been approved in Europe and the US and
several hundred of them are currently in early and advanced clinical trials. Notably, in the last decade,
the field has significantly advanced, and, nowadays, a large proportion of antibodies in development
is made up by engineered antibodies including bispecific antibodies, antibody drug conjugates and
novel antibody-like scaffolds. This Special Issue on ”Monoclonal Antibodies” includes original
manuscripts and reviews covering various aspects related to the discovery, analytical characterization,
manufacturing and development of therapeutic and engineered antibodies.
The collection starts with a number of reviews. Cho and colleagues review the state-of-the-art
in therapy of multiple myeloma where antibody-based immunotherapies are changing the current
treatment paradigm, and Wang-Lin and Balthasar summarize pharmacokinetic and pharmacodynamic
considerations important to consider for the treatment of bacterial infections by monoclonal antibodies.
Finally, Fülöp and colleagues review the role of complement activation in infusion reactions associated
with the application of monoclonal antibodies and the potential use of complement factor H for its
prevention.
A first series of original articles describes novel monoclonal antibodies for potential diagnostic
or therapeutic application. Rashidian and colleagues describe a novel rabbit monoclonal antibody,
MRQ-67, that specifically recognizes the R132H mutation of Isocitrate dehydrogenase 1 (IDH1) which
is prevalent in diffuse astrocytomas, oligodendrogliomas, and secondary glioblastomas but not the
wildtype IDH1. MRQ-67 is able to identify neoplastic cells in glioma tissue specimens, and can be
used as a tool in glioma subtyping. Zhang and colleagues have identified novel monoclonal antibodies
against the plasmodium falciparum Circumsporozoite Protein that is a major and immunodominant
protective antigen on the surface of plasmodium sporozoites. These antibodies are specific for the
central repeat region and mediate protection against challenge with sporozoites. Finally, Rocha and
colleagues generated antibodies directed against novel epitopes of the Dengue nonstructural protein 1
(NS1) which is a multi-functional glycoprotein essential for viral replication and modulation of host
innate immune responses and represents a surrogate marker for infection. These antibodies are
able to differentiate Dengue and Zika virus infections and may contribute to the development of
novel diagnostic tools. In a series of three articles, Strube and colleagues describe approaches useful
for the manufacturing and analytical characterization of monoclonal antibodies. A first article by
Schmidt et al. describes aqueous two-phase extraction (ATPE) as a method to capture monoclonal
antibodies using a combined harvest and capture step during the downstream process. A subsequent
article by Kornecki et al. focuses on the characterization and classification of host cell proteins (HCPs)
and how to categorize and avoid them in the manufacturing process. Finally, Zobel-Roos et al. propose
a process analytical approach allowing for controlled automation of the downstream process by inline
concentration measurements based on UV/VIS spectral analysis. In the same area, Radhakrishnan
and colleagues show how time-dependent media supplementation by MnCl2 can be used to control
the glycosylation profile of antibodies. Castellanos and colleagues use small-angle scattering (SAS)
combined with size-exclusion multi-angle light scattering high-performance liquid chromatography








Lastly, two articles deal with engineering monoclonal and bispecific antibodies. Tam and colleagues
have identified a set of novel mutations in the Fc-portion of antibodies that abrogate immune effector
function of the respective antibodies. Such Fc-mutations are essential for the development of antibody
therapeutics where simultaneous FcgR activation is undesired for the mechanism of action, e.g., for
T-cell bispecific antibodies. Dheilly and colleagues engineered novel CD47-CD19 bispecific antibodies
based on low affinity CD47 inhibitory antibodies. The corresponding CD47-CD19 bispecific antibody
inhibited tumor growth in vivo and induced a long lasting anti-tumor immune response that could be
further enhanced in combination with chemotherapy or PD-1/PD-L1 checkpoint blockade.
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Abstract: Malaria is a mosquito-borne infectious disease caused by the parasite Plasmodium spp.
Malaria continues to have a devastating impact on human health. Sporozoites are the infective forms
of the parasite inside mosquito salivary glands. Circumsporozoite protein (CSP) is a major and
immunodominant protective antigen on the surface of Plasmodium sporozoites. Here, we report a
generation of specific monoclonal antibodies that recognize the central repeat and C-terminal regions
of P. falciparum CSP. The monoclonal antibodies 3C1, 3C2, and 3D3—specific for the central repeat
region—have higher titers and protective efficacies against challenge with sporozoites compared
with 2A10, a gold standard monoclonal antibody that was generated in early 1980s.
Keywords: Plasmodium falciparum; circumsporozoite protein; CSP; monoclonal antibody; 2A10; 3C1;
3C2; 3D3
1. Introduction
In 2015, there were 214 million new cases of malaria (range 149–303 million) and an estimated
438,000 malaria deaths (range 236,000–635,000) worldwide [1]. Malaria is a mosquito-borne disease
caused by the protozoan parasite, Plasmodium spp. Malaria is transmitted among humans by the bite
of female mosquitoes of the genus Anopheles. The battle against malaria has been fought using a wide
range of interventions, including insecticide-treated bed nets, indoor residual spraying, effective
medicines, and vaccine [2–5]. However, emerging antimalarial drug resistance and insecticide
resistance threaten malaria control and public health [6–8]. The only approved malaria vaccine
is RTS,S/A01 (trade name Mosquirix) to date. RTS,S/A01 represents it’s composed of P. falciparum
CSP repeat region (R), T-cell epitopes (T) fused to the hepatitis B surface antigen (S) and assembled
with un-fused copies of hepatitis B surface antigen, and a chemical adjuvant (AS01) is added to
increase the immune system response. The efficacy of RTS,S/AS01 against all episodes of severe
malaria is approximately 50% in young children in Africa [9–11]. A completely effective vaccine is not
yet available for malaria. The novel vectored immunoprophylaxis, an adeno-associated virus-based
technology to introduce effective antibody genes in mammalian host, has been added to currently
available tools to control malaria [12]. A highly efficient neutralization antibody is one of the essential
components of the vectored immunoprophylaxis [12]. Sporozoites are the infectious form of the
parasites inside mosquito salivary glands. The circumsporozoite protein (CSP) is a major protein
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on the surface of Plasmodium sporozoites and an immunodominant protective antigen in irradiated
sporozoites [13]. The overall structure of CSP is conserved among Plasmodium species, consisting of a
species-specific central tandem repeat region flanked by conserved N-terminus and C-terminus [14].
The N-terminus is proteolytically processed during sporozoite invasion into host cells, unmasking the
C-terminal cell-adhesive domain [15,16]. The C-terminus contains a thrombospondin repeat domain
and T cell epitopes. The central repeat region, which is composed of approximately 30 tandem repeats
of asn-ala-asn-pro (NANP), corresponds to highly immune-dominant B-cell epitopes [17,18].
The transmission of malaria from mosquito to mammalian host can be prevented by antibodies
against CSP, such as the monoclonal antibody (mAb) 2A10 [12,19]. The mouse mAb 2A10 is directed
against the central repeat region of P. falciparum CSP (PfCSP) [12,20–22]. The mouse mAb 2A10 is a
useful tool for the study of PfCSP in a mouse model. Delivery of adeno-associated virus expressing
2A10 into mice results in long-lived mAb expression and protection from sporozoite challenge.
Vectored immunoprophylaxis provides an exciting new approach to the urgent goal of effective
malaria control [12]. However, the mice expressing the CSP-specific mAb 2A10 lower than 1 mg/mL
could not be completely protected [12]. Thus, highly potent CSP-specific antibodies are desired for
the immunoprophylaxis to control this infectious disease. Here, we report a generation of novel and
potent CSP-specific antibodies against PfCSP. In addition, we characterized the mAbs’ subclasses,
titers, and protections for sporozoite challenge. Importantly, the protective efficacies of 3C1, 3C2, and
3D3 were found to be better than the reference mAb 2A10.
2. Materials and Methods
2.1. Expression and Purification of Recombinant PfCSP
PfCSP coding sequence without glycosylphosphatidylinositol (GPI) anchor (GenBank: M19752.1)
was amplified using Phusion® high fidelity DNA polymerase (Cat#M0530S, New England Biolabs,
Ipswich, MA, USA) with specific primers containing EcoR I and Not I restriction enzyme recognition
sites. The PCR product was purified using Qiagen PCR cleanup kit (Qiagen, Germantown, MD, USA).
Both the PCR product and pET20b vector were digested with restriction endonucleases EcoR I and
Not I (New England Biolabs) according to the manufacturer’s protocol. After gel purification, the
digested PCR product was ligated into the linearized pET20b vector using Roche rapid DNA ligation
kit (Cat. No. 11635379001, Roche, Branford, CT, USA), and then transformed into Top10F’ chemically
competent E. coli. (Invitrogen, Grand Island, NY, USA) and plated onto Luria-Bertani (LB) agar plates
containing ampicillin. A single colony was picked from the plate and inoculated into LB broth plus
ampicillin. The recombinant plasmid was purified from the overnight culture using Qiagen plasmid
purification kit. The purified plasmid was validated by DNA sequencing and transformed into the
BL21(DE3) strain for protein expression. When the culture reached an optical density (OD, 600 nm) of
0.5–0.6, PfCSP expression was induced using IPTG (1 mM) at 20 ◦C. Then the overnight culture was
pelleted by centrifugation and lysed with lysozyme buffer and followed by sonication. Lysate was
cleared by centrifugation and the His-tagged PfCSP was purified using Ni2+-affinity chromatography
(Qiagen, Germantown, MD, USA).
PfCSP purification: 25 mL of nickel nitrilotriacetic acid (Ni-NTA) agarose beads were loaded onto
a 22 mL phenyl sepharose column (Pharmacia/Pfizer, New York, NY, USA), washed and equilibrated
by 200 mL of His Elution Buffer (50 mM TRIS hydrochloride (Tris-HCl) (pH 8.0), 300 mM imidazole,
50 mM NaCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), and 1 mM phenylmethane sulfonyl
fluoride (PMSF) and 500 mL of His Binding Buffer (50 mM Tris-HCl (pH 8.0), 5 mM imidazole. 100 mM
NaCl, 0.1 mM EDTA, and 1 mM PMSF). Then the clarified lysate from 1 L culture was added to the
column and washed with 250 mL of His Binding Buffer followed by 500 mL of His Wash Buffer (50 mM
Tris-HCl (pH 8.0), 20 mM imidazole. 300 mM NaCl, 0.1 mM EDTA, and 1 mM PMSF). Then, the
bound protein was eluted with 20 × 15 mL of His Elution Buffer (50 mM Tris-HCl (pH 8.0), 200 mM
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sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie Brilliant Blue staining.
Tris-HCl, EDTA, and PMSF are from Sigma-Aldrich, St. Louis, MO, USA.
2.2. Generation of Hybridomas
The recombinant PfCSP was shipped to Green Mountain Antibodies, Inc. (Burlington, VT, USA)
for the immunization of mice, followed by the fusion to generate monoclonal antibodies. Briefly, mice
were primed with 50 μg of PfCSP emulsified with complete Freund’s adjuvant, followed by weekly
immunization of 50 μg of PfCSP emulsified with TiterMax® (Sigma-Aldrich, St. Louis, MO, USA) and
SAS® (Sigma-Aldrich) (alternate week). One week after administering seven doses of immunization,
the lymph node was isolated. B cells were purified from using anti-B220 magnetic-activated cell sorting
(MACS), and then fused with a mouse myeloma cell line. Cloning was achieved by limiting dilution.
After re-cloning, positive clones that secrete immunoglobulin G (IgG) against the full-length PfCSP
were selected by enzyme-linked immunosorbent assay (ELISA) (Table 1).
2.3. ELISA Assay
The ELISA plates were first coated with peptides representing PfCSP N-terminal, the central
repeat, or C-terminal regions (10 μg/mL) and then blocked with 3% bovine serum albumin
(BSA) in phosphate buffered saline with Tween-20 (PBST) (Table 2). MAbs were 10-fold diluted
(0.1–1000 ng/mL) and added to the plates and incubated for 1 h. After washing the plates,
horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc Fragment was added. One hour
later, tetramethylbenzidine (TMB) High Sensitivity Substrate was added, and ODs were read at 450 nm.
Peptide AIAWAKARARQGLEW was used as a negative control. The mAb 2A10 was used as a positive
control [19,23].
2.4. Immuno-Fluorescence Assay
1 × 104 salivary gland PfCSP/Py sporozoites were loaded on MP biomedical multi-test glass
slides (MP Biomedicals, Santa Ana, CA, USA). PfCSP/Py is an infectious P. yoelii parasite bearing a
full length of P. falciparum circumsporozoite protein (25). After air drying at room temperature, the
slides were fixed with 4% paraformaldehyde for 10 min at room temperature, and then blocked with
3% BSA in PBST. The mAbs were two-fold diluted from 1.31 mg/mL to 5 ng/mL, and added to the
PfCSP/Py sporozoites-coated wells on the slides for 45 min. After washing with PBS containing 0.05%
Tween-20 three times, the slides were incubated with Alexa Fluor 594 conjugate goat anti-mouse IgG
(H + L) antibody. One hour later, the slides were washed and mounted in PBS containing 50% glycerol
and 1% (w/v) p-phenylenediamine to reduce bleaching.
2.5. Sporozoite Neutralization Assays
In vitro neutralization assays were conducted by pre-incubating 2 × 104 PfCSP/Py sporozoites
with 100 μg mAb on ice for 45 min, and then adding to 1 × 105 Hepa1-6 cells. Forty-two hours post
infection, liver stage parasite burden wear measured by quantitative polymerase chain reaction
(qPCR) of P. yoelii 18S rRNA as previously described [24]. Mouse glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal control. In vivo neutralization assays were
conducted by pre-incubating 50 PfCSP/Py sporozoites dissected from infected mosquito salivary
glands with 5 or 50 μg mAb on ice for 45 min, and then intravenously injecting into BALB/c mouse.
The presence of parasite in blood was determined by Giemsa staining of the blood smear of the
recipient mouse.
2.6. Giemsa Stain
Starting three days after sporozoite challenge, a drop of blood was collected from the mouse tail
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methanol and then stained with diluted Giemsa stain (1:20, v/v) for 20 min. % parasitemia (% of
parasitized red blood cells among total red blood cells) were examined with a 100× oil immersion
objective under the microscope.
3. Results
3.1. Generation of Hybridomas
PfCSP was expressed and purified from E. coli. (Figure 1), and then immunized BALB/c mice.
The immune spleen cells from the mice producing anti-PfCSP antibodies were fused with myeloma
cells, and six hybridoma cell lines (2D4, 3C1, 3C2, 3D3, 4C1, 4C6) were cloned. The mAbs 4C6 2D4
3D3 were identified as belonging to subclass IgG1. The mAbs 3C2 and 4C1 were isotyped as IgG2b
class. The mAb 3C1 belonged to subclass IgG3 (Table 1).
Figure 1. Expression and purification of a recombinant P. falciparum circumsporozoite protein (PfCSP).
(A) Schematic representation of the recombinant PfCSP. Pf CSP coding sequence excluding C-terminal
glycosylphosphatidylinositol (GPI) anchor, composed of N-terminal, central repeat, and C-terminal
regions, was fused with 6XHis tag at its C-terminus, and cloned into pET20b vector (Stratagene, La Jolla,
CA, USA); (B) Schematic representation of the PfCSP expression plasmid in this study. The full length
of PfCSP without GPI anchor was cloned into pET20b vector between EcoR I and Not I; (C) Expression
and purification of a recombinant PfCSP from E. coli. The recombinant PfCSP was expressed in BL21
(DE3), and then purified by Ni-Affinity Chromatography. Lane 1, Protein marker; Lane 2, crude
extract; Lane 3, flow through; Lane 4–7, washes; Lane 8, elute. Data are representative from three
independent experiments.
Table 1. The titers of the PfCSP-specific mAbs *.
Name of the mAb Titer (IFA) Titer (ELISA) Subclass
2A10 40 ng/mL 10 ng/mL IgG2a
4C6 80 ng/mL 1 μg/mL IgG1
2D4 80 ng/mL 500 ng/mL IgG1
3C2 10 ng/mL 1 ng/mL IgG2b
4C1 328 μg/mL 200 ng/mL IgG2b
3C1 5 ng/mL 5 ng/mL IgG3
3D3 10 ng/mL 2 ng/mL IgG1
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3.2. Specificity of Anti-PfCSP mAbs
The specificity of the mAbs has been explored by measuring their reaction with peptides covering
PfCSP N-terminal, the central repeat, and C-terminal regions (Table 2). The mAbs 2D4, 4C1, and 4C6
recognized the PfCSP C-terminal region. The mAbs 3C1, 3C2, and 3D3 recognized the PfCSP central
repeat region (Figure 2).
Table 2. Synthetic peptides representing PfCSP.
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Figure 2. Specificity of anti-PfCSP monoclonal antibodies (mAbs) by enzyme-linked immunosorbent
assay (ELISA). Peptides representing PfCSP N-terminal, central repeat, and C-terminal regions were
used to evaluate specificity of anti-PfCSP mAbs (Table 1). (A), 2D4; (B), 4C1; (C),4C6; (D), 3C1; (E), 3C2;
(F), 3D3; (G), 2A10. The mAb 2A10 was used as a positive control. ELISA was performed in duplicate.
Data are representative of three independent experiments. OD, Optical density.
3.3. Titration of the PfCSP-Specific mAbs
The antibody titer was tested by enzyme-linked immunosorbent assay (ELISA) and
immunofluorescence assay (IFA) (Table 1 and Figure 3). ELASA using peptides covering PfCSP showed
that the titers of mAbs recognizing the PfCSP central repeat region were higher than those recognizing
the PfCSP C-terminal region. The titers of the three mAbs recognizing the PfCSP central repeat were
higher than the control 2A10 (3C2 > 3D3 > 3C1 > 2A10). IFA using the Plasmodium sporozoites expressing
PfCSP [25] also showed that the titers of the mAbs recognizing the PfCSP central repeat were higher
than those recognizing the PfCSP C-terminal region. The titer of the three mAbs recognizing the PfCSP
central repeat were higher than the control 2A10 (3C1 > 3D3 = 3C2 > 2A10).
Figure 3. Immunofluorescence assays. PfCSP/Py (a P. yoelii parasite bearing P. falciparum
circumsporozoite protein) salivary gland sporozoites [25] were incubated with 160 ng/mL mAbs, except
4C1 at 328 μg/mL, followed by incubation with Alexa Fluor 594 goat anti-mouse IgG (H + L) antibody.
3.4. Protection of the PfCSP mAbs against PfCSP/Py Sprozoite Challenge
We then examined the protection of the PfCSP mAbs against malaria sporozoite challenge in vitro
and in vivo. For the malaria sporozoite challenges, we used the highly infectious hybrid PfCSP/Py
sporozoite, which is based on rodent P. yoelii parasite and its CSP is replaced by the full-length of CSP
from P. falciparum [25]. We found that mAb 3C1, 3C2, and 3D3 significantly inhibited the parasite
development in Hepa 1–6 cells compared with 2A10, which is an effective mouse mAb specific for the
PfCSP central repeat [19,23] (Figure 4). This was in agreement with the in vivo neutralization assay
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sporozoite challenge. The protective effect of 3C1, 3C2, and 3D3 were better than the previously
generated mAb 2A10. Even 5 μg of 3C1 partially protected the challenged mice compared to the
mAb 2A10.
Figure 4. In vitro neutralization assay. 2 × 104 PfCSP/Py sporozoites were pre-incubated with 100 μg
of each mAb, and then added to Hepa1-6 cells. Forty-two hours post infection, liver stage parasite
burden wear measured by P. yoelii 18S rRNA/mouse glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Naive mouse serum was used as control. The in vitro neutralization assay was performed
in triplicate. Data are representative of two independent experiments.
Table 3. In vivo neutralization assay.
Amount of mAb 5 μg 50 μg
Days Post Challenge Day 3 Day 4 Day 5 Day 14 Day 3 Day 4 Day 5 Day 14
2A10 0 *,# 4 5 5 0 0 3 3
4C6 0 5 5 5 0 1 4 4
2D4 0 4 5 5 0 0 3 3
3C2 0 1 5 5 0 0 0 0
4C1 0 5 5 5 0 3 4 4
3C1 0 1 4 4 0 0 0 0
3D3 0 2 5 5 0 0 0 0
Naiive 0 5 5 5 0 5 5 5
* Five mice per group. # The number of infected mice.
Figure 5. Parasitemia of mice in the neutralization assay. Fifty PfCSP/Py sporozoites were incubated
with 50 μg mAbs followed by i.v. injection into BALB/c mice (five mice per group). Parasitemia were
counted by Giemsa stains of mouse tail blood followed by microscopy. Data are parasitemia of the
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4. Discussion
The CSP consists of the N-terminal flanking region, the central region that contains repetitive
immunodominant B-cell epitopes, and the C-terminal flanking region that contains multiple T-cell
epitopes. The N-terminus of the CSP is proteolytically processed during the sporozoite invasion
into host cells [15,16]. This may explain why we did not obtain specific antibodies against the
N-terminus. The abundant NANP repeats present within the central region are likely to contribute
to the high neutralization efficacies of the mAbs against PfCSP central repeat region, as previously
published [26,27]. In fact, mAbs, which recognize the PfCSP central repeat region, have been shown
to exert a potent neutralization activity against the sporozoites [26,27]. All the mAbs 3C1, 3C2, 3D3,
and 2A10, recognize the central repeat region of the PfCSP. Fifty μg of the novel mAbs 3C1, 3C2,
and 3D3 completely protected the mice from PfCSP/Py sporozoites challenge; while the reference
mAb 2A10 only partially protected the mice. A likely explanation is that the native structure of the
central repeats of the CSP is not in a random coil state, and the repeat region is predicted to form
a rod-like structure [28]. It is speculated that these mAbs recognize structurally different epitopes
coded by NANP repeat, resulting in different protection efficacies. The titers (3C1 > 3D3 = 3C2 > 2A10)
of these novel mAbs determined by IFA using a whole malaria parasite (sporozoite), as an antigen,
corroborate their protection efficacies in vitro (3C1 > 3D3 > 3C2 > 2A10), as well as in mice (3C1 > 3D3 =
3C2 > 2A10). These indicate that mAbs having higher titers against the native from of the CSP
expressed by sporozoites exert higher protection efficacies.
Synthesized peptides and sporozoites were used in ELISA and IFA, respectively, to determine
the antibody titers. Sporozoites express a native form of the PfCSP, whereas synthesized peptides
represent the primary structure of PfCSP. B-cell epitopes are typically classified as either linear epitopes
or conformational epitopes, which constitute the spatially folded amino acids and lie far away in
the primary sequence. The difference seen by ELISA and IFA may reflect the structural properties of
unique B-cell epitopes recognized by our mAbs.
Over the past few years, there has been growing interest in use of vectored immunoprophylaxis
to protect hosts from HIV. Vectored immunoprophylaxis is based on adeno-associated virus
(AAV) as a vehicle for generating the existing anti-HIV neutralizing antibodies in humans [29,30].
Recently vectored immunoprophylaxis has been utilized for other diseases including malaria and
colorectal cancer [12,31]. This new tool requires potent neutralizing antibodies. Although human
monoclonal antibodies against PfCSP have been generated, only one mouse mAb against PfCSP, 2A10,
has been used as a gold standard mAb for more than three decades. It is noteworthy that a few new
mouse mAbs against PfCSP, which we generated in this study, are found to be more potent than 2A10.
Therefore, we believe it is important to assess the characteristics of these newly generated mAbs before
humanizing them for the purpose of clinical applications, such as a vectored immunoprophylaxis, in
the future. Moreover, the mouse mAbs generated in this study are useful tools for the study of PfCSP
in a mouse model.
5. Conclusions
In summary, here we report a generation of novel mAbs specific against the CSP from P. falciparum.
The mAbs 2D4, 4C1, and 4C6 recognize the C-terminal region of PfCSP. The mAbs 3C1, 3C2, and 3D3
recognize the central repeat region of PfCSP, and their titers and protection efficacies are higher than
2A10, which has been widely used as a gold standard antibody against PfCSP.
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Abstract: Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG)
antibodies to eliminate their immune effector functions while retaining other Fc characteristics has
numerous applications, including blocking antigens on Fc gamma (Fcγ) receptor-expressing immune
cells. We previously reported on a human IgG2 variant termed IgG2σ with barely detectable activity
in antibody-dependent cellular cytotoxicity, phagocytosis, complement activity, and Fcγ receptor
binding assays. Here, we extend that work to IgG1 and IgG4 antibodies, alternative subtypes which
may offer advantages over IgG2 antibodies. In several in vitro and in vivo assays, the IgG1σ and
IgG4σ variants showed equal or even lower Fc-related activities than the corresponding IgG2σ variant.
In particular, IgG1σ and IgG4σ variants demonstrate complete lack of effector function as measured by
antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent
cellular phagocytosis, and in vivo T-cell activation. The IgG1σ and IgG4σ variants showed acceptable
solubility and stability, and typical human IgG1 pharmacokinetic profiles in human FcRn-transgenic
mice and cynomolgus monkeys. In silico T-cell epitope analyses predict a lack of immunogenicity in
humans. Finally, crystal structures and simulations of the IgG1σ and IgG4σ Fc domains can explain
the lack of Fc-mediated immune functions. These variants show promise for use in those therapeutic
antibodies and Fc fusions for which the Fc domain should be immunologically “silent”.
Keywords: Fc engineering; silent effector function; IgG1; IgG2; IgG4; IgG sigma; developability;
pharmacokinetics; crystal structure
1. Introduction
The biological functionality of therapeutic antibodies depends on the interactions of two regions of
the protein with components of its external environment: the antigen binding region (Fab) interacting
with an antigen, and the fragment crystallizable (Fc) region interacting with components of the immune
system. The Fc region of the immunoglobulin (IgG) antibody, which is the focus of this study, can have
interactions with Fc gamma receptors (FcγR) and first subcomponent of the C1 complex (C1q) that
mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC),
antibody-dependent cellular phagocytosis (ADCP), induction of secretion of mediators, endocytosis of
opsonized particles, as well as modulation of tissue and serum half-life through interaction with the
neonatal Fc receptor (FcRn) [1,2]. Numerous publications have reviewed the application of enhanced
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Fc effector function to increase biologic activity [3–6]. In addition, the coupling of the Fab and Fc regions
can impact the therapeutic window for safety and efficacy of antibodies and Fc fusion proteins [3,7].
Fc-mediated effector functions are best avoided for some applications such as systemic
neutralization of cytokines, targeting cell surface antigens on immune cells, or when engineering
bispecific molecules to bring target diseased cells within proximity of effector immune cells to provide
a more specific immune receptor engagement [3,8,9]. In each of these cases, it is best not to stimulate
unwanted cell and tissue damage or risk undesired effector cell activation, immune cell depletion,
or FcγR cross-linking that might induce cytokine release through engagement of Fc-mediated effector
functions [3]. An important consideration in such biological processes is that the complexity of FcγR
functional properties is increased by the varying densities of activating and inhibitory receptors on the
different effector cell populations [10]. Likewise, since the threshold of activation can be variable with
different patients, it would be prudent for safety considerations to develop antibodies with a more
silent Fc framework. Thus, development of completely silent Fc domains can be critical for biologics
that do not require FcγR or C1q mediated effector functions [11].
When an antibody with no effector function is required, there are different approaches one may
take to generate a molecule with the desired properties. Unfortunately, results of some strategies often
come with liabilities to the molecular profile. For instance, Fab or F(ab′)2 fragments can be generated;
however, such molecules have shorter half-lives in patient sera. Chemical modifications can extend
the half-life of such molecules, but can also bring potential risks with toxicities [12]. Another strategy
has been to eliminate the N-linked glycosylation at residue Asparagine 297 (European Union (EU)
numbering) [13–16]; however, this can reduce antibody solubility and stability. Another approach
employs mutagenesis of specific Fc amino acid residues to specifically influence effector functions [17].
An example of this approach is illustrated in the first marketed therapeutic antibody
(Orthoclone OKT3, a murine IgG2a) in which two mutations in the lower hinge (L324A/L235A,
referred to as AA) were introduced to mitigate the induction of cytokine storm [18,19]. Also, because
FcγRs are highly selective in subclass specificity and affinity [20,21], another approach may be to move
the Fab domains onto Fc regions which elicits less effector function such as human IgG2 (huIgG2)
or IgG4 (huIgG4) [22]. In addition, swapping among the sequences of the four human IgG (huIgG)
subtypes has been used to design more silent Fc domains [3,4,23–25] that have resulted in such
variants as huIgG2/4 [26], huIgG2m4 [27], and L234F/L235E/P331S (FES) [28]. Notably, Vafa and
co-workers employed multiple strategies to develop a huIgG2 variant, termed huIgG2 sigma (IgG2σ)
that showed undetectable Fc-mediated effector function and C1q binding [29]. In utilizing such
strategies for silencing Fc effector function, it needs to be recognized that there is some potential for
huIgG2 subtype molecules to form heterogeneous isoforms which can be a challenge in the generation
of a homogeneous product [30–32].
Although huIgG4 has weak binding affinity to most FcγRs except for the high affinity receptor
FcγRI, it does retain the ability to induce phagocytosis by macrophages (expressing FcγRI, FcγRIIa,
and FcγRIIIa) and possibly activate monocytes when in an immune complex due to activating
FcγRs on specific immune cells. Recent additional approaches to generate antibodies with no
effector function have included disruption of proline sandwich motifs [33], and incorporation of
asymmetric charged mutations in the lower hinge or constant heavy chain domain 2 (CH2) domain [34].
Because development of antibodies with silent Fc domains continues to be important for various
therapies, and because the threshold of activation may be different for each patient or disease
population, efforts are on-going to obtain the most silent Fc variants which will have improved
safety and good manufacturing qualities.
We describe here the functional and structural characteristics of three novel silent Fc designs:
huIgG1 sigma (IgG1σ), which is a variant of huIgG1, and huIgG4 sigma1 (IgG4σ1) and huIgG4 sigma2
(IgG4σ2), which are variants of huIgG4. The effector functions of these silent Fc variants are
compared to those of previously described constructs such as huIgG1 L234A/L235A (AA) [25],
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being employed in a clinical anti-interferon receptor antibody [36]). We also present a comparison
of serum half-lives in mice and cynomolgus monkeys, an evaluation of potential immunogenicity,
and an assessment of biophysical stability. Crystal structures and molecular modeling were carried
out to understand the mechanism for lack of interactions between the IgG variants and the Fc gamma
receptors. The aim of the studies presented here is to provide data on the biological, biophysical,
and structural properties of the huIgG1σ, huIgG4σ1, and huIgG4σ2 along with other commonly used
silent Fc formats to enable development of better quality antibody therapeutics.
2. Results
2.1. Design of Silent Fc HuIgGs
Silent human IgG Fcs were designed by uniquely combining the sequence from previously
characterized variants having mutations in the hinge and CH2 regions [29]. Mutations present in
these variants are listed in Figure 1 and Table 1. All sequences described follow the EU numbering
system [37,38].
Both huIgG1σ and the huIgG2σ constructs contain a total of seven mutations in their hinge and
CH2 domains (Figures 1 and 2; Table 1). However, only six of the mutations are common to both
huIgG2σ and the huIgG1σ variant described here. HuIgG1σ uniquely includes an L234A mutation,
and huIgG2σ has a V309L mutation. HuIgG1 naturally has a leucine at that position.
Compared to huIgG4 PAA, huIgG4σ1 and huIgG4σ2 have two and three additional mutations,
respectively, for a total of five and six mutations (Table 1). While modeled after huIgG2σ, these huIgG4
variants do not have the full set of sigma mutations present in huIgG2σ because the huIgG4 sequence
naturally contains four of those residues.
Figure 1. Alignment of hinge and constant heavy chain domain 2 (CH2) domain amino acid sequences
of wild-type human immunoglobulin G1 (IgG1), IgG2 and IgG4 as well as their sigma variants.
The alignment above uses EU numbering. Residues identical to wild-type IgG1 are indicated as dots;
gaps are indicated with hyphens. Sequence is given explicitly if it differs from wild-type IgG1 or from
the parental subtype for σ variants. In the latter case, sequence is colored red. Open boxes beneath the
alignment correspond to International Immunogenetics Information System (IMGT) strand definitions
(labeled) [39]. Light blue and purple boxes beneath the alignment correspond to the strand and helix
secondary structure assignment for wild-type IgG1 in the Protein Data Bank (PDB) 3AVE (chain A) [40].
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Figure 2. Schematic indicating positions of mutations on generic Fc structure. Positions mutated
relative to parental subtype are depicted as red spheres on a structure of IgG1 Fc having an idealized
hinge (wheat and blue, cartoon) for IgG1σ (A), IgG2σ (B), and IgG4σ1/2 (C). For clarity, the sites of
mutation are labeled on only one of two equivalent Fc chains. IgG4σ2 differs from IgG4σ1 by the
deletion of G236 (position indicated with a small, grey sphere and labeled with an asterisk).
Table 1. List of mutations in the hinge and constant heavy chain domain 2 (CH2) regions of different
silent immunoglobulin (IgG) designs.
IgG1 AA IgG1σ IgG1 FES IgG2σ IgG4 PAA IgG4σ1 IgG4σ2
Core hinge S228P S228P S228P
Lower hinge
L234A L234A L234F V234A F234A F234A F234A
L235A L235A L235E L235A L235A L235A
ΔG236
G237A G237A G237A G237A
P238S P238S P238S P238S





Δ Indicates deletion of residue. European Union (EU) numbering is used for the amino acid substitutions.
2.2. FcγR Binding and Competition
Since effector functions such as ADCC and ADCP are induced by the binding of antibody Fc with
the various FcγRs on the surface of different immune cell types, it is crucial to minimize and if possible
to eliminate this engagement. Testing for binding of the assorted Fc variants to human FcγRs was
determined using an AlphaScreen competitive binding assay. The AlphaScreen competition strategy
involves the following: biotin-labeled huIgG is captured on streptavidin donor beads; His-tagged
FcγRs are captured on nickel acceptor beads; unlabeled competitor (test) antibodies are applied as
serial dilutions. There is a reduction in (maximal) signal when competition takes place. To provide
an avidity component comparable to that created by multiple antibodies bound to a cell surface,
the test antibodies were cross-linked with anti-F(ab′)2. This method increases the sensitivity of the
assay to aid in confirming low-level binding.
Competitive binding analyses of Ab1 (anti-tumor necrosis factor (TNF)α huIgG1) samples
to the different FcγRs are shown in Figure 3. On CD64 receptor (FcγRI), Ab1 huIgG1 wild-type
(WT) binds well with 50% inhibition at approximately 1 μg/mL. HuIgG1 AA and huIgG1 FES
show low level binding at 500 μg/mL, the highest concentration tested. However, the huIgG1σ,
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1 mg/mL (Figure 3A). On CD32a (huFcγRIIa-H131 high and huFcγRIIa-R131 low affinity variants),
CD32b (huFcγRIIb), and CD16a (huFcγRIIIa), the huIgG1 AA and huIgG1 FES variants showed
varying degrees of binding to these receptors, yet the sigma (σ) variants showed complete lack of
binding compared to the huIgG1 wild-type (WT) (Figure 3B–E). HuIgG4 PAA was not included in
this test panel due to reagent constraints, but huIgG4 PAA has been reported to have reduced, but not
eliminated binding to FcγRs [29,33]. These collective data demonstrated that complexes formed from
the IgG1σ and IgG4σ variants did not bind to FcγRs even at high concentrations.




















Figure 3. Testing for interactions of cross-linked huIgG variants with Fcγ receptors. Binding of
huIgG Ab1 (anti-TNFα) molecules to human FcγRs was assessed using AlphaScreen bead assays
in a competitive format. To increase sensitivity of the assays, test samples were cross-linked to
introduce binding avidity by using a goat F(ab′)2 anti-huIgG F(ab′)2-specific fragment in 1:1 molar ratio
with the test antibodies. Cross-linked test antibodies at the designated concentrations were
co-incubated with biotin-labeled huIgG Fc fragment (to avoid binding to cross-linker), the respective
His-tagged FcγRs, nickel chelate acceptor beads, and streptavidin donor beads. Plates were read on
the EnVision multi-label plate reader, and data plotted with GraphPad Prism v6.0 software. Shown are
binding of cross-linked huIgG variants to: (A) huFcγRI, (B) huFcγRIIa-H131, high affinity allotype,
(C) huFcγRIIa-R131, low affinity allotype, (D) huFcγRIIb, (E) huFcγRIIIa-V158, high affinity allotype.
Non-binding of cross-linker alone is shown with the high affinity huFcγRI. All points represent the
mean of duplicate samples ± range. The plot labels refer to IgG1 AA—human IgG1 L234A/L235A;
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2.3. Target Mediated Effector Function In Vitro
2.3.1. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
When the Fc region of an antibody binds to FcγR on immune cells, cytotoxic factors
are released causing ADCC and death of target cells, whose membrane-surface antigens have
been bound by the specific antibody. To compare cytotoxic potential of the silent Fc variants,
K2 cells (T72-18, TNFα SP2/0) expressing the Δ1–12 variant of human TNFα were used as target cells
and human peripheral mononuclear cells (PBMCs) were the immune effector cells in ADCC assays [41].
Figure 4 shows the combined data from six independent experiments that used PBMC effector cells
from 15 different donors. Figure 4A shows that Ab1 huIgG1σ and huIgG2σ have no cytotoxic
activity compared to huIgG1 AA, huIgG1 FES variants and the positive control Ab1 huIgG1 WT.
Figure 4B shows also that Ab1 huIgG4σ1 and huIgG4σ2 have no cytotoxic activity compared to the
huIgG4 PAA and huIgG1. At concentrations up to 1 mg/mL, Ab1 huIgG1σ, huIgG2σ, huIgG4σ1 and
huIgG4σ2 showed minimal to no killing of target cells. In particular, the sigma variants displayed
negligible cytotoxic activity at levels below that of the negative control Ab2 (anti-F glycoprotein of
Respiratory Syncytial Virus a huIgG1) which did not bind to TNFα. In this assay with numerous
donors, Ab1 huIgG1 AA was the least silent Fc variant; HuIgG1 AA, huIgG1 FES, and huIgG4 PAA
showed intermediate cytotoxic levels, and the most ADCC-silent molecules were the huIgG1σ and
huIgG4σ variants.
Figure 4. Antibody-dependent cellular cytotoxicity (ADCC) assays (combined data from six
experiments). Titrating amounts of test antibodies (Abs) were added to K2 target cells, followed
by addition of human PBMC immune effector cells. The extent of target cell lysis was quantitated
after 2 h. Samples were tested in duplicate for each individual experiment. In the combined data
shown here, 15 donors were tested, and each point represents the mean value ± standard error of the
mean. % Specific lysis is shown in (A) for IgG1σ compared to IgG1 AA, FES, and IgG2σ; and in (B) for
IgG4σ1 and IgG4σ2 compared to IgG4 PAA (S228P/F234A/L235A). Ab1 IgG was used as the positive
control and Ab2 IgG1 (neg. control) was the negative control.
2.3.2. Antibody-Dependent Cellular Phagocytosis (ADCP)
Binding of the Fc region to FcγRs on certain immune cells such as macrophages can cause cell
death by phagocytosis. ADCP relies on macrophages to bind and devour target cells following
antibody binding. To further evaluate the lack of effector function with the silent Fc variants,
ADCP flow cytometric assays were performed using macrophages derived from primary human
monocytes as effector cells and K2 cells as target cells. Macrophages and K2 cells were labeled
with separate fluorescent dyes and co-cultured for 5 h in the presence of different concentrations
of test antibody. Quantitation of antibody-opsonized target cells was measured by dual-label
flow cytometry. Representative data from two experiments are shown in Figure 5. Ab1 huIgG1 shows
approximately 30% target cell killing by macrophages, whereas Ab1 huIgG4 PAA, Ab1 huIgG4σ1,
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IgG1 (Figure 5A). In another study, Ab huIgG1 shows a similar extent of cell killing by macrophages
(using a different donor), but Ab1 huIgG4σ1, Ab1 huIgG4σ2 and Ab1 huIgG1σ1 (along with
Ab1 huIgG2σ, Ab1 huIgG4 PAA and Ab2 huIgG1 negative control) show minimal K2 target cell
phagocytosis relative to positive and negative controls at concentrations up to 1 mg/mL (Figure 5B).
These results suggest that the huIgG1σ and huIgG4σ variants would not have Fc-mediated cytotoxic
potential when bound to target immune cells.
Figure 5. Antibody-Dependent Cellular Phagocytosis (ADCP) (phagocytosis) assays. The extent of
phagocytosis was measured using flow cytometry. (A) A representative experiment, showing the
%Target cell killing by macrophages in a 5 h assay with different concentrations of test antibodies;
(B) Results using macrophages from a different donor tested in triplicate with a focus on high
Ab concentrations (200–1000 μg/mL). % Target cell killing is the number of dual-labeled cells
(target cells engulfed by macrophages) divided by total number of target cells × 100. Error bars
represent ± standard error of the mean.
2.3.3. Complement-Dependent Cytotoxicity (CDC)
Complement-dependent cell killing occurs when the Fc portion recruits serum complement
proteins to the cell bound by the specific antibody; leading to induction of a membrane attack complex
and target cell lysis. To determine whether the Fc variants have complement activation capability, CDC
assays were performed using K2 target cells, rabbit complement and a panel of Ab1 huIgG Fc variants.
As shown in Figure 6 using Ab1 variants, CDC results indicate that huIgG1σ, huIgG4 PAA, huIgG4σ1
and huIgG4σ2, and huIgG2σ samples have minimal activity, like that of the negative control Ab2
huIgG1 at concentrations up to 500 μg/mL. In contrast to the negative control, the positive control Ab1
huIgG1 has measurable target mediated specific killing activity at less than 0.1 μg/mL. Relative to these
controls, Ab1 huIgG1 AA and huIgG1 FES show intermediate levels of cytotoxicity. Data indicate that









Figure 6. Cell-based CDC assays with IgG Fc variants. K2 mouse myeloma cells stably expressing
a transmembrane form of human tumor necrosis factor alpha (TNFα) were incubated with varying
concentrations of test antibody and rabbit complement, and then cell viability was measured by
detecting lactate dehydrogenase release in the culture supernatant. Error bars represent standard error
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2.4. FcRn Binding
Interaction with neonatal Fc receptor (FcRn) is a critical factor that contributes to sustaining
circulating antibody half-life [2], thus better binding to FcRn is expected to give a longer
antibody half-life. To determine whether the sigma Fc mutations affect FcRn binding, competition
binding by an enzyme-linked immunosorbent assay (ELISA) was performed with varying
concentrations of unlabeled silent Fc antibody and a fixed amount of biotin-labeled huIgG1 on
plate-bound human FcRn at pH 6. Bound tracer antibody was determined by colorimetric detection
after incubation with streptavidin-horseradish peroxidase (HRP) and tetramethylbenzidine (TMB)
substrate reagents. ELISA results shown in Figure 7 indicate a slight (less than 2-fold) reduction in
binding affinity to FcRn for huIgG1σ relative to the huIgG1 wild-type control. Other tested variants
show up to 4-fold reductions in relative affinity. The negative control variant (huIgG1 H435A) of Ab2
appropriately shows no binding to FcRn. While these findings indicate some reduction in relative
affinity for the variants tested, all the silent Fc variants can bind FcRn, and huIgG1σ appears to bind
FcRn the best.
Figure 7. Binding of IgG variants to neonatal Fc receptor (FcRn). In a competition binding format,
titrating amounts of antibody were combined with a fixed concentration (4 μg/mL) of biotin-labeled
huIgG1. Antibody mixtures were incubated with immobilized human FcRn on a plate for 1 h, washed,
detected with streptavidin-horseradish peroxidase (HRP), and developed with tetramethylbenzidine
(TMB) substrate. Bound tracer antibody was detected via absorbance at 450 nm measured on a plate
reader. (A) Ab1 samples and (B) Ab2 samples were tested in duplicate and error bars represent
mean ± range.
2.5. FcγR Binding Interactions In Vivo
2.5.1. T Cell Immunostimulatory Activity
In vivo, the Fc and FcγR interaction can be evaluated and detected by T cell activation [42].
Human FcγR transgenic mice (FcγR-hu) express all five human FcγRs and have no expression of
endogenous mouse FcγRs [43]. When anti-mouse CD3 antibody (Ab4, 2C11) binds to mouse T cells,
there is an agonistic effect (presumably due to binding of FcγR on neighboring cells at the same time
it is bound to CD3 on T cells) which leads to up-regulation of activation markers such as CD69 and
CD25 [42]. An increase in binding of Fc to FcγR correlates with an increased level of T cell activation.
This agonist activity was used to evaluate T cell activation of the Fc variants in FcγR-hu mice.
An initial study was done to confirm that T cell activation in the FcγR-hu mice is due to FcγR-Fc
binding. Three strains of mice with different gene dosages were used: the 5-transgene FcγR-humanized
mice, mice hemizygous for the 5 transgenes, and FcRα chain null mice (FcγR knockouts). Ab4 huIgG1
and Ab4 huIgG1σ were injected into the intraperitoneal cavity (0.5 mg/kg, 10 mL/kg). Approximately
24 h later, mice were euthanized and their spleens removed for T cell activation analyses by flow
cytometry. Results demonstrated the dependence on the presence of human FcγR, since very little or
no T cell activation using huIgG1 was detected in the null mice, an intermediate level of activation
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(Figure 8A). Low to no activation was observed in T cells of huIgG1σ treated mice. Next, homozygous
FcγR-humanized mice were used to explore a panel of Ab4 silent Fc variants. Twenty-four hours
following the dose of the test antibodies, splenocytes from the mice were isolated and flow analyses
performed to determine T cell levels of the early activation marker (CD69), and a late activation
marker (CD25).
Figure 8. In vivo T cell activation. (A) Results of in vivo T cell activation by IgG1σ relative to wild-type
IgG1. FcγR-humanized mice, homozygous and hemizygous, and mice lacking FcγRs (null) were
injected intraperitoneal with a 0.5 mg/kg dose of either human IgG1σ or wild-type IgG1. After 24 h,
spleens were collected from each mouse and the percent of CD8+ cells (as well as CD3ε cells, not
shown) that stained positive for CD25 was measured by flow cytometric analyses. (B) Comparison of
in vivo T cell CD69 activation with panel of silent IgG Fc variants. (C) Comparison of in vivo T cell
CD25 activation with panel of silent IgG Fc variants. The dashed line represents the level of non-specific
activation, derived from the mean value of un-activated splenocytes and splenocytes treated with a
control IgG1 WT. Error bars represent the standard error of mean from 3 to 6 samples in both studies.
Comparison of CD69 activation results (expressed as a percentage of CD3ε cells) are shown in
Figure 8B for the silent Fc variants, a non-FcγR binding F(ab′)2 fragment and a non-T cell binding
Ab1 huIgG1. Splenocytes from wild-type IgG (Ab4 huIgG1), low fucose IgG1 (Ab4 huG1 LoF with high
affinity binding to CD16), and phorbol myristate acetate treated mice, collectively showed a robust
CD69 signal (mean value 58%) compared to un-activated splenocytes (25%) from phosphate- buffered
saline (PBS) treated mice. Ab4 F(ab′)2 gave a substantial unexpected signal (46%) which suggested that
T cells may have a low level of activation merely by bivalent CD3 binding without FcγR engagement.
Ab4 huIgG1 induced a higher CD69 activation level than Ab1 huIgG1 WT because it has both CD3
and FcγR engagement. The dashed line in Figure 8B represents a “non-specific activation” level (29%),
determined from the average value of untreated splenocytes and splenocytes treated with a non-T cell
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T cell activation relative to the non-specific activation level. However, Ab4 huIgG2σ, Ab4 huG4σ1 and
Ab4 huG4σ2 caused a decrease in CD69 activation relative to the non-specific level, and Ab4 huIgG1σ
caused an activation level like that of the Ab1 huIgG1 WT which does not bind T cells.
CD25 activation levels of splenic T cells (expressed as a percent of CD8+ cells) from mice
treated with the silent Fc variants are shown in Figure 8C. The dashed line represents the level for
non-specific activation derived from splenocytes treated with control Ab1 huG1 WT. Consistent with
CD69 results, Ab4 huG1 AA, huG1 FES, and huG4 PAA produced an increase in CD25 activation
levels that are comparable to that of Ab4 huG1 WT treated mice. As expected, the Ab4 huIgG1 LoF
induced a higher CD25 activation signal. Likewise, Ab4 huG1 F(ab′)2 caused a higher CD25 activation
than expected (such as in the case of CD69 activation) which may be due to bivalent CD3 binding,
clustering, and signaling. Ab4 huIgG1σ, Ab4 huIgG2σ, Ab4 huG4σ1 and Ab4 huG4σ2 induced
minimal CD25 activation. These in vivo CD69 and CD25 results indicated that binding of IgG1σ,
IgG2σ, IgG4σ1 and IgG4σ2 variants did not activate T cells compared to T cells from mice treated with
huIgG WT or huIgG4 PAA.
2.5.2. FcγR-Mediated Anti-Tumor Activity
The B16 metastatic melanoma syngeneic model has been used to assess Fc and FcγR interactions.
B16F10 mouse melanoma tumor cells can stimulate lung tumor metastasis, and murine TA99 antibody
which targets the gp75 antigen on B16F10 cells, can inhibit tumor cell growth in mice [44,45].
Also, human TA99 antibody can inhibit metastasis, whereas a human IgG1 mutant which does
not engage FcγRs has no effect in FcγR-hu mice [43].
This B16 metastatic tumor model was used to test the effect of a huIgG1σ version of
Ab5 (anti-grp75) on lung tumor metastasis in FcγR-hu mice. These mice treated with different
versions of Ab5: huIgG1, huIgG1 LoF (low fucose with enhanced ADCC, in-house data) and mIgG2a
(mouse Ab as positive control) showed a significant reduction in lung tumor metastasis compared to
the mice treated with PBS (Figure 9). Lung metastasis foci were decreased by 2-fold in mice treated
with Ab5 mIgG2a or Ab5 huIgG1, and 3-fold with Ab5 huIgG1 LoF compared to the PBS treated
mice. In contrast, mice treated with huIgG1σ showed no tumor inhibition, and although unexplained,
huIgG1σ treated mice showed more tumor metastasis than the PBS treated mice. Results indicate that
in vivo antibody-mediated tumor clearance appears to be dependent on binding to FcγRs by huIgG1
or huIgG1 LoF, whereas huIgG1σ which does not bind FcγR is unable to prevent tumor cell growth.
Figure 9. Effect of silent Fc mutations on syngeneic tumor cell metastasis. FcγR-humanized
mice were injected IV with B16F10 cells and received either: phosphate-buffered saline (PBS),
Ab5 (TA99) mIgG2a, Ab5 huIgG1, Ab5 huIgG1 LoF (low fucose) or Ab5 huIgG1σ (n = 4 for groups) on
days 0, 2, 4, 7, 9 and 11. On day 21, lungs were harvested and metastasis foci were counted. Data show
the mean number of lung metastasis foci expressed as lung tumor index from mice receiving the
indicated treatment ± standard error.
2.6. Pharmacokinetics (PK)
PK studies were done to determine whether normal antibody half-life would be altered using
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mice (Tg32 hemi, 8–10 weeks old, 3–4 per group) were intravenously-injected once with 2 mg/kg doses
of the test antibody. Blood was collected at various times up to 35 days post-injection and sera
prepared by standard procedure. A Meso Scale Discovery (MSD) assay using anti-human IgG specific
reagents was employed for quantitating human IgG in the mouse serum samples. Terminal half-life
values were obtained using a one-compartment linear fit using Prism 6.0 software (GraphPad,
San Diego, CA, USA).
HuIgG serum concentrations over time for the mice are shown in Figure 10A. PK profiles display
a linear decrease in IgG levels from day 7 through 35. HuIgG2σ (t1/2 = 5.5 ± 0.5 days) shows a 2-fold
shorter half-life than the huIgG1 (t1/2 = 11.4 ± 1.7 days). However, PK values for the other Fc variants:
huIgG1 AA (t1/2 = 7.5 ± 1.1 days), huIgG4 PAA (t1/2 = 7.8 ± 3.2 days), huIgG4σ2 (t1/2 = 7.9 ± 2.1 days),
huIgG4σ1 (t1/2 = 8.9 ± 1.3 days), huIgG1σ (t1/2 = 9.6 days), huIgG2 (t1/2 = 11.2 ± 0.8 days) and huIgG1
FES (t1/2 = 9.7 ± 1.1 days) are not significantly different from that of huIgG1. These results indicate
that the silent Fc mutations do not alter the PK compared to normal huIgG1, except for huIgG2σ which
showed a reduction in half-life.
Figure 10. PK comparison of IgG1 WT and a panel of silent Fc variants in mice and cynomolgus
monkeys. (A) Tg32 human FcRn transgenic mice were IV-injected with 2 mg/kg doses. Serum levels
were expressed as a percent of day 2 values, the first timepoint. Data points represent the mean of
3 or 4 mice ± SEM. (B) Cynomolgus monkeys were injected intravenously with 1.5 mg/kg dose of an
IgG2σ version of Ab3 bispecific antibody and the mean PK profile was compared (in a separate study)
with monkeys injected with 1.5 mg/kg of an huIgG1σ version of Ab3. Similarly, IgG1σ and IgG2σ
versions of Ab2 × Ab5 antibody were evaluated in the two separate studies.
PK studies in cynomolgus monkeys were conducted also to compare the huIgG1σ and
huIgG2σ versions of Ab3, a bispecific antibody (anti-Respiratory Syncytial Virus (RSV)) and
glycoprotein gp120 of HIV envelope, huIgG1). Male cynomolgus monkeys (2.5 to 3 kg, 3 per groups)
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up to 21 days or 28 days, and PK analyzed as described. Although performed in separate
studies, similar half-life values are observed for Ab3 huIgG1σ (t1/2 = 11.7 ± 0.95 days) and its
huIgG2σ counterpart (t1/2 = 10.3 ± 3.1 days); and for Ab2 × Ab5 bispecific (anti-RSV × anti-gp75)
huIgG1σ (t1/2 = 5.6 ± 0.5 days) and its huIgG2σ counterpart (t1/2 = 5.2 ± 0.1 days) (Figure 10B).
Considering that Ab2 huIgG1 historically has shown a half-life of 10–12 day in monkeys (Table S1),
these monkey data along with the above mouse data, suggest that the huIgG1σ variant (as well as the
huIgG2σ) should have a relatively normal serum half-life in humans.
2.7. Immunogenic Potential
To assess the potential immunogenicity of huIgG1 and huIgG4 sigma variants, a T cell epitope
analysis was done using the ImmunoFilterTM v2.7 human leukocyte antigen (HLA) class II-peptide
binding prediction software (Xencor, Inc., Monrovia, CA, USA) to predict potential immunogenicity
in humans. These analyses generate IScores, which are weighted, population-relevant values that
enable separation of individual 9-mer agretopes into groups by predicted immunogenic risk (PIR).
Higher IScores indicate a higher PIR. Areas of sequence in the Fc variants which are identical to
that of huIgG1 WT Fc sequence are excluded by the application of a tolerance threshold. IScores are
averaged across all HLA-class II loci for each sequence of interest to create a single average IScore
value. As shown in Figure 11A, the average IScores of the tested variant sequences are like those
of their respective wild-type isotype controls. The greatest deviation from wild-type Fc results is a
reduction of 1.2% observed with huIgG4 PAA. However, differences observed between the tested
variants are inconsequential because all produce average IScores of less than 5%. IScores of less than
10% are considered to indicate very low risk of immunogenicity with a prediction that less than 10%
of the U.S. population would have at least one allele predicted to bind a 9-mer located within the
tested sequence. A further breakdown of the IScore data into number of predicted agretopes, as well as
number of low, medium and high PIR agretopes for each sequence of interest is shown in Figure 11B.
Again, individual predicted agretopes show all sequences having similar immunogenic risk profiles as
their corresponding wild-type Fc sequences, where predicted agretopes would likely be tolerogenic.
None of the Fc variants are predicted to generate any high PIR agretopes (i.e., over 50% of the U.S.
population having at least one MHC allele predicted to bind the 9-mer).
Figure 11. ImmunoFilterTM analyses of the human IgG variants. The amino acid sequences for the
different variants were analyzed for predicted immunogenicity in silico using ImmunoFilterTM v2.7.
(A) IScores summary which approximated the percent of US population expected to have a human
leukocyte antigen (HLA) allele predicted to bind a nine-mer peptide within a sequence of interest.
(B) The number of individual agretopes and their associated risk potential based on the percent of the
population expected to have an allele predicted to bind each agretope (low (lo) = 10–25%, medium
(med) = 25–50%, and high (hi) = over 50% of the U.S. population). Resulting IScores were averaged
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2.8. Developability Assessment
A panel of biophysical assays was conducted on Abs with Fc variations to assess potential
problems in developability that might impact the development and commercial manufacturing
of therapeutics. These studies included assessing antibody thermal stability, the stability of
highly concentrated samples over time, and stability at low pH. The results are described in the
sub-sections below.
2.8.1. Thermal Stability
Differential Scanning Calorimetry (DSC) was used to assess the thermal stability of Ab1 Fc
variants. A summary which includes the mid-point of denaturation (Tm) for the transitions is shown
in Table 2. HuIgG1 (WT), huIgG1 AA and huIgG2 have similar Tm1 (CH2 domain) transitions,
but huIgG1 FES, huIgG1σ, huIgG2σ, huIgG4 PAA, huIgG4σ1 and huIgG4σ2 show lower Tm1 transition
values, suggesting reduced stability of its CH2 domain attributable to the presence of mutations
(Table 1). Ab1 huIgG2 Tm1 transition is 71.6 ± 0.1 ◦C, while the huIgG2σ variant is 62.0 ± 0.2 ◦C
for Tm1. The Ab1 huIgG4 PAA shows a first transition at 69.5 ± 0.1 ◦C, while the huIgG4σ1 is at
62.0 ± 0.2 ◦C and the huIgG4σ2 is at 61.2 ± 0.6 ◦C, suggesting that the huIgG4 PAA is more thermally
stable than its variants. The huIgG4 PAA differences are interesting given that the only sequence
differences are in the first two or three residues in the lower hinge (Table 1). The Tm2 and Tm3
indicating the Fab and CH3 transitions are included for comparison, but generally show normal
antibody transition profiles between 69 and 83 ◦C [46].
Colloidal stability was evaluated over a temperature range by static light scattering (SLS) at two
different wavelengths (Table 2). The scattering intensity at 266 nm is more sensitive to fluctuations
of smaller aggregates. Measurements of scattering intensity at 473 nm are useful for detection
of larger aggregates. The SLS data indicate the onset of aggregation (Tagg) for each antibody
sample. Results comparing the antibody variants show that huIgG1 variants have higher aggregation
onset temperatures around 68 ◦C (SLS at 266 nm) compared to the huIgG2 or huIgG4 variants
(Tagg = 64–65 ◦C using SLS at 266 nm). SLS measurements at 473 nm display a similar profile.






Tm1 (◦C) Tm2 (◦C) Tm3 (◦C) Tagg266nm (◦C) Tagg473nm (◦C)
Ab1 IgG1 71.7 ± 0.1 75.2 ± 0.1 82.6 ± 0.1 67.7 ± 0.6 69.7 ± 0.7
Ab1 IgG1 AA 71.7 ± 0.2 75.0 ± 0.1 82.2 ± 0.1 68.0 ± 0.3 69.9 ± 0.5
Ab1 IgG1 FES 64.7 ± 0.0 74.0 ± 0.1 82.5 ± 0.0 ND ND
Ab1 IgG1σ 60.8 ± 0.1 74.4 ± 0.1 82.7 ± 0.1 68.3 ± 0.7 69.8 ± 0.6
Ab1 IgG2 71.6 ± 0.1 75.9 ± 0.1 ND 65.3 ± 0.3 67.6 ± 0.3
Ab1 IgG2σ 62.0 ± 0.2 74.5 ± 0.1 71.4 ± 0.2 64.0 ± 2.1 66.0 ± 1.7
Ab1 IgG4 PAA 69.5 ± 0.1 73.4 ± 0.1 ND 63.8 ± 1.7 66.0 ± 0.6
Ab1 IgG4σ1 62.0 ± 0.2 70.8 ± 0.1 73.8 ± 0.1 64.1 ± 1.4 66.0 ± 0.5
Ab1 IgG4σ2 61.2 ± 0.6 69.9 ± 0.6 73.2 ± 0.4 63.8 ± 1.8 66.0 ± 0.5
Antibody (Ab) samples are in PBS; values are shown as ± range. Abbreviations: ND, no data; fragment crystallizable,
Fc; temperature of melting at midpoint, Tm; IgG1 AA, IgG1 L234A/L235A; IgG1 FES, IgG1 L234F/L235E/P331S;
IgG4 PAA, IgG4 S228P/F234A/L235A.
2.8.2. Stability of Concentrated Samples
Samples were concentrated from their initial concentration of 1–2 mg/mL to 40–50 mg/mL
and stored at 4 ◦C. Table 3 summarizes the antibody concentrations and Table 4 summarizes the
size exclusion chromatography (SEC) analyses at time of lot release, week 1, week 2, week 3, and
week 4 post-release. All molecules show stable antibody concentrations for up to 4 weeks storage at
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to sample evaporation during storage. Aliquots at these time points were diluted and analyzed
by SEC. All samples appear visibly clear and SEC analyses results indicate that all molecules at high
concentrations consist of greater than 95% monodisperse monomeric antibody.












IgG1 53.9 ± 0.8 53.1 ± 0.3 57.2 ± 0.7 55.1 ± 0.4 55.0 ± 0.3
IgG1 FES 45.5 ± 0.9 48.8 ± 1.2 46.4 ± 0.7 46.7 ± 0.3 46.6 ± 1.5
IgG1σ 41.9 ± 0.6 41.5 ± 0.2 42.0 ± 0.3 42.5 ± 0.9 43.4 ± 0.5
IgG2 41.4 ± 0.1 40.5 ± 0.2 42.0 ± 0.4 42.9 ± 0.2 43.0 ± 0.8
IgG2σ 40.8 ± 0.5 41.3 ± 0.4 40.9 ± 0.6 41.7 ± 1.1 41.8 ± 0.6
IgG4-PAA 48.6 ± 1.5 50.6 ± 0.6 52.5 ± 1.0 53.2 ± 0.2 50.9 ± 1.3
IgG4σ1 50.4 ± 0.4 50.3 ± 0.1 50.0 ± 0.6 50.0 ± 0.2 51.4 ± 0.8
IgG4σ2 51.7 ± 1.1 51.3 ± 0.4 48.4 ± 2.1 53.4 ± 1.6 54.8 ± 0.7
Ab samples are in PBS and shown as mean ± range. Abbreviations: IgG1 AA, IgG1 L234A/L235A; IgG1 FES,
IgG1 L234F/L235E/P331S; IgG4 PAA, IgG4 S228P/F234A/L235A.
Table 4. Size exclusion chromatography (SEC) analyses with percent monomer of concentrated proteins.
Sample Name Release (%) Week 1 (%) Week 2 (%) Week 4 (%)
IgG1 100.0 100.0 99.6 99.4
IgG1 FES 100.0 100.0 100.0 99.0
IgG1σ 100.0 100.0 99.7 99.3
IgG2 98.17 98.0 97.9 97.7
IgG2σ 100.0 100.0 99.2 100.0
IgG4 PAA 100.0 99.6 99.5 99.5
IgG4σ1 98.0 97.9 97.7 97.5
IgG4σ2 97.8 97.9 97.7 97.4
Representative data of SEC analysis. Abbreviations: IgG1 AA, IgG1 L234A/L235A; IgG1 FES, IgG1 L234F/L235E/P331S;
IgG4 PAA, IgG4 S228P/F234A/L235A.
To obtain a more complete picture of the stability of the Fc variants, protein melting points and
aggregation onset temperature were measured for each by a combination of intrinsic fluorescence and
static light scattering. Table 5 summarizes the mid-point values for thermal transition, Tm1, and for
onset of aggregation at Tagg = 266 nm. Tm values for the concentrated antibody variants are similar
between the release lot and the week 4 samples. Tagg values of the 266 nm values are also similar
for the release lot and week 4 samples. Thus, the variants have not changed their conformational or
colloidal stabilities at high concentrations.
Table 5. Tm and temperature of aggregation (Tagg) of Fc variants at high concentration (40–50 mg/mL).
Antibody Week Tm1 (◦C) Tagg266nm (◦C)
IgG1 R 69.3 ± 1.4 68.0 ± 0.1
IgG1 Week 0 68.2 ± 0.5 67.4 ± 0.6
IgG1 Week 4 68.3 ± 0.3 67.6 ± 0.8
IgG1σ R 61.5 ± 1.0 68.9 ± 0.3
IgG1σ Week 0 60.6 ± 0.2 67.8 ± 0.3
IgG1σ Week 4 60.8 ± 0.1 67.9 ± 0.7
IgG1 AA R 69.3 ± 0.5 68.3 ± 0.3
IgG1 AA Week 0 68.2 ± 0.0 67.7 ± 0.2
IgG1 AA Week 4 68.4 ± 0.1 68.1 ± 0.2
IgG1 FES R 65.9 ± 0.8 67.7 ± 0.1
IgG1 FES Week 0 64.9 ± 0.6 66.9 ± 0.3
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Table 5. Cont.
Antibody Week Tm1 (◦C) Tagg266nm (◦C)
IgG2 R 67.5 ± 1.8 65.1 ± 0.8
IgG2 Week 0 66.5 ± 0.4 65.6 ± 0.1
IgG2 Week 4 66.7 ± 0.4 65.2 ± 1
IgG2σ R 61.7 ± 0.8 61.9 ± 2.4
IgG2σ Week 0 62.6 ± 0.2 66.2 ± 0.1
IgG2σ Week 4 62.7 ± 0.2 66.8 ± 0.4
IgG4 PAA R 66.4 ± 1.9 62.1 ± 0.5
IgG4 PAA Week 0 66.2 ± 0.6 65.5 ± 1.3
IgG4 PAA Week 4 66.3 ± 0.2 65.9 ± 0.1
IgG4σ1 R 61.5 ± 0.1 62.7 ± 0.9
IgG4σ1 Week 0 62.0 ± 0.2 65.5 ± 0.2
IgG4σ1 Week 4 62.0 ± 0.4 66.1 ± 0.0
IgG4σ2 R 61.6 ± 0.7 62.0 ± 1.5
IgG4σ2 Week 0 61.8 ± 0.1 65.6 ± 0.1
IgG4σ2 Week 4 62.1 ± 0.2 65.9 ± 0.1
Tm1 and Tagg266nm values = mean ± range; Ab samples are in PBS. R is the Release material; Week 0 is data after
concentration of material; Week 4 is data after week 4 of incubation.
2.8.3. Stability of Low pH Treated Antibody Fc Variants
To assess whether the Fc variants are stable after low pH treatment for viral load reduction in
manufacturing, antibody samples were treated at pH 3.5 for 6 h and dialyzed back to pH 7.4 in PBS.
Dynamic light scattering analyses were performed to quantitate presence of soluble aggregates and
sub-visible particles. Table 6 shows the average hydrodynamic radius (Rh), percent polydispersity
(% Pd) values, and percent mass comparison between the release lot and the low pH treated samples.
All samples yielded a peak with an average radius of 5–7 nm, average % Pd of less than 15%, and an
average % Mass of greater than 99%. These features are indicative of a mono-dispersed species for the
antibody variants.
Table 6. Dynamic light scattering data after low pH treatment.
Ab1
Avg Rh Avg %Pd Avg %Mass Avg Rh Avg %Pd Avg %Mass
Release Material Low pH Material
IgG1 5.4 ± 0.1 10.3 ± 2.1 100.0 ± 0.0 5.1 ± 0.2 12.2 ± 1.7 100.0 ± 0.0
IgG1σ 5.4 ± 0.0 9.6 ± 0.3 100.0 ± 0.0 5.0 ± 0.2 13.2 ± 0.8 100.0 ± 0.0
IgG1 AA 5.8 ± 0.3 16.7 ± 10.1 100.0 ± 0.1 5.5 ± 0.2 12.2 ± 7.1 100.0 ± 0.0
IgG1 FES 5.5 ± 0.0 7.7 ± 1.6 100 ± 0.0 5.2 ± 0.1 11.9 ± 1.3 99.7 ± 0.6
IgG2 5.8 ± 0.1 18.2 ± 5.2 99.6 ± 0.1 5.0 ± 0.1 13.2 ± 0.6 100.0 ± 0.0
IgG2σ 5.4 ± 0.0 13.0 ± 3.6 100.0 ± 0.0 5.1 ± 0.2 12.5 ± 1.5 99.6 ± 0.8
IgG4—PAA 5.3 ± 0.1 9.9 ± 0.6 100.0 ± 0.0 5.3 ± 0.0 10.4 ± 0.8 100.0 ± 0.0
IgG4σ1 5.4 ± 0.1 9.3 ± 0.5 100.0 ± 0.0 6.4 ± 0.2 15.5 ± 1.6 100.0 ± 0.0
IgG4σ2 5.4 ± 0.0 8.9 ± 0.4 100.0 ± 0.0 6.6 ± 0.1 14.8 ± 1.3 100.0 ± 0.0
Samples were tested at 1 mg/mL in triplicate and shown as mean ± standard deviation (STD). Avg—average;
Percent polydispersity (% Pd); hydrodynamic radius (Rh).
2.9. Fc Crystal Structures
To assess the impact of the silencing mutations on the structure of the Fc, crystal structures of the
Fc fragments of huIgG1σ, huIgG4σ1, and huIgG4σ2 were determined to resolutions of 1.90 Å, 1.90 Å,
and 1.85 Å, respectively. Data collection and refinement statistics are summarized in Table 7. Crystals
of all three Fc constructs belonged to space group P212121, and had similar unit cell parameters. This
isomorphism reflects a similarity in Fc packing within the crystal lattice where one intact Fc dimer
is present in the asymmetric unit. In this crystal form, the A chain CH2 domain is less ordered as
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atoms. The reason for this is that the CH2 domains of the A and B chains have a difference in the crystal
contacts. For the three Fc structures reported here and excluding the glycan contributions, the B chain
has an average of 2082 ± 186 Å2 of buried surface area through interaction with symmetry related Fc
molecules compared with only 1477 ± 181 Å2 of buried surface area for chain A. Consequently, for the
three structures, the average B-factor calculated over residues 238–339 and glycan residues for chains B
and A was 37.6 ± 4.5 Å2 and 54.1 ± 1.8 Å2, respectively.
The huIgG1σ Fc structure includes residues G236-S444 and A235-S444 for chains A and B,
respectively, which are only those observed in the electron density map (Figure S1). The structure
reveals conformational differences in ordered residues N-terminal to V240 and within the BC loop
(residues S267 to V273) relative to wild-type huIgG1 Fc (e.g., PDB 3AVE [40]) and receptor-bound
Fc structures (e.g., PDB 3SGK [47]). These regions can directly influence interactions with FcγRs.
The lower hinge regions of wild-type huIgG1 structures, including those in complex with FcγRs, show
extended conformations while that of huIgG1σ has a kinked conformation at S239 (Figures 12 and S1).
The backbone psi angle value for S239 averaged over both chains in the huIgG1σ Fc structure is 10◦
compared to an average value of 145◦ for wild-type huIgG1 in structure 3AVE [40]. It should be
noted that the altered lower hinge conformation is not a requirement of crystal packing (Figure S2).
Interestingly, the kinked conformation is observed in structures of two other engineered Fcs in complex
with FcγRIIb, a P238D mutant (PDB 3WJJ [48]) and an Fc having the P238D mutation in addition to six
other mutations (PDB 3WJL [48]) (Figure 12).
Table 7. X-ray crystallographic data and refinement statistics.
IgG1σ Fc IgG4σ1 Fc IgG4σ2 Fc
Crystal Data
Space group P212121 P212121 P212121
Unit cell parameters
a, b, c (Å) 73.36, 79.17, 101.44 74.74, 78.39, 97.39 74.52, 78.47, 97.51
α, β, γ (◦) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å) 50.00–1.90 (1.95–1.90) a 50.00–1.90 (1.95–1.90) 50.0–1.85 (1.90–1.85)
Measured reflections 256,516 (19,366) 248,644 (18,842) 363,451 (27,057)
Unique reflections 47,175 (3427) 45,491 (3348) 49,481 (3648)
Completeness (%) 99.7 (99.7) 99.4 (99.9) 99.9 (100.0)
Redundancy 5.4 (5.7) 5.5 (5.6) 7.3 (7.4)
Rmerge b 0.041 (0.539) 0.045 (0.588) 0.056 (0.670)
<I/σ> c 21.3 (2.9) 18.6 (2.8) 19.8 (3.0)
Refinement Statistics
Resolution (Å) 33.28–1.90 32.70–1.90 47.26–1.85
Number of reflections 47,088 45,473 49,469
Rwork (%) d 19.2 18.2 18.1
Rfree (%) d 22.9 22.5 21.5
Number atoms 3772 3771 3897
Protein 3292 3320 3404
Carbohydrate 220 220 210
Solvent 260 231 283
Mean B-factor (Å2) 41.9 45.9 40.0
Protein 40.4 43.7 37.9
Carbohydrate 58.5 75.7 66.2
Solvent 46.4 50.0 45.9
RMSD e
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Table 7. Cont.
IgG1σ Fc IgG4σ1 Fc IgG4σ2 Fc
Bond angles (◦) 1.213 1.438 1.699
Ramachandran
Favored (%) 98.1 98.8 98.1
Allowed (%) 1.9 1.2 1.9
Outliers (%) 0.0 0.0 0.0
a Values for high resolution shell are shown in parentheses. b Rmerge = ΣhklΣi(|<Ihkl> − Ihkl,i|)/ΣhklΣi Ihkl,I,
where hkl enumerates the unique reflections and i their symmetry-equivalent or multiply-measured contributors.
I is the intensity for a given measurement. c <I/σ> is the average x-ray reflection intensity (I) measurement
divided by the standard deviation of that measurement (σ) for the whole X-ray data set. d R = (Σhkl ||Fobs(hkl)| –
|Fcalc(hkl)||)/(Σhkl |Fobs(hkl)|), where Fobs(hkl) and Fcalc(hkl) are the observed and calculated structure factors.
Rwork includes structure factors for the entire data set minus those data sequestered for computing Rfree. Rfree
includes only the latter randomly chosen subset of the data. e RMSD (Root Mean Square Deviation) in the table
describes how well the atomic bond distances and angles compare to idealized values determined from a set of
reference structures.
Figure 12. Structural consequence of mutation at position 238 reveals an altered conformation of
the lower hinge. Backbone alignment of Fc CH2 domains of huIgG1 (Protein Data Bank (PDB)
3AVE [40]), huIgG1 in complex with FcγRIIIa (chain B, PDB 3SGJ [47]), huIgG1 V12 variant in complex
with FcγRIIb (PDB 3WJL [48]), huIgG1 P238D in complex with FcγRIIb (PDB 3WJJ [48]), huIgG1σ,
huIgG2 (PDB 4HAF [49]), huIgG2σ (PDB 4L4J [29]), huIgG4 (PDB 4C54 [50]), huIgG4σ1, huIgG4σ2.
The Cα positions of residues 238 and 239 are labeled.
The structure of huIgG4σ1 Fc includes residues A237-L443 and G236-S444 for chains A and B,
respectively, that were modeled into the visible electron density. For the huIgG4σ2 Fc structure,
residues S238-L443 and E233-S444 were modeled for the respective chains (Figure S1). The lower
hinge residues in both chains of the huIgG4σ1 Fc structure and in chain B of the huIgG4σ2 Fc structure
adopt a kinked conformation like that described above for huIgG1σ (Figures 12 and S1). In contrast,
the same residues in chain A of the huIgG4σ2 structure adopt a wild-type-like extended conformation
(Figure 12). All these Fcs having a kinked lower hinge also contain the mutation of P238, however,
the structure of huIgG2σ (PDB 4L4J [29]) and chain A of huIgG4σ2 indicate that this mutation does
not restrict the conformation to the kinked form.
Previous crystal structures of huIgG1, huIgG2 and huIgG4 have shown two distinct conformations
for the BC loop (residues 267 to 273) and the FG loop (residues 322 to 332) that seem to
correlate with the ability to bind to FcγRs. Denoting the two conformations as ‘flipped-in’ and
‘flipped-out’, both loops are in the flipped-in conformation in structures of wild-type huIgG1 Fc
(PDB 3AVE [40]) and huIgG2 Fc (PDB 4HAF [49]), whereas they adopt the flipped-out conformation
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huIgG4σ2 (Figure 13). Interestingly, the electron density map for huIgG1σ Fc reveals a deviation from
this pattern such that the primary conformation of the BC loop is the flipped-out conformation while
that of the FG loop is the wild-type flipped-in conformation. In chain A, for which the density is
poorer, these are the only conformations evident. In chain B, density is also present for the flipped-in
conformation of the BC loop, and this conformation refined to an occupancy of 40%. Density for the
FG loop in chain B suggests an increased mobility for this loop, but was not well enough defined
to model a second conformation. Whereas crystal packing precludes a flipped-out FG conformation
for one of the two Fc chains in the huIgG1σ structure, a flipped-out conformation could be tolerated
for the second (Figure S3). In the wild-type huIgG1 Fc structure (PDB 3AVE [40]), residue P271 in
a flipped-out conformation of the BC loop would clash with the flipped-in FG loop. However, this clash
is avoided in huIgG1σ by a deflection of the FG loop as a rigid body (Figure 13). In addition to the
deviation in conformations of the BC and FG loops for the huIgG1σ Fc, the structural studies suggest
an increased mobility for these two loops that may play a direct role in how this Fc interacts with
the FcγRs.
Figure 13. Conformational differences in BC and FG loops in WT and σ variants of huIgG. (A) Overlay
of CH2 domains (cartoon) from huIgG1 (wheat, PDB 3AVE chain A [40]) and huIgG1σ (orange, chain B);
(B) huIgG2 (wheat, PDB 4HAF chain A [49]) and huIgG2σ (orange, PDB 4L4J chain A [29]); (C) huIgG4
(wheat, PDB 4C54 chain A [50]), huIgG4 σ1 (blue, chains A and B), and huIgG4 σ2 (orange, chains A
and B). BC and FG loops are in the flipped-in conformation in huIgG1 (middle, wheat) and flipped-out
conformation in huIgG2σ (middle, orange). Residues at positions 268, 271, 292, 294, 300, 326, and 329
are shown as sticks and are labeled in the middle panel with huIgG2 sequence (mutation at position
268 in huIgG2σ given in parentheses). N-terminal residues 234–236 are omitted from the cartoon of
huIgG1 for clarity, and the alternate conformations modeled for the BC loop of huIgG1σ are shown.
2.10. Molecular Dynamics Simulations of the Fc FG and BC Loops
To further investigate the dynamic stability of the loops in wild-type huIgG1 and huIgG1σ that
could potentially influence FcγR binding, explicit solvent molecular dynamics simulations were
performed starting from the crystal structures of wild-type huIgG1 (PDB 3AVE [40]) and huIgG1σ.
Both simulations were initiated from structures in which the FG loop was in the flipped-in conformation.
For the wild-type simulation, the FG loop remained close (within 2Å Cα RMSD) to the flipped-in
conformation for 57.1% of the simulation as compared to 44.4% in the case of huIgG1σ where the loop
was found to be substantially more flexible (Figures 14 and 15). Notably, the flipped-out conformational
state of the FG loop was not found to have significant population in either simulation. Figure S4 shows
the spatial distribution of P329 in the FG loop, a key residue for binding to various FcγRs (e.g., [29,51]).
The distribution of P329 is more tightly clustered in wild-type than in huIgG1σ suggesting that the FG
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Figure 14. Molecular dynamics simulation of huIgG1 wild-type and mutants. (A) Root mean squared
fluctuations (RMSF) of Cα atoms of chain B of CH2 domain. The trajectories are aligned on the
Cα atoms with respect to the non-BC and non-FG loop residues of chain B of CH2 domain of the
corresponding crystal structures. The peaks corresponding to the BC and FG loop are marked. The
two loops are more flexible in huIgG1σ (red) as compared to wild-type (blue). The fluctuations in
huIgG1-H268A (green, containing only the BC loop mutation) are closer to wild-type while those in
huIgG1-SS (A330S P331S) (black, contains only the FG loop mutations) are closer to the silent variant.
(B) Root mean squared deviation (RMSD) of the Cα atoms of the FG loop with respect to the flipped-in
conformation. RMSD values are shown for all frames of the 100-ns trajectory. The right panel shows a
normalized histogram of the RMSD values.
Figure 15. Conformational distribution of the FG loop of chain B of CH2 domain from molecular
dynamics simulations of huIgG1 wild-type and mutants. Each panel shows the flipped-in (blue cartoon)
and flipped-out (red cartoon) conformations of the two loops. The flipped-in conformation is from the
huIgG1 WT (PDB 3AVE [40]) while the flipped-out conformation is from huIgG4 WT (PDB 4C54 [50]).
All simulations were started from the flipped-in conformation of the FG loop. The panels show fifty
conformations (gray) sampled at an interval of 2 ns after aligning the molecular dynamics (MD)
trajectory on the Cα atoms of the non-BC and non-FG residues of the CH2 domain of chain B in
the corresponding crystal structure. Figure S4 shows the conformation of P329 in the above loop
conformations. The FG loop of huIgG1σ and huIgG1-SS is significantly more flexible than that of
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In addition to the FG loop, the simulations show that the BC loop is also more flexible in huIgG1σ
than in the wild-type huIgG1 (Figures 14 and 16). In the wild-type simulation, the BC loop stays
close to the initial flipped-in conformation throughout the simulation, but occupied both flipped-in
and flipped-out states in the huIgG1σ simulation (Figure 16). This is clearly illustrated by the spatial
distribution of residue P271 in the BC loop which shows a single cluster for wild-type but two distinct
clusters for huIgG1σ (Figure S5) corresponding to the two conformational states. Interestingly, although
the huIgG1σ simulation was initiated from the flipped-out conformation of the BC loop, the flipped-in
conformation turns out to be more populated. The simulations may not be long enough to converge
the populations of the two states, but strongly suggest that the BC loop of silent huIgG1σ is more
flexible than that of the wild-type.
Figure 16. Conformational distribution of the BC loop of chain B of CH2 domain from molecular
dynamics simulations of huIgG1 wild-type and mutants. Each panel shows the flipped-in (blue cartoon)
and flipped-out (red cartoon) conformations of the two loops. The flipped-in conformation is from the
huIgG1 WT (PDB 3AVE [40]) while the flipped-out conformation is from huIgG4 WT (PDB 4C54 [50]).
The huIgG1σ was started with the BC loop in the flipped-out conformation while the other simulations
started from the flipped-in conformation. The panels show fifty conformations (gray) sampled at
an interval of 2 ns after aligning the MD trajectory on the Cα atoms of the non-BC and non-FG residues
of the CH2 domain of chain B in the corresponding crystal structure. Figure S5 shows the conformation
of P271 in the above loop conformations. In the wild-type and huIgG1-H268A simulations, the BC loop
remained close to the initial flipped-in conformation of the loop. The huIgG1σ showed a broader
distribution around the flipped-in state while huIgG1σ samples both flipped-in and flipped-out states
though the flipped-in state was dominant.
HuIgG1 and huIgG1σ differ at position 268 (histidine in huIgG1, alanine in huIgG1σ) in the
BC loop, and at positions 330 (alanine in huIgG1, serine in huIgG1σ) and 331 (proline in huIgG1,
serine in huIgG1σ) in the FG loop. To investigate the impact of these mutations on the flexibility
of the two loops, two additional simulations were performed after modelling the mutations in the
huIgG1 wild-type crystal structure. One simulation (referred to as huIgG1-H268A) contained only
the BC loop mutation, and the other (referred to as huIgG1-SS) contained only the two FG loop
mutations. The flexibility of both loops in the huIgG1-H268A simulation was nearly identical to that
in the wild-type simulation while the flexibility in huIgG1-SS simulation was closer to that in the
huIgG1σ simulation (Figures 14, 15, S5 and S6). The mutant simulations suggest that the A330S P331S
mutations in the FG loop are primarily responsible for the increased flexibility of the two loops in
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3. Discussion
Many therapeutic antibodies and Fc fusion proteins employ Fc activity as part of their mechanisms
of action. Fc engagement with FcγR can activate myeloid cell and NK cell activity as well as the
generation of reactive species that induce apoptosis and release of inflammatory cytokines which are
important for eliminating unwanted target cells (i.e., tumor cells) [52–55]. However, antibody targeting
to cell surface receptors can pose potential safety risks since Fc activity could elicit ADCC, ADCP, CDC,
and/or apoptosis which can cause tissue damage, depletion of target cells, and infusion reactions.
Although numerous antibody engineering efforts to silence the Fc activity of huIgG1 and huIgG2 have
been reported [3,16,24,25,33,34,56], we describe alternative novel mutations in huIgG1σ, huIgG4σ1,
huIgG4σ2, which can provide design choices for future Fc silent huIgG antibodies or Fc fusions.
Several antibody panels (Ab1, Ab2, Ab3, Ab4, Ab5) with Fc silent mutations were constructed,
purified, and tested in vitro for Fc binding and function. The huIgG1σ, huIgG4σ1, and huIgG4σ2
antibodies tested as immune complexes had minimal binding to FcγRI, FcγRIIa, FcγRIIb, and
FcγRIIIa, compared to huIgG1 WT using concentration ranges that could be found in clinical dosing.
Since the TNFα on target cells and FcγRIII on effector cells are both multivalent, the engagement
of IgG1 molecules to both cells would involve avidity. Thus, ADCC activity and the induction of
immune effector function which depend on avidity and could occur at lower concentrations compared
with monovalent antigen (i.e., in plate assays) [57]. Therefore, the aforementioned cell based assays
provide a more sensitive measure of the degree of silencing effector function and provide a meaningful
biological readout. HuIgG1σ, huIgG4σ1 and huIgG4σ2 were more silent in ADCC activity when
compared to huIgG1 AA, IgG1 FES, and IgG4 PAA. HuIgG4 WT was not included in the comparisons
because such molecules can exchange to half-molecules in a dynamic process (Fab-arm exchange) [35].
Instead, subsequent studies were compared with HuIgG4 PAA, which has a stabilized hinge, reduced
effector function, and has been used in therapeutic antibodies [25].
In vivo studies emphasize again the lack of immune functionality with the huIgG sigma
variants. Results using FcγR-hu mice demonstrated significantly lower levels of T cell dependent
activation (CD69 and CD25 upregulation) with the sigma variants compared to huIgG1 AA, IgG1 FES,
and huIgG4 PAA. In vivo half-life in a transgenic mouse model of human FcRn and in cynomolgus
monkeys indicated that the silent mutations did not alter PK properties compared to normal huIgG.
In addition, potential immunogenicity, evaluated in silico (for protein sequence “hot spots” that
favor immune response initiation) predicts minimal immunogenic risk for these silent Fc variants.
Although ex vivo immune responses measured by T cell proliferation and IL-2 secretion, were not
tested here, the huIgG2σ (reported previously) shows relatively low risk of clinical immunogenicity as
determined by comparing the frequency and magnitude of ex vivo T cell responses [29]. The IgG1 and
IgG4 sigma variants with very similar mutations and low predicted immunogenic risk are likely to
have similar non-immunogenic profiles.
The impact of huIgG1σ, huIgG4σ1 and huIgG4σ2 mutations on biophysical properties was
assessed for their effect on manufacturing. Thermal stress for all the sigma variants compared to their
wild-type versions, suggests lower thermal stabilities in the CH2 and hinge regions. However, there is
little evidence that reduced thermal stability of these magnitudes translates into developability issues
or in vivo stability issues. All Fc variants are stable for 4 weeks when concentrated (to 40–50 mg/ML),
or subjected to low pH stress. Also, there are no additional post-translational modifications or
significant changes in solution particle size associated with these Fc mutations.
In the analysis of Fc:FcγR structures, the packing of P329 in the CH2 domain FG loop between
two tryptophan side chains in the Fc receptor is a conserved feature of huIgG Fc interaction with
FcγRI (e.g., 4W4O [51]), FcγRIIb (e.g., 3WJJ [48]), and FcγRIIIa (e.g., 3SGJ [47]). The receptor bound
conformation of the FG loop is like its conformation in apo-structures of huIgG1 Fc and huIgG2 Fc
suggesting that in these subtypes, the FG loop is preconfigured for receptor engagement (Figure S6).
The structure of huIgG2σ, an engineered silent variant of huIgG2, first revealed a unique flipped
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interaction of this variant. The same structure also revealed a unique, flipped conformation of
the BC loop relative to wild-type structures of huIgG1 Fc and huIgG2 Fc. Herein, we denote the
conformations of the BC and FG loops as observed in a prototypical structure of huIgG1 wild-type Fc
(e.g., PDB 3AVE [40]) as flipped-in and the altered conformations of the same loops observed in the
crystal structure of huIgG2σ (PDB 4L4J [29]) as flipped-out (Figure 13).
It has been proposed that, in the case of huIgG2σ, the H268A mutation in the BC loop abolished
an electrostatic interaction with E294 in the DE loop resulting in the observed flipped conformation of
the BC loop which in turn triggered the flip of the FG loop [29]. Indeed, alignment of the CH2 domains
from crystal structures of huIgG2 Fc and huIgG2σ Fc suggested that residue P271 in a flipped-out
BC loop could clash with K326 in a flipped-in FG loop (Figure 4). A similar flipped-out conformation
of the FG loop has since been observed in crystal structures involving huIgG4 Fc [50] (Figure 4).
Davies et al. have suggested that sequence differences within the FG loop between huIgG1 and
huIgG4 were primarily responsible for the FG loop flip in the latter, and not the absence of H268 [50].
Consistently, one CH2 domain in PDB 4D2N [58], a structure of deglycosylated huIgG4 Fc, reveals
an FG loop that, although partially disordered, appears to have a flipped-out conformation while the
BC loop is maintained in a flipped-in conformation. The present crystal structure of the huIgG1σ Fc
demonstrated the possibility of the coexistence of a flipped-out BC loop and a flipped-in FG loop.
A clash between P271 and K326 was avoided by a rigid body displacement rather than conformational
flip of the FG loop away from the flipped BC loop (Figure 4). Furthermore, MD simulations of a single
CH2 domain of huIgG1 wild-type and mutants were consistent with the hypothesis that positions 330
and 331 are of primary importance to the conformational stability of the FG loop. The simulations
showed that the SS (A330S P331S) mutations dramatically increase the flexibility of the FG loop even
in the absence of the H268A mutation. Also, just the H268A mutation, in the absence of the FG loop
mutations, only marginally increases the flexibility of the two loops relative to wild-type.
The results of our in vitro and in vivo studies demonstrated that huIgG4σ1 and huIgG4σ2 are
more silent than huIgG4 PAA as discussed above. Given that all the mutations for these variants
were localized to the lower hinge region (Figure 2) and that structurally the dispositions of the BC
and FG loops were identical to those observed in structures of wild-type huIgG4 Fc (Figure 4), these
mutations could function either by directly disrupting hinge:receptor interactions or indirectly by
altering lower hinge backbone conformation. Structures of huIgG1 in complex with FcγRI and FcγRIIIa
have shown the importance for L235 in receptor engagement (Figure S6). This residue was mutated to
alanine in both huIgG1σ as well as huIgG4σ1/2, and this mutation likely has a direct effect on receptor
engagement. In contrast, an altered conformation of ordered lower hinge residues N-terminal to
position 240 observed in structures of huIgG1σ, huIgG4σ1, and huIgG4σ2 relative to huIgG1 wild-type
was like that observed in structures of huIgG1 P238D and huIgG1 C220S, E233D, G237D, P238D,
H268D, P271G, A330R in complex with FcγRIIb (Figure 3). All Fc variants demonstrating this kinked
conformation commonly share mutation of a conserved proline at position 238 and have an altered
ability to engage Fc receptor. Thus, although P238 does make contacts with Fc receptor, it is likely that
this residue also plays an important indirect role in maintaining receptor affinity, biasing the structure
of the lower hinge toward a conformation competent for receptor engagement.
In summary, antibodies with huIgG1σ, huIgG4σ1, and huIgG4σ2 Fc regions have demonstrated
minimal FcγR interactions by in vitro and in vivo methods. Immunogenicity, developability, and PK
risks of these variants have been evaluated and determined to be comparable to that the huIgG1 WT
(Table 8) and huIgG4 PAA. Thus, we propose that the huIgG1σ, huIgG4σ1 and huIgG4σ2 variants,
which offer several IgG subtype choices, be considered along with the existing silent Fc structures for
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Table 8. Summary of Silent Fc Designs.
IgG1 WT IgG1 AA IgG1σ IgG1 FES IgG2σ IgG4 PAA IgG4σ1 IgG4σ2
Number of Mutations 0 2 7 3 7 3 5 6
Lack of Fc Immune
Functions 1 + ++/+ ++++ ++/+++ ++++ +++ ++++ ++++
Developability 2 ++++ ++++ ++++ ++++ +++ ++++ ++++ ++++
PK 3 ++++ +++ ++++ ++++ +++ ++++ ++++ ++++
Low Immunogenicity
Risk 4 (in silico) ++++ ++++ ++++ ND +++ ++++ ++++ +++
Low PBMC
Immunogenicity 5 ++++ ++++ ND ND ++++ ++++ ND ND
ND indicates no data. 1 Lack of Fc Immune Functions was determined collectively by FcγR binding, ADCC, ADCP,
CDC, in vivo T cell activation, and in vivo tumor cell inhibition studies. The least silent is denoted by + and ranges to
++++ as the most silent. 2 Developability was determined by thermal stability, stability of concentrated IgG samples
and stability after low pH treatment. Good is +, intermediate is +++, and best is ++++. 3 PK was performed
in human FcRn transgenic mice and in cynomolgus monkeys. Variants with longer half-life are denoted ++++,
and ones with slightly shorter half-life are shown as +++. 4 Low Immunogenicity Risk was predicted using a T cell
epitope analyses software. ++++ indicates low risk and +++ is medium to low risk. 5 Low PBMC immunogenicity
data from a previous report are included because huIgG1σ and huIgG4σ variants have very similar sequences. ++++
indicates low risk.
4. Materials and Methods
4.1. Antibodies
Ab1 is a huIgG1 kappa antibody specific for tumor necrosis factor alpha (TNFα); Ab2 is
a huIgG1 kappa monoclonal antibody specific for F glycoprotein of Respiratory Syncytial Virus
(RSV); Ab3 is a huIgG1 bispecific antibody targeted against RSV and glycoprotein gp120 of the human
immunodeficiency virus (HIV) envelope; Ab4 is an anti-mouse CD3ε-chain Ab, 145-2C11, and Ab5 is
TA99, an anti-gp75 antibody which targets gp75 antigen on B16F10 melanoma cells [45,59]. H435A is
a mutation which reduces binding to FcRn [60]. LoF refers to low fucosylated IgG which has increased
ADCC/ADCP effector function in vitro and in vivo [42]. R10Z8E9 is a mouse anti-huIgG antibody
that is specific for the CH2 domain [61]. All antibodies were produced and purified at Sino Biologics by
transient HEK cell transfection. Antibodies were purified using standard protein A chromatography
and confirmed to be greater than 95% purity and low in endotoxin prior to experiments. The bispecific
antibody was made using the DuoBody® technology (Genmab, Copenhagen, Denmark) [62], and
confirmed to be greater than 95% purity.
4.2. Cell Lines
K2 cells are Sp2/0 mouse myeloma cells which express a mutant, transmembrane form of human
TNFα [41,63]. K2 cells were cultured at 37 ◦C, 5% CO2, in Iscove’s Modified Dulbecco’s Medium
(IMDM) with GlutaMAX and 5% (v/v) heat-inactivated fetal bovine serum (FBS), 1× non-essential
amino acids (NEAA), 1× sodium pyruvate, 0.5 μg/mL mycophenolic acid, 2.5 μg/mL hypoxanthine,
and 50 μg/mL xanthine (MHX). Media components were purchased from Life Technologies (as 100×,
Carlsbad, CA, USA) and the MHX components from Sigma (St. Louis, MO, USA).
B16F10 mouse melanoma cell line was obtained from the American Tissue Culture
Collection. Cells were cultured in RPMI 1640 supplemented with 10% (v/v) FBS, 1× NEAA, and
1× sodium pyruvate.
4.3. Fc Gamma Receptor (FcγR) Binding
Binding of Ab1 variants to human FcγRs was assessed using an AlphaScreen (PerkinElmer,
Boston, MA, USA) bead assay in a competition binding format. FcγRs were purchased from R&D
Systems or Sino Biological Inc. (Beijing, China). Since the outcome for huIgG with a silent Fc in a FcγR
binding assay may be a negative result, assay sensitivity was increased by introducing avidity to
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fragment (Jackson ImmunoResearch, West Grove, PA, USA) in 1:1 molar ratio with the test huIgGs.
Cross-linked test antibodies (Thermo Fisher Scientific, Waltham, USA) were added to Corning white
half-well 96-well assay plates (Corning Inc., Corning, NY, USA) at the designated concentrations
in competition with biotin-labeled huIgG Fc fragment (biot-Fc) at either 1 μg/mL (for FcγRI, -RIIa,
and -RIIb assays) or 5 μg/mL (for FcγRIIIa assays). Biotinylated Fc fragment was used to prevent
binding to the biot-Fc by the test article cross-linker described above. FcγRs as specified were added to
a 200 ng/mL final concentration. Nickel chelate acceptor beads were added; followed by streptavidin
donor beads. Plates were covered with foil adhesive plate sealers to protect from light, and placed on
an orbital plate shaker with gentle shaking for 45 min at room temperature (RT). Subsequently, plates
were read on the EnVision multi-label plate reader (Perkin-Elmer), and data plotted with GraphPad
Prism v6.0 software (GraphPad, San Diego, CA, USA).
4.4. Competitive Binding to Recombinant Human FcRn
A competitive binding assay was used to assess relative affinities of different antibody samples to
recombinant human FcRn (in-house expressed with transmembrane and cytoplasmic domains of FcRn
replaced with a poly-histidine affinity tag). Ninety-six-well copper-coated plates (Thermo Scientific)
were used to capture FcRn-His6 at 4 μg/mL in PBS, after which plates were washed with 0.15 M NaCl,
0.02% (w/v) Tween 20, and then incubated with blocking reagent (0.05 M MES, 0.025% (w/v) bovine
serum albumin, 0.001% (w/v) Tween-20, pH 6.0, 10% (v/v) ChemiBlocker from Sigma-Aldrich,
St. Louis, MO, USA. Plates were washed and serial dilutions of competitor test antibody in blocking
reagent were added to plates in the presence of a fixed 4 μg/mL concentration of an indicator antibody
(a biotinylated huIgG1). Plates were incubated at RT for 1 h, washed 3 times, and then incubated
with a 1:10,000 dilution of HRP (Jackson ImmunoResearch Laboratories) at room temperature (RT)
for 30 min to bind biotinylated antibody. Plates were washed and bound streptavidin-HRP was
detected by adding TMB peroxidase substrate (Fitzgerald, Acton, MA, USA). Color development was
stopped by addition of 0.5 M HCl. Optical densities were determined with a SpectraMax Plus384
plate reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm wavelength, and data plotted with
GraphPad Prism v6.0 software.
4.5. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
Peripheral mononuclear cells (PBMCs) were isolated from heparinized blood from in-house
donors. Eighty (80) mL of blood from 2 donors were typically used per experiment. Blood was diluted
2-fold with PBS and 30 mL was layered over 15 mL of Ficoll-Paque (Perkin-Elmer, Waltham, MA, USA)
in a 50 mL conical centrifuge tube. Tubes were centrifuged at 400× g at RT for 30 min. The upper
plasma supernatant was removed and the interface white cell layer was collected and washed twice
with PBS to remove Ficoll and majority of platelets. Cells were resuspended in IMDM-5% heat
inactivated FBS with 1× sodium pyruvate, 1× NEAA, and 1× penicillin-streptomycin (100× from
Life Technologies, Carlsbad, CA, USA) for culturing overnight at 37 ◦C, 5% CO2.
K2 cells were used as target cells at a ratio of 50 effector cells per 1 target cell. Target cells
were pre-labeled with BATDA (bis (acetoxymethyl) 2,2′:6′,2′′-terpyridine-6,′′-dicarboxylate, DELFIA®
EuTDA, PerkinElmer) for 25 min at 37 ◦C, washed 3 times in culture medium (IMDM with
Glutamax, 10% (v/v) heat-inactivated Fetal Bovine serum (FBS), 1× non-essential amino acids (NEAA),
1× sodium pyruvate, 1×, penicillin-streptomycin; all from Life Technologies and resuspended in
culture medium. Target cells (2 × 105 cells/mL, 50 μL) were added to test antibody (100 μL) in
96-well U-bottom plates, then effector cells (1 × 107 cells/mL, 50 μL) were added. Plates were
centrifuged at 200× g for 3 min, incubated at 37 ◦C for 2 h, and then centrifuged again at 200× g for
3 min. A total of 20 μL of supernatant was removed per well, and cell lysis was measured by the
addition of 200 μL of the DELFIA Europium-based reagent (PerkinElmer). Fluorescence was measured
using an Envision 2101 Reader (PerkinElmer). Data were normalized to maximal cytotoxicity with
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PerkinElmer) and minimal lysis using target cells in the absence of any Ab. Samples were tested
in duplicate. Percent specific lysis was calculated to be (sample lysis − minimal lysis) divided
by (maximal lysis-minimal lysis) × 100. Data were fit to a sigmoidal dose-response model using
GraphPad Prism v6.0 software.
4.6. Antibody-Dependent Cellular Phagocytosis (ADCP)
Monocytes were isolated from human PBMCs using a Monocyte Isolation Kit (Miltenyi,
Auburn, AL, USA) and differentiated into macrophages for 1 week by culturing with 10 ng/mL
recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and 10 ng/mL
recombinant human IL-4 (both from R & D Systems, Minneapolis, MN, USA) in IMDM with
Glutamax, 10% heat-inactivated FBS, 1× NEAA, 1× sodium pyruvate, 1× penicillin-streptomycin.
Macrophages were labeled with PKH26 (fluorescent dye for cell membrane, Sigma) and K2 cells were
labeled with PKH67 (Sigma). Labeled cells in IMDM-10% (v/v) heat-inactivated FBS media without
phenol red were incubated for 5 h with a macrophage to K2 cell ratio of 1 effector to 1 target cell in the
presence of test antibody. Two-color flow cytometry analyses were performed with a MACSQuant Flow
Cytometer (Miltenyi) using optimal compensation in the B1 (PKH67) and B2 (PKH26) channels and
gating on single cells. Dual-labeled cells (PKH26+/PKH67+) were considered to represent phagocytosis
of K2 target cells by macrophages. Percent ADCP or phagocytosis of target cells was calculated to be
100× number of dual-labeled cells (macrophage + target) divided by the total number of target cells
in the population (phagocytosed + non-phagocytosed) after >50,000 cell counts. The percent specific
ADCP was obtained by subtracting from each sample the background value (macrophage + target
incubated without Ab) [5].
4.7. Complement-Dependent Cytotoxicity (CDC)
K2 cells were used as target cells for CDC assays. A total of 50 μL of cells was added to wells of
a 96-well plates for a final concentration of 8 × 104 cells per well in IMDM with Glutamax, 10% (w/v)
heat-inactivated PBS, 1× NEAA, 1× sodium pyruvate, 1x penicillin-streptomycin. An additional 50 μL
was added to the wells with or without test Abs and plates were incubated at 37 ◦C for 2 h. A total
of 50 μL of 10% (w/v) rabbit complement (Invitrogen, Carlsbad, CA, USA) was added to the wells,
and plates were incubated for 20 min at 37 ◦C. All samples were performed in triplicate. The plates
were centrifuged at 200× g for 3 min, 50 μL of supernatant was removed to separate plates, and CDC
was measured with a LDH cytotoxicity detection kit (Roche, Indianapolis, IN, USA). Absorbance was
measured using a Spectra Max Plus 384 (PerkinElmer). Data were fit to a sigmoidal dose-response
model using GraphPad Prism v6.0 software. Maximal cytotoxicity was obtained with Triton X-100
(Sigma-Aldrich) and spontaneous release with cells and complement alone. Specific cell lysis was
calculated as follows: Cytotoxicity (%) = 100 × (optical density (OD) of sample − OD of spontaneous
release)/(OD of maximal lysis − OD of spontaneous release).
4.8. Animals
The FcγR-humanized (FcγR-hu) mice used in the T-cell activations studies express the different
human FcγRs: CD16a (FcγRIIIa), CD16b (FcγRIIIb), CD32a (FcγRIIa), CD32b (FcγRIIb) and CD64
(FcγR1) and their endogenous mouse FcγRs have been inactivated [43]. Three strains of these C57BL/6
mice (8–10 weeks old) were used: FcγRα null females, FcγR-hu hemizygous (hemi) females, and
FcγR-hu homozygous (homo) females.
Human FcRn transgenic animals (8–10 weeks old) used in PK studies were derived from C57BL/6
mice [64]. Tg32 mice (B6.Cg-FcgrttmLDcrTg(FCGRT)32Dcr from The Jackson Laboratory) have their
endogenous mouse FcRn α gene knocked out and are transgenic with the human FcRn α gene under
the control of the native human gene promoter [65,66]. The FcRn transgenic strain show clinical
chemical parameters like those found in wild-type mice except for endogenous huIgG levels, which
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the latter derived by mating homozygous transgenic mice with FcRn α knockout mice (transgene copy
number reduced by half).
Naive cynomolgus monkeys used in the PK study at WuXi AppTec., (Suzhong, China) were
approximately 2 to 3.5 years old and weighed between 2.5 and 3.0 kg.
4.9. T Cell Activation
FcγR-hu mice were used in the in vivo binding and T cell activation studies. The preliminary
study was done with three strains of mice (8–10 weeks old): FcRα null females, FcγR-hu (hemi)
females, and FcγR-hu homozygous (homo) females. Test antibody was injected into the intraperitoneal
cavity of the mice at 0.5 mg/kg, 10 mL/kg. Approximately 24 h later, mice were euthanized by CO2
asphyxiation and their spleens removed and placed into tubes containing cold RPMI-1640, 5% (v/v)
heat-inactivated FBS, 1% (w/v) L-glutamine.
Mouse splenocytes were prepared from 3 to 6 mice as single-cell suspensions from each individual
spleen on the day of harvest. They were washed with media, followed by anucleated red blood
cell depletion using hypotonic RBC lysis solution (eBiosciences). Splenocytes were analyzed by
flow cytometry for cell surface expression of CD25 and CD69 T cell activation markers. Cells were
resuspended in staining buffer consisting of PBS for viability staining (IR Live Dead, Invitrogen),
washed, and then incubated with anti-CD16/32 (2.4G2, BD Biosciences, San Jose, CA, USA) to block
nonspecific binding. Immunostaining was done in the presence of APC-CD25, FITC-CD8a, PE-CD4,
PerCP-CD69, PE-Vio770-CD3ε (BD Biosciences, Biolegend or Miltenyi) at 4 ◦C for 30 min protected
from light, and followed by two washes.
Cells were analyzed on the MACSQuant Analyzer (Miltenyi). Analyses of the multivariate data
were performed using FlowJo v10 software (FlowJo, Ashland, OR, USA). The percent of CD8+ and
CD3+ cells that were also positive for CD25 (or CD69) expression were based on data collected with
greater than 50,000 cells from each sample.
4.10. B16F10 Syngeneic Tumor Model
FcγR-hu mice (8–10 weeks old female) were used for the syngeneic mouse lung tumor model.
B16F10 tumor cells were intravenously injected into tail vein at 2 × 105 cells/mouse, 0.2 mL of
1 × 106 cells/mL in PBS [44,45]. At 30–60 min post IV injection, 0.2 mL of the test antibody sample
was injected into the peritoneum. Antibody doses were given on day 0, 2, 4, 7, 9 and 11. On day
21, the mice were sacrificed and the lungs were weighed and scored for the number of metastases.
The lung tumor index was determined by lung weight and tumor grade [68].
Tumor index = lung weight × grade for animal tumor
Grading:
1. Less than 10 tumor foci
2. 10–100 tumor foci
2.5. More than 100 foci, but countable
3. One lobe of the lung is full of tumor
4. Both lobes are full of tumor
5. Lungs are full of tumor and tumor growing out into cavities
4.11. Pharmacokinetics (PK)
For mouse antibody PK studies, female Tg32 hemi mice were injected with test antibody
intravenously via tail vein at a dose of 2 mg/kg into 3 or 4 animals per group. Serial retro-orbital
bleeds were obtained from CO2-anesthesized mice at indicated time points and terminal bleed was
taken by cardiac puncture. After 30 min at RT, blood samples were centrifuged at 2500 rpm for 15 min
and serum collected for analyses. All PK studies were approved by the Institutional Animal Care and
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An electrochemiluminescent immunoassay was used to measure human antibody concentration
in mouse sera. Briefly, Streptavidin Gold multiarray 96-well plates 96-well plates (Meso Scale Discovery,
Rockville, MD, USA) were coated with 50 μL/well of 1 μg/mL biotinylated F(ab′)2 goat anti-human
IgG (H + L, Jackson Immunochemical) in Starting Block T20 (Thermo Scientific) overnight at 4 ◦C and
washed with Tris-buffered saline with 0.05% (w/v) Tween 20 (TBST from Sigma). Standards and
serum samples were prepared in sample buffer (1% (w/v) bovine serum albumin in TBST and
20 mM EDTA) added to plates and incubated for 2 h at RT on a shaker. Plates were washed and
incubated for 1 h with 1 μg/mL MSD-Sulfo (ruthenium)-labeled with a pan huIgG1 Ab, R10Z8E9.
Plates were washed, 1× Read buffer T was added and plates were read on the MSD Sector Imager 6000
(Meso Scale Discovery).
Terminal half-life (t1/2) calculations of the elimination phase for PK studies were determined
using a 1-phase exponential decay model fitted by linear regression of natural log concentration versus
time using Prism version 6.0 software. The least squares nonlinear decay model was weighted by
1/fitted concentration. Half-life calculations of the elimination phase were determined using the
formula t1/2= −ln2/β, where β is the slope of the line fitted by the least square regression analysis
starting after the first dose.
Monkey PK studies were performed at WuXi Apptec in China. Three animals were IV injected
with test antibody at 1.5 mg/kg, and 1 mL of blood was collected via a cephalic vein at pre-dose,
and at day 1, day 3, day 5, day 8, day 15 and day 22 post-dose. Serum samples were prepared and
PK analyses were performed at Frontage (Shanghai) using a similar MSD format. Protocols were
reviewed and approved by WuXi AppTec Institutional Animal Care and Use Committee (IACUC)
prior to procedures (MGMT-011; TECH-030).
4.12. ImmunoFilterTM Analyses
The amino acid sequences for the different variants were analyzed in silico using ImmunoFilterTM,
an HLA class II-peptide binding prediction tool to predict comparative immunogenicity in
humans (v2.7, Xencor, Inc., Monrovia, CA, USA, examples [69–71]). This prediction tool uses
an immunochemical data set of peptide agretope binding to class II major histocompatibility complex
(MHC) which can assess potential immunogenicity for more than 95% of U.S. population, based on
empirical binding data. Output provided includes raw binding scores for peptides across a sequence of
interest, standardized binding scores, binding probabilities to each allelic combination, and summary
IScores, which are weighted, population-relevant values. For analyses, peptides from the wild-type
and variant sequences with 100% identity to each other were excluded by application of a tolerance
threshold, and only peptides spanning the sequences of interest were included. Resulting IScores
were averaged across all loci, and plotted. Higher IScores indicate a higher predicted immunogenic
risk (PIR).
4.13. Developability
To assess whether antibodies with silent Fc regions would have good manufacturing properties,
biophysical analytical tests were performed for thermal stability and solubility.
4.13.1. Differential Scanning Calorimetry (DSC)
DSC experiments were performed using a MicroCal Auto VP-capillary DSC system (Malvern
Instruments Ltd., Malvern, UK) in which temperature differences between the reference and sample
cell were continuously measured and converted to power units. Samples were heated from 25 ◦C to
110 ◦C at a rate of 1 ◦C/min. A pre-scan time of 10 min and a filtering period of 10 s were used for
each run. DSC measurements were made at sample concentrations of approximately 0.5 mg/mL in
1× PBS buffer in duplicate. Analysis of the resulting data was performed using MicroCal Origin 7
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4.13.2. Concentration Assessment
Antibody samples were concentrated by centrifugation at 2250× g using Amicon Ultra-15
centrifugal filter units with Ultracel-30 membranes (Sigma-Aldrich). Samples were inspected
for signs of precipitation until volumes were reached for a concentration of 40–50 mg/mL.
The sequence-predicted absorbance constants (A280/mg/mL) for each antibody were used to calculate
sample concentrations at absorbance 280 nm.
4.13.3. Dynamic Light Scattering (DLS)
Particle size and size distributions were determined using DLS on a DynaPro Plate Reader
(Wyatt Technologies Corporation, Santa Barbara, CA, USA) at 23 ◦C. For each analysis, 30 μL of each
sample at 1 mg/mL was placed in a 384-well black polystyrene plate with a clear flat bottom (Corning,
CLS3540). Triplicate measurements were performed for each sample with each measurement consisting
of 20 runs.
4.13.4. Static Light Scattering (SLS), Thermal Melting (Tm) and Thermal Aggregation (Tagg) Analyses
Tm was determined for each sample using intrinsic fluorescence with the Uncle instrument
(Unchained Labs, Pleasanton, CA, USA). Tagg was assessed by Static Light Scattering (SLS) to monitor
protein aggregation using the same instrument. For the combined Tm and Tagg method, antibody was
loaded and run with a thermal ramp from 15 to 95 ◦C; at a ramp rate of 0.3 ◦C/min.
4.13.5. Size Exclusion Chromatography (SEC)
Samples were separated over a TOSOH TSKgel BioAssist G3SWxL column (7.8 mm × 30 cm,
5 μm, TOSOH) that had been equilibrated with PBS supplemented with 500 mM NaCl, at a flow rate
of 0.5 mL/min using an Agilent 1100-series HPLC (Agilent Technologies, Santa Clara, CA, USA).
A target of 100–200 μg of total protein was injected per run. Peaks were monitored using absorbance
at 280 nm. Data analysis of species found in each sample was performed using ChemStation software
(Agilent Technologies).
4.13.6. Low pH Treatment
Exposure to low pH was performed for accelerated stability testing. Protein samples were
prepared at a concentration of 1 mg/mL. Samples were dialyzed for 6 h into 0.05 M sodium acetate
buffer, pH 3.5; then dialyzed for 16 h in 0.1 M PBS, pH 7.4, and stored at 4 ◦C prior to analyses.
4.14. Crystallography
Recombinant huIgG1σ Fc and huIgG4σ2 Fc were transiently expressed in HEK 293 cells and purified
by Protein A affinity chromatography at Sino Biological Inc. (China). Recombinant huIgG4σ1 Fc
was transiently expressed in 293 Expi cells and purified in two steps using Protein A affinity
chromatography and size exclusion chromatography (Superdex 200 PG) at Aldevron (Fargo, ND, USA).
Proteins were delivered in 20 mM Tris, 50 mM NaCl, pH 7.5 at concentrations ranging from
2 to 4 mg/mL. Fc molecules were further concentrated to 10–13 mg/mL prior to crystallization.
Crystallization experiments employed the vapor-diffusion method. Crystallization drops were set
up using a Mosquito liquid handling robot (TTP Labtech, Melbourn, UK) in 96-well Corning 3550
(huIgG1σ and huIgG4σ2) or MRC 2 well (huIgG4σ1) crystallization plates. Diffraction quality crystal
were obtained for all three Fc regions in 9–10% (w/v) PEG 20,000, 0.1 M sodium acetate, pH 5.5
(reservoir condition for huIgG4σ2 additionally contained 5% (w/v) MPD). Prior to data collection,
crystals were cryo-protected in reservoir supplemented with 20% (w/v) glycerol and flash frozen in
liquid N2. X-ray diffraction data for huIgG1σ and huIgG4σ1 were collected on the IMCA-CAT beam
line (17-ID) at the Advanced Photon Source (APS) at Argonne National Laboratory equipped with
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Structures, LLC on the SER-CAT beam line (22-ID) at APS equipped with a Rayonix 300HS CCD
detector. All data were processed with the program XDS [72].
Initial phases were determined by the method of molecular replacement with the program
Phaser [73] as implemented in the CCP4 suite of programs [74]. Individual CH2 and CH3 domains
isolated from chain A of PDB 3AVE [40] (huIgG1 Fc) were provided as search models for huIgG1σ;
and for huIgG4σ1 and huIgG4σ1, individual CH2 and CH3 domains were used from a previously
refined internal structure of wild-type huIgG4 Fc. Phaser positioned the equivalent of one Fc dimer
in the asymmetric unit in space group P212121. The structures underwent rounds of rebuilding and
refinement with the programs Crystallographic Object-Oriented Toolkit (COOT) [75] and Phenix [76,77]
respectively. Data collection and refinement statistics are provided in Table 2. The atomic coordinates
and structure factors are archived in the Protein Data Bank under the accession numbers 5W5L, 5W5M,
and 5W5N corresponding to huIgG1σ Fc, huIgG4 σ1 Fc, and huIgG4 σ2 Fc, respectively.
4.15. Molecular Dynamics Simulations
Explicit solvent MD simulations were performed on intact Fc to investigate the flexibility of
BC and FG loops. Two simulations were initiated from the available crystal structures: IgG1 WT
using the crystal structure (PDB 3AVE) of IgG1 wild-type Fc and IgG1σ using the crystal structure
described here. Additional two simulations were initiated after modelling mutations in the wild-type
crystal structure: IgG1-H268A containing H268A mutation and IgG1-SS containing A330S and P331S
mutations. The simulations included both chains of CH2 and CH3 domains, and the glycans present
in the corresponding crystal structures. The simulations were set up in the Maestro graphical user
interface and run using the Desmond program (multisim version 3.8.5.19 and mmshare version 3.5) [78],
both part of the Schrodinger 2016-3 suite [79]. The systems were protonated at neutral pH and centered
in an orthorhombic box such that the minimum distance from any protein atom to the box wall
was 10 Å. The box was solvated using SPC [80] water molecules and counter ions were added to
neutralize the system. OPLS3 force field [81] was used as the potential energy function for the protein.
Replica Exchange Solute Tempering [82] (REST) MD simulations were performed at 300 K and 1 bar
using 16 replicas with the BC (residue numbers 267–273) and FG (residue numbers 322–333) residues
of only chain B specified as “hot”. REST MD simulations were designed to enhance sampling of the
hot subset of the full simulation system. Note that sampling is enhanced only in chain B since chain A
loops are cold. To get an idea of the degree by which sampling is enhanced by REST, we compared the
backbone fluctuations of the two chains in the CH2 domain. Figure S7 shows that it was advantageous
to use the REST approach for all systems except IgG1σ. Default implementation of REST in Desmond
was used for initial equilibration, setting up energy function of each replica, specifying exchange
protocol and recording trajectory data. Simulations were performed on AWS (Amazon Web Services)
cloud computing platform with each simulation employing 8 NVIDIA Tesla K80 GPU cards (Nvidia,
Santa Clara, CA, USA). The production run was 100 nanoseconds long and the final trajectory from
each replica contained 4166 conformations saved at an interval of 24 ps. Number of atoms in the
simulations was approximately 53,000 and a single simulation took approximately 74 hours. A time
step of 2 femtoseconds was used and exchanges were attempted at an interval of 1.2 picoseconds.
In all simulations, the acceptance ratio of exchanges between the adjacent replicas was observed to be
between 0.2 and 0.4. The results presented here correspond to the trajectory from the physical replica
for which the energy function is unperturbed.
5. Conclusions
A requirement for truly silent human Fc designs is evident as more antibodies are being developed
for immunotherapy. The Fc engineered human mutations described here as IgG1σ, IgG4σ1 and
IgG4σ2 demonstrate equal or lower immune functionality than the corresponding IgG2σ design.
Lack of immune effector function is demonstrated in vitro with FcγR binding, cytotoxicity assays,
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of these Fc variants reveal altered conformational preferences within the lower hinge and BC
and FG loops relative to wild-type IgG, providing a structural rationalization for diminished Fc
receptor engagement. Immunogenicity predictions, pharmacokinetic studies in mice and monkeys,
and biophysical analyses also support these novel mutations as optimized silent Fc choices for the
development of therapeutic antibodies.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4468/6/3/12/s1; Table S1:
Cynomolgus monkey PK parameters for Ab2. Figure S1: Electron density map about lower hinge residues,
Figure S2: Altered lower hinge conformation of huIgG1σ is not a requirement of crystal packing, Figure S3: Crystal
packing does not prevent huIgG1σ FG loop from adopting a flipped-out conformation, Figure S4: Conformation
distribution of P329, Figure S5: Conformation distribution of P271, Figure S6: Interaction of lower hinge and FG
loop with FcγR, Figure S7: REST MD enhances loop sampling.
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Abstract: Significant progress in the manufacturing of biopharmaceuticals has been made by
increasing the overall titers in the USP (upstream processing) titers without raising the cost of
the USP. In addition, the development of platform processes led to a higher process robustness.
Despite or even due to those achievements, novel challenges are in sight. The higher upstream titers
created more complex impurity profiles, both in mass and composition, demanding higher separation
capacities and selectivity in downstream processing (DSP). This creates a major shift of costs from USP
to DSP. In order to solve this issue, USP and DSP integration approaches can be developed and used
for overall process optimization. This study focuses on the characterization and classification of host
cell proteins (HCPs) in each unit operation of the DSP (i.e., aqueous two-phase extraction, integrated
countercurrent chromatography). The results create a data-driven feedback to the USP, which will
serve for media and process optimizations in order to reduce, or even eliminate nascent critical
HCPs. This will improve separation efficiency and may lead to a quantitative process understanding.
Different HCP species were classified by stringent criteria with regard to DSP separation parameters
into “The Good, the Bad, and the Ugly” in terms of pI and MW using 2D-PAGE analysis depending
on their positions on the gels. Those spots were identified using LC-MS/MS analysis. HCPs,
which are especially difficult to remove and persistent throughout the DSP (i.e., “Bad” or “Ugly”),
have to be evaluated by their ability to be separated. In this approach, HCPs, considered “Ugly,”
represent proteins with a MW larger than 15 kDa and a pI between 7.30 and 9.30. “Bad” HCPs can
likewise be classified using MW (>15 kDa) and pI (4.75–7.30 and 9.30–10.00). HCPs with a MW
smaller than 15 kDa and a pI lower than 4.75 and higher than 10.00 are classified as “Good” since
their physicochemical properties differ significantly from the product. In order to evaluate this
classification scheme, it is of utmost importance to use orthogonal analytical methods such as IEX,
HIC, and SEC.
Keywords: upstream; downstream; host cell protein; CHO; ATPE; iCCC
1. Introduction
The amounts of biotechnology products produced worldwide, prescription as well as
over-the-counter drugs, are estimated to account for around 50% of the most successful pharmaceutical
products by the year 2020 [1]. Oncology constitutes the biggest therapeutic sector, with an annual
growth rate of around 12.5% and sales of approximately $83.2 billion in 2015. Among the five top-selling
oncological products, three will be monoclonal antibodies by the year 2020 [2]. The manufacturing
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process of biopharmaceuticals such as monoclonal antibodies (e.g., IgG, immunoglobulin G) is divided
into upstream (USP) and downstream processing (DSP) [3–8]. The production of the monoclonal
antibody in bioreactors (BR) using mammalian cells as an expression host and the separation of the
liquid phase from the cells using centrifuges or filters is defined as USP [9]. The subsequent DSP
is designed to separate side components like host cell proteins (HCP) or host cell DNA (hDNA)
from the main component [6,7,10]. The most common unit operations used in the DSP are typically
chromatography and filtration.
The commercial success of monoclonal antibodies of course led to significantly increased demand
in their production scale [11]. Coping with these demands without significantly changing the approved
manufacturing facilities almost forced companies to follow the route of increasing titers within the
existing facilities.
Hence, compared to earlier yields of a couple of grams per liter, today antibody concentrations
of up to 25 g/L can be achieved using a modified perfusion process [12,13]. Routinely, antibody
concentrations of between three and five grams per liter can be generated in fed-batch
processes [3,14,15]. However, increasing product titers at constant volumes due to higher cell
concentrations will lead to capacity limitations in the DSP, which has to be compensated for by
longer process times, higher material consumption, and corresponding costs [4]. This will significantly
shift the cost of goods from the USP to the DSP [5]. Therefore, DSP technologies are required that
circumvent this upcoming “downstream bottleneck,” handling high titer volumes [4,16,17].
Optimizations in the USP concepts have led to increasing product titers. Along with this, raised
impurity profiles have been observed [8,9]. Various compositions of the cultivation broth present
challenges in the DSP of biotechnologically produced proteins. Considering the generic platform
production process for antibodies, unit operations like centrifugation, micro- and ultrafiltration,
protein A affinity chromatography, two orthogonal virus inactivation steps, ion-exchange (IEX),
and hydrophobic interaction chromatography (HIC) are being used [5]. For the characterization of
protein purification stages, key performance parameters can be used. These are typically resolution,
speed, recovery, and capacity, as seen in Figure 1.
Figure 1. Key performance parameters of the capture, intermediate purification, and polishing step for
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The objectives vary depending on the purification stage in focus, and therefore generate different
challenges that have to be addressed during process optimization [18]. For example, the protein A
affinity chromatography, used as a capture step, will reach its capacity limitation due to increasing
product titers. This can be problematic since this criterion characterizes the capture step and is one
of its two objectives. Moving downstream, selectivity challenges occurring during the intermediate
purification and polishing step will prevent each step from reaching one of its objectives. Selectivity
challenges are going to affect the resolution in IEX and HIC separation operations when HCP resemble
the product in terms of pI and hydrophobicity, respectively [12,18].
Impurities like HCPs, which resemble the desired product only in one characteristic (e.g., pI),
may challenge the IEX but can probably be easily separated from the product by an additional
chromatographic step (e.g., HIC). Impurities similar to the product in more than one characteristic
(e.g., pI and hydrophobicity) will be troublesome during purification and polishing. Therefore, the
pI and hydrophobic distribution of the impurity spectrum can negatively affect IEX and HIC
separations, respectively.
Critical performance parameters regarding the separation efficiency during the capture of
monoclonal antibodies using affinity chromatography are capacity limitations as well as (un-)specific
HCP co-elution [19]. Consequently, new approaches and technology are needed in order to circumvent
future bottlenecks and separation challenges [4].
Furthermore, the existing challenges in process engineering have worsened since regulatory
agencies demand higher product quality, an advanced understanding of the process and product,
as well as batch-independent product quality [20–22]. Bioprocess engineering will probably focus in
regulated industries on quality by design and process analytical technology mechanisms, in order to
design, analyze, and control manufacturing processes [23]. This shall lead to improved process control
by knowledge-based and statistical methods, which ultimately guarantees the process’ robustness.
For example, monoclonal antibodies and fragments represent an interesting group of
biopharmaceuticals due to their broad field of application (e.g., analysis or diagnostic).
Those glycoproteins are structurally complex and differ in various formats, as can be seen in Figure 2.
IgG is the most common format as a biopharmaceutical drug [2].
Figure 2. Various formats of recombinant antibodies [24].
The post-translational modifications, especially glycosylations, of these proteins are of utmost








Antibodies 2017, 6, 13
the functionality, immunogenicity, and pharmacokinetics of the antibody [24,25]. Due to this,
posttranslational modifications should be considered critical quality attributes (CQA) and verified
throughout the manufacturing of monoclonal antibodies [26–30]. Antibody N-glycans can be
quantitatively determined by normal phase chromatography after N-glycosidase digestion and glycan
labeling, for example [31]. The most prevalent N-linked glycosylation patterns at the Cγ2 domain of
the heavy chain (Fc) of an immunoglobulin G (IgG) are depicted in Figure 3, where the most common
glycosylation of IgG is shown in section D.
Figure 3. Common glycosylation patterns of an IgG. (A) high mannose content; (B) hybrid; (C) complex
biantennary oligosaccharide with core fucosylation; (D) most prevalent oligosaccharide structures of
IgG [20].
Besides critical process parameters (CPP) like pH, pO2 and pCO2, more often impurities play
an important role in affecting CQA of the biopharmaceutical product. For example, extracellular
proteases and glycosidases accumulating during the cultivation negatively influence the CQA of
monoclonal antibodies [14,32–35]. The impurity spectrum consists of a multiplicity of different
substances (HCP, hDNA, virus, cells, and cell debris). In this integration approach, HCPs are considered
as the primary impurity based on their broad composition and range of isoelectric point (pI), molecular
weight (MW), and hydrophobicity, as can be seen in Table 1 [36–40]. They exhibit no constant
level, composition, or property distribution. HCPs caused by secretion or cell lysis can range in pI
(2–11), MW (10–200 kDa), and variable hydrophobicity, and are therefore difficult to separate if their
physicochemical properties resemble the product of interest.
Table 1. Physicochemical properties of the main impurities during the production of
biopharmaceuticals, according to [38].
Class pI MW (kDa) Hydrophobicity Origin Cause
HCP 2–11 10–200 Variable Host cells Secretion, lysis
hDNA 2–3 90–1000 Low Host cells Lysis
Insulin 5.3–5.5 5.8 Low Media Supplement
Virus 4–7.5 200–7200 Variable Host cells, media Contamination
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Primary recovery and purification steps for a biopharmaceutical DSP are based on
physicochemical properties in order to efficiently purify the product. However, especially in the
case of increasing product titers, a sub-population of impurities (i.e., HCP), which negatively affect the
product quality, may remain with the desired protein and represent a certain risk [40]. Therefore, it is
of critical importance to validate qualitatively and quantitatively the separation efficiency of each unit
operation in the DSP.
This assessment will lead to an expanded understanding of each unit operation by classifying the
impurities into “The Good, the Bad, and the Ugly”:
• Impurities, which can be separated easily from the main component, are considered “the Good.”
They possess physicochemical properties significantly different from the protein of interest (i.e., pI,
MW, hydrophobicity). As a result, they may be separated by only one unit operation in an efficient
way (ion exchange in terms of charge differences).
• Side components showing more similarity to the product are more difficult to separate or are
persistent throughout (i.e., not separable from the product) and thus are considered as “the Bad”
or “the Ugly.”
By characterizing the HCP criteria for an efficient DSP, it is possible to gain a deeper understanding
of the process and preserve the quality of the product. This categorization can be used for an USP
DSP integration approach towards an efficient production process by circumventing the generation or
accumulation of “Bad” and “Ugly” impurities (Figure 4).
Figure 4. USP DSP integration approach for a systematic development of a bioprocess.
The considered process for the production of monoclonal antibodies utilizes mammalian cell
cultivations. Afterwards, the aqueous two-phase extraction (ATPE) is used as a cell harvesting or
capture step, depending on the system composition used [41–45]. Following the ATPE, the integrated
counter current chromatography (iCCC), which is a combination of an IEX and HIC, is employed as
a purification and polishing step. This combination of chromatographic columns leads to a highly
purified product [46].
The integration approach begins with a data-driven characterization of HCP occurring in the broth
and in each unit operation. The separation efficiency is determined by analytical methods (i.e., 2D
SDS-PAGE, SEC, IEX, HIC, and HPLC-MS/MS). The SEC chromatograms qualitatively describe the
impurity spectrum and can be used for a determination of impurities in the molecular weight range
of the considered product (150 kDa). The IEX and HIC are used for characterizing the charge and
hydrophobicity of the HCPs. 2D SDS-PAGE analysis, combined with HPLC-MS/MS measurements,
is used for the identification and, of utmost importance, classification of “The Good, the Bad, and
the Ugly” HCPs. This classification is done by evaluating the molecular weight, isoelectric point,
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Afterwards, these findings are used in rational process design in order to minimize or even
eliminate “Ugly” HCPs, which cannot be easily separated from the product (Figure 4).
Table 2. Analytical methods used for the characterization of HCP.
Characteristic Method Orthogonal Method
Isoelectric point 2D-SDS PAGE IEX; HPLC-MS/MS
Molecular weight SEC 2D-SDS PAGE; HPLC-MS/MS
Hydrophobicity HIC -
One possible process design optimization procedure is the improvement of media components.
Media optimization is capable of changing the broth’s HCP composition towards a population that is
easier to separate or at least exhibits a lower HCP concentration. In addition, an optimized medium
not only shifts the HCP profile but also improves the cell growth and product titer, which is depicted
in Table 3 [47].
Table 3. Improved parameters by using an optimized medium according to [47].
Parameter Optimized medium
Titer increase Factor 2.5
Cell growth Factor 2–2.3
IgG/HCP 65%
HCP profile Shift
The shifted HCP profile can be seen in the 2D-SDS PAGE comparison in Figure 5.
Figure 5. Comparison of 2D-SDS PAGE of a reference (right) and optimized medium (left) during a
CHO cultivation according to [47]. Media was improved by a three-level DoE design.
In this work, the results of the characterization of the HCP profile from a mAb production process
are presented. Process-related data as well as analysis-related data are used for the characterization
of the process and for the classification of HCPs. The results of each analytical method are critically
evaluated in order to determine a process flow being suitable for USP DSP integration and process
optimization. Analytical methods such as SEC, 2D-PAGE, IEX, HIC as well as HPLC-MS/MS were
used in order to identify critical HCP in the cell-free broth and during each unit operation (i.e., ATPE,
IEX, and HIC).
2. Results and Discussion
A schematic overview of the considered alternative process as well as process- and analysis-related
data are shown in Figure 6.
The HCP criteria for an efficient DSP have to be evaluated for each unit operation, according to
Figure 4. Here, the classification of HCP focuses on the broth, the broth after diafiltration and on a side
component fraction after HIC separation. Process-related data such as titer, yield, and purity of each

















































































































Antibodies 2017, 6, 13
This analytical procedure focuses on the classification and characterization of HCPs. Therefore,
each unit operation of the DSP has to be evaluated by its separation efficiency, using analytical
methods such as 2D-SDS PAGE, IEX, HIC, and SEC to determine HCP criteria for an efficient DSP,
as seen in Figure 3. Protein A and size-exclusion chromatography are used to determine yield and
purity, respectively. Each unit operation was loaded with the native broth in order to determine their
separation efficiency.
Table 4. Process related data of the cultivation, ATPE, and iCCC. Yield and purity were determined
using protein A chromatography and SEC, respectively.
Cultivation ATPE iCCC
System Mammalian cells PEG400/40 wt% PO4 IEX/HIC combination
Titer/yield 6.5 g/L >95% >95%
Log cell reduction 20.0 E6 cells/mL - 2.08 -
Purity <20% up to 80% * 100%
* Protein-based according to SEC.
The fraction number five occurring on the HIC was chosen due to the high side component
content near the target product, as seen in Figure 7. In the following, the classification of the HCPs will
be performed by 2D-PAGE gels, as depicted in Figure 8.
Figure 7. Chromatograms of an analytical IEX (left) and HIC (right) measurement of the diafiltrated
cell-free CHO supernatant. The vertical sections represent the number of fractions taken, representing
“Good”, “Bad,” and “Ugly” impurities.
The classification criterion of the considered HCP was selected by comparing their pI and
molecular weight to the target product, as seen in Table 5.
Table 5. Classification of the “Good, Bad, and Ugly” HCP in comparison to the physicochemical
properties of the monoclonal antibody (mAb). MW, molecular weight; pI, isoelectric point.
Characteristic mAb Good Bad Ugly
MW [kDa] 144.2 <15 >15 >15
pI [−] 8.30 <4.75>10.00
4.75–7.30
9.30–10.00 7.30–9.30
While considering the 2D-PAGE gels, proteins with a MW lower than 15 kDa can be considered
“Good” since they can be separated by using diafiltration subsequent to an ATPE with a suitable MW
cutoff. Therefore, this filtration step is coupled to a buffer change, which is necessary for the use of
the iCCC, since the specific light phase contains PEG400, resulting in a more viscous solution, which
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Figure 8. 2D SDS-PAGE of the broth, diafiltrated broth (DF) and HIC fraction. Green circles represent
“Good”, yellow circles “Bad,” and red circles “Ugly” HCP.
Proteins larger than 15 kDa have to be separated by another unit operation, which is based on
other physicochemical properties (i.e., pI, hydrophobicity). Therefore, “Bad” and “Ugly” proteins
possess a MW larger than 15 kDa. The horizontal line at 150 kDa represents the target protein in its
functional condition. The vertical lines depict the isoelectric point at 4.75 and 7.0. Impurities with a pI
of 4.75 can be subjected to a possible precipitation step using hydrochloric acid, which significantly
reduces their concentration [42]. Those impurities exhibit a different pI than the target protein and can
efficiently be separated by an IEX and are therefore classified as “Good.” Experimental IEX data show
a distinctly different interaction with the stationary phase due to their surface charge distribution,
as seen in Figure 9, which resemble the “Good” HCP. They elute near the void volume and can be easily
separated. A similar train of thought can be conducted while characterizing the HIC chromatogram.
As can be seen in Figure 9, the target product gets concentrated by each cycle in the iCCC mode.
Figure 9. Chromatograms of the IEX (left) and HIC (right) after various cycles in the iCCC mode.
Impurities with a pI range close to the target protein (i.e., 7.30–9.30) are more difficult to separate
via an IEX and are therefore considered “Ugly.” However, since the separation efficiency of the IEX
will depend on the column, buffer solution, and process parameters, this range can vary depending on
the system used. Impurities with characteristics in between those of “Good” and “Ugly” are defined
as “Bad.” They possess a pI of 4.75–7.30 and 9.30–10.00 and can be difficult to separate when other
physicochemical properties (i.e., hydrophobicity) resemble the target product. This dependency can
of course also occur with “Ugly” HCP but since they are already classified as difficult to separate,
they will not be characterized differently. Regarding the “Good” HCP, this dependency will not
occur even if other physicochemical properties show close similarity to the product, since at least
one physicochemical attribute is significantly different from the target product. The pI is restricted to
10 due to the pH gradient used in the IEF prior to 2D gel electrophoresis.
The 2D-PAGE analysis seen in Figure 8 is suitable for the visualization of the side component
spectrum. However, the sample preparation requires reducing agents such as DTT, which destroys the
protein’s structure by reducing the disulfide bonds. This preparation procedure results in spots on the
gel, which do not resemble their native structure in the supernatant. Following the aforementioned
classification and separation system, proteins with a MW lower than 15 kDa but with an isoelectric
point near the target product will sometimes be classified as “Good” since they can be separated by
filtration. Hence, the native protein can be “Ugly” even if it appears as “Good” in the gel (assuming no
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to validate the classification. In terms of MW, SEC analysis can be conducted in order to determine
the size distribution of side components, as seen in Figure 10. The advantage of using SEC analysis is
the determination of the side component’s native MW distribution as well as their qualitative mass in
proportion to the product’s signal. The disadvantage is the less sensitive detection of low mass content
side components as well as proteins resulting in a signal overlap with the mAb.
In order to identify proteins present in the 2D-PAGE gel spots, their tryptic peptides were
identified via analysis with liquid chromatography (LC) coupled to tandem mass spectrometry
(MS/MS) and a database search. The numbers in the gels in Figure 8 indicate the spots that were
analyzed using LC-MS/MS. The first five spots occurred in every gel. The subsequent spots were
unique in each gel. The identified peptides and their corresponding proteins of each spot in these gels
are presented in the appendix (Tables A1–A3). The identified proteins of the first recurrent spots are
listed alongside with their MW and pI in Table 6.
As can be seen in Table 6, the MW and pI of the spots analyzed with 2D-PAGE do not correspond
to the value in the protein database. This is a result of proteins existing in different species due to
posttranslational modifications and proteolytic processing (proteolytic degradation and sample
preparation, respectively). In contrast, the theoretically calculated pI values obtained by the ExPASy
computation tool (http://web.expasy.org/compute_pi/) represent the unmodified full length amino
acid sequence of a defined protein. SEC analysis, for example, is a non-invasive analytical method for
the determination of MW distribution of side components, if the salt concentration used in aqueous
eluents allows for separation based on molecular size exclusion alone due to the hydrodynamic
radius [48]. Nevertheless, for a systematic integration approach, the classification of HCPs based on
their physicochemical properties can lead to an enhanced process understanding, especially in the DSP.
Figure 10. SEC chromatograms after various cycles as well as the broth after diafiltration.
Table 6. Classification of CHO proteins identified via LC-MS/MS analysis and characterized by
2D-PAGE gel. Comparison of theoretical (UniProt; pI calculated according to the amino acid sequences)















1 25 7.0 Bad 81.56 5.69 Bad Glutathione S-transferaseMu7-like protein A0A061IN16
2 25 7.5 Ugly 102.7 6.02 Bad Actin, cytoplasmic 1 A0A069C7Y3
3 30 7.6 Ugly 38.03 6.08 Bad Purine nucleosidephosphorylase-like protein A0A061ILE8
4 50 9.4 Bad 72.13 7.23 Ugly Pyruvate kinase A0A098KXF7
5 25 6.3 Bad 38.03 6.08 Bad Purine nucleosidephosphorylase-like protein A0A061ILE8
1 Theoretical values according to the unmodified full length protein according to UniProt; 2 Theoretical values
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3. Materials and Methods
Chinese hamster ovary cells (CHO DG44) were used for the production of a monoclonal antibody.
The culture conditions were 37 ◦C, 5% carbon dioxide, and 130 rpm. The cultivations were carried out
in shake flasks in a serum-free medium.
The ATP system applied consisted of 44.5% broth, 15.5% PEG400 (Merck KGaA, Darmstadt,
Germany), and 40% of a 40 wt% phosphate buffer. All the components were weighed. The extraction
was carried out at pH 6.0 in 50-mL beakers at room temperature. The system was mixed for 15 min at
140 rpm in an incubator shaker. Phase separation took place within 30 min in a separatory funnel.
The broth was diafiltrated using a SARTOFLOW® Slice 200 Benchtop system from Sartorius
Stedim (Germany). A 10 kDa Hydrosart® (Sartorius Stedim, Göttingen, Germany) was utilized as a
membrane module.
The iCCC (integrated counter-current chromatography) is run by using Fractogel® EMD SO3−(s)
and Fractogel® EMD Phenyl(s) (Merck KGaA, Darmstadt, Germany). The buffers consisted of a 20 mM
sodium phosphate buffer (Na2HPO4, NaH2PO4) as well as a 20 mM sodium phosphate buffer with
1 M Na2SO4.
The product was quantified by Protein A chromatography (PA ID Sensor Cartridge, Applied
Biosystems, Bedford, MA, USA). Dulbecco’s PBS buffer (Sigma-Aldrich, St. Louis, MO, USA) was
used as a loading buffer at pH 7.4 and as an elution buffer at pH 2.6. The absorbance was monitored at
280 nm.
The size exclusion chromatography was done by using a Yarra™ 3 μm SEC-3000
column (Phenomenex Ltd., Aschaffenburg, Germany) with 0.1 M Na2SO4, 0.1 M Na2HPO4,
and 0.1 M NaH2PO4 (Merck KGaA, Germany) as a buffer system.
Isoelectric focusing was carried out using IPG strips (ReadyStripTM IPG Strips, linear, pH 3–10,
BIO-RAD, Hercules, CA, USA) and an isoelectric focusing unit of Hoefer (Hoefer Inc., Holliston, MA,
USA). A subsequent SDS PAGE was carried out using gels (Criterion TGX Precast Gel, 4–15% Bis-Tris,
BIO-RAD), buffers, and an electrophoresis chamber from BIO-RAD. The resulting gels were colored by
Coomassie Brilliant Blue G-250 (VWR International, Radnor, PA, USA).
For the identification of proteins, selected 2D GE spots were cut out and reduced into 1-mm2
pieces. After reduction of the disulfide bonds with 10 mM DL-dithiothreitol (Sigma-Aldrich) and
alkylation with 50 mM iodoacetamide (Sigma-Aldrich), an in-gel proteolytic digestion was performed
with 8 ng/μL trypsin (Promega, Madison, WI, USA) at 37 ◦C overnight. The peptides were extracted
from the gel with 65% acetonitrile and 5% acetic acid in water and the solvent was evaporated to
complete dryness. The peptides were re-suspended in 20 μL 0.1% formic acid (Fluka) and subjected
to LC-MS/MS analysis with a nano-flow ultra-performance liquid chromatography (nano-UPLC)
system (nanoACQUITY, Waters, Manchester, UK) coupled via an electrospray-ionization (ESI) source
to a tandem mass spectrometer (MS/MS) consisting of a quadrupole and a orbitrap mass analyzer
(Orbitrap QExcactive, Thermo Scientific, Bremen, Germany). Four microliters of each sample were
loaded onto a reversed-phase (RP) trapping column (Symetry C18 Trap Column; 100 Å, 5 μm,
180 μm × 20 mm) and washed with 1% buffer B for 5 min. The peptides were eluted onto a RP
capillary column (nanoAcquity Peptide BEH analytical column; 130 Å, 1.7 μm, 75 μm × 200 mm) and
separated by a gradient from 3 to 35% buffer B in 35 min (250 nL/min). Eluting peptides were ionized
and desorbed by ESI in the positive mode using a fused-silica emitter (I.D. 10 μm, New Objective,
Woburn, MA, USA) at a capillary voltage of 1800 V. Data-dependent acquisition mode was used
with the following parameters: MS level over a m/z range from 400 to 1500, with a resolution of
70,000 FWHM at m/z 200. Maximum injection time was set to 120 ms for an AGC target of 1E6. For
MS/MS analysis the top 12 signals were isolated in a 2 m/z window and fragmented with a normalized
HCD collision energy of 25. Fragment spectra were recorded with a resolution of 17,500 FWHM at
m/z 200. Maximum injection time was set to 60 ms for an AGC target 5E5.
LC–MS raw data were processed with MaxQuant (Max Planck Institute of Biochemistry, Planegg,
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a hamster (Cricetulus griseus) (www.uniprot.org, downloaded on 31 January 2017) and a contaminant
database. The searches were performed using a precursor mass tolerance set to 10 ppm and fragment
mass tolerance set to 20 ppm. For peptide identification, two missed cleavages were allowed,
a carbamidomethylation on the cysteine as a fixed modification and oxidation of the methionine
as a variable modification. A maximum of five modifications per peptide were allowed.
4. Conclusions
The presented approach of integrating USP and DSP is based on the classification and
characterization of impurities generated during USP. This will lead to a deeper quantitative process
understanding and identification of issues in the DSP early on. Here, the HCPs were categorized
into “The Good, the Bad, and the Ugly” by evaluating their physicochemical properties compared
to the monoclonal antibody. In this approach “Good” impurities possess a MW lower than 15 kDa
and a pI lower than 4.75. “Ugly” impurities on the other hand exhibit a pI of 7.3–9.3, whereas “Bad”
impurities feature a pI between 4.75 and 7.3 as well as between 9.3 and 10.0. In order to evaluate the
classification system for the generated HCPs, orthogonal analytical methods are of utmost importance.
IEX and SEC analysis were conducted for the identification of impurities. Theoretical pI and MW
calculated based on the amino acid sequence differ from the experimental values obtained in 2D gel
electrophoresis. This is due to not considering posttranslational modifications, as well as in vivo and
ex vivo proteolytic processing.
Nevertheless, it is possible to characterize HCP based on pI and MW properties. In order to fully
categorize the separation efficiency of each unit operation in the DSP as well as of their combinations,
the HCP profile has to be determined with the aforementioned analytical methods in future approaches.
This portfolio can of course be extended by adding supplementary methods like NMR technologies,
preferably online [49].
Considering the significant amount of work in terms of characterization, monitoring, and removal
of impurities and contaminations created by the USP step, as well as the time and cost associated
with their removal, it may be worthwhile to reflect in more detail how these impurities and product
variations are generated in the first place. Work to this end already started some time ago. Initial results
and corresponding concepts for a more balanced integrated process design will be presented in the
near future.
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Abstract: Dengue nonstructural protein 1 (NS1) is a multi-functional glycoprotein with essential
functions both in viral replication and modulation of host innate immune responses. NS1 has been
established as a good surrogate marker for infection. In the present study, we generated four anti-NS1
monoclonal antibodies against recombinant NS1 protein from dengue virus serotype 2 (DENV2),
which were used to map three NS1 epitopes. The sequence 193AVHADMGYWIESALNDT209 was
recognized by monoclonal antibodies 2H5 and 4H1BC, which also cross-reacted with Zika virus
(ZIKV) protein. On the other hand, the sequence 25VHTWTEQYKFQPES38 was recognized by mAb
4F6 that did not cross react with ZIKV. Lastly, a previously unidentified DENV2 NS1-specific epitope,
represented by the sequence 127ELHNQTFLIDGPETAEC143, is described in the present study after
reaction with mAb 4H2, which also did not cross react with ZIKV. The selection and characterization
of the epitope, specificity of anti-NS1 mAbs, may contribute to the development of diagnostic tools
able to differentiate DENV and ZIKV infections.
Keywords: dengue virus; NS1; Zika virus; mAbs; antibody recognition; amino acid sequences
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1. Introduction
Dengue fever is an important mosquito-borne and the most prevalent and costly arbovirus
affecting humans, caused by one of the four serotypes of dengue virus (DENV 1–4) [1]. In the last
decade, a large number of dengue epidemics have occurred, which resulted in enormous economic
and human loss in parts of Asia and South America [2,3]. Considering Brazil only, more than three
million cases of confirmed dengue infections occurred between 2015 and 2017, with 70 cases per
100,000 inhabitants [4].
The DENV genome is composed of a single positive-sense RNA that encodes a single viral
polyprotein that is further processed by viral and host proteases into three structural proteins
(C, prM/M, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).
NS1 is the first nonstructural protein to be translated and is essential to virus replication [5]. It is
a conserved N-linked glycoprotein with a variable molecular mass of 46–55 kDa, which depends
on its glycosylation status [6]. The NS1 protein can be found as a dimer associated with vesicular
compartments within the cell, where it plays an important role as an essential cofactor in the virus
replication process [7]. Alternatively, NS1 can be secreted into the extracellular space as a hexameric
lipoprotein particle [8] that interacts with several plasma proteins [9,10].
The recent introduction of the Zika virus (ZIKV) to the American continent represented a regional
and worldwide public health challenge [11]. The close evolutionary relationship between DENV and
ZIKV is reflected by the high sequence conservation of both structural and non-structural proteins [12].
In this aspect, the identification of monoclonal antibodies (mAbs) able to react specifically with DENV
or cross-react with ZIKV proteins is a relevant feature for the validation of the diagnostic tools based
on the NS1 protein.
In pioneering work by Falconar et al. [8], the immunogenic regions of DENV2 NS1 employing
mAbs were extensively studied. Recently, certain studies have been using new methods to predict the
binding epitopes of proteins to specific antibodies [13,14]. This approach was also applied to identify
binding epitopes of DENV NS1 protein serotypes [15–17]. Also, the crystal structure of the DENV2
NS1 protein (PDB code: 4O6B) has been solved in both dimeric and hexameric configurations [6],
which provides a useful guide for the selection of potential epitopes for therapy and vaccine strategies.
In the present study, recombinant DENV2 NS1 was used to immunize mice and generate murine
mAbs. Four mAbs were isolated, purified, characterized and tested for reactivity with native NS1
produced by all DENV serotypes in Vero-infected cells and also for cross-reactivity with ZIKV NS1.
2. Results
2.1. Isolation and Characterization of NS1-Specific DENV mAbs
Fusion of popliteal lymph node cells, from mice immunized with DENV2 rNS1, with a
non-Ig-secreting or synthesizing line derived from a cell line created by fusing a BALB/c mouse spleen
cell and the mouse myeloma P3X63Ag8 (SP2/O-Ag14) mouse myeloma cells, generated 25 secretory
hybridomas. Among them, four hybridomas were selected by enzyme-linked immunosorbent assay
(ELISA) and sub cloned by limiting dilution and named as 4F6, 4H2, 4H1BC, and 2H5. The clones
were expanded, supernatants collected and mAbs purified for further characterization. Accordingly,
mAbs 4F6 and 4H2 were characterized as IgG2a (immunoglobulin G), and 2H5 and 4H1BC as IgG1.
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The recognition pattern of the four NS1 mAbs was evaluated by ELISA using either intact or
heat-denaturated rNS1. All NS1 mAbs recognized the intact rNS1 protein, and although mAb 4F6
reacted similarly with the intact and the heated-treated rNS1 (Figure 1A), the other three mAbs
(4H2, 2H5 and 4H1BC) reacted more efficiently with the intact protein (Figure 1B–D, respectively),
which indicated that the recognized epitopes were, at least, partially represented by conformational
structures. All four MAbs also recognized rNS1 in an immunoblot assay (Figure S1).
Figure 1. Characterization of nonstructural protein 1-specific (NS1) monoclonal antibodies (mAbs)
reactivity by enzyme-linked immunosorbent assay (ELISA). Reactivity of mAbs to heated-treated or
intact rNS1, as solid phase-bound antigens. The mAbs 4F6 (A), 4H2 (B), 2H5 (C) and 4H1BC (D) were
serially diluted (log2) from an initial concentration of 2.5 μg/mL. Each well was adsorbed with 400 ng
of rNS1. Heat denaturation was performed at 100 ◦C for 10 min. Statistical analyses were performed
by two-way variance analysis followed by Bonferroni’s post-test. (*** p < 0.01; ** p < 0.1; * p < 0.5).
2.2. Detection of Native DENV2 NS1 and Epitope Mapping
After selection, mAbs were tested by immunofluorescence assays using fixed DENV2-infected
Vero cells. All four mAbs recognized the native viral NS1 expressed in infected cells, as shown in
Figure 2. To localize the specific mAbs binding sites/epitopes, peptide mapping array experiments
were performed (Figure S2). The results showed that mAb 4F6 reacted with the peptide corresponding
to the sequence 25VHTWTEQYKFQPES38 of NS1 (Table 1), which is located in an external loop of the
protein 3D structure (Figure 3). The 4H2 mAb recognized the peptide corresponding to the sequence
127ELHNQTFLIDGPETAEC143 of NS1 (Table 1), which is located in beta-sheets in an external region of
the protein 3D structure (Figure 4). The other two mAbs (2H5 and 4H1BC) showed the same binding
specificity and recognized the peptide 193AVHADMGYWIESALNDT209 (Table 1). This sequence was
also located in a beta-sheet structure, located in an internal region of the protein (Figure 5). The
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Figure 2. Reactivity of NS1-specific mAbs to dengue-serotype 2-infected Vero cells. Cells were
infected with a multiplicity of infection (MOI) of 0.5, fixed, permeabilized and treated with each of
the tested mAbs 48 h post infection. Then, cells were labeled with Alexa fluor® conjugated goat-anti
mouse IgG. The negative controls: Mock-infected cells treated with a pool of mAbs anti-NS1 (A) and
DENV2-infected cells labeled only with secondary antibody (B); Tested mAbs: (C) 4F6; (D) 4H2; (E) 2H5
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Figure 3. Three-dimensional structural model of a NS1 dimer and regions corresponding to epitopes
recognized by 4F6 mAb. The NS1 3D model was generated by the program Python Molecular (PyMOL)
in green. The sequence 25VHTWTEQYKFQPES38 is highlighted in yellow.
Figure 4. Three-dimensional structural model of a NS1 dimer and regions corresponding to epitopes
recognized by 4H2 mAb. The NS1 3D model was generated by the program PyMOL in green.
The sequence 127ELHNQTFLIDGPETAEC143 is highlighted in red and white. In the detail the red
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Figure 5. Three-dimensional structural model of a NS1 dimer and regions corresponding to epitopes
recognized by 2H5 and 4H1BC mAbs. The NS1 3D model was generated by the program PyMOL in
green. The sequence 193AVHADMGYWIESALNDT209 is highlighted in blue.
2.3. Analyses of mAbs’ Cross-Reactivity with Different DENV Serotype and ZIKV
Since NS1 shares a high homology with amino acid sequences found among different flavivirus,
the selected mAbs were tested for recognition of native ZIKV NS1 by immunofluorescence assay,
using fixed ZIKV-infected Vero cells. In Figure 6, two mAbs are observed to cross-react with native
ZIKV-NS1 in this test (2H5 and 4H1BC) (Figure 6C,D, Table 1). The other two mAbs (4F6 and 4H2)
were specific for DENV NS1 (Figure 6A,B, Table 1). We also tested in vitro the reactivity of 4F6 and
4H2 mAbs with DENV serotypes, other than DENV2, and only the 4H2 mAb reacted with all four
DENV serotypes (Figure 7, Table 1).
Figure 6. Reactivity of NS1-specific mAbs to zika virus-infected Vero cells. Cells were infected with a
MOI of 0.05. 72 h post infection, cells were fixed, permeabilized and treated with each of the tested
mAbs. Then, cells were labeled with FITC-conjugated goat-anti mouse IgG. Tested mAbs: (A) 4F6;
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Figure 7. Reactivity of 4H2 mAb to Vero cells infected with DENV of different serotypes. Vero cells
were infected with a MOI of 0.5, fixed, permeabilized and treated with mAb 4H2 48 h post infection.
Then, cells were labeled with Alexa fluor® conjugated goat-anti mouse IgG. The negative controls:
(A) Mock infected cells treated with a pool of mAbs anti-NS1 and (B) DENV-infected cells labeled
only with secondary antibody; Tested DENV serotypes: (C) DENV1; (D) DENV3 and (E) DENV4.
Magnification of 200×.
3. Discussion
The DENV NS1 has been used as a target antigen against dengue infection either for vaccines,
antiviral drug design or diagnostic methods. Indeed, this protein is secreted by infected cells during
the acute phase and circulates in the blood at high concentrations [19]. Nevertheless, the NS1 shares
parts of its amino acid sequence among flavivirus. In the present study, we generated four mAbs
against DENV2 recombinant NS1 and analyzed their reactivity with the dimeric-NS1 form. The
mAbs were also reactive with the native NS1 produced in infected cells but showed different features.
The epitope sequences recognized by different mAbs have been recently described and been considered
the strategic point for understanding these interactions [15–17].
The mAbs 2H5 and 4H1BC showed a similar recognition pattern and share the same
epitope binding, 193AVHADMGYWIESALNDT209. This epitope has been reported as one of the
immunodominant B cell epitopes in DENV2 NS1 [20]. This sequence was described in silico and is
buried in a beta-sheet structure [15,17]. The recognition of the heat-denatured rNS1 was lower for
these mAbs when compared with the non-denatured rNS1, suggesting that these mAbs recognize
mainly a conformational epitope. Indeed, by immunofluorescence, both 2H5 and 4H1BC mAbs reacted
with dengue virus serotype 2 infected Vero cells. However, they cross-reacted with native ZIKV NS1
in Vero infected cells. The in silico analyses of the similarity of this peptide sequence between different
flaviviruses showed that this epitope is highly conserved in these virus but not Yellow fever, Japanese
encephalitis and West Nile viruses (Table S2).
The mAb 4F6 recognizes the DENV2 complex-conserved LD2 epitope 25VHTWTEQYKFQPES38,
located on the surface of NS1 fusion loop [8,15,17]. A previous study showed a mAb that binds in
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4F6 mAb was able to detect only DENV2 native monomeric NS1 by immunofluorescence but no other
serotypes. The divergent results may be accounted to methodological issues, since immunofluorescence
is less sensitive and aims to detect infected cells expressing mainly monomeric intracellular NS1,
while the purified hexamers were used in an ELISA-based detection system. Hence, this epitope may
be exposed depending on the NS1 oligomeric level and the DENV serotype.
The fourth mAb obtained, 4H2, recognized the amino acid sequence 127ELHNQTFLIDGPET
AEC143. A preceding work described a shorter sequence, 125STESHNQTFL134 exposed in the same
loop of DENV2 NS1 [15]. Interestingly, the sequence herein described has nine additional amino acids
not previously reported as a B cell epitope and shifting the exposed region to a beta-sheet structure.
It recognizes the native protein assessed by immunofluorescence of the four DENV serotypes infected
Vero cells, but it did not cross-react with native ZIKV NS1 in Vero-infected cells.
Differentiation of DENV and ZIKV infections is a challenge for current serological tests,
particularly in areas where both viruses circulate and co-infection can occur. Thus, mAbs, like 4H2,
may be particularly useful for the development of an immunofluorescence based-assay that minimizes
the risks associated with false positive results among ZIKV-infected subjects.
4. Materials and Methods
4.1. Viral Strains and Viral Antigen
The obtention of purified DENV2 NS1 dimers was achieved after denaturation/refolding
steps of the protein expressed in E. coli followed by affinity chromatography, as previously
reported [22]. This recombinant protein was utilized as an antigen for monoclonal antibody
development and characterization. Four dengue serotypes and one Zika virus strain were used
for further characterization of the mAbs obtained: a dengue virus serotype 2 JHA1 strain [23,24],
a rDEN1Δ30 vaccine strain obtained by Δ30 deletion in 3′UTR of DENV1 Western Pacific strain [25],
a rDEN3Δ30/31-7164 vaccine strain obtained by Δ30 and Δ31 deletions in 3′ untranslated region (UTR)
of DENV3 Slemann/78 strain [26], a rDEN4Δ30 vaccine strain obtained by Δ30 deletion in 3′ UTR
of DENV4 Dominica/81 strain [27], and a Brazilian Zika virus strain (ZIKVBR) (Evandro Chagas
Institute, Belem, PA, Brazil).
4.2. Dengue NS1 Monoclonal Antibody (mAb) Production
Four to six week-old female BALB/c mice were immunized via footpad route with 10 μg rNS1
adsorbed to 1 μg recombinant heat-labile toxin (rLT) [22] as adjuvant. The immunization protocols
consisted of three booster injections of the rNS1 and rLT in 0.01 M phosphate buffered saline (PBS),
pH 7.4 at 15 days intervals. The mouse with the highest antibody titer was boosted with 10 μg of
rNS1 three days prior to cell fusion. The popliteal lymph node cells were fused to SP2/O-Ag14
mouse myeloma cells (2:1) using polyethylene glycol 1500 (Sigma Aldrich, St Louis, MO, USA) [28],
with modifications [29]. The supernatant fluids were screened for specific antibodies by indirect ELISA
in which 100 μL of hybridoma supernatant was added to a 96-well MaxiSorp microplates (Nunc®,
Rochester, NY, USA) previously coated with 1 μg/mL of purified rNS1 to screen cultures for antibody
production. Antibody-secreting cells were expanded and cloned at limiting dilution [29]. This study
was carried out in accordance with the recommendations of Ethical Principles in Animal Research,
adopted by the Brazilian College of Animal Experimentation. The protocol was approved by the
Ethical Committee for Animal Research of Butantan Institute (995/12).
4.3. Dengue NS1 mAbs Characterization
Hybridoma supernatants were incubated with each of the anti-isotype (anti-IgG1, anti-IgG2a,
anti-IgG2b, anti-IgG3, anti-IgA and anti-IgM antibodies) previously coated at MaxiSorp microplates
followed by incubation with horseradish peroxidase-conjugated rabbit anti-mouse-IgG+A+M+ (1:1000)
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and purified by protein G affinity chromatography (GE-Healthcare, Freiburg, Germany). MAb purity
was observed in a 12% polyacrylamide gel electrophoresis containing sodium dodecyl sulphate
(SDS-PAGE) staining with Coomassie blue R-250.
The detection limit was established using rNS1 concentrations from 1 to 512 ng coated on
microplates, followed incubation with 10 μg/mL of NS1 mAb and with goat anti-mouse
peroxidase-conjugated antibody (Invitrogen, Carlsbad, CA, USA) diluted 1:5000. The three-step
ELISA was employed to determine the dissociation constants (KD) of antigen-antibody interactions
under equilibrium conditions [28].
ELISA assay was also applied in order to observe the reactivity of mAb NS1 against intact and
denatured rNS1. For this, MaxiSorp microplates (Thermo Fischer Scientific, Waltham, MA, USA) were
coated with 4 μg/mL of Dengue virus serotype 2 (DENV2) rNS1 heat-treated (100 ◦C for 10 min)
or non-heated. The NS1 mAbs were serially diluted (log2) in an initial concentration of 2.5 μg/mL
followed by incubation with goat anti-IgG mouse conjugated with horseradish peroxidase (1:10,000).
The reactivity of NS1 mAb against intact and denatured rNS1 was also analyzed by
immunoblotting. Thus, 1 μg or 0.5 μg of rNS1 denatured (heat-treated for 10 min at 100 ◦C) or intact
(non-heated) were separated by electrophoresis in denaturing condition polyacrylamide gel containing
sodium dodecyl sulphate (SDS-PAGE) 15%. Nitrocellulose membranes (GE-Healthcare, Freiburg,
Germany) containing the transferred proteins were tested with NS1 mAbs at a final concentration
of 200 ng/mL. Thus, the membranes were incubated with goat anti-IgG mouse conjugated with
peroxidase (1:10,000). The reactive protein bands were identified by exposing membranes to a solution
of luminol-hydrogen peroxide according to the manufacturer’s instructions (Sigma Aldrich, St Louis,
MO, USA). Images were captured by Image Lab™ software (Bio-Rad, Hercules, CA, USA).
4.4. Epitope Characterization and Structure Analysis
Peptide mapping was performed using CelluSpot Peptide Array (Intavis, Heidelberg, Germany)
following the manufacturer’s recommendations. The slides were produced with dots containing
11 amino acids with overlapping of eight amino acids. Briefly, the slides were blocked, followed
by incubation with 30 μg/mL mAb. Next, the slides were incubated with anti-mouse horseradish
peroxidase conjugate (1:5000). After washing, diaminobenzidine and hydrogen peroxide were added
and the reaction was stopped by the addition of distilled water.
We employed PyMol program (DeLano Scientific LLC, San Carlos, CA, USA, 2009) to predict
the structure and the epitope of NS1. For the NS1 structure, we used the available PDB file from
Protein Data Bank (code: 4O6B) [6]. For the structure of monoclonal antibodies, we first performed the
prediction with Phyre [30].
4.5. NS1 Sequences Database Building
One database consisting of amino acid sequences of the NS1 protein in FASTA format was built.
Sequences were retrieved from the National Center for Biotechnology Information (NCBI) protein
database. Sequences from serotype 1 of DENV have the following accession numbers: ABG75766,
ABG75761 and AFN54943. Sequences from serotype 2 of DENV have the following accession numbers:
AIE17400, ABK51383 and AFZ40226. Sequences from serotype 3 of DENV have the following accession
numbers: ADM63678, AAT79552 and ALI16137. Sequences from serotype 4 of DENV have the
following accession numbers: AGI95993, ALB78116 and AFD53008. Sequences from ZIKV isolates
have the following accession numbers: AMR39836, AMD61710, ASK51714, ARB07991, AMD16557
and ARB07967.
4.6. Conservancy Analysis
The IEDB conservancy analysis was used to determine the conservancy of epitopes for monoclonal
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4.7. NS1 mAbs Reactivity to Dengue Virus Serotypes and Zika Virus
Vero cells grown on six-well plates were infected with the viral strains at a MOI of 0.5 for 48 h for
DENV and at a MOI of 0.05 for 72 h for ZIKV. The cells were fixed with 1% formaldehyde for 10 min at
4 ◦C and then permeabilized with 0.5% saponin in PBS for DENV and with cold acetone at −20 ◦C
for ZIKV. The cells were then blocked with PBS containing 10% bovine fetal serum for 30 min. Both
cells were treated with mAbs diluted in permeabilization buffer at a concentration of 10 μg/mL for 1 h
at room temperature for DENV and 37 ◦C for 30 min for ZIKV. After three washing steps with PBS,
the cells were further treated with Alexa fluor488® (Thermo Fisher, Waltham, MA, USA) conjugated
goat anti-mouse IgG at room temperature for 1 h. After another washing period (five times) with
PBS, cells were examined using an EVOS digital inverted microscope. Mock infected and cell infected
marked with just secondary antibody was the negative control. Also, Vero cells infected with ZIKVBR
were tested in order to determine the cross reactivity of the mAbs.
5. Conclusions
In the present study we generated four monoclonal antibodies against the nonstructural protein
1 (NS1) of dengue virus serotype 2. One of them (4H2 mAb) recognizes by immunofluorescence the
four-dengue virus serotype and did not cross react to zika virus. Thus, the selection and characterization
of the epitope, specificity of anti-NS1 mAbs, may contribute to the development of diagnostic tools
able to differentiate DENV and ZIKV infections.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4468/6/3/14/s1,
Figure S1: Characterization of NS1-specific mAbs reactivity by immunoblotting; Figure S2: Epitope mapping with
NS1-derived synthetic peptides; Table S1: Epitope analysis of conservancy in DENV serotypes. Table S2: Epitope
analysis of conservancy in different strains of DENV, ZIKV, YFV, JEV and WNV strains.
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Abstract: 2015 was a groundbreaking year for the multiple myeloma community partly due to the
breakthrough approval of the first two monoclonal antibodies in the treatment for patients with
relapsed and refractory disease. Despite early disappointments, monoclonal antibodies targeting CD38
(daratumumab) and signaling lymphocytic activation molecule F7 (SLAMF7) (elotuzumab) have become
available for patients with multiple myeloma in the same year. Specifically, phase 3 clinical trials of
combination therapies incorporating daratumumab or elotuzumab indicate both efficacy and a very
favorable toxicity profile. These therapeutic monoclonal antibodies for multiple myeloma can kill
target cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity,
and antibody-dependent phagocytosis, as well as by direct blockade of signaling cascades. In addition,
their immunomodulatory effects may simultaneously inhibit the immunosuppressive bone marrow
microenvironment and restore the key function of immune effector cells. In this review, we focus on
monoclonal antibodies that have shown clinical efficacy or promising preclinical anti-multiple myeloma
activities that warrant further clinical development. We summarize mechanisms that account for the
in vitro and in vivo anti-myeloma effects of these monoclonal antibodies, as well as relevant preclinical
and clinical results. Monoclonal antibody-based immunotherapies have already and will continue to
transform the treatment landscape in multiple myeloma.
Keywords: multiple myeloma; monoclonal antibody; immunomodulatory activity;
bone marrow microenvironment
1. Introduction
Multiple myeloma is the second most common hematologic malignancy, characterized by
the proliferation of malignant plasma cells in the bone marrow and excessive production of
immunoglobulins [1,2]. The clinical outcome of patients with multiple myeloma has been improved in
recent decades due to the development of novel therapeutic agents such as the proteasome inhibitors
bortezomib [3], carfilzomib [4,5], and ixazomib [6] or immunomodulatory drugs (IMiDs) including
thalidomide [7], lenalidomide [8], and pomalidomide [9,10]. With the incorporation of these novel
agents into myeloma treatment strategies, the response rate and extent, progression-free survival,
and overall survival have also been significantly improved in newly diagnosed patients [11–17].
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However, in most cases, it remains a chronic and incurable disease due to its typical pattern of remission
and relapse [18,19]. In addition, patients with refractory disease or who relapse after treatment
with proteasome inhibitors and IMiDs have a very poor prognosis [18,20]. Thus, exploring novel
approaches targeting different mechanisms to overcome drug resistance and minimize disease relapse
are urgently needed.
With increased understanding of the biology of the disease, the development and evolution of
multiple myeloma has been closely linked to specific immune system impairments. Malignant plasma
cells express lower levels of tumor antigens and human leukocyte antigen (HLA) molecules [21,22],
as well as higher levels of programmed cell death ligand 1 (PD-L1), which have been linked
to defects in the antigen-presenting capacity of dendritic cells and a state of immune tolerance,
respectively [23,24]. In addition, the bone marrow microenvironment in multiple myeloma has been
shown to be immunosuppressive, providing a protective niche for the proliferation, migration, survival,
and acquisition of drug resistance by malignant plasma cells [25–29]. Previous studies revealed that
secreted inflammatory cytokines support the growth of immunosuppressive cells such as myeloid
derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T-cells
(Treg). Bone marrow stromal cells (BMSCs), osteoclasts (OCs), and plasmacytoid dendritic cells
(pDC), as well as cytokines, i.e., interleukin-6 (IL-6), Macrophage colony-stimulating factor (M-CSF),
interleukin-10 (IL-10), tumor necrosis factor beta (TGFβ), C-C Motif Chemokine Ligand 2 (CCL2),
and vascular endothelial growth factor (VEGF), also play important roles in maintaining
an immunosuppressive environment in the bone marrow of multiple myeloma patients [25,27].
These findings suggest that an effective anti-myeloma treatment will require not only targeting
the malignant plasma cell itself but also restoring the anti-tumor responses of immune effector cells
via blockade of tumor evasion and disruption of inhibitory signals on effector cells.
Monoclonal antibody-based treatments which provide additional effector cell-mediated tumor
killing mechanisms when compared with targeted small molecules are successful therapeutic
strategies for cancer. Monoclonal antibodies targeting specific surface antigens on cancer cells
can kill the targeted cell via various effector-dependent and -independent mechanisms. Thus far,
therapeutic IgG1-based monoclonal antibodies are designed to induce effector-mediated tumor
cell lysis, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent
cytotoxicity (CDC), and/or antibody-dependent phagocytosis (ADPC). Dependent on target antigens,
therapeutic antibodies also act via receptor blockade to inhibit cell growth, induce apoptosis,
or specifically deliver drug, radiation, or cytotoxic agent. Furthermore, the Fc region of antibodies
plays an important role in mediating the killing of cancer cells via activation of certain immune
cells (NK cells or cytotoxic T cells) as well as the induction of phagocytosis, CDC or ADCC [30,31].
For the treatment of hematological malignancies, the development of the anti-CD20 monoclonal
antibody rituximab represents an important landmark and opened new venues for targeted cancer
immunotherapies. Due to the success of rituximab in the treatment of B-cell lymphomas, the search
for novel monoclonal antibodies for myeloma treatment has been rigorously pursued. Only small
percentages of MM patients express CD20, so rituximab is not generally useful in myeloma [32,33].
Following the demonstration of promising preclinical and clinical activities [34–36], two monoclonal
antibodies targeting CD38 (daratumumab) [37] and SLAMF7 (elotuzumab) [38] were approved by the
Food and Drug Administration (FDA) to treat patients with relapsed and refractory multiple myeloma
in late 2015.
Here, we focus on monoclonal antibodies showing multiple anti-myeloma mechanisms,
including those with immunomodulatory effects (Figure 1). The preclinical and clinical data of these
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Figure 1. Therapeutic monoclonal antibodies for current multiple myeloma treatment. Daratumumab
and elotuzumab, targeting CD38 and signaling lymphocytic activation molecule F7 (SLAMF7)/CS1,
respectively, are naked IgG1 monoclonal antibodies which have been approved by FDA for treatment
of relapsed/refractory multiple myeloma in late 2015. GSK2857916 is an antibody-drug conjugate
composed of Fc-engineered IgG and a potent anti-tubulin drug MMAF. EM801 and BI836909 are
bispecific T cell engagers targeting B-cell maturation antigen (BCMA) on myeloma cells and re-directing
CD3+T cells to kill myeloma cells. BION-1301 exerts anti-myeloma activity by blocking the binding
of APRIL to its cognate receptors BMCA and Transmembrane activator and CAML interactor
(TACI), thereby abrogating growth, survival, and immuno-suppression signaling for myeloma
cells. Clinical investigations of above agents are ongoing. * The clinical trials of PD-1 inhibitors
(pembrolizumab and nivolumab) have been hold by Food and Drug Administration (FDA).
2. Targets and Monoclonal Antibodies
2.1. CD38
CD38 is a 46-kDa type II transmembrane glycoprotein with a short N-terminal cytoplasmic tail
(20-aa) and a long extracellular domain (256-aa), which is identified on the surface of several cells of the
immune system [39]. The intensity of CD38 expression is increased when lymphocytes are activated,
and its expression is found in the majorities of hematopoietic linage cells. It is widely represented on
lymphoid and myeloid cells, but absent from most mature resting lymphocytes. It catalyzes production of
secondary messengers that affect Ca2+ mobilization. The biological function of CD38 has been linked to the
regulation of calcium homeostasis in CD38-expressing lymphocytes [40]. Moreover, CD38 plays multiple
but independent biologic roles since it acts both as a bifunctional enzyme responsible for the synthesis and
hydrolysis of cyclic ADP-ribose, and as a signal-transducing surface receptor. CD38-/- mice are viable,
without histological or pathological abnormalities. The natural ligands for CD38 are nicotinamide adenine
dinucleotide (NAD)+, the substrate for its ecto-enzyme activity (ADP-ribosyl cyclase), and CD31/PECAM.
Binding of CD31/PECAM and CD38 induces tyrosine phosphorylation and downstream signaling
events regulating proliferation and cytokine release in lymphocytes. Regarding CD38 and multiple
myeloma, previous studies have revealed that this glycoprotein is strongly and homogeneously
expressed in terminally differentiated normal and malignant plasma cells [41,42]. A role of CD38 in the
pathophysiology is postulated due to its high expression on a variety of hematological malignancies [43]
including multiple myeloma [42,44], B- and T- acute lymphoblastic leukemia (ALL) [45,46], Non-Hodgkin
lymphoma (NHL) [47], Acute myeloid leukemia (AML) [48] and Chronic Lymphocytic Leukemia
(CLL) [49,50]. A recent study also suggested that CD38 enzymatic activity may be associated with
immunosuppression in patients with multiple myeloma patients, due to its involvement in the production
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2.1.1. Daratumumab
Daratumumab, a human IgG1-kappa monoclonal antibody, was the first naked CD38 monoclonal
antibody to be further developed for clinical use following demonstration of promising anti-myeloma
activity in preclinical studies with cell lines and animal models. In preclinical studies, it was
found that daratumumab (formerly named HumaxCD38) kills CD38-expressing lymphoma and
myeloma cells by various mechanisms including CDC, ADCC, ADCP, and induction of apoptosis after
Fcγ receptor-mediated crosslinking with anti-human IgG1 secondary antibody [36,52,53]. In other
CD38-expressing cells such as human NK cells, B and T cells, activated T cells or monocytes, the process
of CDC cytotoxicity induced by daratumumab was not seen [36]. CD38 expression is relatively low on
the cell membrane of these cells when compared with malignant plasma cells from multiple myeloma
patients. Possible explanations for this therapeutic index include increased expression of complement
regulatory proteins on the surface membrane of these cells or the need for a minimum threshold level
of antigen expression needed to activate CDC [54,55]. Unlike CDC, daratumumab-mediated ADCC
was seen in these cells and in primary tumor cells. In another study, ADCC was significantly enhanced
if mononuclear effector cells derived from healthy peripheral blood donors were pretreated with
lenalidomide, associated with activation of NK effector cells by lenalidomide [56]. Daratumumab also
demonstrated potent antitumor activity in CD38-expressing xenografts in immune deficient mice [36],
suggesting that daratumumab may mediate non-immune mediated anti-tumor activities in vivo.
A recent correlative study analyzed via flow cytometry on bone marrow and peripheral blood
samples from participants in a clinical trial showed that daratumumab treatment rapidly depleted
CD38 high-expressing immunosuppressive regulatory T cells (Treg) and B cells (Breg), as well as
myeloid-derived suppressor cells (MDSC) [57]. In contrast, the numbers of immune effector cells such
as helper and cytotoxic T cells increased [57,58]. CD38 levels are heterogenous among sub-populations
of hematopoietic lineage cells. It is found to be expressed at significantly higher levels in Treg, Breg,
and MDSCs, when compared with normal T, B, NK, and monocytes. This study therefore indicates that
daratumumab quickly reduces these key immune inhibitory cellular components, thereby relieving their
suppressive immune function and increasing effector cell-induced tumor cell lysis. Thus, in addition to its
multiple FcR-dependent tumor cell killing mechanisms, daratumumab further blocks immunosuppressive
cellular components, which may provide for more long-term responses [57].
Clinical Trials of Daratumumab
In phase 1–2 study, daratumumab monotherapy was administered to heavily pretreated
patients with relapsed or refractory multiple myeloma (with a median of 5.5 lines of prior therapy,
75% refractory to lenalidomide and bortezomib) [37]. There were 32 patients enrolled in the
dose-escalation phase. Daratumumab was administered weekly for 8 weeks, at doses ranging from
0.005 to 24 mg/kg. The maximum tolerated dose was not reached. In the expansion phase, 72 patients
received 8 mg/kg or 16 mg/kg of daratumumab. The patients who received 16 mg/kg of daratumumab
showed a better overall response rate (36% vs. 10%) and longer median progression-free survival
(5.6 vs. 2.4 months) than patients treated with 8 mg/kg. Infusion-related reactions were the most
frequently reported adverse effects, occurring in 71% of patients in the dose expansion group,
mostly grade 1 or 2. In terms of hematologic adverse effects, neutropenia was most common, occurring
in 12% of patients in the 16 mg/kg cohort [37]. Results of this small clinical study demonstrated
the impressive activity of monotherapy with this agent in patients with no other available treatment
options, leading the approval by the FDA in 2015 [37].
In the phase 2 SIRIUS study, 106 patients with multiple myeloma refractory to proteasome
inhibitors and IMiDs (with a median of 5 lines of prior treatment) received daratumumab at 16 mg/kg.
The overall response rate was 29.2% [59]. The time to response and median progression-free
survival were 1.0 month and 3.7 months, respectively. The 12-month overall survival was 64.8%,
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of patients, mostly grade 1 or 2 The most common grade 3 or 4 adverse effects were anemia (24%),
thrombocytopenia (19%) and neutropenia (12%) [59].
With respect to combination studies, the results of two phase 3 studies have been published [60,61].
In the CASTOR trial, 498 patients with relapsed or refractory multiple myeloma (≥1 prior line of therapy)
received bortezomib plus dexamethasone with or without daratumumab [60]. The incorporation of
daratumumab in the treatment regimen significantly improved the overall response rate (82.9% vs. 63.2%,
p < 0.001), the 12-month progression-free survival (60.7% vs. 26.9%), and the median progression-free
survival (not reached vs. 7.2 months, p < 0.001). The most common grade 3 or 4 adverse events reported
in the daratumumab group were thrombocytopenia (45.3%), anemia (14.4%), and neutropenia (12.8%).
Infusion related reactions were noted in 45.3% of patients from the daratumumab group.
In another phase 3 trial, the POLLUX study, daratumumab proved to be a good therapeutic
combination with lenalidomide and dexamethasone [61]. In this study, 569 patients who had received
one or more lines of anti-myeloma treatment received lenalidomide with or without daratumumab.
Adding daratumumab to lenalidomide and dexamethasone was associated with better response rates
(93% vs. 76%, p < 0.0001), complete response rates (43.1% vs. 19.2%, p < 0.0001) and progression-free
survival at 12 months (83.2% vs. 60.1%). The daratumumab group also showed a higher rate of
minimal residual disease negativity (22.4% vs. 4.6%, p < 0.001). The most common grade 3 or 4 adverse
effects in the daratumumab group were neutropenia (51.9%), thrombocytopenia (12.7%) and anemia
(12.4%). Infusion-related reactions were noted in 47.7% of patients of the daratumumab group [61].
An important finding from both CASTOR and POLLUX was that the benefit of the addition
of daratumumab to existing doublets persisted regardless of the number of prior lines of therapy.
Greater benefit was seen when the triplet modality was used earlier in the disease course. Although close
to half of the patients experienced daratumumab-related infusion reactions, >90% of these events occurred
only upon the first infusion. This observation indicated that repeated dosing is safe. Both regimens
were approved in November 2016 by the FDA for the treatment of multiple myeloma patients who have
received at least one prior therapy. In addition, the unprecedented results stimulated studies for the
detection of minimal residual disease (MRD) with next generation sequencing (NSG) and next generation
flow-cytometry. The new MRD categories are currently being standardized to report across clinical trials
in order to validate their importance as key prognostic markers and to guide treatment decisions.
2.1.2. Isatuximab (SAR650984)
Isatuximab, formerly called SAR650984 [62], is a novel humanized IgG1-kappa anti-CD38 monoclonal
antibody currently under clinical development. Isatuximab was selected because of its direct induction
of apoptosis in CD38-expressing lymphoma cell lines, in addition to its multiple effector cell-dependent
cytotoxicity. In a preclinical study, isatuximab induced cell death in myeloma cell lines by ADCC,
CDC, and ADCP, as well as the induction of tumor cell death in a CD38-dependent manner [62]. It is
the latter activity which differentiates isatuximab from other therapeutic CD38 monoclonal antibodies
because tumor cell death is directly induced by isatuximab in the absence of immune effector cells.
It has similar half maximal effective concentrations (EC50 ~0.1 μg/mL) and maximal binding as
daratumumab but MOR03087 (MOR202) (discussed later in this article) has a lower apparent affinity
(EC50 ~0.3 μg/mL) [63]. These three CD38 monocloncal antibodies were equally potent at inducing
ADCC against CD38-expressing tumor cells [63]. Daratumumab demonstrated superior induction of
CDC in Daudi lymphoma cells as determined by flow cytometry, when compared with other CD38
antibodies in current clinical development. Specifically, isatuximab, more potently than daratumumab,
inhibits ecto-enzyme function of CD38. It produced the largest inhibition of cyclic GDP-ribose (cGDPR)
production, indicating a higher modulation of CD38 cyclase activity.
In in vivo studies using the same multiple myeloma cell lines xenografted in Severe combined
immunodeficiency (SCID) mice, isatuximab showed more potent anti-myeloma activity than
bortezomib [62]. Importantly, without the addition of Fc crosslinking agents or effector cells, isatuximab
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In contrast, under similar conditions in ex vivo co-cultures, daratumumab shows no direct toxicity against
multiple myeloma cells. Significantly, its F(ab)’2 fragments, just like the full-length version of isatuximab,
could trigger lysosome-dependent cell death via upregulation of lysosome related protease cathepsin B and
the translocation of lysosomal-associated membrane protein 1 (LAMP1) from lysosome to cell membrane,
as well as increased reactive oxygen species. This effect was preferentially seen in myeloma cells expressing
elevated levels of CD38 regardless of p53 mutation, which represents a key feature of most resistant
patient group. Isatuximab specifically induced lysosome-dependent cell death by enlarging lysosomes
and increasing lysosomal membrane permeability, despite the presence of protective IL-6 or bone marrow
stromal cells. Furthermore, the addition of pomalidomide augments the direct and indirect killing effects of
isatuximab in pomalidomide/lenalidomide-resistant myeloma cells [64]. Caspase 3/7-mediated apoptosis
in drug-resistant myeloma cells was synergistically enhanced when both Isatuximab and pomalidomide
were added together. Pomalidomide also increased ADCC mediated by isatuximab, further supporting
ongoing phase III combination clinical trials.
Most recently, the effects of isatuximab on immune cell populations in the bone marrow
microenvironment were investigated, since CD38 is widely expressed on hematopoietic cells [65].
First, significantly increased levels of CD38 were shown on the cell membrane of Tregs
(CD4+CD25highFoxp3+) and myeloma cells when compared with conventional T (Tcon, CD4+CD25−)
cells containing the majority of effector T cells. Higher CD38 expression and higher CD38+ subsets
were identified on the cell membrane of Tregs (CD4+CD25highFoxp3+) versus Tcon, in accord with
findings from a recent study of daratumumab trials [57]. Importantly, following isatuximab treatment,
the percentage and function of CD38 high-expressing Tregs were decreased via the induction of
apoptosis and decreased proliferation. In parallel, isatuximab blocked Treg-inhibited growth of
conventional T cells in a dose-dependent manner. Longer ex vivo cocultures in the presence of low
dose lenalidomide or pomalidomide further increased CD38 levels and percentages of the CD38+
sub-population in the viable Tregs. This result indicates that IMiDs can enhance the sensitivity
of this immune inhibitory subset to isatuximab, providing an additional mechanism to support
combination trials of these reagents to sustain T effector cell function. Significantly, isatuximab
augmented degranulation of NK and CD8+ T effector cells leading to increased multiple myeloma cell
lysis, which was further enhanced by pomalidomide or lenalidomide. Isatuximab also reduced Foxp3
and IL10, associated with the inhibitory function of Tregs, and restored the proliferation of CD4+CD25−
naive T cells. Importantly, patients with multiple myeloma have elevated CD38high Tregs that block
the proliferation of Tcons; and multiple myeloma cells convert Tcon into Tregs in ex vivo co-cultures.
Myeloma cells induce the generation of Tregs (iTreg) which also highly express CD38 in addition
to other known Treg markers. This study further showed that Tregs can be induced by cell-to-cell
contact-dependent and -independent interactions between myeloma cells and Tcons, mimicking
increased frequency of Tregs in MM patients versus normal donors. These iTregs generated in ex vivo
co-cultures show significantly elevated CD38 and Foxp3 levels when compared with Tcons. They still
demonstrate inhibitory function and significantly decrease proliferation of Tcons, which is overcome
by isatuximab [65]. In a similar fashion as occurred in multiple myeloma cells overexpressing CD38,
isatuximab preferentially targets CD38high-expressing Tregs of patient MM cells [65]. These results
are in accord with a recent report showing that these immune inhibitory CD38high subsets were
rapidly depleted by daratumumab in a recent correlative study [57]. These studies indicate that
isatuximab can mitigate the immunosuppressive bone marrow microenvironment, thereby further
restoring anti-multiple myeloma immunity.
Clinical Trials of Isatuximab
In a phase 1b dose-escalation study, isatuximab was administered in combination with
lenalidomide and dexamethasone to treat patients with relapsed and refractory multiple myeloma
(with a median of five prior regimens) [66]. Isatuximab was given at different doses and in two
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thereafter (QW/Q2W)). The maximum tolerated dose was not reached in this study. The analysis of
efficacy revealed that the overall response rate was 56%. The median progression-free survival was
8.5 months. The most common treatment-related adverse events were fatigue and nausea, mostly grade
1 or 2. Infusion related reactions were noted in 56% of patients, mostly grade 1 or 2, and mainly occurred
during the first infusion [66].
The combination of isatuximab and pomalidomide/dexamethasone is also generally well tolerated
and clinically active in patients with heavily pre-treated relapsed and refractory multiple myeloma [67].
Of the eight patients who achieved at least PR up to 10 mg/kg, all continued to respond without
confirmed disease progression at data cut-off. The pharmacokinetic (PK) parameters of isatuximab
were not affected by co-administration with pomalidomide/dexamethasone. Data are continuing to
be collected for longer-term follow up, including the 20 mg/kg cohort. A Phase III trial to evaluate
isatuximab plus pomalidomide/dexamethasone is planned.
2.1.3. MOR03087 (MOR202)
MOR202 (HuCAL) is a novel fully human anti-CD38 IgG1 monoclonal antibody. In preclinical studies,
MOR202 killed CD38-expressing cell lines and primary myeloma cells from patients by ADCC and ADCP.
In SCID-mouse xenograft models, MOR202 inhibited tumor growth [68]. Furthermore, the addition of
lenalidomide to MOR202 activated immune effector cells and augmented ADCP-mediated cytotoxicity [69].
Pomalidomide also enhances the cytotoxicity of MOR on MM cells [70].
Clinical trials of MOR03087 (MOR202)
In a phase I/II dose-escalation clinical trial, MOR202 was administered alone or combined with
IMiDs (lenalidomide or pomalidomide) to treat 66 patients with relapsed or refractory multiple myeloma
(more than 2 lines of prior therapy) [71]. MOR202 was infused for 2 h. The maximum tolerated dose was not
reached in this study. Of 16 evaluable patients in the MOR202 monotherapy cohort, 3 patients (19%) showed
partial responses and 2 patients (13%) showed very good partial responses. In the MOR202/lenalidomide
cohort, 5 of 7 patients exhibited partial responses. In the MOR202/pomalidomide cohort, 3 of 5 patients
showed a response to treatment, including 2 complete responses. Infusion-related reactions were seen in
3 patients (3/31, 10%), all occurring during the first infusion and less than grade 2.
2.1.4. Side Effects of CD38 Monoclonal Antibody
Some important clinical scenarios should be considered when using daratumumab to treat myeloma
patients. First, daratumamab can be detected as an individual monoclonal band, which would interfere with
serum immunofixation electrophoresis tests (IFE) [72,73]. To address this issue, daratumumab IFE reflex
assay was developed to abrogate interference. Second, daratumumab has been shown to interfere with
evaluation of bone marrow aspirates by multiparameter flow cytometry in a small study [74]. There were
no CD38 or CD138 events detected in two patients treated with daratumumab. This was contrasting to the
finding of the aspirate morphology and immunohistochemical study, which showed abnormal plasma
cells positive for CD38 or CD138. Utilization of antibodies binding to different epitopes of CD38 may
address this issue. Third, daratumumab also interferes with blood typing because CD38 is expressed on
human red blood cells. Daratumumab binds to CD38 antigen on the reagent blood cells and leads to
a positive indirect Coombs test. Treatment of dithiothreitol on reagent red cells with to denatures CD38 on
the surface represents a potential method to circumvent this issue.
To prevent an infusion related reaction, medications such as glucocorticoid, antihistamine and
acetaminophen can be administered before infusion during the initial cycles of treatment [75–77].
If an infusion related reaction occurs despite the administration of premedication, the infusion should
be held until the appropriate symptom management is done and symptoms have resolved. After the
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2.2. SLAMF7/CS1
SLAMF7 (signaling lymphocytic activation molecule F7), previously known as CS1 (cell surface 1), is
a cell surface glycoprotein that is a member of the signaling lymphocytic activation molecule family [78].
SLAMF7 is expressed on NK cells, activated monocytes, T cell subsets, and normal plasma cells. The
biological function of SLAMF has been linked to the regulation and activation of NK cells [78,79].
Importantly, >90% of patients with myeloma cells expressed SLAMF7 messenger RNA (mRNA) and
protein, regardless of disease status and treatments [34,35]. High SLAMF7 protein expression on the cell
surface of multiple myeloma cell lines and patient myeloma cells spurred the development of monoclonal
antibodies targeting SLAMF7 for the treatment of this cancer.
2.2.1. Elotuzumab
Elotuzumab is a humanized IgG1-kappa monoclonal antibody that targets SLAMF7. In a preclinical
study, elotuzumab specifically bound to CD138+ myeloma cells, natural killer (NK), NK-like T cells,
and CD8+ T cells, but not to hematopoietic CD34+ stem cells. The major mechanism for the anti-
myeloma activity of elotuzumab was the induction of dose-dependent NK cell-mediated ADCC [34,35],
since elotuzumab did not induce CDC against myeloma cells. In a mouse xenograft model, elotuzumab
showed in vivo efficacy mainly via NK effector cell-mediated toxicity [34]. In addition, it inhibited
the adhesion of myeloma cells to bone marrow stromal cells, thereby blocking their proliferation and
survival [34]. The anti-myeloma ADCC effect of elotuzumab was further enhanced by pretreatment with
lenalidomide or bortezomib [34,80], providing the rationale for the combination trial of elotuzumab with
lenalidomide/dexamethasone [38] or bortezomib [81].
Clinical Trials of Elotuzumab
In a phase I dose-escalation study, elotuzumab monotherapy was administered to thirty-five
patients with relapsed or refractory myeloma (≥2 prior therapies, median 4.5) [82]. Elotuzumab was
administered in doses ranging from 0.5 to 20 mg/kg once every two weeks. The maximum tolerated
dose was not reached. The treatment response, evaluated according to the European Group for Blood
and Marrow Transplantation myeloma response criteria, showed that nine patients (26.5%) had stable
disease. Common adverse events such as chills, fever and flushing were generally mild to moderate
in severity (grade 1 or 2). Before the protocol amendment, 13 of 25 treated patients suffered from
infusion-related reactions. This study found that CS1 on myeloma cells was highly saturated (>95%)
with antibodies at dose levels of 10 and 20 mg/kg without dose-limiting toxicity. Two more two phases
1 studies were conducted to evaluate the efficacy of combining elotuzumab with other anti-myeloma
agents [81,83]. In the first study, patients with relapsed and refractory multiple myeloma (≥1 prior
therapies (median 3), pretreated with lenalidomide were eligible) were treated with elotuzumab,
lenalidomide and dexamethasone [83]. The overall response rate was 82%, with 29% showing at
least a very good partial response (VGPR) [83]. In the second study, elotuzumab was combined with
bortezomib to treat patients with relapsed and refractory multiple myeloma (1 to 3 prior treatments
(median 2), pretreated with bortezomib were eligible) [81]. The overall response rate was 48%, and the
median time to progression was 9.46 months.
In the pivotal phase III ELOQUENT-2 study, 646 patients with relapsed or refractory multiple myeloma
(1 to 3 prior lines of treatment) received lenalidomide plus dexamethasone with or without elotuzumab [38].
Patients with prior lenalidomide treatment were enrolled if the best response seen was a partial response or
better. The elotuzumab group showed a higher overall response rate than the control group (79% vs. 66%,
p < 0.001). After a median follow-up of 24.5 months, the elotuzumab group showed better progression-free
survival when compared with the control group (19.4 vs. 14.9 months, p < 0.001). Infection was noted
in 81% and 74% of patients in the elotuzumab and control groups, respectively. The most common
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and pneumonia. With steroid premedication, infusion-related reactions occurred in 10% of patients
of the elotuzumab group, mostly grade 1 or 2 [38].
2.3. PD-1/PD-L1
The immune checkpoint inhibitor programmed cell death protein 1 (PD-1)/programmed cell
death ligand 1 (PD-L1) pathway plays a significant role in the evasion of host immunity by tumor
cells [84]. PD-1 is a cell surface receptor of the immunoglobulin superfamily and is expressed on T cells,
B cells, and NK cells [84,85]. Blockade of the PD-1 pathway may restore the cytotoxic function of T cells
against myeloma cells in vitro [86]. Furthermore, T cells produce INFγ, which upregulates PD-L1
expression on tumor and infiltrating immune cells, forming a feedback loop that generates a PD-1
signal maintaining immunosuppression [87]. PD-L1 is highly expressed on malignant plasma cells
from myeloma patients, especially in those with relapsed and refractory disease, but not on normal
plasma cells [86,88]. In multiple myeloma, the expression of PD-L1 can be induced by IL-6, and higher
levels of PD-L1 expression are associated with increased anti-apoptotic ability and more aggressive
behavior of myeloma cells. The binding of PD-1 to PD-L1 has been associated with drug resistance by
myeloma cells [89]. Significantly, PD-L1 is also expressed on cells with immunosuppressive effects
that support the growth of myeloma cells in the bone marrow microenvironment, such as pDCs and
MDSCs [86,90,91], leading to T cell anergy upon cellular contact. PD-L1 is further induced on multiple
myeloma cells by a proliferation-inducing ligand (APRIL) [28,92] or the contact with bone marrow
accessory cells [65,91,93]. It is also expressed on osteoclasts which support myeloma cell growth
and survival in addition to the induction of bone lesions [28]. In preclinical studies, blockade of the
PD-1/PD-L1 pathway was shown to inhibit myeloma cell growth mediated by bone marrow stromal
cells [93]. These studies suggest that targeting PD-1/PD-L1 is promising immunotherapeutic strategy
to overcome the ability of tumor cells to evade host immunity.
Since lenalidomide and pomalidomide (IMiDs) represent an efficient clinical approach in MM
treatment to improve patients’ survival, studies on the regulation of PD-1/PD-L1 pathway by IMiDs
have been reported [93,94]. In addition to promoting tumor apoptosis, IMiDs activate T and NK cells,
thereby increasing NK-mediated tumor recognition and killing. IMiDs stimulate T cell proliferation
and cytokine secretion, decrease the expression of PD-1 on both T and NK cells in MM patients, as well
as decrease both PD-1 and PD-L1 on MM cells. This leads to the inhibition of the negative signal
induced by PD-1/PD-L1 axis on NK and T cells, restoring NK and T cell cytotoxic functions [91].
Thus, the combination of IMiDs with anti-PD-1/PD-L1 blocking strategies could represent a promising
approach to re-establish the recognition of myeloma cells by exhausted NK and T cells to induce
effective immune response. A recent study showed that PD-1/PD-L1 blockade induces anti-multiple
myeloma immune response that can be enhanced by lenalidomide, which provides the framework
for clinical evaluation of combination therapy [93]. Currently, there are at least two PD-1 inhibitors,
nivolumab (IgG4-kappa) and pembrolizumab (IgG4-kappa) approved for solid cancer treatment.
Clinical trials of PD-1/PD-L1 Inhibitors
In a phase 1b study, a PD-1 inhibitor, nivolumab, was administered to patients with relapsed or
refractory hematologic malignancies, including twenty-seven patients with multiple myeloma [95].
No significant disease regression was observed. Stable disease was noted in seventeen patients,
with a median duration of 11.4 weeks.
With respect to the other PD-1 inhibitor, there are two trials showing promising results. In a phase
I trial (Keynote-023), pembrolizumab was combined with lenalidomide and dexamethasone to treat
relapsed or refractory myeloma patients (≥2 lines of prior therapy) [96]. The maximum tolerated dose
for pembrolizumab was a fixed dose of 200 mg with 25 mg of lenalidomide and low-dose (40 mg)
dexamethasone. Thrombocytopenia (47%), neutropenia (41%), and fatigue (29%) were the most
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(76%) responded to treatment, with 4 showing a very good partial response and 9 showing a partial
response. The median duration of response was 9.7 months.
In a phase II study, pembrolizumab was administered with pomalidomide and dexamethasone
to treat forty-eight patients with relapsed or refractory multiple myeloma (≥2 prior therapies) [97].
Autoimmune pneumonitis and hypothyroidism were seen in 13% and 10% of patients, respectively,
mostly less than grade 2. The overall response rate was 60%. With a median follow-up of 15.6 months,
the progression-free survival was 17.4 months. The median overall survival was not reached. A higher
level of expression of PD-1 in bone marrow samples may correlate with improved progression-free
survival [97]. However, two phase III trials comparing lenalidomide or pomalidomide with or
without pembrolizumab have been put on hold due to excess deaths in the pembrolizumab cohort
(http://www.ascopost.com/News/57813) [98].
Regarding antibodies targeting PD-L1, durvalumab is being studied alone and in combination
with lenalidomide (NCT02685826) in patients with newly diagnosed multiple myeloma. Durvalumab,
alone and in combination with pomalidomide (NCT02616640), is being evaluated in patients with
relapsed/refractory disease. Durvalumab in combination with daratumumab or in combination with
pomalidomide, dexamethasone, and daratumumab (NCT02807454). The other anti-PD-L1 antibody
atezolizumab is currently being tested with daratumumab in patients with refractory multiple myeloma
(NCT02431208) and in patients with asymptomatic multiple myeloma (NCT02784483). However, FDA
recently placed a full clinical hold of checkpoint blockade in myeloma based on risks identified in other
trials for an anti-PD-1 antibody, pembrolizumab.
2.4. B-Cell Maturation Antigen (BCMA)
BCMA (B-cell maturation antigen), a glycoprotein and non-tyrosine kinase receptor, is selectively
expressed on the surface of mature B cells or plasma cells, but not naive B cells or most memory
B cells [99–101]. BCMA can be induced by stimulation with cytokines during the differentiation of
plasma cells [102] and plays an important role in the survival of long-lived plasma cells in the bone
marrow [103,104]. It is not required for B cell homeostasis, and BCMA knockout mice is not lethal [104].
Importantly, BCMA is highly expressed in all multiple myeloma patient cells [99–101,105] and its
expression levels correlates with disease status [105,106]. BCMA was being identified as a target
of donor B-cell immunity in patients with myeloma who respond to donor lymphocyte infusion
(DLI) [107]. Thus, in addition to donor T cells mediated graft-versus-myeloma response following
allogenic hematopoietic stem-cell transplantation, the induction of specific antibodies against cell
surface BCMA may directly contribute to tumor rejection in vivo [107]. Importantly, BCMA has a more
specific expression pattern when compared with the other multiple myeloma antigens CD38 and
SLAMF7. Malignant plasma cells have significantly increased BCMA when compared with normal
plasma cells. Other than on plasma cells, BCMA is only detected on pDCs [105,108] which can promote
myeloma cell growth, survival, and drug resistance. However, BCMA expression levels are significantly
lower on pDCs when compared with plasma cells from the same individual, regardless of disease
status. In contrast, all other cells including monocytic DCs, normal cells, and stem cells, do not express
this antigen at mRNA and protein levels. The expression of BCMA on pDCs is significantly greater in
myeloma patients than in normal individuals [105], further supporting BCMA as an ideal target for
myeloma treatment. Moreover, BCMA upregulation in multiple myeloma cells has been associated
with higher PD-L1 expression levels in addition to key survival proteins Mcl1, Bcl2, and Bcl-xL [92].
These data suggest that BCMA may modulate the immune response against multiple myeloma in the
bone marrow microenvironment.
BCMA is shed by gamma-secretase, and soluble BCMA levels in serum are elevated and correlate
with disease activity in systemic lupus erythematosus [102]. Gamma-secretase releases soluble BCMA
that acts as a decoy, neutralizing its cognate ligand a proliferation-inducing ligand (APRIL). Like other
multiple myeloma antigens, i.e., SLAMF7, CD138, CD38, soluble BCMA was detected in the elevated
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proposed that serum BCMA levels may be a new biomarker for monitoring disease status and
overall survival of MM patients. Soluble BCMA levels may also play a pathophysiological role
in multiple myeloma since they could inhibit the ligand (B cell activating factor, BAFF) binding to its
membrane-bound BCMA to induce signaling and stimulate normal B-cell and plasma cell development,
thereby resulting in reduced polyclonal antibody levels [109].
Immunotherapeutically Targeting BCMA
BCMA antibodies were developed with ligand blocking activity that could promote cytotoxicity of
multiple myeloma cell lines as naked antibodies or as antibody-drug conjugates [110]. Recently, antagonistic
humanized anti-BCMA antibody-drug conjugates via a noncleavable linker with auristatins (monomethyl
auristatin E, MMAE or monomethyl auristatin F, MMAF) in preclinical studies demonstrated impressive
in vitro and in vivo anti-multiple myeloma activity [105,111]. The BCMA antibody MMAF (GSK2857916)
directly induces potent G2-M arrest, followed by apoptosis in multiple myeloma cell lines and patient
cells [105]. Compared with its MMAE counterpart, GSK2857916 did not induce any bystander cytotoxicity
when evaluated in co-cultures of MM cells with bone marrow stromal cells. Importantly, GSK2857916 also
induces 1-log higher ADCC and ADPC against MM cells due to its afucosylation via FcR engineering,
when compared with its homolog with normal FcR fragment. A phase 1 clinical study is ongoing,
and preliminary data suggested a clinical activity at higher doses in patients with recurrent disease
(NCT02064387) [112]. Thus far, maximal tolerated dose has not been reached. Adverse events were
manageable, with ocular toxicity emerging as the most frequent reason for dose modifications.
One potential immunotherapeutic strategy is the development of T-cell bispecific antibodies,
which bind simultaneously to a surface tumor cell antigen and a T-cell receptor to induce T cell-mediated
killing of tumor cells harboring the target surface antigen. A BCMA/CD3 bispecific T-cell engager (BiTE®,
Amgen, Thousand Oaks, CA, USA) antibody (BI836909), which was made based on blinatumomab
(Anti-CD19/CD3 BiTE® antibody, Amgen, Thousand Oaks, CA, USA), was tested in a preclinical study
using BCMA on myeloma cells as a target and CD3 on T cells as the other target [113]. Following treatment
with BI836909, selective lysis of BCMA-positive myeloma cells, activation and proliferation of T cells,
as well as release of multiple key cytokines related to effector T cell function (IFNγ, IL-2, IL-6, TNFα,
IL-10) were noted. The anti-myeloma effect of BI836909 was not significantly affected by the presence of
bone marrow stromal cells, soluble BCMA and APRIL (up to 150 and 100 ng/ml, respectively). BI836909
potently induces autologous patient myeloma cell lysis regardless of disease status. Clinical trial of BI836909
(NCT02514239) is ongoing in relapsed and refractory multiple myeloma.
An IgG-based BCMA-T cell bispecific antibody (EM801) also increased CD3+ T cell/myeloma
cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-gamma,
granzyme B, and perforin A [101]. It induced autologous T cell-mediated cell death in 34 of 43 bone
marrow aspirates from patients with myeloma, including those with relapsed or refractory disease.
Pharmacokinetics and pharmacodynamics indicate weekly intravenous/subcutaneous administration
of EM801. Another bispecific antibody against BCMA (BiFab-BCMA) also potently and specifically
redirects T cells to lyse malignant multiple myeloma cells [114]. BiFab-BCMA lysed BCMA-positive
cell lines up to 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed
in an analogous fashion. In addition, the in vitro and in vivo activities of BiFab-BCMA are comparable
to those of anti-BCMA chimeric antigen receptor T cell therapy (CAR-T-BCMA) [114], which has
demonstrated impressive anti-myeloma activity in at least 4 recent clinical trials [115,116].
2.5. A Proliferation-Inducing Ligand (APRIL)
APRIL (a proliferation-inducing ligand), a member of the tumor necrosis factor family, is one of two
ligands for BCMA [117–119]. Compared with the other ligand, BAFF, APRIL is more plasma cell-specific
because it has stronger binding affinity towards receptors on plasma cells [120]. APRIL also binds to the
receptor transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI), but the
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produced by cells in the bone marrow, including myeloid-derived cells, osteoclasts, and DCs. APRIL
can promote the survival of malignant plasma cells and rescue myeloma cell lines from apoptosis after
IL-6 deprivation [92,121,123,124]. APRIL also promotes cell cycle progression in myeloma cells [92,125].
Based on these findings, targeting APRIL to prevent BCMA-mediated activation of myeloma cells
constitutes a potential therapeutic strategy.
Blocking APRIL Biotherapeutics
An antagonistic anti-APRIL antibody hAPRIL01A (01A) was generated to block APRIL binding
to BCMA and TACI [126]. It prevents in vitro proliferation and IgA production of APRIL-reactive
B cells, and effectively impairs the chronic lymphocytic leukemia (CLL)-like phenotype of aging
APRIL transgenic mice. Importantly, this antibody blocks APRIL binding to human B-cell
lymphomas and prevents the survival effect induced by APRIL. Importantly, 01A inhibits APRIL-
and osteoclast-induced myeloma cell proliferation and further induces apoptosis of myeloma cells in
co-cultures [92]. 01A significantly blocks the growth of myeloma cells in a SCID-hu murine model,
where multiple myeloma cells grow in the bone chips implanted in SCID mice. 01A augmented the
cytotoxicity mediated by IMiDs and proteasome inhibitors in the co-cultures of myeloma cells with
BCMA-negative bone marrow accessory cells and effector cells. Furthermore, following 01A treatment,
APRIL-induced expression of genes involved in immunosuppression, i.e., PD-1, transforming growth
factor beta (TGF-β), and interleukin 10 (IL-10), is decreased in multiple myeloma cells [28,92,127].
BION-1301, the clinical candidate for 01A, will be tested soon in multiple myeloma.
2.6. Potential Targets
Several additional cell surface antigens with therapeutic potential have been identified [128–131].
BAFF (B-cell activating factor) is a member of the TNFα superfamily that promotes the adhesion of
myeloma cells to bone marrow stromal cells via activation of the AKT/NF-κB signaling pathway [122].
High levels of BAFF have been described in patients with multiple myeloma [121,132]. In an animal
model of MM, mice treated with anti-BAFF antibody had significantly lower levels of soluble human
IL-6 receptor and improved survival when compared with controls [132]. Tabalumab, a humanized
monoclonal antibody targeting BAFF, was evaluated in a phase I clinical trial with bortezomib [133].
FcRH5, a B-cell lineage marker broadly expressed in myeloma, was targeted as one of the T-cell
bispecific antibodies to induce T cell-mediated killing of FcRH5-expressing tumor cells [131]. PD-L1
blockade further enhanced the activity of FcRH5-CD3 T-cell bispecific antibody, suggesting the
possibility for combination therapy in patients with multiple myeloma. Other therapeutic targets that
are also being rigorously evaluated include IL-6 [134–137], CD40 [138], CD138 [139], MUC-1 [140] and
Dickkopf-1(DKK-1) [141].
3. Conclusions
The development of monoclonal antibodies targeting selective multiple myeloma antigens
represents an important advance in the improvement of effective immunotherapies for patients
with multiple myeloma. In addition to various mechanisms mediated via FcR-expressing effector
cells (ADCC, CDC or ADCP), monoclonal antibodies can produce immunomodulatory effects
on immune cells in the bone marrow microenvironment by decreasing the function and number
of immunosuppressive cells and restoring the tumor-killing activities of immune effector cells
(Table 1). Such novel immunomodulatory effects may further lead to deepened clinical responses
and improved efficacy, which is exemplified by daratumumab in recent large phase 3 clinical trials.
Previous clinical trials have demonstrated that monoclonal antibodies constitute an efficacious
therapeutic option even for heavily pretreated patients with relapsed and refractory multiple
myeloma [142]. Either as a single agent or combined with other anti-myeloma drugs as well as
immune checkpoint blockade and vaccination strategies, these antibodies will further improve the
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ideal partners to combine with other anti-myeloma agents in the search for better and more durable
responses in patients with all stages, especially in early disease when the immune cells are still
functional. In the case of monoclonal antibodies that have already been approved for the treatment
of relapsed and refractory myeloma, their possible role as frontline treatments is being rigorously
investigated. Ongoing and future studies are addressing the issue of which combinations are most
effective at various stages of the disease. With the continued rapid development of novel monoclonal
antibodies, we can expect transformation of the treatment landscape and associated improvement in
patient outcome.
Table 1. Summary of monoclonal antibodies used in the treatment of myeloma.
Target Name of the Antibody Anti-Myeloma Mechanism Immunomodulatory Effects
CD38 Daratumumab
CDC, ADCC, ADCP, induction of apoptosis
when crosslinked, enzymatic modulation [36]
1. Deletion of CD38+ Tregs and Bregs [57]
2. Expansion of CD8+ cytotoxic T cells
and CD4+ helper T cells [57]
[34,35] CD38 Isatuximab
ADCC, CDC, ADCP, direct cell death via
lysosome-mediated and apoptotic pathway [62]
1. Augmentation of NK and CD8+ T
effector cell-mediated anti-tumor
immune responses [65]
2. Reduction of Foxp3 and IL10 in Tregs [65]
3. Restoration of proliferation and function
of naive T cells [65]
CD38 MOR03087 ADCC, ADCP [69,70]
Activation of immune effector cells
(Combined with IMID) [69,70]
SLAMF7/CS1 Elotuzumab ADCC [34,35] Activation of NK cells [79,143]
PD1 Pembrolizumab Induction of apoptosis [86] Activation and proliferation of T cells [86]
Nivolumab
BCMA BI 836909 Potent induction of apoptosis [113]
BCMA- induced T-cell activation and
cytokine release [113]
GSK2857916
ADCC, ADCP, G2-M arrest followed
by apoptosis [105]
1. Improved potency and efficacy of
effector cell-mediated MM cell lysis [105]
2. G2-M growth arrest followed
by apoptosis
EM801 Induce myeloma cell death by autologousT cells [101] Activation of CD4
+/CD8+ T cells [101]
APRIL BION-1301 Blockage of APRIL-induced growth andsurvival, induction of apoptosis [92]
Decreased expression of PD-1,
TGF-βand IL-1 genes) [92]
CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-
dependent cellular phagocytosis. IMID, immunomodulatory drugs; NK, natural killer cell; SLAMF, signaling
lymphocytic activation molecule F7; BCMA, B-cell maturation antigen; APRIL, proliferation-inducing ligand.
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Abstract: Isocitrate dehydrogenase 1 (IDH1) gene mutations have been observed in a majority of
diffuse astrocytomas, oligodendrogliomas, and secondary glioblastomas, and the mutant IDH1
R132H is detectable in most of these lesions. By specifically targeting the R132H mutation through
B-cell cloning, a novel rabbit monoclonal antibody, MRQ-67, was produced that can recognize mutant
IDH1 R132H and does not react with the wild type protein as demonstrated by Enzyme-linked
immunosorbent assay (ELISA) and Western blotting. Through immunohistochemistry, the antibody
is able to highlight neoplastic cells in glioma tissue specimens, and can be used as a tool in
glioma subtyping. Immunohistochemistry (IHC) detection of IDH1 mutant protein may also be
used to visualize single infiltrating tumor cells in surrounding brain tissue with an otherwise
normal appearance.
Keywords: IDH1; R132H; novel rabbit monoclonal antibody; B-cell cloning; immunohistochemistry
1. Introduction
Isocitrate dehydrogenase 1 (IDH1) functions as an enzyme in the Krebs (citric acid) cycle and is
biologically active in the cytoplasmic and peroxisomal compartments under normal conditions [1].
Somatic mutations in the gene that encodes IDH1 have been reported to be present in some glioma
subtypes in high frequencies. The majority of these particular tumors have been found to harbor
heterozygous point mutations in codon 132, with a missense amino acid substitution of arginine
to histidine (R132H) being observed to have highest rate of occurrence [2]. The high incidence of
glioma-specific IDH1 mutations has implicated them as an early event that occurs during gliomagenesis
and provides utility in distinguishing low grade astrocytomas and oligodendrogliomas, as well as
secondary glioblastomas from reactive gliosis and primary glioblastomas [3]. The value of this mutant
marker is further illustrated by the 2016 World Health Organization (WHO) Classification of Tumors
of the Central Nervous System that newly incorporates IDH1 mutation status as a parameter for
sub-classifying diffuse astrocytic and oligodendrogliomal tumors [4]. While genetic testing can be
burdensome, a clinically established routine procedure like immunohistochemistry (IHC), using a
specific monoclonal antibody directed against IDH1 R132H mutant protein, represents a useful tool
for overcoming this diagnostic challenge.
This study describes the generation and performance of a novel rabbit monoclonal IDH1 R132H
antibody (MRQ-67) by single B-cell cloning technology, a recently emerging strategy for monoclonal
antibody development [5]. The capacity of MRQ-67 to identify mutant IDH1 R132H without reacting
with wild type protein is demonstrated through binding specificity assays. The functional utility
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of the antibody to specifically detect mutant IDH1 protein in astrocytomas, oligodendrogliomas,
and glioblastomas is also examined through immunohistochemical analysis.
2. Materials and Methods
2.1. Tissue Specimens
Immunohistochemical evaluation of MRQ-67 performance was assessed using formalin-fixed,
paraffin-embedded (FFPE) tissue specimens, which included 18 cases of astrocytoma, 7 cases of
oligodendroglioma, 7 cases of glioblastoma, 12 cases of meningioma, and 15 cases of non-neoplastic
brain tissue. The FFPE tissue specimens used in this study were procured, qualified, and tested in
accordance with the U.S. Food and Drug Administration (FDA) “Guidance on Informed Consent
for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually
Identifiable”. This study exclusively used leftover tissue specimens that are not individually identifiable
for conducting IHC testing. More specifically, these are remnants of human specimens collected for
routine clinical care or analysis that would have otherwise been discarded and where the identity
of the subject is not known to, or may not be readily ascertained by, any individual associated with
this study.
2.2. Immunization
New Zealand White Rabbits were immunized with synthetic peptide CKPIIIGHHAYGD coupled
to Keyhole limpet hemocyanin (KLH) corresponding the amino acids 126 to 137 of the human IDH1
containing R132H mutation. All of the housing and immunization procedures were performed by
Antibodies Incorporated (Antibodies Inc., Davis, CA, USA), according to the approved protocols and
guidelines of the Institutional Animal Care and Use Committee (IACUC). The project numbers were
5834 and 5835 under IACUC protocol 0298-9 “Custom Polyclonal Antibody Production in Rabbits”,
approved on 1 July 2016 (PHS Assurance number A4064-01).
2.3. Isolation and Sorting of Rabbit B-Cells
Peripheral blood mononuclear cells (PBMCs) were isolated from the ethylenediaminetetraacetic
acid (EDTA) containing peripheral blood by density-gradient centrifugation with Lympholyte-Mammal
(Cedarlane, Burlington, NC, USA), as described in the manual. The isolated PBMCs (107 cells) were next
washed with RPMI (Life Technologies, Carlsbad, CA, USA) containing DNase I (Roche, Basel, Switzerland)
and re-suspended in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA). Then,
the IgG expressing B-cells were isolated using Anti-Rabbit IgG Microbeads (Miltenyi Biotech, Auburn,
CA, USA).
The isolated B-cells were stained for viability, incubated with a cocktail of anti-rabbit IgG and
fluorochrome-conjugated specific peptide in the dark for 30 min at 4 ◦C, and washed with ice-cold PBS.
Finally, cells were re-suspended in PBS and subjected to Fluorescence Activated Cell Sorting (FACS)
analyses. Sorting was carried out using BD Influx Cell Sorter and BD FACS DIVA software (UC Davis
Medical Center, Sacramento, CA, USA). Single B-cells expressing IgG were sorted into a 96-well plate
(omitting row H).
2.4. Cloning Antibody Variable Regions
Single-cell reverse transcription polymerase chain reaction (RT-PCR) was performed with reverse
transcriptase Superscript III First-Strand Synthesis system (Life Technologies, Carlsbad, CA, USA).
Next, the RT-PCR reaction mixtures were used for subsequent polymerase chain reaction (PCR)
reactions to amplify variable regions of IgG heavy chain (VH) and light chain (VL). The VH and VL
were separately cloned in pTrans-CMV-MCS expression vectors (CEVEC, Köln, Germany) containing
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2.5. Transfection
Primary human amniocytes CAP-T cells (CEVEC, Köln, Germany) were transiently co-transfected
with vectors containing the codon sequences of heavy chain and light chain originating from the
same sorted cell using NovaCHOice® transfection kit (MilliporeSigma, Billerica, MA, USA), and the
supernatants were harvested after seven days for evaluation by Enzyme-linked immunosorbent assay
(ELISA), Western blotting, and IHC.
2.6. ELISA
The concentration of the IgG released by transfected cells was measured using Rabbit IgG ELISA
kit (ZeptoMetrix Corp., Franklin, MA, USA). Serial dilutions of a rabbit IgG antibody (60, 30, 15, 7.5,
3.75, and 0 ng/mL), provided by the kit, were used to set up a standard curve. The specificity of the
antibody was determined by immobilizing biotinylated synthetic peptides (provided by Antibodies Inc.,
Davis, CA, USA) KPIIIGHHAYGD (mutant) or KPIIIGRHAYGD (wild type) on a 96-well plate. The plate
was coated with 2 μg/mL streptavidin (MilliporeSigma, Billerica, MA, USA) overnight at 4 ◦C and
then the peptides were immobilized at 1 μg/mL for one hour at room temperature. After blocking
with 5% skim milk for an hour, the plate was probed with the supernatant of transfected cells or a
commercially available mouse monoclonal IDH1 R132H H09 antibody (Dianova, Hamburg, Germany)
at different concentrations, starting from 1 μg/mL and lower and incubated for an hour at 37 ◦C.
Next, a peroxidase-conjugated anti-rabbit IgG anibody (Jackson ImmunoResearch Lab, West Grove,
PA, USA) (1:1000) was added to the plate and incubated for an hour at room temperature. The enzymatic
reaction was conducted with Tetramethylbenzidine (TMB) (MilliporeSigma, Billerica, MA, USA) at room
temperature and stopped by 0.25 M Sulfuric acid (MilliporeSigma, Billerica, MA, USA). The optical
density was measured at 450 nm. The plate was washed four times after every step with PBS containing
0.05% Tween 20 (MilliporeSigma, Billerica, MA, USA).
2.7. Western Blotting
100 ng of recombinant human IDH1 R132H protein and wild type IDH1 protein (Abcam, Cambridge,
MA, USA) were loaded onto 4–12% Bis-Tris mini gels (Life Technologies, Carlsbad, CA, USA) and blotted
to PVDF membranes (iBlot™ Transfer Stack, PVDF, Invitrogen, Carlsbad, CA, USA). The Western
blot was carried out using WesternBreeze Chromogenic kit (Invitrogen, Carlsbad, CA, USA) and the
supernatant of the transfected cells (0.5 μg/mL IgG) or H09 (0.5 μg/mL antibody) were used to probe
the membranes.
2.8. Immunohistochemistry
FFPE tissue samples were sectioned at a thickness of 4 μm and were prepared on Superfrost™
Plus microscope slides (Fisherbrand™, Pittsburgh, PA, USA). Prepared slides were stained by routine
IHC on a BenchMark ULTRA automated staining instrument (Ventana Medical Systems Inc., Tucson,
AZ, USA). Tissue slides were incubated for 64 min at 95 ◦C using an EDTA-based epitope retrieval
solution, followed by a 32 min primary antibody incubation at 36 ◦C. Staining signal was visualized
through a horseradish peroxidase (HRP)-based multimer detection system and 3-3′-Diaminobenzidine
(DAB) chromogen. Counterstaining was performed by incubating tissue slides for 4 min with
Hematoxylin II, followed by a 4 min incubation with bluing reagent. Stained slides were evaluated
using light microscopy for target signal intensity and background signal by a qualified pathologist.
Tumor cells exhibiting a strong, diffuse cytoplasmic staining pattern, as well as weaker nuclear labeling,
were scored as positive for IDH1 mutant protein. The H09 antibody was used as a reference comparison
during performance testing of the antisera from immunized rabbits and optimization of the selected
MRQ-67 clone. The H09 clone further served in establishing the IDH1 R132H mutation status of glioma
samples that were used in this study. The same automated staining conditions were used for both the
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each clone individually. The MRQ-67 and H09 clones were determined to perform optimally in IHC at
concentrations of 2.54 μg/mL and 3.25 μg/mL, respectively.
3. Results
Four rabbits were immunized with the synthetic IDH1 R132H mutant peptide. Sera from
immunized rabbits were tested by IHC. The PBMCs from the rabbit with the best immune response
were isolated for cloning of VH and VL, followed by co-transfection in CAP-T cells.
ELISA analyses of the transfection reactions confirmed the production of rabbit IgG by 73% of
the clones (Figure 1a). The positive clones were further screened for specificity of the antibodies
and among them, antibody MRQ-67 generated by clone C5 was selected for further evaluations.
As shown in Figure 1b, the MRQ-67 antibody specifically reacted with mutant peptide IDH1 R132H in
a dose-dependent manner, but not with the wild type peptide IDH1 in ELISA assay, indicating that
MRQ-67 specifically recognized IDH1 R132H. This result was consistent with the result obtained using
the control antibody, H09 (Figure 1b).
Figure 1. Generation and performance of rabbit monoclonal MRQ-67 antibody against IDH1 R132H
and comparing its function with the H09 antibody by Enzyme-linked immunosorbent assay (ELISA)
and Western blotting assays: (a) The concentration of antibody generated by clones was measured in
μg/mL by rabbit IgG ELISA kit; (b) Peptide binding ELISA. MRQ-67 antibody specifically recognized
only mutant IDH1 R132H peptide and not wild type IDH1 peptide. The ELISA binding assay result
for the H09 antibody has been included as a control; (c,d) Analysis of MRQ-67 and H09 for detecting
recombinant human IDH1 R132H and recombinant human IDH1 wild type proteins in Western blotting.
MRQ-67 (c) and H09 (d) antibodies (0.5 μg/mL) were used to probe the membranes. Coomassie blue
stainings of the proteins are shown as loading control.
The MRQ-67 antibody’s specificity was further analyzed by Western blotting and compared
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recombinant IDH1 R132H protein at a predicted molecular weight of 48 kDa for human IDH1 protein.
Notably, while MRQ-67 antibody did not detect any band on the blot with wild type recombinant IDH1
protein (Figure 1c), the H09 antibody showed a weak reaction with this protein (Figure 1d). Overall,
this data indicates that MRQ-67 is also useful in detecting not only IDH1 R132H peptide, but also the
mutant IDH1 R132H protein.
To further characterize the rabbit IDH1 R132H monoclonal antibody, the capacity of the MRQ-67
antibody to immunohistochemically identify IDH1 mutant protein in FFPE tissues was investigated.
The IHC staining results summarized in Table 1 demonstrate equivalent sensitivity and specificity
performance of the MRQ-67 clone in comparison to H09 for distinguishing low grade gliomas from
glioblastomas, meningiomas, and benign brain samples. The MRQ-67 clone generated strong, diffuse
cytoplasmic staining with weaker nuclear reactivity in 50% of the diffuse and anaplastic astrocytomas
(Figure 2a) that was equivalent to performance observed with H09 (Figure 2b). Positive tumor staining
in 71% of oligodendroglioma samples by MRQ-67 was primarily demonstrated by cytoplasmic
reactivity (Figure 3a) and was comparable to observed results from H09 testing (Figure 3b). From the
seven high grade glioblastoma cases that were tested, only one reacted positively with MRQ-67 as
indicated by weakly diffuse cytoplasmic and nuclear staining (Figure 4a), while no tumor cells were
labeled in the rest of the tested cases (Figure 4b).
Table 1. IDH1 R132H immunohistochemistry (IHC) staining data. Summary of IHC staining results
comparing the number of cases stained positive out of the total number of cases tested with the MRQ-67
and H09 clones.
Tissue Cases Stained (MRQ-67) Cases Stained (H09)
Astrocytoma 9/18 (50%) 9/18 (50%)
Oligodendroglioma 5/7 (71%) 5/7 (71%)
Gliobastoma 1/7 (14%) 1/7 (14%)
Meningioma 0/12 0/12
Non-neoplastic Brain 0/15 0/15
Figure 2. Comparison immunohistochemistry (IHC) staining results with MRQ-67 and H09 in
astrocytoma: (a) Strong, diffuse cytoplasmic and weak nuclear labeling of tumor cells with MRQ-67 in
a case of anaplastic astrocytoma (100×); (b) Equivalent cytoplasmic and nuclear staining of tumor cells
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Figure 3. Comparison immunohistochemistry (IHC) staining results with MRQ-67 and H09 in
oligodendroglioma: (a) Strong cytoplasmic and weak nuclear labeling of tumor cells with MRQ-67 in a
case of WHO grade II oligodendroglioma (200×); (b) Comparable cytoplasmic and nuclear staining of
tumor cells with H09 in the same case of oligodendroglioma (200×).
Figure 4. MRQ-67 immunohistochemistry (IHC) staining results in high grade glioblastoma: (a) Weak,
diffuse cytoplasmic and nuclear labeling of tumor cells in a case of WHO grade IV glioblastoma with
anaplastic astrocytoma involvement (200×); (b) No observed reactivity in tumor cells in another case
of WHO grade IV glioblastoma (100×).
In all cancerous and benign brain samples tested, the MRQ-67 antibody did not react with
endothelial cells, lymphocytic cells, or normal glial cells. The 15 cases of benign brain (Figure 5a,b)
and 12 cases of meningioma (Figure 6c,d) that were assessed displayed no observable cross-reactivity,
with only two cases (16%) of meningioma demonstrating equivocal background staining signal when
tested using MRQ-67. However, meningioma samples stained with the H09 clone generated nonspecific
background signal in fibrillar and spindle cell components in 11 out of 12 cases (92%), with 4 cases
(33%) in particular developing notably strong background staining (Figure 6a,b). One particular case
of benign brain was observed to have a small focus of tumor cells that was identified by anti-IDH1
R132H (Figure 7a). Importantly, the surrounding distal nervous tissue was identified to consist of
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Figure 5. MRQ-67 immunohistochemistry (IHC) staining results in normal brain: (a) No observed
reactivity in the normal cell types that constitute the gray and white matter in the cerebellar region of
the brain (40×); (b) No observed reactivity in normal cerebral nervous tissue (100×).
Figure 6. Comparison immunohistochemistry (IHC) staining results of MRQ-67 and H09 in meningioma
specimens: (a) The H09 clone displayed positive reactivity in spindle cells of a meningioma sample
(200×); (b) Positive labeling of fine fibrous elements by the H09 clone in another case of meningioma
(200×); (c) The MRQ-67 clone demonstrated no cross-reactivity with spindle cells in the same meningioma
case stained with the H09 clone (200×); (d) MRQ-67 also did not generate cross-reaction with fibrous
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Figure 7. MRQ-67 immunohistochemistry (IHC) staining results in a primarily benign brain sample with
a small tumor focus and some scattered tumor cells: (a) Cytoplasmic and weak nuclear labeling of cells
within a small tumor focus of a benign brain sample (200×); (b) Scattered reactivity in single infiltrative
tumor cells of the same benign brain case that have dispersed from the focal tumor site (100×).
4. Discussion
In the specific targeting of the IDH1 R132H mutation through B-cell cloning, a novel rabbit
monoclonal antibody was produced that promises to be a useful tool for overcoming the diagnostic
challenge of differentiating between different subtypes of glioma. The single B-cell cloning technology
used to generate MRQ-67 is an attractive method for developing high quality monoclonal antibodies
that has several advantages over previously established techniques. This technology is more efficient
than cell fusion in hybridoma technique [6], and unlike display methods (e.g., phage display [7] and
yeast surface display [8]), both heavy and light chains originate from a single sorted cell. This allows
for the natural cognate pairing of the heavy and light chains to be preserved during synthesis and
maturation of the antibody [5]. Moreover, culturing of isolated B-cells is not required, which removes
a potential source of technical complications from the process.
In ELISA assays and Western blotting analyses, the MRQ-67 rabbit monoclonal antibody reacted
with mutant IDH1 R132H, but not with wild type IDH1. This data indicates that MRQ-67 is capable of
specifically detecting not only IDH1 R132H peptide, but also the mutant IDH1 R132H protein without
cross-reacting with wild type IDH1. The specificity of MRQ-67 to the R132H mutation had not been
tested against other less frequent mutations of IDH1 at the time of this report.
Identification of IDH1 mutation status by IHC presents a useful tool for many diagnostic
institutions where genetic testing can be burdensome and may be inaccurate, especially regarding
tissue samples with low tumor cell content. Detection by IHC provides the opportunity to visualize
even single infiltrating tumor cells in otherwise normal appearing brain tissue. The IDH1 status of FFPE
tissue samples used in this study had not been determined by sequencing at the time of this report.
IDH1 mutation status of these tissues was therefore established through the use of the commercially
available mouse monoclonal IDH1 R132H (H09) antibody.
Rabbit monoclonal anti-IDH1 R132H (MRQ-67) labeled each of the same cases as H09, indicating
comparable ability to detect IDH1 mutant protein by IHC. However, the H09 clone generated
nonspecific background signals in the fibrillar and spindle cell components in nearly all meningioma
cases tested, with a few cases in particular developing notably strong background staining.
The observed cross-reaction with fibrous elements in meningioma cases has been previously identified
as nonspecific binding by anti-IDH1 R132H to extracellular matrix protein or a subtype of collagen
fiber [9]. Staining with the MRQ-67 clone demonstrated only two instances of weak, nonspecific
background signal in meningioma samples, indicating a particular advantage in specificity compared
to the H09 clone. Since no immunoreaction was observed in meningioma tumor cells or normal brain
samples, all tumor cells that stained are considered to be IDH1 mutant-positive, including the single
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The presence of IDH1 mutations has been indicated to be much more frequent in secondary
glioblastomas compared to primary glioblastomas [10]. Clinical information regarding the progression
of the single case of glioblastoma in this study with identified mutant IDH1 staining signal was
not available, but histopathological evidence of lower grade glioma involvement was observed.
Further, population-based data indicates a considerably greater incidence rate of primary glioblastoma
compared to that of secondary glioblastoma [11]. These observations, together with H09 comparison
staining data in glioblastoma samples, suggest that MRQ-67 functions as intended for IHC applications.
Overall, the results from ELISA assays, Western blotting, and IHC analyses support the proposed
utility of the novel rabbit monoclonal MRQ-67 antibody in the identification of mutated human IDH1
protein. IDH1 (MRQ-67) rabbit monoclonal antibody is a specific marker for immunohistochemical
detection of IDH1 mutant protein in glioma subtypes and may have value as a tool in distinguishing
between diffuse astrocytomas and oligodendrogliomas from secondary glioblastoma.
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Abstract: Substantial improvements have been made to cell culturing processes (e.g., higher product
titer) in recent years by raising cell densities and optimizing cultivation time. However, this has
been accompanied by an increase in product-related impurities and therefore greater challenges
in subsequent clarification and capture operations. Considering the paradigm shift towards the
design of continuously operating dedicated plants at smaller scales—with or without disposable
technology—for treating smaller patient populations due to new indications or personalized medicine
approaches, the rising need for new, innovative strategies for both clarification and capture technology
becomes evident. Aqueous two-phase extraction (ATPE) is now considered to be a feasible unit
operation, e.g., for the capture of monoclonal antibodies or recombinant proteins. However, most of
the published work so far investigates the applicability of ATPE in antibody-manufacturing processes
at the lab-scale and for the most part, only during the capture step. This work shows the integration
of ATPE as a combined harvest and capture step into a downstream process. Additionally, a model is
applied that allows early prediction of settler dimensions with high prediction accuracy. Finally, a
reliable process development concept, which guides through the necessary steps, starting from the
definition of the separation task to the final stages of integration and scale-up, is presented.
Keywords: interfacial partitioning; cell harvest; capture; aqueous two-phase extraction; horizontal
settler; static mixer; process integration; continuous phase separation
1. Introduction
Clarification processes and their corresponding devices, which are already well established
in other industry sectors, e.g., flocculation, precipitation, or flotation, are increasingly being taken
into consideration as alternatives in monoclonal antibodies (mAb) production in spite of individual
limitations like process robustness, process cost, toxicity of flocculation or precipitation agents, and
easy scale-up [1]. A quite promising concept is the application of aqueous two-phase extraction
(ATPE) as a combined harvest and capture step, especially since this approach deals with all the
aforementioned issues.
Interfacial partitioning of cells, cell debris, and other bioparticles occurs when a mixed system
composed of phase-forming components begins to separate into its specific light and heavy phases [2–4].
During the process of settling and coalescence, particles and small solid objects accumulate at the
surface of the dispersed phase (Figure 1). This phenomenon can be explained by the fact that the
partitioning behavior of small particles is strongly dependent on surface forces [5].
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Figure 1. Cell clearance through interfacial partitioning. ATPE: Aqueous two-phase extraction.
Approaches for the combination of liquid–liquid extraction (LLE) and the separation of small
particles by adsorption towards a dispersed phase are well investigated. These include interfacial
partitioning for the recovery of bioparticles in general, three-phase partitioning (TPP) where interfacial
partitioning is combined with the precipitation of proteins, or more recently, aqueous two-phase
flotation, where gas bubbles are introduced as a dispersed third phase into an already separated
aqueous two-phase system (ATPS) [6–8]. However, most approaches so far design the process around
the particle-loaded phase because the solid phase contains the product. Some research has also been
conducted towards interfacial partitioning for the removal of unwanted particles from a feed stream,
which is especially necessary during the clarification of cultivation broths in the manufacturing process
of monoclonal antibodies. However, to establish this technology in industry, there is also the need for
a process development strategy that guides through the necessary steps, starting from the definition of
the exact separation task, to the experiments necessary for the determination of crucial process and
model parameters, up to the design considerations for optimal equipment dimensions. In this work,
an ATPE process is outlined for the clarification of up to 12,000 L of cultivation broth in a time window
of less than 3 h.
2. Theory
2.1. General Considerations
Unlike in the conventional production process of mAb, centrifugation and microfiltration as
harvest and clearance operations are replaced with the outlined ATPE process. After the filtration trains,
the product stream can, depending on the future process strategy, be further purified by precipitation
or by integrated counter-current chromatography (iCCC) for continuous capture, replacing traditional
protein A chromatography, as wells as ion-exchange and hydrophobic interaction chromatography for
further purification and polishing [9–14].
The flowsheet of the discussed process, including the two purification and polishing operations,
is shown in Figure 2. It provides a precise and straightforward view of how ATPE is integrated into
the overall purification strategy. To quickly get an overview of all process-relevant effects, it is helpful
to construct a cause-and-effect diagram, also known as an Ishikawa or fish bone diagram. It is meant
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is constructed of primary branches, which organize specific groups of effects. They can be fanned
out further into major branches, representing major causes. Minor branches can be integrated as
well to show the relationship between cause and effect in even more detail. Most diagrams have
environment, people, materials, equipment, measurement systems, and methods as the primary
branches. Though the diagram can be constructed like this, the causes and effects specific to the
outlined ATPE targets is shown in Figure 3.
Figure 2. Process segment as discussed in the risk assessment. LP: Light phase. HP: Heavy phase.
iCCC: integrated counter-current chromatography.
Figure 3. Ishikawa diagram illustrating the main groups of causes affecting yield, purity, and cell
reduction in the outlined ATPE process. ATPS: separated aqueous two-phase system; HCP: host
cell proteins.
The groups of causes in the diagram are set up by considering so-called prior knowledge.
The green branch summarizes the factors that arise from upstream processing (USP) during cultivation
and harvesting of the target parameters in this process step. There are several factors that can be
optimized during upstream process development, like cultivation time, feed media, and supplement
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by Gronemeyer et al. [15]. The overall cell number or cell concentration is very important to consider,
since ATPE as a harvest operation aims to remove most of the particles to lower the burden for the
subsequent filtration trains. In addition to that, higher cell numbers decrease the settling velocity
inside the apparatus as during interfacial partitioning the cells adsorb on the dispersed phase and
hinder the coalescence of the droplets [3,16,17]. The effect of overall protein content, which is, for
the most part, the sum of the mAb and the host cell proteins (HCP), needs to be considered as well.
In most cases, protein partitioning between the specific light phase and heavy phase is a function of
protein concentration, where total partitioning is only observable for low protein concentrations [18,19].
However, by increasing the polarity of the heavy phase, protein solubility can be significantly lowered
due to salting-out effects, resulting in very high partitioning coefficients for the target component
towards the light phase [18,20,21]. There are two main side-effects of this: firstly, salting-out very often
affects HCP in the same way as mAb, which means that achieving high yield comes at the cost of
low protein-based purity. Secondly, total partitioning of all proteins, in combination with purposely
lowering the volume of the light phase in order to concentrate the target component, can lead to
protein saturation and precipitation [22,23].
The considered effects are also included in the second primary branch, which organizes the
effects of ATPS composition and phase properties (marked blue in Figure 3). The effects of ATPS type,
composition, and phase properties are discussed widely in literature [21,24–28]. The identification
of a potential operation space should, at this point, already have occurred in a system optimization
study [29].
The third primary branch organizes the influences of the applied equipment (marked red in
Figure 3). There are several potential devices available for LLE in general, and ATPE specifically.
An extensive overview was published by Espitia-Saloma et al. [30]. In the outlined ATPE process, the
combination of a static mixing pipe and a horizontal settler is applied. Although gravity settling is a
relatively robust process, even slight changes to inlet geometry or the installation of a baffle have been
shown to have a noticeable impact on the settling behavior [31].
As a further step, a risk assessment considering the relative impact and the relative occurrence of
the different branches is applied. This assessment considers factors like temperature, which influences
the settling behavior, and changing flow rates, which influences the hydrodynamic residence time and
the specific power input.
Both parameters—temperature and changing flow rates—can potentially negatively impact the
yield, purity, and cell reduction performance of the ATPE as illustrated in Figure 4. Increasing process
temperatures can alter the intrinsic material properties of the phase-forming components which,
like reducing the viscosities, could result in the creation of smaller droplets and, in the presence of
cells, cell debris, and other solids, very large separation times [31]. However, coalescence kinetics in
general are accelerated at higher temperatures, such that particle-free ATPS separation times can be
reduced. Furthermore, the phase equilibrium itself is dependent on the temperature, since it affects
the composition of the specific light and heavy phases, and therefore also changes the partitioning
behavior of the target and side components [32–34]. The total flow rate determines the hydrodynamic
residence time within the apparatus, but can result in an unnecessary firm dispersion. It is even
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Figure 4. Occurrence–impact diagram for the outlined ATPE process.
2.2. Process Development
Process development starts by defining the design space that is feasible from an economic point of
view, but also safe in terms of reliable process performance. Since ATPE in this work is applied mainly
as a clarification operation, the parameter which characterizes the process performance of this step, is
the reduction in total cell number. One important quality measure for the monitoring of subsequent
filtration, precipitation, or chromatography steps is the particle load of intermediate pools. This is
because, other than the cells themselves, cell debris (precipitated material, etc.) can also lead, above
certain values, to either a blockage or the underperformance of these further purification and polishing
steps. Particle load can be characterized by turbidity measurements or state-of-the-art DLS (dynamic
light scattering) methods. Based on so-called prior knowledge, the equipment chosen for mixing the
phase-forming components is a static mixing pipe, which offers gentle and homogeneous mixing at
the same time. ATPS loaded with bio-particles tends to form strong emulsions when too much power
is introduced into the system [31]. The specific light and heavy phases are separated in a horizontal
settler unit. This apparatus is ideal for single stage LLE since it is easy to scale-up and is proven to
show reliable separation performance even when confronted with high particle burdens.
2.3. Batch-Settling Behavior
To enable the early prediction of settler dimensions, other than physical properties, settling and
coalescence rates must also be determined.
The settling behavior of an ATPS can be mathematically described by three model parameters.
The aim is to describe the influence of different material parameters on the separation behavior.
















The settling time is dependent on the ratio of the interfacial tension between the phases (σ) and the
viscosity of the continuous phase (μc). The values are composed of the dispersed (μd) and continuous
viscosities, the interfacial tension of water (σw) and the two phases, as well as the density difference of
the dispersed and continuous phases (Δρ) and the density of the continuous phase (ρc). The exponents
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2.4. Early Prediction of Settler Dimensions
To get a rough estimation of the dimensions of the apparatus, volume flow (
.
V) is calculated,







The length can then be calculated using volume flow and the predetermined residence time (tRDT),






Further influencing variables, such as the drop size, sedimentation rates, or other parameters
influencing coalescence, are not taken into account. This quick estimation is often referred to as
minimum-apparatus-volume (MAV).
2.5. Henschke Method for Settler Dimensioning
A procedure to calculate the dimensions of horizontal settler units was introduced in 1994 [38].
It was derived from aqueous organic systems and is investigated here in terms of its suitability for
bio-particle loaded aqueous two-phase systems. In this model, the power input, sedimentation rate,
and coalescence behavior of the single droplets are taken into account. To examine these influencing
factors more precisely, the length of the separator (LS) is divided into two regions: the inlet area of the
dispersion (Lin) and the coalescence region (Lc) (Figure 5).
Figure 5. Structure of the settler unit [38]. ATPS: Aqueous two-phase system. LS: Length of the
separator. Lin: Inlet length. Lc: Coalescence length.
In the inlet area, occurring turbulences and the formation of a droplet layer are considered.
Within the apparatus, drop coalescence and the formation of the densely packed layer (hp) are of





VDis × (11.3 × s × ηDis + 126 × (ηc + ηd))
hp × D3S × εp × (1 − εP)× Δρ × g
(3)
It is dependent on the dispersion volume flow (
.
VDis), the dispersion viscosity (ηDis), a slippage
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layer (εP). The settling time (ts) is normalized to level out the influence of long coalescence times at
the boundary surface. The compensation parameter is (C*). With the aid of these two parameters, the













It is dependent on the final height of dispersed phase in a batch-settling experiment (Hd,0), the
volume flow of dispersed phase (
.
Vd,0) and the starting droplet diameter in a batch-settling experiment
(Φ32,0,settle) and inside the settler (Φ32,0,settler). The height of the densely packed layer inside the settler
(Hp) should be predefined. The inlet length must also be determined. It is dependent on the velocity
inside the settler (vS) the volume of the inlet (Vin), the diameter of the inlet (Din), earth gravity (g)
and the dispersion band height inside the settler (HDis). In this case, the mean density ( ) and the
hold-up (ε0), which corresponds to the volume fraction of the dispersed phase in the total volume,
are determined:
Lin =















The total length of the separator (LS) is composed of the inlet length (Lin) and the coalescence
length (Lc):
LS = Lin + Lc (8)
The geometry of the dispersion layer is not further considered in the simplified model. For further
explanations, reference is made to Henschke et al. [38].
3. Results and Discussion
3.1. System Selection and Batch-Settling Experiments
Based on the shaking flask results, focus is placed on system point 1 (SP1) in the following
experiments, since the achievable yield is the highest of the investigated compositions at around 95%,
while also showing high cell reduction capabilities. Concentration of IgG is nearly doubled in SP4, due
to its phase-split, however, this comes at the cost of insufficient cell reduction (Table 1).
Table 1. Yield, purity, and cell reduction of the investigated ATPS.
System Point Yield (%) SEC-Purity (%) Log Cell Reduction (−)
SP1 95 ± 2.33 80.93 ± 0.02 2.08 ± 0.1
SP2 80 ± 0.39 81.97 ± 1.7 2.47 ± 0.02
SP3 63 ± 3.00 67.98 ± 1.8 3.45 ± 0.2
SP4 80 ± 1.62 80.98 ± 0.03 0.61 ± 0.02
ATPS: aqueous two-phase system; SEC: size exclusion chromatography; SP: system point.
In Figure 6, the height profile for the specific light and heavy phases observed in the batch-settling
experiments is plotted. The specific light phase begins at a reactor height of approximately 47 mm
with settling, and is complete after approximately 9 min at a reactor height of approximately 21 mm.
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height of about 17 mm. This is related to the delayed coalescence of the dispersed droplets. In Table 2
the resulting sedimentation and coalescence rates, including the standard errors, are listed.
Figure 6. Settling curves obtained by triplicate batch-settling experiments.
The results from the settling experiments are used below to calculate the exponents of the Mistry
model. This model only considers the settling behavior of the interphase. This is divided into two
areas. In the first section, up to 9 min sedimentation of the specific light phase and coalescence of
the heavy phase are observable. After that, only the heavy phase coalesces. The height change of the
interphase can be determined from the batch-settling experiments. The results are shown in Table 2.




540 s 3.8 3.87 3.62
1340 s 2.09 2.07 2.17
The interphase, up to the time of 9 min, settles down at approximately 3.7 mm per minute.
With the range up to 22 min, a sedimentation rate of 2 mm per minute is obtained. The results of the
settling behavior of the interphase can be used in Equation (1) to determine the exponents a, b, and c
(Table 3). The other parameters for the calculation are listed in Table 4.
Table 3. Parameter set for the calculation of phase separation rates.
Time Interval a b c
540 s 0.6230 0.1604 3.1096
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Table 4. Material data for the calculation of phase separation rate.
σ (mN/m) σw (mN/m) ρ (kg/m3) Δρ (kg/m3) ηc (Pa·s) ηd (Pa·s)
0.0702 72.75 1102.5 0.1337 0.0074 0.0048
For 9 min, a correlation between the calculated settling time and the experimental settling time
can be seen. The linear course of the interphase, which results from the deposition of both phases,
is well represented by Equation (1). The exponential course of the settling curve results when the
sedimentation behavior is considered up to complete separation. This results from the much longer
settling time of the dispersed, heavy phase (Figure 7). The applied approach can not reflect this trend.
In order to further verify the results, the settling times of other ATPS would have to be compared
experimentally and theoretically. Furthermore, cell-loading and power input must be taken into
account, because they influence the settling behavior of the system.
Figure 7. Height of the densely packed layer from triplicate batch-settling experiments (red, green,
blue) as well as from the calculated separation rates (straight lines).
3.2. Model-Based Design
For the calculation of the separator length some parameters were fixed in advance.
The hydrodynamic residence time for the MAV calculations equals the settling times (ts) from the
batch-settling experiments. In contrast, these settling times do not equal the residence times in the more
detailed calculation because this model considers not only the inlet length, but also the actual height of
the densely packed layer at the apparatus end, as well as the mean droplet size. The separation times
used in both calculations are 300, 540, and 1340 s.
In the calculations, the ratio DS/LS = 1/5 is chosen to achieve comparability for the MAV and the
detailed calculations of the laboratory settler devices used in the experiments. The specifications for
the inlet diameter (Din) and the inlet length of the separator (Lin) are based on the dimensions of the
laboratory separator for small volumes as well. If the system volume exceeds 160 L, the specifications
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also reveal a slightly higher dispersion level (HDis) than the densely packed dispersion layer (Hp)
at the end of the settler. The height of the densely packed dispersion layer is set in relation to the
diameter of the settler. In addition, the height of the densely packed dispersion layer varies depending
on the predetermined separation time. For this reason, a factor is used in the calculation linking the
height of the densely packed dispersion layer to the diameter of the separator. This results in the
following ratios:
• Hp/DS = 0.54 at a cut-off time of 300 s,
• Hp/DS = 0.303 at a separation time of 540 s,
• Hp/DS = 0.1 with a separation time of 1340 s.
The ratio is obtained from the filling height of the batch-settling reactor and the height of the
experimentally-determined densely packed layer (Figure 8).
Firstly, a cut-off time of 300 s (hereinafter called H300) is considered. At this point, the light phase
has not yet completely settled. However, there is sufficient separation to retrieve clear phase at the top.
The interphase is strongly pronounced at this point and it is possible that a large part of the cells are
withdrawn together with the heavy phase. However, there is also the risk of losing a small amount of
the specific light phase.
A separation time of 540 s is considered next (hereinafter, H540). At this point, the specific light
phase in the settling test has completely settled down. The specific heavy phase can be withdrawn
together with cells between the dispersed droplets without obtaining significant losses in the yield.
Figure 8. Marked separation times for the calculation from the settling experiments.
Complete separation of both phases is now observed at 1340 s (hereinafter called H1340). Both
phases are completely separated now and it is possible to remove them separately from the separator.
Removal of the densely packed layer in combination with the cells in between is only possible in this
case if the phase is withdrawn very close to the phase boundary.
The length of the separator is calculated in each case for different specifications at a fixed system
volume, and only for variation in the diameter of the separators to a ratio of 0.2. The investigated
system volumes vary between 2 L and the industrially realizable volume of 24,000 L (roughly 12,000 L
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At low system volumes between 1 L and 10 L, the sizes of the separators according to H1340 are
significantly larger than the designs according to the MAV-method (Figure 9) and H300 and H540,
respectively (Figure 10). This is due to the sm all, predetermined height of the densely packed layer
at the end of the separator. This results in a very large separator length, necessary to realize such
a complete separation. In comparison, the settler volumes at H300 are very small due to the early
withdrawal of the light phase and the accompanying larger densely packed layer. In the designs for
H540, the settler dimensions are approximately 20 times smaller than the system volume. Between the
increasing system volumes, a linear profile of the separator volume is indicated.
Figure 9. Settler volume as a function of residence time for different system scales obtained for the MAV
method. MAV: minimum-apparatus-volume. MAV300, MAV540 and MAV1340 represent separation
times of 300, 540 and 1340 s.
Figure 10. Settler volume as a function of residence time for different system scales obtained for the
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3.3. Process Performance
To evaluate the validity of the early prediction of settler dimensions, experimental studies were
performed at lab- and pilot-scale.
Figure 11 shows the results of eight continuous settling experiments that were conducted utilizing
a settler with a nominal diameter (DN) of 50 mm (750 mL hold-up). Product yield was, across the
experiments, higher than 80%. Cell reduction was at least 1 log or higher, except for experiments
S6 and S7. The reason for this was a change in flowrate. S6 and S7 were part of a phase inversion
study. By increasing the volume flow, effects on yield, phase separation, and cell clearance should
be determined. The relatively high yields of 90–100% indicate that mass transfer, as well as phase
separation, is not negatively affected by the increase in flowrate.
Figure 11. Yield and cell clearance for eight continuous settling experiments (S1–S8).
However, as can be seen in Figure 12, since the length of the static mixing pipe is fixed, the
residence times in S6 and S7 are decreased not only in the settler, but more importantly in the mixing
pipe as well. As a result, the phase-forming components are insufficiently mixed and no interfacial
partitioning occurs. This system behavior can be reproduced in the batch-settling experiments as well.
Leaving the standard set-up conditions constant, but reducing the mixing time from 5 to less than
1 min, results in an absence of interfacial partitioning (Figure 13).
Figure 12. Exit area of the DN50 settler at three different flowrates but an otherwise identical set-up
(DN: Diameter nominal). In experiment S2, cells can be retrieved together with heavy phase through
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Figure 13. SP1 after batch-settling. Clear light phase due to interfacial cell partitioning (left). High
turbidity in light phase, because of insufficient mixing (right).
3.4. Comparison of Experiment and Model
In Figure 14, the phase separation profile inside a laboratory settler during continuous settling
operation is shown. A volume flow of 35 mL/min is constantly separated during the procedure. For 3 h
process time, this results in a processed ATPS volume of around 6.3 L. Complete phase separation of
light and heavy phases is achieved.
Figure 14. Side view of the laboratory settler (DN35, 175 mL hold-up. DN: diameter nominal) during
continuous settling operation (300 s residence time). The image shows the inlet area (left) and the
heavy phase outlet (right).
Also, the pronounced interphase, composed of cells and densely packed dispersed phase,
meets the coalescence profile from the batch-settling experiment (Figure 8). The continuous settling
experiments executed in the DN50 settler, except for S6 and S7 for the above-discussed reasons, show
very narrow interphase bands (Figure 12, left), which is also in accordance with the batch-settling
profile, considering that the residence times are beyond the 1340 s marking line.
Finally, a pilot-scale operation of the continuous settling process is discussed. Figure 15 shows the
experimental set-up. Like in the lab-scale studies, phase-forming components, after passing through a
static mixer pipe, continuously enter the apparatus. To ensure total sedimentation of the light phase,
a residence time of 900 s was adjusted. Due to a small measurement inaccuracy of the flow meters,
the PEG content in the system was lower (13 instead of 15.5 w%) and the percentage of phosphate
rose from 15.5 to 18.7 w%. Thus, the operating point is closer to SP4 than to SP1. This results in phase
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filtration train, large parts of the light phase with the cells were withdrawn through the immersion tube
during operation, which led to a product yield of 80.4%. For better comparability, the same process
was carried out in batch-settling mode simultaneously. The comparisons in yield, cell reduction, and
subsequent filterability are listed in Table 5.
Both operation modes clarified approximately 160 L total volume within the aimed-at time-frame
of less than 3 h. No filter blockage occurred, however, due to the discussed shift in system composition,
the product phase from the continuous settling process showed a higher yield loss. Also, the necessary
filtration pressure was significantly higher.
Figure 15. Side view of the pilot-scale settler (DN150, 12.6 L hold-up) during continuous settling
operation (900 s residence time).
Table 5. Comparison of batch and continuous ATPE of 160 L system volume. The pressure increase
refers to 117 L/m2 area-specific filtration volumes.
Mode Yield IgG (%) Log Cell Reduction (−) Pressure Increase (bar)
Batch 95 1.29 0.1
Continuous 80.4 0.44 0.9
Compared to the settler dimensions, modeled only on the basis of batch-settling experiments
(Figure 16, dashed lines indicate tested scenarios), the used DN150 settler (12.6 L hold-up), is very
close to the calculated 10.9 L settler volume (H540), and in accordance to the thick dispersion layer
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Figure 16. Settler volume as a function of residence time for different system scales obtained
for the MAV (left) and simplified Henschke method (right). The dashed lines indicate the
experimentally-tested scenarios (from top to bottom): 12.6 L, 0.75 L, and 0.175 L settler volumes
for 160 L, 10 L, and 4 L ATPS volumes.
4. Materials and Methods
4.1. Aqueous Two-Phase Systems
In this work, four ATPS are considered. The components of the individual systems with their
approximate phase splits are listed in Table 6.
Table 6. Composition of the investigated ATPS.
SP1 SP2 SP3 SP4
PEG 400 (w%) 15.5 17 20 9
Buffer (w%) 40 43.75 45 53
Broth (w%) 44.5 39.75 35 38
Volume split LP/HP 1:1 1:1 1:1 1:4
4.2. Cultivation
The fed-batch cultivation of Chinese hamster ovary cells (cell line CHO DG44), used for mAb
production, is carried out in a commercial serum-free medium. The cells were cultivated one week at
37 ◦C, 5% CO2, and 130 rpm in shaking flasks.
4.3. Analytical Procedure
Protein A chromatography (PA ID Sensor Cartridge, Applied Biosystems, Bedford, MA, USA) was
carried out for the determination of IgG concentrations. The buffers were PBS A (pH 7.4) for binding
and PBS B (pH 2.6) for elution. For the analysis, a flow of 1.6 mL/min was applied. The injection
mass for the calibration varied between 10 μg and 95 μg. Sample quantities of 50 μg are applied.
The measured signals (280 nm) were evaluated via peak areas.
For size exclusion chromatography (SEC), a 1 M disodium hydrogen/sodium dihydrogen
phosphate buffer containing 1 M sodium sulfate was used (Merck KGaA, Darmstadt, Germany).
The column was a Yarra™ 3 μm SEC-3000 (Phenomenex Ltd., Aschaffenburg, Germany). The analysis
was carried out at a flow rate of 0.35 mL/min and a duration of 23 min.
Cells are counted using a Motic BA 310 microscope (Motic Deutschland GmbH, Wetzlar, Germany).
A sample is taken and dyed with trypan blue ((Sigma-Aldrich, St. Louis, MO, USA) in order to
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Density (DMA 500, Anton Paar GmbH, Graz, Austria), pH (InoLab pH 720, WTW, Weilheim,
Germany), and conductivity (InoLab pH 720, WTW, Weilheim, Germany) were measured for each
ATPS. Dynamic viscosity (Rotary viscometer of the type HAAKE™ ViscoTester™ 550, ThermoFisher
Scientific™, Waltham, MA, USA) and interfacial tension (Spinning Drop Tensiometer (SDT), Krüss
GmbH, Hamburg, Germany) were determined for model calculations as well.
4.4. Procedures
4.4.1. Shaking Flask Experiments
The system was weighed in tubes and was sealed. PEG 400 is added first and afterwards the broth
and buffer must be added quickly. The samples rest for at least 15 min. A sample, approx. 8–10 mL,
was taken from the light phase and heavy phase and centrifuged in 15 mL tubes at 3000 rpm for 10 min
to separate phase residues and solids from the product.
4.4.2. Batch-Settling Experiments
At the beginning of the experiment, the cell count in the cultivation flask was determined. The cell
count was adjusted via dilution with a cell free broth or a concentration of the cells using a centrifuge.
The predetermined stirrer speed of 300 rpm was set up with a tachometer in order to obtain a defined
power input. Furthermore, 100 g of ATPS was weighed into the reactor at a cell number of around
200E5 cells/mL and then mixed for 5 min with a blade stirrer (4 blades, 45◦ blade angle, 29 mm
diameter, 5 mm height). These parameters were sufficient for mixing the system. The settling height of
the light phase and the heavy phase was recorded in 30 s intervals. From a settling time of 15 min, the
values were recorded every minute. After separation of the light phase, heavy phase, and interphase, a
sample of each phase was taken. The samples were centrifuged at 3000 rpm for 10 min to separate cell
and phase residues.
4.4.3. Continuous-Settling Experiments
In order to prevent sedimentation of the cells in the feed vessel, the feed vessel was stirred on a
magnetic stirring plate at about 290 rpm. The components were combined in two Y-pieces by three
peristaltic pumps (Ismatec IP65, Cole-Parmer GmbH, Wertheim, Germany) according to mass-flow
measurements (Mini Cori-Flow, Bronkhorst Deutschland Nord GmbH, Kamen, Germany) and mixed
by static helix mixers (ESSKA.de GmbH, Hamburg, Germany). The mass-flow was recorded during
the test by a Labbox (Labbox 3 M, HiTec Zang GmbH, Herzogenrath, Germany). At the outlet of the
separator, the phases were collected separately from each other. During the experiment, samples were
taken in order to detect changes in product yield or cell reduction over time.
5. Conclusions
The presented work displays development and implementation strategies for aqueous two-phase
extraction as a cell harvest operation (Figure 17). After defining the operation space for the specific
separation task in terms of cell reduction, yield, and process time by a limited number of shaking flask
experiments to obtain equilibrium composition and material data by lab-scale batch and continuous
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Figure 17. Process development strategy.
The batch-settling experiments in particular enable the identification of the separation times that
are necessary to obtain the desired sedimentation profile inside the settler. Knowledge about the
sedimentation rates can then be used for more sophisticated calculation of settler dimensions. For 3 h
continuous processing of up to 12,000 L cultivation broth, a settler with a length of 3.6 m and a volume
of approximately 1.4 m3 is proposed (Figure 16, H540).
The investigated operating point is characterized by a yield of between 80 and close to 100%, as
well as up to 2 log step reductions in cell number. For small system volumes (2–10 L), the calculated
settler dimensions are consistent with laboratory tests as well as with pilot-scale volumes of up to 160 L
cultivation broth. In order to achieve the above-described yield, the correct system composition (SP1)
must be observed. In the case of deviations, this may lead to a reversed direction of phase inversion.
Since the heavy phase must be dispersed for a reduction of cells, this is of upmost importance.
The focus of further research is shown in an illustrated concept (Figure 17). Further work packages
should optimize process integration (i.e., automation, control, and control strategy) as well as the
robustness of the process. The applicability for alternative ATPS, i.e., polymer-citrate, as well as for
other products, i.e., virus-like particles or different proteins, should also be investigated to evaluate
the robustness of the process and the reliability of the development concept.
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Abstract: Downstream of pharmaceutical proteins, such as monoclonal antibodies, is mainly done
by chromatography, where concentration determination of coeluting components presents a major
problem. Inline concentration measurements (ICM) by Ultraviolet/Visible light (UV/VIS)-spectral
data analysis provide a label-free and noninvasive approach to significantly speed up the analysis
and process time. Here, two different approaches are presented. For a test mixture of three proteins,
a fast and easily calibrated method based on the non-negative least-squares algorithm is shown,
which reduces the calibration effort compared to a partial least-squares approach. The accuracy of
ICM for analytical separations of three proteins on an ion exchange column is over 99%, compared
to less than 85% for classical peak area evaluation. The power of the partial least squares algorithm
(PLS) is shown by measuring the concentrations of Immunoglobulin G (IgG) monomer and dimer
under a worst-case scenario of completely overlapping peaks. Here, the faster SIMPLS algorithm
is used in comparison to the nonlinear iterative partial least squares (NIPALS) algorithm. Both
approaches provide concentrations as well as purities in real-time, enabling live-pooling decisions
based on product quality. This is one important step towards advanced process automation of
chromatographic processes. Analysis time is less than 100 ms and only one program is used for all
the necessary communications and calculations.
Keywords: inline concentration measurements; UV/VIS spectral analysis; PAT for monoclonal
antibodies; live pooling; peak deconvolution
1. Introduction
Inline concentration measurements (ICM) of individual components in a mixture are critical for
almost every unit operation in the field of chemical and biotechnological processes. Although most
processes are designed to match specific concentration and purity criteria, the actual values still have
to be monitored inline or offline [1].
This becomes even more important for batch operations, like chromatography, where
concentration and purity vary over time. For such processes, the inline measurement of concentrations
and purities become a game winning objective, but often also a major challenge.
In the field of analytical chromatography, concentration or purity quantifications are usually based
on peak areas. Therefore, great effort is put into the chromatographic separation to achieve a baseline
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separation, if possible. Nevertheless, this is not always achieved. Very closely related components are
often especially difficult to separate. The deconvolution of overlapping peaks allows for better results
as well as shorter and less expensive separations.
For preparative chromatography, complete baseline separation is not desirable; on the contrary,
it conflicts with process efficiency and economy. The separation process is optimized for a maximum
resin utilization and productivity. The product fractionation is often controlled via timed cut points,
where the exact moment for the fraction start and end points are derived from earlier experiments
and are therefore not directly related to the current chromatographic run. In this case, critical product
attributes like the concentration and purity have to be measured offline after the run. Anomalies
in elution behavior often result in shifts of the chromatogram leading to large variations from the
expected design chromatogram. Thus, the time-based cut points do not match the purity criteria and
might lead to a batch failure or require reprocessing. This problem becomes even worse for continuous
chromatography processes. Start- and end-pooling criteria based on real-time, online detection of
volume and Ultraviolet/Visible light (UV/VIS) absorbance have proven to be very successful in
delivering consistent yield and purity. Online concentration and purity identification as presented
here will help to shift the process design from timed to data-based fractionation or column switching
and therefore give a greater certainty to match purity and yield targets, thus reducing the risk of batch
failure. Also, the safety margins for data based fractionation can be smaller, leading to higher yield
and productivity.
Furthermore, the knowledge of concentrations of all components online throughout the
chromatographic run will help during process design. At the moment, the chromatographic run
has to be fractionated into a lot of small volumes and analyzed offline to identify the actual
concentration profiles. This is cost intensive as well as time consuming and, in addition, carries
a significant risk of product degeneration of sensitive proteins because of long analysis times. The same
problem and solution respectively apply for model parameter determination and model validation for
a simulation-based design process [2,3].
Hence, a lot of research has been undertaken to achieve a deconvolution of chromatographic
peaks. In general, the approaches can be split into inline and offline methods.
For offline or at-line peak deconvolution in particular two different approaches can be found.
A classical at-line method is the division of the complete run into small fractions. These fractions
are then investigated by a suitable analytical method afflicted with the method specific failure [4–8].
Although analysis time might be rather short, online sampling always results in a rather large response
time. Especially the use of gas or liquid chromatographic analysis often has to deal with overlapping
peaks itself due to selectivity variances [9].
Another offline or delayed online approach is a full mathematical analysis of the chromatogram.
This analysis assumes that every peak will follow a mathematical function, e.g., Gaussian or modified
Gaussian, and estimates the function parameters. This assumes a Gaussian or modified Gaussian shape
might be approximately right for analytical chromatography, but is rather uncommon for preparative
separations. The identification of peaks occurs by first, second or higher order derivatives of the
chromatographic signal [10–12].
To identify a component and determine the parameters for its Gaussian function, the peak must
be processed to a certain point. In most cases, at least the first inflection point has to be reached. More
often, the peak maximum and second inflection point have to be detected already. Hence, this peak
deconvolution method cannot be performed in real-time.
For preparative separations, an improvement can be achieved by the use of process modelling.
Having a valid process model implemented during process design, the real behavior and elution of
the components can be monitored [13–15].
Spectroscopy is among the most common methods of detection. Hence, major progress was
achieved in terms of a multicomponent analysis using ultraviolet (UV), visible (VIS) or infrared
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UV/VIS spectroscopy for determining the protein and nucleic acid content of viruses [17] as well as
for a variety of proteins in a multicomponent mixture [18–20].
According to the Beer–Lambert law, the UV-extinction Eλ of a component at a given wavelength
λ is the product of the concentration c, the path length d and a component specific coefficient called






= Eλ,i = ελ,i·ci·d. (1)
Technically, this law applies to highly diluted mixtures only. Nevertheless, the deviations are
often negligible.
The UV/VIS extinction over the wavelengths, viz. the UV/VIS spectrum, is unique for almost
every component. Thus, the sum spectrum of a mixture can be disassembled into the single component
spectra. It can be found that the absorbance of a mixture of n components sums up from the single






A diode array-based UV/VIS measurement provides as many extinction values as there are
diodes in the detector, often 256 or 1024. Each diode represents one specific wavelength sector. Hence,
Equation (2) can be formulated for each diode leading to a large set of linear expressions. With
prior knowledge of the extinction coefficients of each component ελ,i, this set of linear equations can
be solved for the concentrations ci. This can be done with several mathematical methods like the
least-squares or non-negative least-squares (NNLS) [25,26] algorithm. In theory, the experimental
effort to measure the extinction coefficients ελ,i, is low. For each single component one injection
with known concentration is sufficient. There is no need to calibrate a large set of mixtures with
different compositions and concentrations. However, it might be necessary to measure the extinction
coefficients ελ,i for different concentrations of the single components. It can be shown that for higher
concentrations, peaks appear in the UV/VIS spectrum that are not visible at lower concentrations.
This is due to detector sensitivity only.
The first example in this paper shows the application of the NNLS-algorithm by measuring the
concentrations of three proteins from an analytical ion exchange chromatography.
Another approach for UV/VIS-diode array detector (DAD) based concentration measurements
was introduced by Brestrich et al. [18,27,28]. Partial least-squares regression is used to create a statistical
model. The PLS regression compresses a set of even highly collinear predictor data X into a set of latent
variables T. With these orthogonal latent variables observations can be fitted to depended variables Y.
In this case, X is the UV/VIS spectra and Y represent the concentrations. For a better understanding of
PLS, see [29–31].
In both the work of Brestrich et al. [27] and this work, the SIMPLS-algorithm [30] is used. This does
not solve the set of linear equations spanned by Equation (2), but creates a statistic model. This model
has to be trained by a set of experiments. Contrary to the non-negative least-squares approach, it is
not sufficient to only calibrate for single components. The experimental design has to account for
different compositions and different concentrations of each component present in the mixture that
should be analyzed later. Thus, the amount of experiments increases dramatically with the number of
components. Again, the detector sensitivity has a major impact, as does the detector type, age and
utilization status.
The second example in this paper shows the application of the SIMPLS-algorithm for inline and
real-time monomer and dimer concentration measurements of monoclonal antibody IgG.
Although the used algorithm is the same, this work differs from other work by a simpler setup.
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acquisition, all calculations, data storage and communication with the programmable logic controller
(PLC). Therefore, there is no software bottleneck allowing for very fast measurements. The PLC
controls the pumps and valves of a continuous chromatography prototype that was not used in this
work. This work is rather a major milestone to achieving a fully automated and self-optimizing system
for the prototype, enabling life pooling, purity-based column switching and advanced quality control.
2. Materials and Methods
2.1. Model Proteins, Buffers and Columns
All experiments with proteins were carried out in 20 mM NaPi buffer at pH 6.0. For ion exchange
chromatographic separations, this buffer was used as equilibration buffer A. For elution buffer B, 1 M
NaCl was added. For analytical size exclusion chromatography (SEC), a buffer containing 100 mM
sodium sulfate and 100 mM NaPi was used at pH 6.6. All salts were obtained from Merck KGaA,
Darmstadt, Germany.
For the three component mixture experiments Chymotrypsinogen A, Lysozyme (AppliChem
GmbH, Darmstadt, Germany) and Cytochrome C (Merck KGaA, Darmstadt, Germany) were used.
IgG was obtained from our own cell culture with an industrial Chinese Hamster Ovary (CHO)
cell line and purified by protein A chromatography prior to the experiments.
Ion exchange separations were performed on prepacked strong cation exchange columns with
Fractogel® EMD SO3− (M) (5–50, 1 mL, Atoll GmbH, Weingarten, Germany).
Analytical size exclusion columns Yarra® SEC-3000 (3 μm, 300 × 4.6 mm) were obtained from
Phenomenex® Inc., Torrance, CA, USA.
Protein A chromatography was performed with PA ID Poros® Protein A Sensor Cartridges
(Applied Biosystems, Waltham, MA, USA).
2.2. Devices and Instruments
The experimental setup consisted of a standard VWR-Hitachi LaChrom Elite® HPLC system
with a quaternary gradient pump L-2130, Autosampler L-2200 and diode array detector L-2455
(VWR International, Radnor, PA, USA). The later was not used for the ICM but for comparative
measurements. For the ICM measurements, a Smartline DAD 2600 with 10 mm, 10 μL flow cell from
Knauer Wissenschaftliche Geräte GmbH, Berlin, Germany was used. Experimental validations were
based on SEC analysis after online fractionation with a Foxy Jr.® from Teledyn Isco, Lincoln, NE, USA.
2.3. Inline Concentration Measurements
The inline concentration measurements are based on UV/VIS spectra measured with a diode
array detector (Smartline DAD 2600 from Knauer Wissenschaftliche Geräte GmbH, Berlin, Germany)
with 256 diodes and a wavelength range of 190 to 510 nm. The selectable bandwidth is 4 to 25 nm.
The highest sampling rate is 10 Hz, which is 100 ms [32]. Data collection and analyses were performed
by a conventional Windows desktop computer, which uses a standard EIA RS-232 serial port for
the communication with the detector. Since the communication between different applications and
programs tends to be a major bottleneck, a self-written program was used. An object-oriented,
concurrent and class-based programming language [33] was used (Java). Java runs on its own Java
Virtual Machine (JVM), which is available for a variety of platforms and computer architectures. Hence,
programming in Java follows the “write once, run anywhere” idea. This makes a program written in
Java easily applicable on different machines [33]. The ICM application handles the communication
between the DAD and the computer, processes the data, displays the results in different charts and
stores the data in “comma separated values” (*.csv) files. The user can choose from several algorithms
to implement. Amongst those are the least squares, non-negative least squares [25,26] and SIMPLS
(a partial least squares variant) [30], the simplex and powell algorithm and some more. It should be
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squares algorithm is used to solve the equation system described earlier (Equation (2)). However,
PLS provides a statistical model that is related to the spectral data. Which algorithm should be used
depends on the complexity of the given sample. As a starting point, the single-component spectra of
each component should be compared. In this work, an application for the non-negative least squares
and one for the SIMPLS is shown.
2.4. ICM Examples
2.4.1. Protein Test Mixture on Ion Exchange Column under Analytical Conditions with NNLS
To show the power of ICM for analytical separations, a separation of three proteins on an ion
exchange column was performed. Fractogel® EMD SO3− (M) was used in prepacked 1-mL columns
(5–50, Atoll GmbH, Weingarten, Germany).
The binding buffer A was 20 mM NaPi buffer with a pH of 6.0. For elution, buffer B 1 M NaCl was
added. The chromatographic run started with 100% buffer A and proceeded with a 10 CV gradient
to 100% buffer B. A flow rate of 1 mL/min was used. This method is meant not to achieve baseline
separation, but produce widely overlapping peaks.
The test mixture contained Chymotrypsinogen A, Cytochrome C and Lysozyme. 10 mg of each
protein were dissolved separately in 1-mL binding buffer, leading to three samples with a concentration
of 10 g/L each. To identify the differences in UV/VIS spectra, 20 μL of each sample was injected onto
the column and measured with the DAD detector at a certain peak height corresponding to 0.01 g/L.
The single component spectra are shown in Figure 1. It can be seen that Chymotrypsinogene
A and Lysozyme have similar spectra. Cytochrome C, however, is relatively unique. Nevertheless, the
differences are big enough not to need PLS.
Figure 1. Single-component spectra of Chymotrypsinogene A, Cytochrome C and Lysozyme.
The inline concentration measurements were done by solving the set of linear equations
(Equation (2)) for the concentrations with the non-negative least-squares algorithm. Hence, the
extinction coefficients ελ,i for the three proteins were needed.
The extinction coefficients ελ,i were measured separately for each component. The proteins were
dissolved in buffer A separately and injected onto the ion exchange column as described previously.
The resulting chromatogram at 280 nm wavelength was converted from extinction to concentration
course according to Equation (3):
ci(t) = F·Eλ=280(t). (3)
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Now, the concentration is known for every time point of the chromatogram. Thus, the extinction
coefficients ελ,i, are the only unknown variable left in Equation (2). In this work, Equation (2) was
solved for the coefficients at a time point corresponding to 0.1 g/L protein concentration. This
calibration has to be done for each protein.
One problem of this approach is the superposition of the protein spectrum with any other spectrum
of co eluting components. This might result from UV/VIS active compounds in the chromatographic
buffer or from leachables/extractables of the column itself. To overcome this problem, a blank run can
be done before the actual measurements to perform a baseline correction.
For some components, one might find that different concentrations lead to different spectra.
Physically speaking, this is not possible. However, for rising concentrations, peaks in the spectrum
might appear that were not present at lower concentrations. These peaks were simply not visible
at lower concentrations due to low detector sensitivity. In this case, it is best to analyze the peak
at different concentrations, hence obtaining extinction coefficient values at different concentrations.
This should be equal except for these cases where detector sensitivity comes into account. For those
coefficients, a spline interpolation over the concentration is done.
The actual separation for testing the peak deconvolution was performed with the same column
under the same conditions. The test mixture contained all three proteins.
Quantitative analysis is usually performed based on peak areas. The peak area is a function of
the amount of protein injected. To produce the exact same peak areas in the three-component run
compared to the single component runs, the same amount of each protein must be injected. Thus,
the sample was produced by mixing 0.5 mL of each of the protein solutions used previously. Therefore,
this sample has exactly one third of the concentration of each protein compared to the single component
samples. Hence, 60 μL were injected to the column.
The peak areas of the single component runs are easily calculated. The corresponding areas from
the mixture experiment were obtained by three different methods. First by integrating the concentration
curve obtained with the inline concentration measurements. Second, by the perpendicular method.
As a typical chromatographic approach, the extinction curve is integrated. The areas between two
peaks were divided by a vertical line at the local minima. These areas have to be compared to
a calibration curve. The third method is a typical offline peak deconvolution method. The real peak
shape is approximated by assuming Gaussian or modified Gaussian behavior. These peaks can then
again be integrated and compared to a calibration curve.
2.4.2. Immunoglobulin G (IgG) Monomer and Dime with SIMPLS
A mixture of IgG monomer and dimer was used to show the potential for pharmaceutical
production. Both molecules have almost identical UV/VIS spectra. To distinguish between both is
therefore relatively hard. Nevertheless, from a product quality point of view, it is very important to
know the concentrations of IgG oligomers.
Since the differences in UV/VIS spectra are low, the SIMPLS algorithm was used. This must be
calibrated with a training set of data containing different IgG monomer and dimer concentrations.
The monoclonal antibody IgG came from our own fed batch fermentation of an industrial
cell culture line. The cell culture was clarified with centrifugation (3000 g) and filtration (0.2 μm
syringe filter, VWR International, Radnor, PA, USA). Afterwards, purification was done with protein
A chromatography (PA ID Sensor Cartridges, Applied Biosystems, Waltham, MA, USA). The protein
A product peak was then loaded to a size exclusion column (Yarra® SEC-3000, 3 μm, 300 × 4.6 mm,
Phenomenex Inc., Torrance, CA, USA). Here, only the upper 50% of the dimer and the monomer
peak were fractionated. Hence, the overlapping region of monomer and dimer was not used. After
protein A and size exclusion chromatography, no other protein besides IgG and no other contaminates
are present. We did not find a fixed equilibrium between the monomer and dimer concentration.
However, conversions from one form into the other occur, so that there was no pure dimer or monomer.
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0.5 mg/mL monomer and 0.02 mg/mL dimer. The dimer fraction contained 0.2 mg/mL monomer
and 0.1 mg/mL dimer.
Out of these two fractions, 11 mixtures were created to calibrate the statistic model. Therefore,
different volumetric mix ratios were prepared, starting with 100 vol.% monomer and 0 vol.% dimer.
The ratios decreased respectively increased with a 10 vol.% step size to 0 vol.% monomer and 100 vol.%
dimer. From eleven mixtures, nine were used as a training set and the other three as validation sets,
namely 80 vol.% monomer, 50 vol.% monomer and 20 vol.% monomer.
For each sample, analytical size exclusion chromatography was performed again to get the actual
monomer and dimer concentrations.
The experiments itself were performed by injecting 0.1 mL into a small stirred tank of 2 mL total
volume. The inlet stream consisted of chromatographic buffer A with a volumetric flow of 1 mL/min.
The outlet stream, also 1 mL/min, was directly connected to the Smartline DAD 2600. After the DAD,
the stream was fractionated with a Foxy Jr.® (Teledyn Isco, Lincoln, NE, USA) fraction collection
module. 0.5 min fractions were taken and this 0.5 mL fractions were analyzed offline with the size
exclusion chromatography already mentioned.
This setup represents a worst-case scenario, since no column or separation takes place. With
moderately overlapping peaks, one might enhance your result by applying some mathematical
assumptions; this cannot be done here. Furthermore, this experiment simulates conditions one would
find in several other, non-chromatographic unit operations within the downstream of monoclonal
antibodies, like filtration. This shows the applicability for inline quality control for example in the last
filtration step.
3. Results and Discussion
The presented inline concentration measurement method shows wide, almost general applicability
whenever UV/VIS active component mixtures are involved. In this work, the ability to enhance the
accuracy of analytical measurements, and to make real time pooling decisions based on real time
data could be shown. For the latter case, the calculation time is of major interest. Since only one
program is used for data collection and processing, no time delay could be found throughout all
experiments. The UV/VIS diode array detector was run with a sampling rate of 100 ms. The data
transfer and all calculations were finished prior to the measurement of the next data point. Thus, one
ICM concentration measurement lasts less than 100 ms.
It should be noted that every method or calibration comes with a systematic error itself. In this
case, impurities present in the assumed to be pure calibration mixture could not be detected later on.
This applies for example for low level impurities in the protein standard or in the IgG fractions after
size exclusion chromatography.
3.1. Protein Test Mixture on Ion Exchange Column under Analytical Conditions with NNLS
One chromatogram and the corresponding inline concentration measurements are displayed
in Figure 2. The reference extinction is 280 nm. It is important to understand that the protein
concentrations (light blue, red, green) do not have to match the reference extinction plot (dark blue).
The proportions would match only if all three proteins had the same extinction coefficient at 280 nm
which is obviously not the case.
Prior to the injection of the three component mixture, the exact same amount of each component
was injected separately as described earlier. The comparisons between the single component injections
with the ICM peak of the same component in the three component run are shown in Figure 3.
It can be seen that the Chymotrypsinogene-A peak in the mixture is pushed a little bit to an earlier
elution. The mean residence time shifts from 6.07 min to 5.96 min. Although, the dilution front of
this peak is sharper. This is in good agreement with the displacement theory of chromatography.
The Cytochrome-C peak has mainly the same shape in both experiments, but tends to co-elute with
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For both later proteins, there are only minor changes in the residence time. All values are displayed
in Table 1.
Figure 2. Inline concentration measurement of a three component protein mixture.
Figure 3. Comparison between the single component injection (blue line) and the deconvoluted peak
(red line) of the same component in the mixture for the three proteins Chymotrypsinogene-A (a);
Cytochrome-C (b) and Lysozyme (c).








The chromatograms in Figure 3 allow for an easy comparison of the total amount of protein in
both experiments. Since the ICM method measures concentrations not extinction, the deviations for this
method are calculated comparing the total protein amount measured for single component injections to
the three component system. This is calculated from feed concentration and injection volume. The mean
deviation for the ICM method used for the chromatogram in Figure 2 is 0.02% with a standard deviation
of 0.58% compared to −16.99% ± 7.01% for the perpendicular, 17.58% ± 15.82% for the Gaussian
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Table 2. Deviation from single component to mixture measurement.
Protein
ICM Perpendicular Gaussian Modified Gaussian
(%) (%) (%) (%)
Chymotrypsinogen-A −0.63 −7.09 9.92 12.71
Cytochrom-C 0.50 −22.37 3.21 8.02
Lysozyme 0.19 −21.52 39.62 43.09
Mean Value 0.02 −16.99 17.58 21.27
Standard deviation 0.48 7.01 15.82 15.54
It should be noted that the ICM measurements might be sensitive to the gradient. Some gradients,
more specific some modifier, are UV/VIS active itself. Even if the gradient does not become visible
in the chromatogram at a specific wavelength, there might be an effect to the measurement. When
the calibration is done with chromatographic runs of the single components as described, most of
this problem is already solved since the gradient is already present in the calibration measurements.
Otherwise, a blank run should be made before the measurements. The UV data measured during the
actual run are than corrected by subtracting the blank run UV/VIS data.
Figure 4 shows the course of the different peak deconvolution methods. The peak in the middle is
left out for clarity. It can be seen that the perpendicular area determination is always neglecting some
area. On the other hand, both Gaussian functions (grey and light grey) overestimate the real behavior.
It can be seen that the mathematical fits show the first and third peak to be overlapping, which is not
the case in reality. The ICM method represents the real behavior best. Because it is not based on some
model assumptions, the ICM method further has the potential to also identify tag along effects.
Figure 4. Comparison of the different peak deconvolution methods.
The mathematical methods can only be applied after the run or with huge delay, since the
peak needs to be fully developed or at least needs to be developed past the maximum. The ICM
measurements presented above were performed inline and with 100 ms between each data point.
Since the self-written program is capable of communication with PLC, the data can be used to do live
pooling or process optimization during a production run.
The results above were produced with extinction coefficients known beforehand. Similar results
could be obtained without knowing the coefficients beforehand. An analysis of the complete run
can calculate the extinction coefficients and deconvolute the overlapping peaks by assuming pure
components at the beginning and end of the first or last peak respectively. The coefficients for the
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the total spectra. This would deconvolute the peaks, but not give the exact concentration, since the
link between concentration, extinction coefficients and the spectra is missing. In combination with
known extinction coefficients for known components, this approach can be used to detect unknown
components and give their concentration as a pseudo concentration linked to a known component.
3.2. Immunoglobulin G (IgG) Monomer and Dimer with SIMPLS
As mentioned before, eleven different ratios of IgG monomer and dimer were measured from
which nine were used for the SIMPLS calibration and three for the validation. The corresponding
UV/VIS spectra for the mixture with the highest and lowest monomer content are shown in Figure 5a.
The spectra are standardized (z-score) to emphasize the differences. One statistic model was created
to calculate both IgG monomer and dimer concentration at the same time as opposed to creating
two models, one for each component. The Variable Importance on Projections (VIP) can be found
in Figure 5b. Both Figure 5a,b show, that there are only minor differences in UV/VIS absorption
for IgG monomer and dimer. The most important region is from 200 to 290 nm. This predication is
supported by Figure 6a, which shows the loadings for each latent variable over wavelength. Again, the
highest values are in the region from 200 to 290 nm. The region beyond 390 nm might be dominated by
noise. Figure 6b shows the importance of each latent variable for the concentration results (Y-matrix).
As expected, the first latent variables are the most important. But especially for the dimer concentration,
variables 5 to 7 also show significant contribution.
Figure 5. (a) Ultraviolet/Visible light (UV/VIS) spectra of the trainings data with the highest and
lowest Immunoglobulin G (IgG) monomer content. The red dots represent the mixture with 100 vol.%
monomer, the green dots with 100 vol.% dimer, respectively. However, this does not mean pure
monomer or dimer since a conversion from one into the other takes place; (b) Variable Importance on
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Figure 6. (a) Loading over wavelength diagram for the first eight latent variables. The higher the
absolute value, the more important is this wavelength for the latent variable; (b) loadings of the Y
results over latent variables. The higher the absolute value, the higher is the importance of this latent
variable for the concentration calculation of monomer or dimer respectively.
As expected, the percentage of explained variance in the response increases with the number
of latent variables used in the algorithm. For three latent variables, the percentage of explanation is
80%, for six variables it is over 93%. It maxes out at 98% with eight or more latent variables. Thus,
eight latent variables where used for the validation measurements. The root mean square error of
calibration (RSMEC) for eight latent variables is 0.14 mg/L for the IgG monomer and 0.025 mg/L for
IgG dimer.
Figures 7a and 4b show the results for two of the validation measurements. These experiments
represent the injection of the sample with 80 vol.% monomer/20 vol.% dimer (Figure 4a) and 20 vol.%
monomer/80 vol.% dimer (Figure 4b), respectively. Again, these numbers represent the volumetric
mixing ratio of the SEC fractions as described earlier. Due to conversion of either monomer to dimer
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Figure 7. Concentration measurements over time of IgG monomer and dimer after injecting into
a continuous stirred-tank reactor: (a) Volumetric mixing ratio of 80% monomer and 20% dimer;
(b) Volumetric mixing ratio of 20% monomer and 80% dimer.
The solid lines represent the ICM measurements whereas the squares with the same color represent
the corresponding SEC analysis. The later are done by fractionation the stirred tank outlet with
an interval of 0.5 min. The ICM measurements however are continuous. To compare the results,
the ICM values for the 0.5 min interval were not averaged. Instead, the ICM concentration value for
the corresponding time at the middle of the fractionation interval was used.
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Figure 8. Concentrations based on fractionation and size exclusion chromatography (SEC) analyses
compared to concentrations measured with inline concentration measurements (ICM).
The results in Figures 7 and 8 show that the ICM measurements are in good agreement with the
SEC measurements. The overall coefficient of determination R2 is 0.98 for both IgG monomer and
dimer. The root mean square error of prediction (RMSEP) is 0.13 mg/L for the IgG monomer and
0.019 mg/L for IgG dimer.
The ICM measurements provide the concentrations and therefore composition of the outlet stream.
This can be used to calculate the purity of the product stream in almost real time (100 ms). Purity
calculation based on ICM measurements compared to the corresponding offline SEC gives a mean
derivation of 0.15%. Within the 24 data points, the minimum deviation was 0.01% and the maximum
deviation was 6%.
Since the SIMPLS-algorithm reduces the UV/VIS spectra to a statistic model, it is possible that
it only finds a certain fixed distribution between the two components. This would presumably give
the same multiplier between both concentrations. Figure 4a,b however show that this is not the case.
The extinction values for the 20 vol.% monomer run are roughly 25% lower than for the 80 vol.%
monomer run. The IgG monomer concentration however is more than 50% lower and the dimer
concentration is 15% higher. Hence, it is reasonable to assume that the algorithm determines the
concentrations correctly instead of just splitting the extinction with a fixed proportion.
Since the test mixture was prepared with IgG samples after Protein A and SEC, the purity of the
IgG was relatively high. For in-process measurements, for example after protein A, more components
and impurities have to be taken into account. Depending on the impurities, the distinction between
the IgG monomer and dimer might become more challenging. However, it is hypothesized that at least
the distinction between IgG in total and other impurities should be possible.
4. Conclusions
The proposed inline concentration measurement based on UV/VIS spectral data is a new
and comparatively easy method for the real time quantification of UV/VIS active components.
This indicates a huge potential for analytical as well as preparative and production-scale
chromatography as well as for other unit operations. It is a key-enabling methodology for process
development by aid of process modelling in order to determine model parameters efficiently—which
is currently the major obstacle preventing a general use of simulation instead of empirics in industry
for piloting and operation of almost any unit operation in regulated industry under Process Analytical
Technology (PAT) and QbD design methods.
The inherent problem of overlapping peaks in analytical chromatography is reduced significantly
by applying ICM. The accuracy of the quantitative determination of proteins could be shown to be
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The analysis time is less than 100 ms, so that the rate-limiting step is the data acquisition done
by the detector itself. This enables a variety of process control options like live pooling and online
optimization of the chromatographic process.
In the case of preparative separations, even for very similar components the purity can be
measured at approximately 99.8% accuracy. This is an enormous advantage, since the real-time
concentrations and purities are completely unknown for current process analytics. This leads to
new possibilities for process control strategies. For example, batch chromatography could perform
real-time pooling decisions based on the ICM data, leading to less batch failure and a higher product
quality. Since product-related purity data are measured inline, there is a huge potential for cost and
time savings by reducing offline analytics. The derived method overcomes obstacles in industrial
application resulting from the dependency of extinction coefficients on detector type, age and signal
strength by adopting reliable self-adjusting methods based on optimization algorithms, which provide
mathematically proven quantitative reliability.
New process control options of multicolumn chromatography processes like Simulated Moving
Bed (SMB) and their derivatives, e.g., integrated counter current chromatography (see [34]) based on
the ICM-approach will be presented in the near future.
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Abstract: The determination of monoclonal antibody interactions with protein antigens in solution
can lead to important insights guiding physical characterization and molecular engineering
of therapeutic targets. We used small-angle scattering (SAS) combined with size-exclusion
multi-angle light scattering high-performance liquid chromatography to obtain monodisperse
samples with defined stoichiometry to study an anti-streptavidin monoclonal antibody interacting
with tetrameric streptavidin. Ensembles of structures with both monodentate and bidentate
antibody–antigen complexes were generated using molecular docking protocols and molecular
simulations. By comparing theoretical SAS profiles to the experimental data it was determined that
the primary component(s) were compact monodentate and/or bidentate complexes. SAS profiles
of extended monodentate complexes were not consistent with the experimental data. These results
highlight the capability for determining the shape of monoclonal antibody–antigen complexes in
solution using SAS data and physics-based molecular modeling.
Keywords: antibody; antigen; small-angle scattering; docking; modeling; simulation; Monte Carlo
1. Introduction
Understanding protein–protein interactions is a primary goal of structural biology, which can
have direct impact on the manufacturing and therapeutic applications of monoclonal antibodies.
Antibody–antigen interactions are specific and often have favorable equilibrium properties. With two
potential antigen binding sites per molecule, antibodies can provide insights into protein interactions
that are not possible with typical proteins with a single defined binding site per molecule. For decades,
the majority of experimental data elucidating antibody–antigen interactions has come from studying
such complexes in crystals using X-ray diffraction [1,2] and in solution using nuclear magnetic
resonance spectroscopy [3,4]. Knowledge of the specific atomic interactions that define these
interactions can be used to engineer new antibody molecules to elucidate the nature of the association
to add value to improved candidate antibodies in terms of their efficacy and their ability to be
manufactured, stored, and administered. In addition, knowledge of antibody–antigen structures in the
case where the antigen has the capability to bind multiple copies of the same monoclonal antibody
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could have important biochemical impacts on the basic biology of the immune response and in-vivo
response in therapeutic settings.
Small-angle scattering (SAS) using X-rays (SAXS) or neutrons (SANS) is a valuable method
to obtain low-resolution shape information from a large variety of soft-matter systems including
proteins. While the number of unique constraints in SAS data is limited, the use of atomistic models to
interpret SAS data can offer useful insight as the atomic interactions and molecular topology are valid,
physics-based constraints on the models. SAS is often used to provide shape information for problems
in structural biology [5–7]. With selective or random deuteration of hydrogens one can use SANS via
contrast matching to elucidate the shape of independent elements of a multidomain complex [8–10].
The sample requirements to measure the SAS of proteins are generally similar to other biophysical
characterization methods, with concentrations of 0.5 g/L and higher for measurements in solution [7].
SANS can also be used to study proteins in amorphous and solid phases as there is no upper limit to
the protein concentration that can be studied. However, the nature of the scattering can change with
increasing concentration due to intermolecular correlations, and thus knowledge of the shape of the
proteins can be lost as a result of contributions due to time-averaged spatial ordering of proteins in the
sample [11]. Many SAS studies of monoclonal antibodies have been carried out to explore various
aspects of antibody function, physical chemistry, and manufacturing [12–26]. Many of these studies
report that single structures exist in solution by modeling the data using heuristic methods that lead to
overfitting an underdetermined problem. It is understood that antibodies are flexible molecules in
solution [27–29] and very few atomic structures of complete antibodies have been determined by X-ray
crystallography [22]. The three complete structures of antibodies reported to date consist of two IgG1
structures [30,31] and a single IgG2 structure [32]. These studies considered the antibody structure to
be dynamic and the single set of coordinates reported in each case should be considered “snapshots”
of likely configurations sampled in solution. Ensembles of structures to model the SAS data of a
monoclonal antibody form a more accurate representation of antibody structures in solution [18],
and this has been validated by recent studies using atomic force microscopy and individual particle
electron tomography [33,34]. SAXS has been used to determine the relative position of domains
and characterize the epitope of an antigen–Fab complex [35], but SAS has been under-utilized to
characterize antibody–antigen complexes.
Molecular dynamics, Monte Carlo simulation, and physics-based docking protocols to determine
protein–protein interactions are viable tools to predict and model experimental data [36]. There are
many simulation methods that one can use to enhance sampling and model the physics of the
interactions, often using various approximations. Yet it remains a daunting challenge to accurately
predict protein–protein interactions for systems of increasing size, and this is complicated further for
flexible or disordered molecules. The sampling of antibody structures in solution can be a intractable
task using molecular dynamics simulation, as antibodies have ∼20,000 atoms and require hundreds of
thousands of water atoms to accurately represent a model system to natively explore conformational
space. While advances have been made in the simulation community using specialty processors such
as Anton 2 [37] and graphical processing units [38–40], generally, systems the size of a single antibody
are currently near the upper limit of what one might hope to simulate in a reasonable amount of
time if one has access to the specialized computational hardware. That said, molecular simulations
using all-atom [18,25,41–44], coarse-grain [45,46], and colloidal models [23,26,47–50] can provide
insights into antibody structure and dynamics to probe basic biological, physical, and manufacturing
properties [23–26,42,51]. The complexity and tractability of the problem becomes more challenging
when one considers the interaction of protein antigens with an ensemble of flexible antibody
configurations. There are a variety of tools available to predict antibody–antigen interactions, such as
Rosetta, Modeller, and Haddock, among others [52–56]. A recent re-assessment of antibody binding
site conformation prediction has provided insight into the viability of computational methods [57].
We have used SAXS and molecular modeling to characterize the stoichiometry and structures
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A series of starting models of varied compositions and binding arrangements were then subjected to
molecular simulation to provide ensembles of structures to compare to SAXS profiles. Ensembles were
generated using backbone torsion-angle Monte Carlo (TAMC) sampling to provide tens of thousands
of unique ASA-IgG2–tSA complexes that allowed for a thorough representation of the physical space
that ASA-IgG2 and bound tSA could occupy, thus enabling the evaluation of structural models by
comparison of theoretical SAXS profiles to the experimental data. This in turn improves the viability
of models derived from SAXS (or SANS) data, that inherently contains few constraints. By enhancing
the resolution of the experimental SAXS profiles using size-exclusion chromatography (SEC) in line
with SAXS detection, together in combination with molecular modeling, it will be shown that specific
models of ASA-IgG2–tSA complexes in solution are consistent with the experimental SAXS data.
2. Results
2.1. Binding Affinity Measurements
To assess the specificity of ASA-IgG2 to monomeric streptavidin (mSA) versus tSA, a series of
binding affinity measurements were performed using surface-plasmon resonance (SPR) with a Biacore
3000 instrument. Figure 1 shows the measured response after covalently bonding ASA-IgG2 to the
surface of the sensor chip and flowing solutions of either mSA and tSA at various concentrations over
the chip. The experiment clearly reveals that ASA-IgG2 has no affinity for mSA up to a concentration of
1 μM (M = mol/L). On the contrary, changes in the response were detected after flowing tSA over the
immobilized ASA-IgG2. Using a simple 1:1 interaction model, a KD estimate of 40 nM was obtained
for tSA and ASA-IgG2.
Figure 1. Measured responses for monomeric streptavidin (mSA) and tetrameric streptavidin (tSA)
with immobilized anti-streptavidin IgG2 monoclonal antibody (ASA-IgG2).
In addition, fast protein liquid chromatography (FPLC) measurements were performed on
mixtures of ASA-IgG2 with mSA and tSA, respectively. Figure 2 presents FPLC measurements
of ASA-IgG2 in buffer compared to a mixture of ASA-IgG2 with each type of streptavidin.
Both chromatograms show the results for ASA-IgG2 only and mixtures of ASA-IgG2 with streptavidin.
For the ASA-IgG2 samples, a major peak was observed for the monomer, although about 2% of dimer
was observed in the chromatograms. For the mixtures of tSA with ASA-IgG2, two major peaks were
observed, representing tSA and the complex of tSA and ASA-IgG2. In the case of mSA and ASA-IgG2,
no species eluted before ASA-IgG2, and the two major peaks observed correspond to ASA-IgG2 and
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Figure 2. Fast protein liquid chromatography (FPLC) chromatograms of samples with ASA-IgG2 and
streptavidin. (A) mSA and ASA-IgG2 with a molar ratio of 4:1 (flow rate 0.75 mL/min). (B) tSA and
ASA-IgG2 with a molar ratio of 5:2 (flow rate 0.50 mL/min). Different concentrations of the free species
were used in each chromatogram.
Since no binding was observed between mSA and ASA-IgG2, no further studies were performed
with mSA. The following results refer to tSA and the complex formed with ASA-IgG2.
To further characterize the complex of tSA and ASA-IgG2, size-exclusion high-pressure liquid
chromatography measurements were coupled with multi-angle light scattering (MALS), known as
SEC-MALS, to study various concentration ratios of antigens to antibodies. Figure 3A displays the
chromatograms representing the free and bound species after mixing tSA and ASA-IgG2 at different
molar ratios. In these chromatograms, the free ASA-IgG2 eluted at about 10 min, whereas tSA eluted
after 12 min. The antigen–antibody complex eluted first, which can be seen as a main peak at 8 min
with an overlapping left peak or shoulder, depending on the molar ratio. These results suggest that
there is not a single complex stoichiometry between tSA and ASA-IgG2. Depending on which free
species was in excess and the molar ratios, different amounts of the complex species were formed.
When the stoichiometry of the species was close to 1:1, the maximum amount of the complex was
formed as most of the ASA-IgG2 and all the tSA were consumed. Regardless, the molecular weight of
the main peak in the complex was constant at the center of the peak and during the remainder of the
elution, as seen in Figure 3B. Therefore, the most abundant species of the antigen–antibody complex
was monodisperse in molecular weight and can be studied by collecting fractions of the main complex
peak. Note that the left shoulder in the complex peak became more pronounced with higher molar
ratios of tSA:ASA-IgG2 and when free ASA-IgG2 species were depleted.
Figure 4 shows the percentage of complex formed after mixing tSA and ASA-IgG2 at different
molar ratios. The maximum percentage of the complex was formed when the molar ratio of the
species was close to one. Moreover, when the antigen and antibody were mixed at the same molar
concentration, very low amounts of the free species were present, suggesting that most of the antigens
and antibodies were used to form the complex up to the point that one of the species was depleted.
Thus, the equilibrium is favored toward the formation of the complex, in agreement with the low KD
estimated from SPR. These results also suggest that molar ratios close to one should be used for the
SAXS measurements to obtain higher concentrations of the bound species.
From the SEC-MALS measurements, the molecular weights of the free and bound species
were obtained. Table 1 shows the molecular weights of tSA, ASA-IgG2, and the main complex
formed. The values for the free species are in agreement with the known values for these molecules.
The molecular weight obtained for the main complex is 447 ± 12 kDa. This is an average of
eight measurements. The only stoichiometry that results in the experimentally calculated value
is a combination of two molecules of tSA and two of ASA-IgG2. Using the values of Table 1,
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the experimental value for the main complex. For the remainder of the discussion of the results, unless
specified, the main complex refers to two ASA-IgG2 molecules associated with two tSA molecules.
Figure 3. Size-exclusion chromatograms (SECs) of ASA-IgG2 at pH 6.5. (A) Different ratios of molar
concentration of tSA:ASA-IgG2. (B) Molecular weight of the ASA-IgG2–tSA complex peak.
Figure 4. Percentages of the main ASA-IgG2–tSA complex formed at pH 6.5 after mixing ASA-IgG2
and tSA at different molar ratios.
Table 1. Molecular weight of the free and bound species for the main ASA-IgG2–tSA complex
Species Molecular Weight (kDa) Number of Measurements
tSA 63.3 ± 0.8 3
ASA-IgG2 160 ± 3 5
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The formation of the main complex as well as peak shape and separation in the chromatogram
were evaluated in acidic pH. However, ASA-IgG2 was unstable at pH 3. Figure 5 shows the SEC
chromatogram combined with the MALS data close to neutral and acidic pH. As shown in Figure 2,
ASA-IgG2 was mostly monomeric at pH 6.5, with only 2% aggregates. In the case of pH 3.0, the main
peak that eluted at 9.5 min represents the ASA-IgG2 monomer, whereas the first elution peaks account
for dimers and aggregates of higher molecular weight. Based on the area of the peaks, only 67% of the
sample was monomeric at pH 3.0. The peak that eluted before the monomer corresponds to the dimer,
and the first peak, which overlaps with the dimer peak, corresponds to aggregates with a wide range
of molecular weights. Although acidic pH is not suitable for this system because of aggregation of
ASA-IgG2, mixtures of the antigen and the antibody were studied with SEC. Regardless of aggregation,
the main complex did not form at acidic pH (data not shown), as the peak area was directly proportional
to the prepared concentration of antibody and antigen and neither were associated in a complex.
Note that data shown in Figures 1–5 correspond to single measurements and do not represent mean
values from multiple measurements.
Figure 5. Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) data
of ASA-IgG2 at (A) pH 6.5 and (B) pH 3.0. Light green represents the UV absorption data. Black marks
represent the molecular weight of the eluted species.
2.2. Small-Angle X-ray Scattering
Based on the binding affinity results, SAXS measurements were performed in antigen–antibody
mixtures with similar molar ratios at pH 6.5. Figure 6 presents the SAXS data of the antigen–antibody
complex using different separation techniques. Although peak fractionation and separation of the main
complex peak were clearly needed for SAXS measurements, scattering measurements were performed
in bulk (without fractionation), after collecting fractions of the main complex peak (fractionation),
and coupling SEC with SAXS (SEC-SAXS). The bulk measurement consisted of a mixture of tSA
and ASA-IgG2 at a molar ratio of 1:1, in which the main complex corresponds to 67% of the sample
according to the SEC. The SAXS profile for this sample shows a linear slope in the intermediate Q
region (0.01–0.1 Å−1), which is characteristic of polydisperse systems. In addition, the profile displays
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profile after SEC-fractionation of the main complex peak shows significantly less polydispersity and
lower amounts of aggregates. This is confirmed by the SEC-MALS analysis, which shows that 86% of
the fractionated sample corresponds to the main complex. Finally, the SEC-SAXS displays the profile of
the main complex right after eluting from the SEC column. Although all profiles show similar features,
the profile obtained with SEC-SAXS shows the lowest polydispersity and aggregation.
Figure 6. Small-angle X-ray scattering (SAXS) data of the ASA-IgG2–tSA complex at pH 6.5 using
different separation methods. (A) Profiles are arbitrarily shifted for better visualization. (B) Scaled
profiles. Error bars correspond to ±1 propagated standard error.
Figure 7 shows the SAXS profiles for tSA, ASA-IgG2, and the main complex from the SEC-SAXS
measurement. tSA and the ASA-IgG2 had the expected curvature and features in the intermediate Q
region for a globular protein and an antibody, respectively [44]. Figure 7B presents the scaled profiles
of these species, which show higher intensities at low Q for the complex, followed by the ASA-IgG2
and tSA. The low Q intensity is proportional to molecular weight, in agreement with the SEC-MALS
results. In addition, the radius of gyration (Rg) for each sample can be calculated using Guinier
analysis. Table 2 displays the results of the Guinier analysis using the SAXS profiles in Figures 6 and 7.
As expected, the main complex is the species with the largest size. However, depending on the
method used to separate the main complex, some differences are observed. Using fractionation or no
separation for the main complex results in larger radii of gyration due to the presence of other higher
molecular weight species (see Figure 3). Nonetheless, the method of fractionation provides results that
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Figure 7. SAXS data of the ASA-IgG2–tSA complex and the free species at pH 6.5. (A) Profiles
are arbitrarily shifted for better visualization. (B) Scaled profiles. Error bars correspond to the ±1
propagated standard error.
Table 2. Guinier Analysis of the SAXS profiles for the free and bound species.
Sample Method Radius of Gyration (Å) QminRg QmaxRg r2
tSA Bulk 27.4 0.52 1.3 0.98
ASA-IgG2 SEC 49.2 0.44 1.0 0.99
ASA-IgG2–tSA complex SEC 84.8 0.56 1.3 0.95
ASA-IgG2–tSA complex Fractionation 88.9 0.69 1.3 0.91
ASA-IgG2–tSA complex Bulk 123 1.0 1.2 0.62
Figure 8 shows the pair distribution function and Kratky plot for tSA, ASA-IgG2, and the main
complex using different separation methods. tSA and ASA-IgG2 show the expected profiles for a
globular protein and an antibody, respectively [44]. For the complex, a shoulder is observed in the pair
distribution function at about 50 Å and a maximum at 88 Å. The first shoulder matches the maximum
of the pair distribution function for tSA and ASA-IgG2, suggesting that it corresponds to distribution
of distances in each of the antibody domains and subdomains of the components. On the contrary,
the maximum at 88 Å is shifted by 10 Å to larger distances compared to the ASA-IgG2 distribution,
which suggests that the peak maximum corresponds to distances between ASA-IgG2 domains and the
antigen-binding fragment (Fab) with tSA. A Kratky plot is useful to qualitatively assess the folded
or globular state of proteins. ASA-IgG2 has a Kratky plot that is asymmetric, as shown in Figure 8B,
indicating some degree of non-globular shape most likely due to inherent flexibility that has been
noted for other flexible monoclonal antibodies [18,44]. However, due to the low signal-to-noise in the
samples with ASA-IgG2–tSA complexes, it is difficult to judge the degree of flexibility of the complex
compared to antibodies alone or to globular proteins. For tSA, a bell-shaped curve characteristic of
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Figure 8. (A) Pair distribution function and (B) Kratky plot for the ASA-IgG2–tSA complex and its
components at pH 6.5.
2.3. Model Building
The generation of atomistic models for use to model the SAXS data was carried out in two
steps as described in Materials and Methods, and is summarized here. First, a series of building
blocks were created in order to systematically create variant models of the various species involved.
These structures included ASA-IgG2, tSA, the ASA-IgG2 Fab–tSA complex derived from docking,
ASA-IgG2 (Fab)2-tSA derived by symmetrizing the ASA-IgG2 Fab–tSA complex, and the ASA-IgG2
fragment crystallizable region (Fc) domain as shown in Figure 9. As the stoichiometry derived
from SEC-SAXS indicates that complexes with two ASA-IgG2 and two tSA molecules are the major
components in the main fraction, the building blocks were used to create models of monodentate
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Figure 9. Schematic representation of protein structures used to create models. Fc: orange; Fab light
chains: red; Fab heavy chains: grey; linkers between Fc and Fab domains: blue; tSA: mulberry.
Brackets indicate that ensembles of structures were created. (A) ASA-IgG2; (B) tSA; (C) Fab–tSA from
the docking protocol; (D) the Fab–tSA–Fab (Fab2–tSA) complex created by symmetrizing structures
from (C,E) Fc. Coordinates for Fc and Fab were from the original ASA-IgG2 model [18]. Fc: fragment
crystallizable region; Fab: antigen-binding region.
Figure 10. Schematic of model building process for monodentate (A,B) and bidentate (C–E) ASA-IgG2–tSA
complexes. (A) Fc and a secondary Fab structure were aligned to ensembles of Fab2–tSA (depicted in
blue box) to create preliminary Fab2–tSA 2ASA-IgG2 structures. (B) Ensembles of Fab–tSA were added to
structures built in (A). Note that the predicted Fab–tSA docked configurations were maintained. (C) Fc and
secondary Fab structures were aligned to ensembles of Fab2–tSA (depicted in blue boxes) to create
preliminary Fab2–tSA single ASA-IgG2 structures. Only structures with Fab–Fc–Fab angles between
70 and 90 degrees were considered. (D) Fc and secondary Fab structures were aligned to ensembles of
Fab2–tSA (depicted in blue boxes) to create preliminary Fab2–tSA single ASA-IgG2–two Fab structures.
Only structures with distances between terminal C-alpha atoms of heavy chain residues 211 of less than
40 Å were considered. (E) Fc structures were added to structures from (D) that were subsequently
energy-minimized and equilibrated using molecular dynamics simulation.
2.4. Comparison of Models to SAXS Data
In order to thoroughly model the SEC-SAXS data, a comprehensive comparison of ensembles
of models representing potential molecular species in solution was carried out. While many of these
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the theoretical SAXS profiles to the experimental SEC-SAXS data. As shown in Figure 11 models of
tSA, ASA-IgG2, ASA-IgG2–tSA and ASA-IgG2–(tSA)2 are not in agreement with the experimental
data as χ2 > 150 for all models for each ensemble, as shown in Figure 11A–D. Note that the blue
volumetric densities represent the physical space occupied for each simulation and the single structure
depicted within each density plot represents the single best structure from that ensemble determined
by comparison of the theoretical SAXS profile to the experimental data. The ensemble of structures of
two ASA-IgG2 plus one tSA molecule contained configurations that were by themselves consistent
with the SAXS profiles (see Figure 11E) but have to be ruled out based on the measured molecular
weight by SEC-MALS.
Evaluation of monodentate (Figure 11F) and bidentate (Figure 11G) models indicates that both
contain structures that are in agreement with the SEC-SAXS data. The comparison of the scattering
profiles from the structural models to SEC-SAXS profiles indicates that larger extended structures are
not consistent with the experimental data and that the most likely set of configurations are compact
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Figure 11. Structures and comparisons of the experimental and simulated scattering profiles. (A) tSA;
(B) ASA-IgG2; (C) One ASA-IgG2 and one tSA molecule; (D) One ASA-IgG2 and two tSA molecules;
(E) Two ASA-IgG2 and one tSA molecule; (F) Two ASA-IgG2 and two tSA molecules in monodentate
configuration; (G) Two ASA-IgG2 and two tSA molecules in bidentate configuration. Blue mesh
represents the configurational space samples by the ensembles referenced to one Fc. “Goal” represents
the experimental data; “Best” represents the best match to the experimental data; and “Worst”
represents the worst match to the experimental data. The plots in the right column represent the
goodness-of-fit of the models to the experimental data in terms of reduced χ2 as a function of the size
of the models via radius of gyration (Rg).
3. Discussion
We have applied SEC-MALS, and SEC-SAXS with molecular docking and modeling to derive
models of the complex formed by a monoclonal antibody and an antigen with the propensity to bind
two Fab domains simultaneously. As expected for antibody–antigen complexes, the obtained KD was
in the nanomolar range for tSA and ASA-IgG2. The engineered mutations in mSA significantly affected
the binding affinity with the ASA-IgG2 and no binding was observed up to micromolar concentrations
of the antigen in its monomeric form. Combining SEC with a light scattering detector provided the
stoichiometry of the main complex formed by the antibody–antigen complex and the suitable ratios of
the free species for the SAXS measurements.
The use of SEC-SAXS improved the homogeneity and monodispersity of the samples, which
enabled the evaluation of the structure of the complex using high resolution atomistic models. By using
ensembles of viable models obtained from simulation, we were able to explore the specificity of
SEC-SAXS to evaluate atomistic models consistent with the solution scattering data. Knowledge of the
molecular weight of the species provided discriminating information to rule out models of the two
ASA-IgG2 molecules and single tSA molecule in the case where the theoretical SAXS profiles were in
agreement with the experimental data.
Finally, we found that compact models of monodentate and bidentate complexes were consistent
with the SEC-SAXS data, although further discrimination of whether the monodentate and bidentate
complexes are in equilibrium is not available without further experimental constraints. Thus, the use
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complexes and could have impact for those cases where stoichiometry and/or symmetry allows a
discrimination of scattering profiles for putative models. Furthermore, the use of modern docking
protocols to create physics-based structures to calculate SAS data in order to compare to SEC-SAXS
data is a valuable orthogonal constraint that can be useful in modeling such data.
4. Materials and Methods
4.1. Sample Preparation
ASA-IgG2 was provided by Amgen in frozen solutions of 10 mM sodium acetate buffer, 10 mM
acetic acid, 9% w/v sucrose, with pH 5.2 at concentrations of 30 mg/mL. The tSA (product number
S4762 Sigma-Aldrich, St. Louis, MO, USA) was received as a lyophilized powder and stored at −80 ◦C.
The mSA (product number 1385, Kerafast, Boston, MA, USA) is an engineered protein with high
affinity to biotin that prevents multivalent interactions. mSA was provided in a 50-mM Tris (pH 7.5)
with 150 mM of NaCl buffer and stored at 4 ◦C for up to two weeks. Frozen samples were thawed
overnight at 4 ◦C one day before usage.
A phosphate buffer solution was prepared using sodium phosphate dibasic anhydrous (product
number MSX0720-1, EMD Millipore, Burlington, MA, USA) and potassium phosphate monobasic
(product number 231-913-4, Sigma-Aldrich, St. Louis, MO, USA) in Millipore SuperQ water, adjusting
the pH to 6.5. Solutions were buffer exchanged using Slide-A-Lyzer dialysis cassettes (product number
66330, Thermo Scientific, Grand Island, NY, USA) with a 3.5-K molecular weight cutoff for mSA.
For ASA-IgG2 and tSA samples, solutions were buffer-exchanged using Float-a-Lyzer dialysis devices
(product number G235031, SpectrumLabs, Rancho Dominguez, CA, USA) with a 8–10 K molecular
weight cutoff. The samples were immersed for at least 10 hours in fresh buffer up to three times
while stirring to reach more than 99.9% of the final desired buffer composition. Solutions at pH 3.0
were prepared using a buffer with sodium phosphate dibasic anhydrous (product number MSX0720-1,
EMD Millipore, Burlington, MA, USA) and phosphoric acid (product number 79617, Sigma-Aldrich,
St. Louis, MO, USA) in Millipore SuperQ adjusted to pH 3.0.
Sample concentration was performed using Amicon Ultra-0.5 centrifugal filters (product number
UFC501096, EMD Millipore, Burlington, MA, USA) with a 10-kDa molecular weight cutoff in a swinging
bucket centrifuge (product number 75003181, Thermo Scientific, Grand Island, NY, USA) at 4000 relative
centrifugal force until reaching the desired concentration. Final protein concentration was measured
with a Nanodrop 2000 spectrometer (ND-2000, Thermo Scientific, Grand Island, NY, USA) using percent
extinction coefficients (εpercent) of 24.1, 31.7, and 16.0 for the mSA, tSA, and ASA-IgG2, respectively.
4.2. Binding Measurements
Binding affinity was assessed using the Biacore 3000. A protein A sensor chip (product number
29127558, GE Healthcare, Pittsburg, PA, USA) was used with a pre-immobilized recombinant protein
A that has high affinity for the Fc region of antibodies. A solution of ASA-IgG2 at a concentration
of 30 μg/mL was flowed through the cell until reaching a steady-state response, that was used as
a baseline. Solutions containing antigen were then injected at concentrations from 1 to 1000 nM for
60 s. Samples and buffer were filtered using a 0.2-μm filter and degassed prior to the measurements.
Size exclusion chromatography was performed using a Superdex200 10/300 GL column with an ÄKTA
Purifier system (GE Healthcare, Pittsburg, PA, USA). All measurements were performed at 25 ◦C.
This system was used for fractionation, collecting 1 mL of volume(s), and the resulting fractions were
concentrated to 2 mg/mL for the SAXS measurements as described above.
High-performance liquid chromatography coupled with multi-angle light scattering was
performed using a Thermo Scientific/Dionex U3000. Samples were injected onto a TSKgel G3000SWxl
column (product number 08541, Tosoh Bioscience, South San Franciso, CA, USA) and absorbance
was measured at 280 nm. After equilibrating the system and the column with the mobile phase,
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mobile phase. Light scattering was performed with a DAWN HELEOS II detector (Wyatt Technology,
Santa Barbara, CA, USA) at a wavelength of 664 nm. An Optilab T-rEX instrument (Wyatt Technology,
Santa Barbara, CA, USA) was used for differential refractive index detection. Data were analyzed with
the ASTRA®V software (Wyatt Technology, Santa Barbara, CA, USA).
4.3. Small-Angle X-ray Scattering Measurements
SAXS measurements were performed using an in-house Rigaku X-ray source and the SAXSLab
Ganesha platform at the Institute for Bioscience and Biotechnology Research. Samples were loaded
into a 96-well plate and sealed with tape to prevent solvent evaporation. Then, 20 μL of each sample
was loaded into a 1.3-mm capillary by an automated robot. Sample to detector distance was varied
from 0.7 to 1.7 m and a wavelength of 1.5418 Å was used to cover the range 0.005 Å−1 < Q < 0.45 Å−1.
Scattered photons were detected with a two-dimensional Pilatus 300 K detector (Dectris, Baden-Dättwil,
Switzerland). Data reduction was performed using RAW [58]. This setup was used for all samples,
with the exception of those measurements for the complex that were coupled with SEC. Pair distribution
functions and Guinier fits were calculated using RAW [58].
SAXS was also performed at BioCAT (beamline 18ID at the Advanced Photon Source, Chicago,
IL, USA) with in-line size exclusion chromatography (SEC-SAXS) to separate the species of interest
from other species and contaminants, thus ensuring optimal sample quality. Samples were loaded
onto a Superdex-200 Increase 10/300 GL column (GE Healthcare, Pittsburg, PA, USA), which was run
at 0.75 mL/min, and the eluate, after passing through the UV monitor, was directed through a SAXS
flow cell. The SAXS flow cell had a 1.5-mm quartz capillary with 10-μm walls. Scattering intensity
was recorded using a Pilatus3 1M detector (Dectris, CH) that was placed ∼3.5 m from the sample
resulting in a q-range of 0.0057 to 0.36 Å−1. 0.5 s exposures were acquired every 2 s during elution
and data was reduced by the beam line specific pipeline that uses the ATSAS program suite [59].
Exposures corresponding to the regions flanking the elution peak were averaged to generate a buffer
file which was subtracted from all the exposures. The buffer-subtracted exposures corresponding to
the elution peak were used for subsequent analysis. This setup was used for the antigen–antibody
complex and the antibody.
The profiles for ASA-IgG2 were consistent between the two SAXS instruments and methods.
No radiation damage was observed when using the in-house source or the synchrotron facility.
This was confirmed by collecting short exposures as the sample eluted and comparing the radius of
gyration and low-Q scattering profile of the initial and final exposures. The free species were measured
at concentrations of 1 and 2 mg/mL. No inter-particle interaction effects were observed at the highest
concentration used. The complex sample was obtained by mixing the free-species using a molar ratio
of 1:1 and separated using SEC-SAXS and fractionation as described in the results.
Certain commercial equipment, instruments, materials, suppliers, or software are identified in this
paper to foster understanding. Such identification does not imply recommendation or endorsement by
the National Institute of Standards and Technology, nor does it imply that the materials or equipment
identified are necessarily the best available for the purpose.
4.4. Molecular Modeling
A sequence homology model of the ASA-IgG2 with 19,668 atoms, from an earlier study [18],
was energy-minimized for 2500 steps, and subject to 1 ns dynamics as described previously. Note that
the disulfide bonds in this model correspond to the IgG2-A form [60] characterized by structurally
independent Fab domains and hinge region. The resulting structure was used as a starting structure
for torsion-angle Monte Carlo (TAMC) studies. The program SASSIE [61] was used to generate
47,319 non-overlapping configurations by sampling backbone angles Φ or Ψ of the amino acid residues
212–214 of the upper hinge region of the heavy chain. Details of the TAMC method applied to
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A model of the tSA protein was created using the coordinates from the crystal structure (PDB ID:
1SWB) [62] obtained from the protein data bank [63] where all missing atoms were added using the
program PSFGEN distributed as part of NAMD [64]. The complete model was energy-minimized for
2500 steps with the molecular dynamics program NAMD [64] using the CHARMM22 force field [65].
Subsequently, the structure was immersed in a previously equilibrated 200 Å cubic box of water (using
the TIP3P water model [66]) and overlapping waters were removed and a neutralizing number of ions
were added. The system was equilibrated at 300 K and 1 bar followed by a production run for 2 ns in
the isothermal-isobaric (NPT) ensemble and compared to the SEC-SAXS data shown in Figure 11A.
For clarity, in the remainder of this section, Fab refers to ASA-IgG2 Fab domain and Fc refers to
ASA-2 IgG2 Fc domain. Starting with coordinates taken from the TAMC ensemble for the ASA-IgG2
and the final tSA structure from the solvated molecular dynamics simulation, a starting structure
for docking was constructed. This structure consisted of a Fab subunit and the tSA protein initially
positioned near the Fab paratope region. The Fab subunit consisted of the light chain and residues
1–211 of the heavy chain. The RosettaDock [67] full protocol was used to create 150,000 docking decoys
by generating random reorientations of both the Fab and tSA proteins independently. Optimization of
side chain conformations of both partners were performed prior to docking using the RosettaDock
pre-packing protocol. Subsequent post-analysis involved ranking the decoys using clustering. The set
of decoys were sorted by score and the top 10,000 decoys were selected for clustering analysis.
The Calibur program [68] was used for clustering with the Rosetta option selected for finding the
clustering threshold. The largest cluster was selected, that contained 383 structures.
Assembly of the complexes shown in Figures 9 and 10 involved alignment using the heavy chain
of Fab. Structural alignment was carried out using the Align module in SASSIE. For these alignments,
care was taken to retain, specifically, the heavy chain which was originally interfaced with tSA from
the docking protocol. Moreover, the region of the heavy chains used for alignment was selected to
exclude residues which comprised or were near the interfacial region between the tSA and Fab binding
site defined by the predictions from docking. Following alignment, atom distances between the pair
of aligned molecules were monitored and if any of these distances were less than 8.0 Å, the aligned
structure was rejected.
Fab–tSA–Fab complexes (Fab2–tSA) comprising the ensemble shown in Figure 9D were derived
by symmetric replication of tSA from the ensemble of Figure 9C. The Fc and secondary Fab were then
added to the complex by alignment of the heavy chains of both the full-length ASA-IgG2 structure
from the TAMC ensemble (Figure 9A) and the Fab2–streptavidin (SA) complex to give the full-length
Fab2–tSA 2 ASA-IgG2 complex shown in Figure 10A. The monodentate ASA-IgG2–tSA complex
(Figure 9B) was then constructed by aligning Fab heavy chains of Fab2–tSA structures from the
ensemble of Figure 9C and the Fab2–SA 2 ASA-IgG2 complex (Figure 10A). The resulting structures
were energy-minimized and subjected to 10 ps Born implicit solvent molecular dynamics (MD). These
structures were then used to generate approximately 50,000 accepted configurations in a TAMC
simulation. Each TAMC configuration was energy minimized for 2500 steps, and then subjected to
10 ps MD to relax the structural ensemble to compare to SEC-SAXS data shown in Figure 11F.
To construct the bidentate complex, a subset of the TAMC ensemble of full-length ASA-IgG2
with Fab–Fc–Fab angles between 70 and 90 degrees was first collected to provide structures poised to
represent more likely candidates for the general bidendate configuration. Subsequently, Fab heavy
chains of Fab2–tSA structures from the ensemble of Figure 9C were aligned with heavy chains of both
Fab subunits of the selected subset of ASA-IgG2. Only structures with distances between C-alpha
atoms of residue 211 of less than 40 Å were retained. Fc structures were then added. The resulting
structures were energy-minimized for 2500 steps, and then subjected to 10 ps MD to relax the structural
ensemble. A single structure from the ensemble was used for a 10 ns generalized Born MD simulation
to provide a trajectory to compare to the SEC-SAXS data shown in Figure 11G.
Theoretical SAS profiles were calculated using the SasCalc [69] module within SASSIE.
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a SAS profile calculated for the experimental SAXS data. Nineteen grid points of momentum transfer,
Q, between 0 and 0.19 Å−1 were used. All the images of protein structures were generated using visual
molecular dynamics [70].
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Abstract: In order to meet desired drug product quality targets, the glycosylation profile of
biotherapeutics such as monoclonal antibodies (mAbs) must be maintained consistently during
manufacturing. Achieving consistent glycan distribution profiles requires identifying factors that
influence glycosylation, and manipulating them appropriately via well-designed control strategies.
Now, the cell culture media supplement, MnCl2, is known to alter the glycosylation profile in
mAbs generally, but its effect, particularly when introduced at different stages during cell growth,
has yet to be investigated and quantified. In this study, we evaluate the effect of time-dependent
addition of MnCl2 on the glycan profile quantitatively, using factorial design experiments. Our
results show that MnCl2 addition during the lag and exponential phases affects the glycan profile
significantly more than stationary phase supplementation does. Also, using a novel computational
technique, we identify various combinations of glycan species that are affected by this dynamic media
supplementation scheme, and quantify the effects mathematically. Our experiments demonstrate
the importance of taking into consideration the time of addition of these trace supplements, not just
their concentrations, and our computational analysis provides insight into what supplements to add,
when, and how much, in order to induce desired changes.
Keywords: cell culture; glycosylation; media supplementation; MnCl2; controllability analysis
1. Introduction
The global market for pharmaceuticals is predicted to grow to $1.5 trillion by 2021, with biologics
such as monoclonal antibodies (mAbs), hormones, and therapeutic enzymes accounting for nearly
20% of the market share, based on current projections. With US sales rising from $8.29 billion in
2005 to $24.6 billion in 2012 [1,2]—coupled with the increase in regulatory agencies approvals of
mAb treatments for different indications ranging from cancer to rheumatoid arthritis and Crohn’s
disease [3,4], the growing market for mAbs has resulted in active development of these biological
products. While several different mammalian cell expression systems can be used to synthesize
mAb therapeutics, over half of all currently approved mAbs are produced in Chinese Hamster
Ovary (CHO) cell lines. CHO cells are the preferred host for a large number of recombinant mAb
therapeutics because of the ease of adapting them to suspension growth, and the availability of
powerful gene amplification systems to improve specific productivity [5]. However, more importantly,
the post-translational modification machinery in CHO cells produces human-like structures in mAbs,
thus ensuring biocompatibility.
One important post-translational modification in mAbs is N-glycosylation, a process by which an
oligosaccharyltransferase complex in the endoplasmic reticulum adds a sugar substrate (glycan) to the
Asn-X-Ser/Thr motif in the heavy chain of the mAb (where X is any amino acid other than Pro). As the
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mAb traverses the Golgi complex, the core glycan undergoes a series of non-template driven reactions that
are mediated by the localized glycosyltransferase enzymes in the different Golgi compartments [6,7]. The result
is a heterogeneous distribution of glycan residues or glycoforms, which affects the immunogenicity,
effector functions, and the pharmacokinetic properties of the mAb, and consequently the final drug
product quality [8–10]. Thus, there is considerable motivation for manufacturers and regulators to
understand, characterize, and, if necessary, modulate the glycoform distribution in mAbs during
production, in order to maintain a consistent glycan profile [11–14]. However, manipulating the glycan
distribution effectively requires (i) identifying the factors that can influence the glycan distribution;
(ii) quantifying the degree to which these factors affect the concentration of the glycoform species;
and (iii) using such information to design effective control systems.
Previous studies have demonstrated that protein glycosylation can be influenced by various
factors [15], such as pH [16,17], temperature [18–20], dissolved oxygen [21,22], ammonia [23], and media
supplements such as nucleotide sugar precursors [24] and manganese chloride (MnCl2) [25–28]. Each
study focused on an individual factor, establishing empirical relationships between the individual
factor in question and the specific set of glycan species it affects. However, modulating the complete
glycan distribution profile requires manipulating multiple input factors simultaneously, and to be
effective, such action must be based on a thorough, holistic understanding of how these inputs
individually and jointly affect various glycan species. Such process understanding can be generated
systematically by using statistical design of experiments whereby input factors are judiciously varied
simultaneously to generate data on the main and interaction effects they exert on all the output
responses of interest. Such structural information indicates which inputs to manipulate, and by how
much, in order to alter the relative concentrations of different glycan species appropriately. In most
cases, however, the available inputs are fewer than the glycan species to be controlled, resulting in
a system with insufficient degrees of freedom. Consequently, we must first answer a fundamental
question: given a limited set of inputs, to what extent can we independently control the concentrations
of all the desired glycan species? In other words, is the desired change in the glycan distribution
achievable using the available inputs? We address this question using “controllability analysis”,
by which we can determine quantitatively the extent to which the system is controllable. (Informally,
a system is considered completely controllable if it is possible to drive the complete set of outputs from
some initial value to any arbitrarily specified final, desired value, by manipulating the available set of
inputs.) We have previously introduced, in [29], the concept of output controllability, demonstrated
how to use it to assess the controllability of the glycan reaction network using data generated from
statistical design of experiments, and in [30] we illustrated practical applicability by using it to identify
in an experimental system, the glycan species whose concentrations can be controlled using such
media supplements as MnCl2, galactose and NH4Cl as manipulated variables.
The role of different media supplements in modulating critical quality attributes of the mAb
in general, and the glycan distribution profile in particular, has received considerable attention
recently [31]. Typically, supplements such as MnCl2, which are known to affect the expression and
activity of several glycosyltransferase enzymes, are added to the media at the start of the batch to
alter the glycan distribution. However, over the course of the batch run, as the cells continue to grow
and produce mAb molecules, it is clear that changes in the cellular availability of supplements will
influence not just the antibody productivity but also the activity of the glycosyltransferase enzymes,
thus affecting the final glycan distribution. Consequently, we postulate that it is possible to control the
glycosylation profile in mAbs by introducing specific media supplements at different stages of cell
growth. We postulate further that introducing a chelating agent to the media can alter the effect of
MnCl2 addition on the glycan distribution. Consequently, a chelating agent such as EDTA provides an
additional degree of freedom for fine-tuning the effect of MnCl2, the media supplement of primary
interest. Although EDTA is toxic to cells and can titrate both Mn++ and other bivalent ions in the
medium that are necessary for cell growth and may be cofactors for other glycosyltransferase enzymes,
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supplements. (It is important to stress that the proposed time-dependent media supplementation is
distinct from current fed-batch strategies where the objective is primarily to meet the nutrient demand
in the culture, for the express purpose of enhancing cell growth and productivity—not to ensure that
the product quality meets specific targets.) Specifically, we aim to identify the glycan species that can
be controlled by adding MnCl2 during lag, exponential, and stationary phases of cell growth, and to
quantify the effect of such time-dependent MnCl2 additions on the glycan distribution.
In this work, we use a mixed factorial experimental design to add MnCl2 and EDTA at various
stages of cell growth and, via appropriate analysis of the resulting data, we quantify the effect of
time-dependent media supplementation on the antibody productivity and the glycosylation profile
in mAbs. Subsequently, we use controllability analysis to identify the glycan species whose relative
percentages can be controlled effectively by introducing MnCl2 and EDTA to the media at different
time points, and quantify the effect of these time-dependent additions. Overall, our results highlight
the importance of taking into account the dynamic nature of media supplementation, and also provide
concepts that can be exploited to develop new strategies for controlling the glycosylation profile
in mAbs.
2. Materials and Methods
2.1. Cell Culture
All experiments were conducted using an IgG1 producing CHO-K1 cell line donated by Genentech,
San Francisco, California. The cells were scaled up in a custom CD OptiCHOTM medium formulation
(Thermo Fisher Scientific, Waltham, MA, USA) that was supplemented with 4 mM glutamine, 5 g/L
glucose and 25 nM MTX. The osmolality was adjusted to 300 mOsm by adding NaCl stock solution.
The concentration of MnCl2 in the media was adjusted using a 0.5 M stock solution (Sigma Aldrich,
St. Louis, MO, USA). Similarly, a 0.5 M EDTA sterile stock solution was prepared and added to the
media as required. The cells were inoculated with an initial seeding density of 0.5 × 106 cells/mL
in vented-cap Erlenmeyer shake flasks with a working volume of 50 mL and grown in batch in
suspension in an incubator maintained at 37 ◦C with a 5% CO2 overlay, with supplements only as
indicated by experimental design below. Cell count measurements were taken every two days using
a hemocytometer. Metabolite (glutamine, glucose, glutamate and lactate) concentrations, media pH,
and osmolality were measured using a Bioprofile 100+ analyzer (Nova Biomedical, Waltham, MA,
USA). Antibody titer was measured with an Agilent 1200 HPLC instrument using 1X PBS buffer on a
Thermo ScientificTM MAbPac Protein A chromatography column (12 micron particle size, 35 × 4.0 mm
I.D., Thermo Fisher Scientific, Waltham, MA, USA).
2.2. Experimental Design
The shake flask experiments were conducted according to a (22, 32) mixed level experimental
design for the following factors: (i) MnCl2 concentration (high and low levels); (ii) EDTA concentration
(high and low levels); (iii) time of addition of MnCl2 (high, intermediate, and low levels); and (iv) time
of addition of EDTA (high, intermediate and low levels). The concentration of MnCl2 in the basal
media corresponds to the low-level condition (−1) for MnCl2, while the high-level condition (+1)
corresponds to the final concentration of MnCl2 supplemented media (0.04 mM). High and low levels
for MnCl2 were-based upon previous experiments performed using the same cell line [30]. Similarly,
the low-level condition (−1) for EDTA corresponds to “no EDTA” added to the media, while the
high level (+1) corresponds to 0.08 mM EDTA added to the media. MnCl2 and EDTA are added on
day 0 (D0), day 3 (D3), or day 6 (D6) after inoculation, corresponding respectively to the low (−1),
intermediate (0), and high (+1) levels. Thus, this full factorial mixed level (22, 32) experimental design
yields a total of 36 different possible shake flask conditions to be tested. However, the 36 conditions are
not unique because some of the cases correspond to identical experimental conditions. For instance,
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low (−1), intermediate (0) and high levels (+1). The low level condition for MnCl2 represents basal
concentrations, while the low level for EDTA represents no EDTA supplementation. Thus, these 9 cases
represent identical conditions where the flask has basal levels of MnCl2 with no EDTA supplementation
either on D0, D3, or D6. A single flask (F1) was used for all nine cases and was treated as the control
flask because of what the conditions represent—basal level of MnCl2 and no EDTA supplementation on
any day. It can be shown that there are in fact only 16 unique experimental cases/conditions, as listed
in Table 1. Each condition was tested with two biological replicates. The glycan distribution profile
was determined using the permethylation assay described below, and the resulting relative glycan
percentages data obtained for each condition were analyzed in MINITAB using standard analysis of
variance (ANOVA) to obtain the factor effects/coefficients and associated p-values.













1 0.01 0 D0 D0 Control
2 0.01 0.08 D0 D0 ED D0
3 0.04 0.08 D0 D0 Mn D0/ED D0
4 0.04 0.08 D3 D0 Mn D3/ED D0
5 0.04 0.08 D6 D0 Mn D6/ED D0
6 0.01 0.08 D0 D3 ED D3
7 0.04 0.08 D0 D3 Mn D0/ED D3
8 0.04 0.08 D3 D3 Mn D3/ED D3
9 0.04 0.08 D6 D3 Mn D6/ED D3
10 0.01 0.08 D0 D6 ED D6
11 0.04 0.08 D0 D6 Mn D0/ED D6
12 0.04 0.08 D3 D6 Mn D3/ED D6
13 0.04 0.08 D6 D6 Mn D6/ED D6
14 0.04 0 D0 D0 Mn D0
15 0.04 0 D3 D0 Mn D3
16 0.04 0 D6 D0 Mn D6
1 D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation, respectively.
2.3. Glycan Permethylation Assay
On day 8 after inoculation, the cells were centrifuged at 3000 rpm for 10 min and the spent media
was harvested. The IgG1 antibody was then purified from the spent media using a PhyNexus Benchtop
MEA2 system using Protein A chromatography resin packed in a 2 mL PhyTip column (PhyNexus,
San Jose, CA, USA). The glycan permethylation assay was then carried out with 100 microgram of the
purified antibody using a previously described method [30]. Briefly, the antibody was first digested
with trypsin (Promega, Madison, WI, USA) for four hours in an incubator held at 37 ◦C, followed
by enzymatic deglycosylation using PNGase-F (ProZyme, Hayward, CA, USA) for a minimum of
16 h at 37 ◦C. The free separated glycans were captured on Hypersep Hyper Carb SPE cartridges
(Thermo Fisher Scientific, Waltham, MA, USA) and permethylated following the Ciucanu method
using methyl iodide and NaOH in the presence of DMSO [32,33]. The permethylated glycans were
purified in a liquid-liquid extraction step with chloroform (Sigma Aldrich, St. Louis, MO, USA),
dried and resuspended in 80% methanol (Sigma Aldrich, St. Louis, MO, USA). The resuspended
glycans were spotted onto a MALDI/TOF plate with a DHB matrix and analyzed using a 4800 MALDI
TOF/TOF Analyzer (ABSciex) in positive ion, reflector mode. The data collected using the mass
spectrometer was then exported to DataExplorer to obtain the peak heights for the identified glycans
(see Supplementary Table S8). The relative glycan distribution in each sample was calculated from the
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2.4. Glycosylation Index
For each experimental condition, glycosylation indices were calculated from the relative
percentages of individual glycan species [17,34]. For example, the galactosylation index (GI), defined as
the percentage of mono- and di-galactosylated species in the total glycan distribution, was determined
according to Equation (1):
GI =
2 × G2 + G1
2 × (G0 + G1 + G2)%, (1)
where G0 is the sum of all agalactosylated species, G1 is the sum of all monogalactosylated species,
and G2 is the sum of all digalactosylated species. Similarly, we calculated the fucosylation index (FI)





where F0 and F1 are the sum of all afucosylated and fucosylated species, respectively.
2.5. Controllability Analysis
Using the technique presented in St.Amand et al. [29], we performed controllability analysis to
quantify the effect of time dependent media supplementation on the glycosylation profile in mAbs.
Briefly, we note first that estimates of factor coefficients obtained after analyzing the mixed factorial
design data correspond to the various “process gains”, defined as the change observed in the glycan
distribution (output), Δy, in response to a unit change in the input factor with which the coefficient in
question is associated. By selecting statistically significant factor coefficients (at the significance level
of α = 0.05) and setting all non-significant coefficients to zero, we generateed the process gain matrix K
so that:
Δy = KΔu, (3)
where Δu represents the change in the input factor. Singular value decomposition of the process gain
matrix produces the diagonal singular value matrix, Σ, and the unitary matrices, W and VT, that are
subsequently used to obtain the orthogonal input (μ) and output (η) modes, which, along with the
corresponding singular values are used to assess controllability.
3. Results
3.1. Early Addition of EDTA Was Detrimental to Cell Growth and Reduces Antibody Titer
Figures 1 and 2 show the effect that introducing media supplements (MnCl2 or EDTA) at different
time points had on viable cell density and final antibody titer, compared to corresponding results
obtained from a control flask (F1), which contained MnCl2 at basal media concentrations and no
EDTA (see Figure S2 in supplementary information for the normalized glucose concentration in each
shake flask).
Compared to the conditions in the control flask, early addition of EDTA on D0 reduced the
cell density significantly, which is consistent with hampered cell growth. However, this effect was
offset somewhat by introducing MnCl2 in addition to EDTA on D0. The average viable cell density
(VCD) measured on day 4 for samples in which both MnCl2 and EDTA were introduced on D0, was
1.31 × 109 cells/L, which was nearly three times as large as the value of the VCD in the flasks where
only EDTA was added on D0 (~0.4 × 109 cells/L). Introducing MnCl2 on D3 or D6 after the addition
of EDTA on D0 did not improve the VCD. Similarly, when EDTA was introduced on D3, the VCD in
samples with no additional MnCl2 supplementation dropped sharply. By contrast, when the media
was supplemented with MnCl2 on D0 or D3, the VCD was slightly higher than when the media
was supplemented with just EDTA on D3. Supplementing the samples with MnCl2 on D6 after the
addition of EDTA did not improve the VCD significantly. In all cases, the observed VCD was generally
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regardless of the time of introduction of MnCl2. Similarly, as shown in Figure 1d, early addition of
MnCl2 on D0 and D3 reduced the VCD, while addition of MnCl2 on D6 did not alter the VCD. Thus,
in summary, early addition of EDTA reduced cell viability in the absence of MnCl2 supplementation,
but the addition of MnCl2 by itself did not alter cell viability significantly.
Figure 2 shows the effect of media supplementation on antibody titers. The average mAb titer
in the control flask F1 (with no MnCl2 or EDTA supplementation) was 0.13 g/L. The addition of
EDTA to the media on D0 in the absence of MnCl2 supplementation decreased the titer by about a
fourth, to 0.03 g/L. This decrease in the titer was marginally offset when MnCl2 was introduced on D0,
D3, or D6, with earlier MnCl2 supplementation resulting in higher titers than later supplementation.
When EDTA was introduced on D3, the resulting titer was 0.10 g/L, three times higher than that
observed with EDTA supplementation on D0. Further supplementing the media with MnCl2 on D0,
D3, or D6, increased the titer observed with EDTA supplementation on D3 to values comparable to
that of the control case. Supplementing the flasks on D6 with EDTA increased titers even further to
0.15 g/L, beyond values obtained in the control case. The titer values were also higher when EDTA
supplementation on D6 was combined with MnCl2 supplementation on D0 (0.17 g/L), D3 (0.17 g/L) or
D6 (0.16 g/L). Finally, MnCl2 supplementation alone on D0, D3, or D6 increased the titer to an average
of 0.14 g/L. Thus, while early EDTA supplementation has an adverse effect on the antibody titer,
late EDTA addition improves the final titer. Consequently, we conclude that early addition of EDTA
reduces antibody titer, while latter addition of EDTA helps to increase the titer by a marginal amount.
Figure 1. Average viable cell concentration data for CHO-K1 cells when (a) EDTA is added by itself
on D0 ( ), or in the presence of MnCl2 on D0 (), D3 (*), and D6 (); (b) EDTA is added by itself on
D3 ( ), or in the presence of MnCl2 on D0 (), D3 (*), and D6 (); (c) EDTA is added by itself on D6 ( ),
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Figure 2. Average antibody titer for the 16 experimental conditions. Mn and ED refer to the media
supplements MnCl2 and EDTA, while D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation,
respectively. Error bars represent the range of biological replicates (n = 2).
3.2. Early Addition of MnCl2 Alters the Glycan Distribution Significantly
The addition of EDTA and MnCl2 at different time points altered the glycan distribution, with
earlier addition of MnCl2 having the more significant effect. Figure 3 shows the effect of media
supplementation on select glycan species, with panels 3(a), (b) and (c) showing the changes in the
glycan profile as a result of media supplementation with EDTA on D0, D3, and D6, with or without
additional MnCl2 supplementation, and 3(d) showing the impact of MnCl2 addition in the absence of
EDTA supplementation. (See Supplementary Information Figure S3 for the average relative glycan
percentage of all the glycan species.)
Adding EDTA to the cell culture media on D0 (Figure 3a) decreased the amount of biantennary
fucosylated species, FA2, by 5.58%, which was offset by a concomitant increase in its galactosylated
isoforms, FA2G1 (4.52%) and FA2G2 (1.52%). (See supplementary information Table S1 for a complete
list of experimentally observed glycan species and their structures.) The mannosylated species M5 also
increased by 1.52%, with a corresponding reduction of 1.79% in the concentration of the biantennary
group A2 (which is produced from M5 in the Golgi compartment). Adding MnCl2 on D0, D3,
or D6 to media in which EDTA was introduced on D0 resulted in a further increase in the relative
concentrations of the galactosylated isoforms FA2G1 and FA2G2, in addition to a decrease in the
relative percentage of FA2, A2, and A2G1 species, compared to the distribution in the control flask.
However, the increase in FA2G1 and FA2G2 was more pronounced when MnCl2 was introduced on
D3 or D6 after adding EDTA. When EDTA was added on D3 (Figure 3b) the relative percentages of the
biantennary species FA2, FA2G1, and A2G1 decreased, while the relative percentages of glycan species
M5, A1, and FA1 increased. When MnCl2 was added on D0 followed by EDTA supplementation on D3,
the concentrations of M5 and FA1 increased, while the concentration of FA2 decreased. Additionally,
there was an increase in the relative percentage of A2G1 that was offset by the decrease in the
concentration of A1G1. When both EDTA and MnCl2 were added to the media on D3, the change in
the glycan distribution mirrors the trend observed when only EDTA was introduced on D3. The main
difference occurs when MnCl2 was added to the media after EDTA addition, i.e., on D6. Here,
the relative percentages of M5, FA1, FA2G1, and FA2G2 increased while the relative percentages of
A2, A2G1, and FA2 decreased, similar to the trends observed with the addition of MnCl2 on D3 or
D6 following EDTA supplementation on D0. Although the late addition of EDTA on D6 of the cell
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percentages change, the trend was similar to that observed with EDTA supplementation on D0 and
D3, i.e., an increase in the relative percentage of M5 and A1 accompanied by a decrease in that of FA2
and FA2G1. When the media was first supplemented with MnCl2 on D0 or D3, followed by EDTA
supplementation on D6, the relative percentage of FA2 species decreased while the relative percentages
of M5, A2 and FA2G1 species increased. A simultaneous addition of both EDTA and MnCl2 toward
the end of the batch increased the relative percentage of A2G1 while decreasing the relative amount of
its fucosylated isoform FA2G1.
Figure 3. Average relative glycan percentage of select IgG1 glycans produced in CHO-K1 cells when:
(a) EDTA is added on D0 with no MnCl2 supplementation or with MnCl2 supplementation on D0, D3,
and D6; (b) EDTA added on D3 with no MnCl2 supplementation or with MnCl2 supplementation on D0,
D3, and D6; (c) EDTA added on D6 with no MnCl2 supplementation or with MnCl2 supplementation
on D0, D3, and D6; and (d) MnCl2 is added on D0, D3, and D6.
The solo effect of MnCl2 on the glycan profile was observed by supplementing the media with
MnCl2 in the absence of EDTA on D0, D3 or D6 (Figure 3d). Adding MnCl2 on D0 decreased the relative
percentage of the FA2 species from the control value of 51.79% (with a 95% confidence interval range
of ±0.94%) to 39.50% (±1.55%). Similarly, the relative percentage of the monogalactosylated species
FA2G1 dropped from the control value of 23.87% (±0.94%) to 17.95% (±1.55%). This decrease in the
fucosylated species was offset by an increase in the biantennary species A2 (which increased by 13.24%),
the mannosylated species M5 (2.62%), and the galactosylated biantennary species A2G1 (4.29%). It is
important to note that this trend (observed in the glycan distribution when only MnCl2 is added to the
shake flask) is consistent with the trend previously observed in experiments performed using the same
cell line [30]. Introducing MnCl2 to the culture medium on D3 resulted in a similar trend, with the
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(which increased by 10.20%), the mannosylated species M5 (increasing by 6.59%) and only a marginal
increase in the A2G1 species (by 0.76%). Adding MnCl2 during the peak exponential phase (D6)
produced similar changes in the glycan distribution, but these changes were smaller in comparison
to the changes in the glycan distribution due to earlier addition of MnCl2. The concentrations of the
fucosylated species FA2 and FA2G1 decreased by 2.36% and 1.28% respectively, with the corresponding
increases in the concentrations of A2 and M5 species being 2.52% and 1.94%, respectively.
While such qualitative discussions of the glycan distribution profiles may be instructive in
general, for our purposes in this work, a quantitative analysis relating the changes in the experimental
conditions to the observed changes in the glycan profile is more informative.
3.3. The Type of Media Supplement and the Time of Addition both Showed Statistically Significant Effects on
Glycan Distribution
The concentrations of MnCl2 and EDTA and the time of addition of each one constitute the
four factors in the (22, 32) mixed factorial experimental design used in this study. In general,
the full complement of this factorial experimental design consists of 4 × 9 = 36 independent
experimental conditions, and the resulting model, in principle, consists of 35 main and interaction
effects. The statistically significant factor coefficients (at the significance level of α = 0.05) estimated
using ANOVA, were used to generate a “gain” matrix (see Table S3 in Supplementary Information),
whose elements represent “by how much” each output variable (relative glycan distribution) will
change in response to a unit change in each input factor, including multi-factor interactions (since
multiple combinations of single inputs are considered as valid inputs in this case). However, in this
case, the full factorial experiment consists of only 16 unique cases (see Materials and Methods);
consequently, eliminating the redundant rows in our gain matrix resulting in a reduced gain matrix
with 15 input factors, some of which are multi-factor combinations (see Supplementary Information
Table S4). Figure 4 shows a heat map of the elements of the gain matrix, indicating which input factor
affects which glycan. The input factors include both main effects such as the concentration of media
supplements (EDTA, MnCl2), times of addition (Mn T1, ED T1, etc.) as well as interaction effects, such
as those between the times of addition (e.g., Mn T1-ED T1) or between concentration and the times of
addition (e.g., EDTA—Mn T2, EDTA—Mn T1—ED T2, etc.). The colors indicate the direction of the
effect (green for increase; red for decrease) and the intensity indicates magnitude.
An examination of the heat map indicates that the glycan species FA2, FA2G1, and A2 are affected
by most of the factors and their combinatorial interactions. For instance, the concentration of the
most abundant glycoform, FA2 (which accounts for nearly 52% of the glycan concentration in the
control sample), is affected by the concentration of MnCl2, the two-way interaction of MnCl2 and
EDTA, and the late stage addition of MnCl2. In particular, a unit change in the concentration of MnCl2
causes an increase in the average concentration of FA2 (as indicated by the positive coefficient for
the MnCl2 effect), while introducing MnCl2 on D3 causes a reduction in the average concentration
of FA2. By contrast, the monogalactosylated form FA2G1 is not affected by changes in the media
concentration of MnCl2; rather it is influenced by changes in the concentration of EDTA, the early
addition of MnCl2, and the two-way interaction of MnCl2 and EDTA. Further, we observe that two of
the interaction factors, Mn T1-ED T1 and Mn T2-ED T1, have statistically significant and opposing
effects on the concentration of FA2G1. The factor Mn T1-ED T1 represents the two-way interaction
of adding MnCl2 on D0 and adding EDTA on D0, whereas Mn T2-ED T1 represents the two-way
interaction of adding MnCl2 on D3 when EDTA is introduced on D0. We observe therefore that the
concentration of FA2G1 is affected by multiple input factors, including complex interactions between
the amount of supplements added, and the times of addition of the supplements. One is thus able to
assess the impact of each input factor on the response of all other individual glycan species in similar
fashion. As indicated by the heat map, the effects of higher order interactions on most of the glycan
species are negligible (if they exist at all) because estimates of the coefficients associated with most
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Figure 4. Heat map of significant factor coefficients (α = 0.05, see Table S3 for details) obtained from
experimental data analysis using ANOVA. The input factors are on the horizontal axis, and individual
glycan species on the vertical axis. The color red indicates a decrease in the concentration of a particular
glycan in response to a positive change on the input factor in questions, while green indicates an
increase. The color intensity represents the magnitude of the significant coefficient, with increasingly
darker hues indicating increasingly larger magnitudes and progressively lighter hues indicating
commensurately lower magnitudes.
4. Discussion
While the addition of specific media supplements has been studied widely for its effect
on the quality attributes of mAbs, such studies have been limited to the introduction of media
supplements exclusively at the start of the culture, and the results, when quantitative, have yielded
only isolated single factor relationships. The results from the current study show that introducing
media supplements at different time points during cell culture does in fact have an effect on cell growth
conditions and antibody glycosylation distribution, and the effects can be quantified globally and
potentially used to design effective control schemes.
Specifically, we have shown that earlier addition of EDTA is detrimental to cell growth and results
in a decrease in antibody titer. When EDTA was added on D0 (at the inoculation stage) the peak
viable cell density (VCD) remained close to the seeding density, indicating a hampering of cell growth.
This result is consistent with the well-known fact that EDTA is toxic to cells [35]. The decline in the
viable cell densities due to EDTA addition during the growth phase can also be attributed to the
removal of such trace metals as Ca++, Zn++ etc. that are essential for cell survival, from the media
(as a result of EDTA’s chelating effect). By contrast, when both EDTA and MnCl2 were added on D0,
the peak VCD increased two-fold. While this peak VCD is lower than the peak VCD of the control
flask (5.78 × 106 cells/mL), the increased viability can be attributed to the presence of excess MnCl2
titrating EDTA, resulting in reduced cytotoxicity. When EDTA was added on D3, the cells were in
the middle of the growth phase and the addition of the cytotoxic EDTA hampered further growth,
leading to a steep decline in the cell viability beyond D3 (Figure 1b). By contrast, when MnCl2 was
added to the media (on D0 or D3) in the presence of EDTA, the cells did not experience a similar
reduction in viability. When EDTA was added on D6, the cells were already at the end of the growth
phase and hence the introduction of EDTA did not alter the cell viability. However, unlike the other
cases where EDTA addition on D0 or D3 resulted in low titers, adding EDTA on D6 along with MnCl2
supplementation on D0, D3 or D6, resulted in end of run (EOR) titers higher than the titer value
in the control flask. The increase in antibody titer in the presence of EDTA was observed by others
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analyzing the EOR titer data using ANOVA shows that the factor coefficients for the concentration
of EDTA, the concentration of MnCl2, and time of addition of EDTA are all statistically significant
(at a significance level of α = 0.05). The expected change in the EOR titer in response to a unit change
in any of these factors is quantified by the magnitude of that factor coefficient, while the sign of the
factor coefficient indicates the direction of change. Thus, for example, a unit positive step change in
the concentration of EDTA (with a factor coefficient of −0.017) or time of addition of EDTA (factor
coefficient −0.032) results in a decrease in EOR titer; a unit positive step change in the concentration
of MnCl2 (factor coefficient 0.008) causes an increase in titer. Quantifying the effect of these input
factors on the EOR titer provides a rational basis for selecting which particular supplement to add,
and how much of it to add, at a given stage of cell culture in order to maximize product yield. However,
any media supplementation strategy must meet not just the desired specifications for final titer but
also for product quality, i.e., to be effective, the implemented media supplementation strategy must
not alter the glycan distributions significantly.
The EOR titer represents the total amount of antibody accumulated at the end of the batch, while
the measured glycan distribution represents the relative amount of each individual glycan isoform
that has accumulated over the duration of the batch. Now, the relative amount of individual glycan
species is a function of antibody productivity and it changes over the course of the batch. In our
case, the addition of different media supplements at different stages of batch cultures affected both
viability and antibody titer; consequently, the observed change in the glycan distribution has been
induced by dynamic media supplementation and changes in productivity. To develop a mechanistic
understanding of the effect of dynamic media supplementation on the glycosylation profile, therefore,
we first decouple the effect of antibody productivity on the glycan distribution from the overall change
observed at the end of the batch. One such decoupling approach involves estimating the mass fractions
















for fi, the fraction of mAb glycoform i produced in the time period [t1, t2] relative to the total amount
of antibody secreted in the same period. However, we cannot use this expression for our purpose
because we only measured EOR titer and final glycan distribution, not intermittent antibody titer or
glycan concentration. Consequently, we propose an alternative metric-based solely on the final titer
and glycan measurements.
To illustrate, consider the glycan distribution in the control flask and in the flask with MnCl2
added on D6. In both flasks, the cell growth profile and antibody productivity will be the same until
Day 6, when MnCl2 is introduced to the latter flask. Thus, the amount of ith glycoform fractions
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Recognizing that the D6 values in Equations (5) and (6) above are identical, we can eliminate the
intermittent time point by simple arithmetic manipulations and obtain the change in the accumulation
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Thus, this fractional difference allows us to group together different experimental conditions with
similar antibody titers, making it possible to compare final glycan distributions and hence quantify the
effect of individual media supplements on the glycan profile appropriately. Such analyses extended
to other experimental conditions produced the comparative fractional difference in the glycoform
distribution shown in Figure 5.
Figure 5. Fractional difference in glycoform distribution due to (a) MnCl2 addition on D0
(cross-hatched), D3 (red bar), and D6 (blue bar) after EDTA addition on D0, relative to the baseline
glycan distribution in EDTA D0 supplemented flask; (b) MnCl2 addition on D3 (cross-hatched), and D6
(red) after EDTA addition on D3 relative to the baseline glycan distribution in EDTA D3 supplemented
flask, and MnCl2 addition on D6 after EDTA addition on D6 (blue) relative to the baseline glycan
distribution in EDTA D6 supplemented flask; (c) EDTA addition on D6 after MnCl2 addition on D0
(red) and D3 (blue) relative to the respective glycan distributions due to MnCl2 addition on D0 and D3;
and (d) MnCl2 addition on D0 (cross-hatched), D3 (red bar), and D6 (blue bar) relative to the glycan
distribution in the control case.
A comparison of the fractional difference in the glycan distribution in flasks where MnCl2 is
added to D0 EDTA supplemented flasks relative to the glycan distribution in D0 EDTA supplemented
flasks (Figure 5a), shows the following: an increase in the amount of FA2 (by nearly 50% in all cases),
FA2G1 (by 29% during D0 supplementation, 60% during D3 supplementation, and 122% during
D6 supplementation), and FA2G2 (by 3%, 10%, and 20% respectively), with a relative decrease in
A2 and M5 by 2% and 4% when MnCl2 is added on D3, and nearly 14% when MnCl2 is added on
D6. A similar trend is observed in the fractional difference in the glycan distribution in flasks where
MnCl2 is added on D3 and D6 to D3 EDTA supplemented flasks, and when MnCl2 is added on
D6 to D6 EDTA supplemented flasks (Figure 5b). Again, we notice an increase in FA2, FA2G1 and
FA2G2, with a decrease in A2, M5, and A2G1 observed only when MnCl2 is added on day 6 after the
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of galactosyltransferase enzymes [30], and subsequently in increased galactosylation [26,27]. Hence,
the increase in the amount of FA2G1 and FA2G2 species can be attributed to the effect of late stage
manganese addition on the galactosyltransferase enzyme. Figure 5c shows fractional difference when
EDTA is added on D6 after MnCl2 has been added to the culture on D0 and D3. These differences are
calculated relative to the glycan distribution observed due to the addition of MnCl2 on D3 and D6,
respectively. We note that the fractional difference in the fucosylated species FA2 and FA2G1 is positive
when EDTA is added after MnCl2 supplementation, indicating that the addition of EDTA increases
the concentration of these species relative to their respective concentrations in MnCl2 supplemented
cultures. Also, a comparison of the fractional difference in the glycan distribution when MnCl2 was
introduced on D0, D3, or D6 relative to the glycan distribution in the control flask (Figure 5d), shows
that the relative concentrations of FA2 and FA2G1 species decreased in flasks with D0, while late stage
addition of MnCl2 did not have a significant effect on the overall glycan distribution. Taken together,
our findings indicate that the latter addition of EDTA reverses the changes in the glycan distribution
induced by MnCl2.
Fractional difference analysis helps to identify which glycan species are altered as a result of
the addition of specific media supplements, but not why those particular glycan species changed.
To identify the kinetic mechanisms underlying the changes observed in the glycan distribution upon
adding MnCl2 to the media, we use an existing dynamic mathematical model of glycosylation [39] to
simulate the system response under control conditions and when MnCl2 is added on D0, and obtain
predictions of both the control and D0 glycan distributions (see Supplementary Information section S4
for details). The simulation results show that changes in the glycan distribution due to the addition of
MnCl2 can be directly attributed to the changes in the reaction rates associated with the FucT enzyme.
In addition to fractional difference analysis, we use the glycan indices computed for each
experimental condition (Table 2), as a metric for quantitative assessment of the change in the final
glycosylation profile caused by the addition of different media supplements. Specifically, a comparison
of the individual glycan indices for each condition against the corresponding values under control
conditions allows us to establish, objectively, that altering the availability of MnCl2 in the media using
a chelating agent reverses the changes in the glycan distribution. While MnCl2 addition on D0 resulted
in a decrease in the fucosylation index from 79.9% in the control flask to 60.5%, we see that subsequent
introduction of EDTA on either D0, D3, or D6 reversed that trend. Early stage addition of EDTA on D0
increased the fucosylation index to 82.46%, while adding EDTA on D3 and D6 resulted in fucosylation
indices of 78.8%, and 76.5% respectively. Similarly, the decrease in the galactosylation index, upon
adding MnCl2 on D0, from 17.9% in the control flask to 15.8%, could be reversed by subsequently
adding EDTA on D3. Adding MnCl2 to the media on D3 reduced the fucosylation index to 61.9%,
but if we then added EDTA on D6, the fucosylation index increased to 77.8%, which is comparable to
the value of 79.9% in the control flask. It is important to note however, that the reversal in the glycan
indices observed due to the addition of EDTA on D0 and D3 is achieved at the expense of reduced
titer and reduced viability, as discussed above. The indication from our results is that changes in the
glycan distribution due to MnCl2 addition can be reversed only when EDTA is added to the media
after MnCl2 addition. Thus, the effect of MnCl2 supplementation can be reversed, without decreasing
productivity, by adding EDTA on D6 to MnCl2 supplemented media, providing a means of ensuring
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Table 2. Galactosylation index (GI) and fucosylation index (FI) for each experimental condition.
Experimental Condition 1 Galactosylation Index (GI) Fucosylation Index (FI)
Control 17.9 79.9
Mn D0 15.8 60.5
Mn D0/ED D0 20.6 82.5
Mn D0/ED D3 18.0 78.8
Mn D0/ED D6 19.3 76.5
Mn D3 15.7 61.8
Mn D3/ED D0 25.2 88.6
Mn D3/ED D3 15.1 73.9
Mn D3/ED D6 18.0 77.8
Mn D6 16.7 76.3
Mn D6/ED D0 24.8 90.3
Mn D6/ED D3 19.9 86.4
Mn D6/ED D6 17.9 77.3
ED D0 21.6 81.0
ED D3 16.5 75.3
ED D6 16.9 77.7
1 Mn and ED refer to the media supplements MnCl2 and EDTA, while D0, D3 and D6 refer to Day 0, Day 3 and
Day 6 after inoculation, respectively.
Although such observations as these provide useful qualitative information about the system, they
cannot be used to develop an automatic control strategy; that requires a quantitative representation
(and hence understanding) of the effects of media supplementation on glycan distribution. Such
quantitative representation can be obtained via formal analysis of the experimental data using
analysis of variance (ANOVA) to generate the process gain matrix, K, as described in Materials
and Methods. Singular value decomposition of the gain matrix K produces a (diagonal) matrix of
singular values, Σ, and two unitary matrices, W and VT. Together these three matrices provide a
particularly insightful representation of the process information encapsulated in the gain matrix,
K: Equation (3) is transformed into a series of n individual and independent equations (see [29]) where,
in each case, a linear combination of the original process input factors, with weighting coefficients from
the matrix W, now constituting an “input mode”, μi, is connected through the associated singular value
σi, to the corresponding linear combination of the output glycans, (with weighting coefficients from
the matrix V), now constituting an output mode ηi [29]. Furthermore, as a result of this decoupling
transformation, the magnitude of each singular value naturally quantifies the extent to which the
output mode in question will change in response to a change in the corresponding input mode. Thus,
the larger the value of σi, the greater will be the change in the corresponding output mode ηi as a
result of changes in the input mode μi, so that output modes associated with larger values of σi will
be more “controllable” than modes associated with smaller values of σi.
The first ten singular values (σ1—σ10) for our experimental system are listed in Table 3 in
decreasing order of magnitude. As modes associated with singular values of smaller magnitude
are less controllable, we limit our analysis only to those modes that are practically controllable; we
do this by using a threshold cutoff value, σ*, arbitrarily selected to be 0.50 in this example, thereby
limiting our analysis to the first five singular values. From a process control perspective, modes
associated with singular values below this threshold are considered to be of no practical importance
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Next, since by definition, each input–output mode pair represents the linear combination of output
glycan species that can be controlled by manipulating the specific input factors in the corresponding
input mode, the coefficients of each output factor in the output modes and of each input factor in the
input modes provide further information about the relative influences exerted by each original input
factor on each output factor. Specifically, the coefficient of a particular output factor in a particular
mode represents the magnitude by which the relative percentages of those particular glycans will
change in response to a unit change in the input mode. On the other hand, the coefficient of a particular
input factor in the associated input mode corresponds to the relative contribution of that input factor
to the unit change the input mode in question. Thus, the inputs with the largest coefficients in an input
mode represent the dominant factors and hence the largest contributors to the influence of that mode,
while the output glycans with the largest coefficients in an output mode represent those species whose
relative percentages will change the most under the influence of the input modes. The input-output
mode pairs and their associated coefficients are shown in Figure 6.
Because it is associated with the largest singular value of σ1 = 6.62, the first output mode η1
is the most controllable output mode. The value of σ1 represents the change in the overall output
mode η1 resulting from a unit change in the input mode μ1. For this output mode, we note that the
dominant glycan species are A2, with a coefficient of 0.64, followed by FA2G1 (with a coefficient
of −0.62), FA2 (−0.38), M5 (0.14), and A1 (0.13), indicating that a unit positive change in the input
mode μ1 will result in an increase in A2, M5, and A1, accompanied by a decrease in FA2G1 and
FA2, each in the amount indicated by the identified coefficients. The biantennary species A2, with
the largest coefficient, is the most controllable glycan in the first mode, followed by FA2G1 and FA2.
The indicated coupling between the glycans A2, FA2G1, and FA2 makes sense because an increase in
the afucosylated glycoforms occurs at the expense of the fucosylated forms, as our experimental results
show. The associated input mode μ1 is a linear combination of different input factors representing
the media supplements MnCl2 and EDTA as well as the times of their addition. Mode μ1 is primarily
dominated by the interaction of MnCl2 and EDTA, and the concentrations of EDTA and MnCl2, with
associated coefficients −0.58, 0.44, and −0.39 respectively, indicating that the addition of these two
media supplements has opposing individual effects on output mode 1. Early stage addition of EDTA
and MnCl2, denoted by the factors EDT1 and MnT1, with associated coefficients −0.38 and 0.25
respectively, also exert important influences on the first output mode. Based on the different elements
that comprise the first input mode, this analysis indicates that one can control the glycans in output
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Figure 6. Graphical representation of the coefficients associated with the first five input and output
modes (with σi ≥ σ* = 0.5) obtained from controllability analysis. (a) Output mode η1 and the
corresponding input mode μ1; (b) Output mode η2 and the corresponding input mode μ2; (c) Output
mode η3 and the corresponding input mode μ3; (d) Output mode η4 and the corresponding input
mode μ4; (e) Output mode η5 and the corresponding input mode μ5.
The next controllable output mode η2 is associated with the singular value σ2 = 3.68, and the linear
combination of glycans represented by this mode is dominated by the glycan species FA2G1, FA2, A2,
M5, and FA2G2. The coefficients associated with these glycans are −0.71, 0.56, −0.33, −0.20 and −0.11,
respectively, indicating that a unit positive change in the input mode μ2 will cause a relative increase in
FA2 while causing the other glycan species to decrease. The increase in FA2 coupled with the decrease
in FA2G1 and FA2G2 indicates that perturbations to the input mode μ2 affect the galactosylated species
particularly. Since the singular values are arranged in decreasing order, the influence of mode μ2 on
output mode η2 is less than that of μ1 on mode η1. The largest coefficients in mode μ2 are associated
with the input factors MnCl2 (with a coefficient of 0.6), the early stage addition of EDTA denoted by
factors EDT1 (with a coefficient of −0.47) and EDT2 (0.35), and the interaction effect of MnCl2 and
EDTA (0.24).
A unit positive change to the input mode μ3 causes the following changes in the relative
concentrations of the glycan species that comprise output mode η3 (with σ3 = 2.21): A2, A2G1,
FA2, and FA2G1 increase, and M5, A1, and FA1 decrease, simultaneously. This indicates that input
mode μ3 can be used to increase the biantennary species, but at the expense of a (perfectly logical)
concomitant decrease in the species that are upstream of these biantennary species. The input mode μ3
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(with coefficient 0.45), and the early stage addition of MnCl2 denoted by the factor MnT1). In each
of the three input modes, the coefficients associated with the interaction effect of MnCl2 and EDTA
indicate the importance of this combination input factor in altering the concentrations of the glycan
species associated with the respective modes.
The fourth and the fifth modes are less controllable, as they are associated with singular values
of comparatively smaller magnitudes (σ4 = 0.80 and σ5 = 0.61). η4 is dominated by glycans A1, A2,
FA1, FA2, FA2G1, and FA2G2, while η5 is dominated by FA1, A2G1, and FA2G2. The input mode
μ4 is dominated by the interaction effects Mn T2-ED T2 and EDTA*Mn T2-ED T2 representing the
interaction between the time of addition of the media supplements. By contrast, the predominant
factors in mode μ5 are MnT1 and EDT2, which represent the addition of MnCl2 on D0 and EDTA on
D3 respectively.
It is worth mentioning the following facts about the controllability analysis presented here: (i) even
though it is a theoretical analysis, the process gain matrix, K (on which the analysis is-based), was
obtained entirely from experimental data. The information it contains about how changes in the inputs
(amount of supplement added, and time of addition) affect glycan species, come directly from our
designed experiments; (ii) Notwithstanding, a follow-up independent experimental validation of the
modal analysis predictions (which contributor to which mode is affected in what manner) will be
valuable. Such a validation experimental study, which lies outside the intended scope of this current
work, is slated for future work. That study’s focus will not only be to validate the controllability
analysis results; it will also encompass the more consequential design and implementation of a control
system to achieve effective control of glycan distribution during a batch.
For now, we note that the controllability analysis provides a data-based quantification of the
effect that the addition of specified amounts of particular media supplements and the respective
times of addition jointly have on the output glycan distribution at the end of the batch. As discussed
above, introducing these media supplements dynamically also results in quantifiable changes in the
antibody titer. Thus, the dynamic supplementation strategies discussed here present a challenging
problem involving a trade-off between product yield and product quality. To be effective, a control
strategy based on these considerations, must therefore be carefully designed to resolve these conflicts
appropriately in order to optimize both the titer and the quality simultaneously. These matters will be
addressed theoretically and experimentally in a follow up study.
In closing, we note that
(1) the relationships between time-dependent changes in media supplements and the corresponding
changes in glycan distribution are (understandably) complex and not necessarily obvious or
easily amenable to qualitative thinking; but
(2) controllability analysis via singular value decomposition, and the resulting input-output mode
pairs determined specifically for our experimental system, using data from carefully designed
experiments, have enabled us to identify which input factors are best manipulated, in order to
effect changes in the relative percentage of specific glycan species;
(3) in addition, the coefficients in the equations representing the input and output modes allow
us to quantify by how much we expect the glycan species to change in response to specific
time-dependent media supplementation actions.
5. Conclusions
There is growing interest in evaluating the role of media supplements, especially MnCl2,
in modulating glycoform distributions in mAbs. However, most media supplementation studies
(where supplements are added to the media before starting the batch) do not take into consideration
the impact of introducing media supplements at different stages of cell growth. In this paper, we have
presented a systematic approach for evaluating the effects of time dependent media supplementation
on the glycan profile, and provided a methodology for quantifying and analyzing the complex effects.
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in order to alter specific glycan species, when they are to be added is just as important. In addition
to this general observation about what to change and when, our results and analysis technique also
demonstrate how to quantify “by how much” we can expect specific glycan species to change as a
result of the changes in the media supplements.
For instance, we observe that early stage addition of MnCl2 affects fucosylated species and
alters the glycan distribution more significantly than a late stage addition. Similarly, early stage
addition of EDTA affects not just the antibody titer, but also the relative percentages of biantennary and
galactosylated species; late stage addition of EDTA does not alter the glycan distribution significantly.
The glycan distribution profile is also affected by the addition of both EDTA and MnCl2 to the media
at different time points and it is possible to develop a mechanistic understanding of the effect of
individual media components on the glycan distribution by studying the fractional difference in the
glycan distribution. However, we note that early stage addition of EDTA is detrimental to cell growth
and antibody production, while late stage addition of EDTA improves titer with no appreciable effect on
glycan distribution. This study does not recommend using EDTA as a media supplement—instead, our
work presents a systematic approach to studying the complex interactions between media supplements
when introduced at different time points during batch culture. Additionally, our results demonstrate
that changes in the glycan distribution profile due to the addition of MnCl2 are not immutable; they
can be reversed by adding EDTA after MnCl2 has been added to the media. We were able to identify
the specific combinations of input factors which, when manipulated, result in quantifiable changes in
the relative percentage of specific glycan species via controllability analysis using our experimental
data. For the specific experimental system, our analyses show that A2, FA2G1 and FA2 are the most
controllable glycan species whose concentrations can be changed by early stage supplementation of
EDTA and late stage supplementation of MnCl2.
While this work has focused on establishing a rational framework for studying the influence of
time-dependent media supplementation on the glycosylation profile, the techniques introduced here
can be extended to tackle the complementary problem of designing and implementing appropriate
control strategies to achieve desired glycan distribution profiles. Traditionally, the composition of cell
culture media is fixed prior to starting the batch. However, we have demonstrated that introducing
supplements at different points in time can influence both the productivity and the quality attribute
of the antibody. Although we have examined only two specific media components in the current set
of experiments, in principle, the systematic approach presented here can be extended easily to other
media components such as amino acids, or trace metals. Future work will involve a comprehensive
validation study where a control system will be designed on the basis of these results, and implemented
on our experimental systems.
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Abstract: CD47 serves as an anti-phagocytic receptor that is upregulated by cancer to promote
immune escape. As such, CD47 is the focus of intense immuno-oncology drug development efforts.
However, as CD47 is expressed ubiquitously, clinical development of conventional drugs, e.g.,
monoclonal antibodies, is confronted with patient safety issues and poor pharmacology due to
the widespread CD47 “antigen sink”. A potential solution is tumor-directed blockade of CD47,
which can be achieved with bispecific antibodies (biAbs). Using mouse CD47-blocking biAbs in a
syngeneic tumor model allowed us to evaluate the efficacy of tumor-directed blockade of CD47 in
the presence of the CD47 antigen sink and a functional adaptive immune system. We show here that
CD47-targeting biAbs inhibited tumor growth in vivo, promoting durable antitumor responses and
stimulating CD8+ T cell activation in vitro. In vivo efficacy of the biAbs could be further enhanced
when combined with chemotherapy or PD-1/PD-L1 immune checkpoint blockade. We also show
that selectivity and pharmacological properties of the biAb are dependent on the affinity of the
anti-CD47 arm. Taken together, our study validates the approach to use CD47-blocking biAbs either
as a monotherapy or part of a multi-drug approach to enhance antitumor immunity.
Keywords: bispecific antibodies; CD47; antitumor immunity; immunotherapy; immunosurveillance;
checkpoint inhibitors; phagocytosis
1. Introduction
CD47 is a ubiquitous anti-phagocytic receptor widely known as the “don’t eat me” signal, as it
inhibits phagocytosis by engaging a signal regulatory protein alpha (SIRPα) on macrophages and
other phagocytes (reviewed in [1–4]). In addition, CD47 carries out other important physiological
functions, such as regulation of cardiovascular homeostasis, neuronal development, bone remodeling,
adaptive immunity, cellular response to stress, stem cell renewal, cell adhesion, motility, proliferation,
and survival (reviewed in: [1,2,4–6]).
Cancer cells upregulate CD47 expression in order to evade antitumor immunity. In nearly all
hematological and solid cancers, increased levels of CD47 expression correlate with more aggressive
disease and poorer prognosis (reviewed in [7–9]). Blockade of CD47 increases phagocytosis of tumor
cells and stimulates macrophage-mediated tumor elimination in various human xenograft tumor
models (reviewed in [7–9]). In addition, when studied in tumor models in immunocompetent animals,
the induction of adaptive immune responses in mediating therapeutic efficacy of CD47 neutralization
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has been observed [10–18]. These studies revealed that CD47 expressed on tumor cells is a key
suppressor of antitumor immunity as well as a mediator of resistance to PD1 checkpoint blockade
therapy [19,20]. However, it is not clear how CD47 blockade facilitates tumor immunosurveillance.
Several mechanisms have been proposed, including enhanced immune cell infiltration [11,15,19],
dendritic cell activation [17,21], and increased tumor antigen cross-presentation with activation
of cytotoxic T cell responses due to enhanced phagocytosis of tumor cells [7,8,22,23]. Given the
involvement of CD47 in various physiological and cellular functions, multiple non-mutually exclusive
mechanisms may be involved. As such, a rationale for therapeutically targeting CD47 in cancer has
evolved. Thus, several CD47-directed therapeutic strategies are being pursued (reviewed in [8,9]).
Nonetheless, ubiquitous CD47 expression on healthy cells presents a considerable hurdle for the
development of CD47-blocking therapies. Molecules that block CD47 have been observed to induce
hematotoxicity in mice and non-human primates. Furthermore, they have poor pharmacokinetic
properties, which reflects the substantial target-mediated drug disposition due to the CD47 antigen
sink [16,24–29]. Hematotoxicity was found to be dependent on the Fc region of the molecules as
CD47-blocking mAbs and SIRPα-Fc fusion proteins bearing a functional Fc region show significant
hematological toxicity, while Fc effector functionless CD47 blockers display a better safety profile [16,26,29].
Dual targeting bispecific antibodies (biAbs) co-engage two antigens at the cell surface,
which stabilizes binding through avidity [30,31]. Therefore, creating anti-CD47/antitumor-associated
antigen (TAA) biAbs to steer CD47 blockade towards TAA-positive malignant cells, and away from
TAA-negative healthy cells expressing CD47 alone, provides a solution to poor pharmacology and
safety issues related to ubiquitous CD47 expression [32–34]. We have previously demonstrated that
selective targeting of CD47 on tumor cells can be achieved with anti-CD47/TAA biAbs with a
low-affinity anti-CD47 arm and a high-affinity anti-TAA arm [34]. Such an “unbalanced affinity”
design minimizes CD47 binding to TAA-negative cells while driving bivalent attachment of the biAb
to double-positive cells via TAA/CD47 co-engagement. Furthermore, with an increased selectivity,
a biAb can be safely endowed with an immunologically active Fc region, thus maximizing tumor
cell phagocytosis via the engagement of FcγRs and a concurrent blockade of the “don’t eat me”
signal [34,35]. Indeed, the unbalanced affinity exemplified by our anti-human CD47/CD19 therapeutic
biAb candidate, NI-1701, demonstrated potent antitumor activity in xenograft models. Moreover,
in non-human primates, it displayed favorable pharmacokinetics and the absence of toxicity following
multiple administrations of super-therapeutic doses [35].
However, the lack of cross-reactivity of anti-human therapeutic biAbs with mouse CD47 precludes
in vivo evaluation in a physiologically relevant context, i.e., with tumors grown in syngeneic,
immunocompetent mouse strains in the presence of the CD47 antigen sink. To overcome this limitation,
we generated anti-mouse CD47-specific biAbs. Using these reagents and a syngeneic mouse model of
B cell lymphoma, we show that the affinity of the anti-mouse CD47 biAb arm determines the safety,
pharmacokinetic properties, and in vivo efficacy in the presence of the CD47 antigen sink. We observed
that tumor-directed blockade of CD47 enhances tumor antigen cross-presentation and CD8+ T cell
activation in vitro. Finally, we show that tumor-directed blockade of CD47 via biAbs can increase
the therapeutic effect of standard of care oncology treatments such as PD-L1-blocking antibodies
and cyclophosphamide.
2. Materials and Methods
2.1. Antibodies
Generation of bispecific antibodies based on one heavy chain and two different light chains (one κ
and one λ), including light chain library construction, phage display selection and screening, bispecific
antibody production, purification, and analytical characterization, are described in detail in [36]. Briefly,
anti-mouse CD47 antibody sequences were identified with the κλ body phage display platform [36]
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or transfected with mouse CD47. Screening was performed as described in [36], and positive hits
were reformatted into hIgG1 monoclonal antibodies for further evaluation. A panel of anti-mouse
CD47 antibody arms with different affinities was generated and two of these candidates were used for
the generation of bispecific antibodies analyzed in this study. The human anti-mouse CD47 variable
domains (κ-light chain) and the human variable domain of an anti-human CD19 antibody (λ-light
chain) [36] were grafted on mouse heavy and light chain constant domains, giving rise to bispecific
human-mouse chimeric mIgG2a molecules (Figure S1). Therefore, the two mouse CD47-targeting
biAbs (biAb1 and biAb2) comprised two distinct anti-mouse CD47 arms with different affinities
(Table S1), a common, previously described, high-affinity antitumor associated antigen (TAA) antibody
arm recognizing the human CD19 antigen (hCD19), and a wild type mIgG2a Fc portion. For the
construction of monovalent anti-mouse CD47 antibodies, the anti-human CD19 arm was replaced with
a non-binding arm (non-cross-reactive anti-human CD47 arm, ref. [34]). In addition, we generated
human-mouse chimeric anti-CD47 mAbs, consisting of human anti-mouse CD47 variable domains of
biAb1 and biAb2 grafted on mouse IgG2aλ constant domains (CD47 mAb1 and CD47 mAb2). Finally,
the human anti-human CD19 variable domain was also used to generate a chimeric CD19 mAb and a
chimeric CD19 monovalent antibody, both with a mouse IgG2a constant region.
2.2. Cell Lines and Reagents
Mouse Diffuse Large B Cell Lymphoma cell line A20 (ATCC (Wesel, Germany) TIB208™,
BALB/c) was cultured in RPMI-1840 medium and supplemented with 10% heat-inactivated fetal
calf serum (FCS), 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 5 mM D-glucose
(all from Sigma-Aldrich, Buchs, Switzerland) and 50 μM 2-mercaptoethanol (Gibco/Thermo Fisher
Scientific, Reinach, Switzerland). Mouse melanoma cell line B16–F10 (ATCC® CRL6475™, C57Bl/6)
was cultured in DMEM-Hi glucose medium and supplemented with 10% heat-inactivated FCS,
4 mM L-glutamine, and 1 mM sodium pyruvate. Cells were maintained at 37 ◦C in a water-jacketed
incubator containing 5% CO2. A20-hCD19, A20-hCD19-HA-GFP, A20-mCherry, A20-hCD19-GFP,
and B16F10-hCD19 cell lines were obtained by transfecting with Lipofectamine 2000 (Thermo Fisher
Scientific, Reinach, Switzerland) the parental wild type cell lines with the corresponding transgenes:
human CD19 transmembrane and extracellular domains (UniProtKB-P15391), and hemagglutinin (HA)
gene from influenza virus strain A/Puerto Rico/8/1934 H1N1 (UniProtKB-P03452). Proteins were
addressed to the cell surface via a signal peptide. Stably expressing pools were enriched by successive
Fluorescence-Activated Cell Sorting (FACS) of positive cells. Once stable pools were obtained, clones
were generated by single cell FACS sorting in the absence of selective pressure. Cell surface mCD47
and hCD19 densities were determined by an indirect immunofluorescence assay (QIFIKIT) according
to the manufacturer’s instructions (Agilent Technologies, Basel, Switzerland). As the primary antibody,
saturating concentrations of the high-affinity anti-mCD47 mAb1 and the anti-hCD19 mAb described
in this manuscript were used.
2.3. Mice
Six- to eight-week-old female BALB/c mice and C57BL/6J mice were purchased from Charles
River Laboratories (Ecully, France). All animal experiments were performed in accordance with the
Swiss Federal Veterinary Office guidelines and as authorized by the Cantonal Veterinary Office.
2.4. Antibody Binding Assays
Harvested cells were washed with a FACS buffer (PBS, 2% BSA, and 0.1% sodium azide), incubated
with test antibodies for 30 min at 4 ◦C in FACS buffer, washed once to remove unbound antibody,
and stained with a fluorescently labeled anti-mouse IgG detection antibody (either an anti-mouse IgG
(H + L) (A865, Life technologies/Thermo Fisher Scientific, Reinach, Switzerland) or an anti-mouse IgG
(Fc) (115-606-072 Jackson ImmunoResearch, West Grove, PA, USA) for 15 min at 4 ◦C. A viability marker,
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Buchs, Switzerland), was added before acquisition to exclude dead cells. Antibody binding was
measured by flow cytometry using either a Cytoflex flow cytometer (Beckman Coulter, Indianapolis,
IN, USA) or a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA). FACS data were
analyzed with FlowJo software (FlowJo LLC, Ashland, OR, USA).
For binding assays performed with A20 cells, cells were first incubated with anti-mouse Fc (same
as secondary/detection antibody but unlabeled) to block the Fc portion of IgGs expressed at the surface
of A20 cells. The staining procedure was as detailed above. To assess antibody selectivity to human
CD19 positive A20 cells, A20-hCD19-GFP cells were mixed with A20-mCherry cells at a 1:1 ratio and
stained and analyzed using the protocol described above. Data are presented as the ratio between
Mean Fluorescent Intensity (MFI) measured with A20-hCD19-GFP and A20-mCherry cells.
Antibody binding to red blood cells (RBC) in whole blood was determined as follows. First,
test antibody was pre-incubated with a fluorescently-labeled Fab Fragment Anti-Mouse IgG (H + L)
(115-007-003, Jackson ImmunoResearch, West Grove, PA, USA) at a 2:1 ratio for 15 min at 4 ◦C to
minimize interference arising from the secondary (detection) antibody binding to cell surface and
serum IgG. This antibody mixture was prepared 20 times concentrated and was added to heparinized
blood from BALB/c mice and incubated for 15 min at room temperature. Blood cells were then washed
three times and antibody binding was analyzed by flow cytometry. RBC were identified and gated
based on their SSC-FSC parameters.
2.5. CD47 Competition Assay
A20-hCD19 cells were incubated with CD47-blocking test antibodies for 30 min at room
temperature (rt). Test antibodies were then subject to competition by a fluorescently-conjugated low
affinity anti-mouseCD47-blocking mAb (mAb3, see Figure S1) on ice for 20 min. After that, cells were
washed and the percentage of test antibody outcompeted by the indicator antibody was measured by
quantifying the MFI of cells by flow cytometry.
2.6. Phagocytosis Assay
A single cell suspension of bone marrow cells was obtained from BALB/c or C57BL/6J mice and
cultured for 7 days in complete macrophage medium (RPMI 1640, 10% heat-inactivated FCS, 2 mM
L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer, 50 μM 2-mercaptoethanol, 25 μg/mL
gentamicin (Sigma-Aldrich, Buchs, Switzerland)) supplemented with 20 ng/mL M-CSF (PeproTech,
London, UK). On the day of the experiment, non-adherent cells were eliminated by washing the culture
flasks with PBS. Adherent macrophages were detached using a non-enzymatic cell dissociation solution
(Sigma-Aldrich, Buchs, Switzerland) and washed in complete macrophage medium. For phagocytosis
to proceed, macrophages were mixed with CFSE-labeled target cells (effector to target ratio of 1:5)
in ultra-low attachment plates (Corning/Sigma-Aldrich, Buchs, Switzerland) and incubated in the
presence of the test antibody for 2.5 h at 37 ◦C. Macrophages were subsequently stained with an
Alexa Fluor 647-labeled anti-mouse anti-F4/80 secondary antibody (Clone A3-1, Biorad, Cressier,
Switzerland) and a viability marker (Sytox Blue by Thermo Fischer Scientific, Reinach, Switzerland)
was added to exclude dead cells before acquisition using a Cytoflex flow cytometer (Beckman Coulter,
Indianapolis, IN, USA). Double-positive events (positive for F4/80 and CFSE-labeled target cell) were
identified as phagocytosis events. Phagocytosis is presented as the percentage of macrophages which
have engulfed at least one target cell (double-positive events/total macrophages × 100).
2.7. Isolation of HA-Specific TCR CD8+ T Cells
HA-specific TCR CD8+ T cells were isolated from lymph nodes and spleens of CL4 transgenic mice
kindly provided by Dr. Roland Liblau (Research Center Toulouse Purpan, CPTP-INSERM). The CL4
mice were bred and maintained in Novimmune’s animal facility. Spleens and lymph nodes were
digested using collagenase IV (Lubiosciences, Zürich, Switzerland) and DNase I (Sigma-Aldrich, Buchs,
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CD8 isolation kit (STEMCELL Technologies, Vancouver, BC, Canada) following the manufacturer’s
instructions. Purified CD8+ T cells were subsequently stained with CellTrace Violet (Thermo Fisher
Scientific, Reinach, Switzerland) before being used in cross-presentation experiments.
2.8. Cross-Presentation Assay
Phagocytosis was set up as described above except for the incubation time at 37 ◦C, which was
extended from 2.5 h to overnight. Then 4.5 × 104 F4/80+ macrophages were sorted for each condition
with an Astrios FACS sorter (Beckman Coulter, Indianapolis, IN, USA) and subsequently co-cultured
with 17.5 × 105 CellTrace Violet labeled, HA-specific TCR CD8+ T cells for 48 h at 37 ◦C. At the end
of the macrophage/T cell co-culture, supernatants were collected and analyzed for IFN-γ and IL-2
levels using Luminex bead-based multiplex assay (Thermo Fisher Scientific, Reinach, Switzerland).
In parallel, the proliferation of T cells stained with an anti-mouse CD8a antibody (Clone 53-6.7,
BD Biosciences, San Jose, CA, USA) was evaluated by quantifying CellTrace violet proliferation peaks
by flow cytometry.
2.9. In Vivo Efficacy Experiments
In vivo, 3 × 106 A20-hCD19 cells were injected subcutaneously (sc) into the left flank of
6–8-week-old BALB/c mice (Charles River Laboratories). Tumors were measured every 2–3 days using
a digital caliper and volumes were calculated using the formula (width × length × height × Pi)/6.
Animals were euthanized when the tumor volume exceeded 1000 mm3 or at the experimental endpoint.
In biAb monotherapy experiments, the treatment began when the tumors reached 6 × 6 mm. Mice were
either treated intraperitoneally with 400 μg every other day or intratumorally with 100 μg of antibody
every three days. The number of injections varied between experiments and is specified in the
corresponding figure legend. In combination therapy experiments, mice were recruited when the
tumors reached 100 mm3. For cyclophosphamide (CTX) combination therapy, we used a sequential
combination therapy protocol as described by [12]. In brief, mice were treated with a single dose
of 60 mg/kg CTX (Sandoz Pharmaceuticals AG, Rotkreuz, Switzerland) on day 6 followed by
100 μg antibody injected intratumorally on day 7, 10 and 13. For anti-PD-L1 combination therapy,
mice received a mixture of 200 μg anti-PD-L1 (clone 10F.9G2, BioXcell, Lebanon, NH, USA) plus 400 μg
biAb intraperitoneally on day 6, 8, 10, 12, 14. For rechallenge experiments, tumor-free mice and naive
mice were injected (sc) with 3 × 106 of either A20 wild type (wt) or A20-hCD19 cells on the opposite
flank 2 months after rejecting the primary tumor. For B16F10-hCD19 experiments, 6–8-week-old
C57BL/6J mice were engrafted with 1 × 105 B16F10-hCD19 on the left flank and recruited once tumors
became palpable. Mice received 1.2 mg antibody treatment on the day of recruitment and were
subsequently treated every other day with 400 μg antibody.
2.10. Evaluation of biAb Bioavailability and Binding to RBC
BALB/c mice were injected intraperitoneally every other day with 400 μg antibody for a total
of three injections. Mice were bled two days after the last injection to evaluate RBC concentration,
antibody binding to RBC, and antibody bioavailability in the blood. RBC counts were determined
using a HEMAVET 950 hematology analyzer (Drew Scientific Inc., Miami Lakes, FL, USA). To evaluate
antibody binding to RBC, 2 μL of blood were washed three time with FACS buffer and subsequently
stained with an anti-Mouse IgG (Life Technologies/Thermo Fisher Scientific, Reinach, Switzerland) for
20 min at room temperature. Cells were then washed three times in FACS Buffer and antibody binding
was determined by flow cytometry.
For the assessment of blood bioavailability, blood was collected into serum separator tubes (BD
Microtainer) and centrifuged at 10,000× g for 5 min. Resultant serum supernatant was stored at
−20 ◦C until further analysis. Serum concentration of hCD19-specific antibody was determined by
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streptavidin-coated plates. A dose range antibody spiked in serum from non-treated mice was used to
calibrate the assay.
3. Results and Discussion
3.1. Generating Tumor Cells and Anti-CD47/TAA biAbs to Study Tumor-Specific CD47 Targeting In Vitro and
In Vivo
To study immunosurveillance, and thus the ability to generate antitumor adaptive immune
responses, we needed to work with immunocompetent mice and syngeneic tumor models. For the
model tumor antigen, we chose to work with human CD19 (hCD19) transfected into an A20 cell line
derived from a BALB/c diffuse large B cell lymphoma. In order to study biAb-mediated tumor-directed
blockade of CD47, various anti-mouse CD47-targeting antibody sequences were identified using the
κλ body biAb platform [36]. The two sequences analyzed in this study were initially expressed as
mAbs and were shown to block mouse CD47-SIRPα interaction with different potency (CD47 mAb1
and CD47 mAb2, Figure S1). These sequences were then combined as biAb1 and biAb2 with the
previously described high-affinity TAA sequence recognizing the human CD19 antigen, an anti-hCD19
sequence which is not cross-reactive with mouse CD19 [36]. Thus, biAb1 and biAb2 share the same
anti-hCD19 arm but have different anti-mouse CD47 arms. These two anti-CD47 sequences bind
overlapping epitopes on mouse CD47 but with significantly different affinities. The equilibrium
dissociation constant (KD) between biAb1 and mouse CD47 is in the nanomolar range (Table S1),
while the affinity of biAb2 to CD47 was too weak to be reliably measured. The CD47/CD19 biAbs
and the corresponding monovalent CD47 and CD19 antibodies used in this study are schematically
depicted in Figure S2.
3.2. CD47/CD19 biAbs Selectively Target Mouse Lymphoma Cells Expressing Human CD19
After engineering, the A20-hCD19 cells displayed 30,000 copies of mouse CD47 per cell, similar
to non-transfected A20 cells (“wild type”, A20 wt), and 65,000 copies of hCD19. Figure 1 shows that
the targeting of A20-hCD19 tumor cells is primarily driven by the anti-hCD19 antibody arm of the
biAbs. Both biAb1 and biAb2 bind strongly to A20-hCD19 cells, but only weakly (biAb1) or negligibly
(biAb2) to A20 wt cells (Figure 1a,b). Of note, the binding of the two biAbs is comparable to CD19
monovalent antibody binding to A20-hCD19 cells, with a slight EC50 shift in favor of the biAbs,
reflecting a contribution of the CD47 arms to the aggregate binding affinity (Figure 1a,b). To test if
CD47/CD19 biAbs are able to block mouse CD47 on double-positive cells upon hCD19 co-engagement,
we used a CD47 competitive binding assay. Both biAbs efficiently out-competed fluorescently labeled
CD47 ligand (Figure 1c) more potently than the corresponding CD47 monovalent antibodies (i.e.,
κλ bodies with a non-binding arm instead of the anti-hCD19 arm) as well as the ‘bivalent’ CD47 mAbs.
Noticeably, biAb1 and biAb2 blocked CD47 with similar potency despite different affinities of their
anti-CD47 arms (see Table S1 and compare binding to A20 wt cells on Figure 1a,b) illustrating the













Figure 1. CD47/CD19 bispecific antibody (biAb) selectivity. (a,b) Binding, reported as mean
fluorescence intensity values, to A20 mouse B cell lymphoma cells (A20 wild type (wt)) and A20
cells expressing human CD19 (A20-hCD19), of biAb1 (a) and biAb2 (b) as well as the anti-human
CD19 mAb and the corresponding anti-mouse CD47 mAbs (mAb1 for biAb1 and mAb2 for biAb2).
(c) Percent binding inhibition curves obtained by flow cytometry of a fluorescently-labeled CD47/ signal
regulatory protein alpha (SIRPα) blocking mAb to A20-hCD19 cells by the biAbs and the corresponding
anti-CD47 monovalent antibodies. (d,e) CD47/CD19 biAb-mediated antibody-dependent cellular
phagocytosis (ADCP) as assessed by incubating fluorescently labeled A20-hCD19 (d) or A20 wt (e)
cells with mouse macrophages (E:T ratio 1:5) in the presence of increasing concentrations of biAbs.
Phagocytosis was assessed by flow cytometry and is expressed as the percentage of macrophages that
ingested at least one target cell. The corresponding mAbs were tested for comparison.
3.3. Antitumor Efficacy of CD47-Blocking biAbs
The mouse IgG2a isotype binds activating Fcγ receptors with high affinity, mediating potent
effector functions such as antibody-dependent cellular phagocytosis (ADCP). Phagocytosis of tumor
cells can be further enhanced by blockade of CD47; the “don’t eat me” signal [3,4,7–9,37]. Here we show
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cells in vitro as compared to anti-CD47 and anti-CD19 mAbs, anti-CD47 and anti-CD19 monovalent
antibodies, or a combination of both monovalent antibodies (Figures 1d and S3). We also show that the
Fc region of CD47/CD19 biAbs is crucial for ADCP efficacy, as the F(ab’)2 fragments of biAb1 and
biAb2 did not trigger the phagocytosis of target cells (Figure S4). As expected, the biAbs induced only
minimal phagocytosis of hCD19-negative (A20-wt) cells (Figure 1e). As in the CD47 blocking assay
(Figure 1c), biAb1 and biAb2 showed comparable activity in the ADCP assay (Figure 1d), confirming
that: (i) the affinity for binding hCD19 is the driving force of biAb activity; and (ii) the avidity generated
upon hCD19 co-engagement on the cell surface of double-positive cells forces efficient CD47 blockade,
compensating for differences in CD47 arm affinity. It is also likely that CD47 binding and blockade on
the tumor cell is locally stabilized at the site of the phagocytic synapse, arising through the interactions
of antibody Fc regions with Fcγ receptors on the macrophage.
To assess antitumor activity in vivo, BALB/c mice, engrafted subcutaneously (sc) with A20-hCD19
cells, received either intra-tumoral (it) or intra-peritoneal (ip) biAb treatment, initiated after the tumors
reached a measurable volume. When administered locally, both biAbs were able to delay tumor growth
(Figure 2a). However, upon ip administration, only biAb2 showed an antitumor effect (Figure 2b).
This result was striking but not totally unexpected. While target cell selectivity of the CD47/CD19
biAbs is principally determined by the anti-hCD19 antibody arm, the higher-affinity anti-CD47 arm of
biAb1 shows autonomous binding activity, in particular at higher antibody concentrations (Figure 1a).
Thus, the higher affinity of the anti-CD47 arm in biAb1 resulted in a less stringent discrimination
between double-positive and hCD19-negative cells as compared to biAb2 (Figure 1b). We hypothesized
that the lack of in vivo efficacy of biAb1 administered systemically results from its interactions with
CD47 expressed ubiquitously on healthy cells (i.e., the CD47 antigen sink), which, in turn, negatively
impacts the pharmacokinetics, the level of toxicity, and eventually the efficacy of the biAb upon
systemic administration.
(a) (b)
Figure 2. In vivo efficacy of CD47/CD19 bispecific antibodies. Treatment of BALB/c mice engrafted
subcutaneously (sc) with A20-hCD19 cells began when the tumor size reached about 6 × 6 mm (n = 7
mice per group). (a) 100 μg of CD47/CD19 biAb was administered intra-tumorally on day 7, 10 and 13;
(b) 400 μg of CD47/CD19 biAb was systemically administered intra-peritoneally on day 11, 13, 15 and
17. Tumor growth was measured three times a week and the average tumor volume per group +/−
SEM (Standard Error of the Mean) reported. Statistical significance was determined using two way
ANOVA comparing groups on d 31, p-value: * p < 0.05, ** p < 0.01; n.s., not significant.
3.4. The Affinity of the Anti-CD47 Arm Is Important for biAb Selectivity and Pharmacological Properties
To further assess the contribution of biAb anti-CD47 arms to cell binding, we incubated a 1:1 mix
of fluorescently labeled A20-hCD19 cells and A20 wt cells with increasing concentrations of biAb and
evaluated antibody binding by flow cytometry. Figure 3a shows relative binding, i.e., the ratio between
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showed a preference for double-positive cells (A20-hCD19), but biAb1 completely lost this binding





Figure 3. Affinity of the anti-CD47 arm influences biAb binding selectivity, hematological toxicity and
bioavailability. (a) Binding selectivity was assessed using green fluorescent protein (GFP)-expressing
A20-hCD19 cells and mCherry-expressing A20 wt cells at a 1:1 ratio, incubated with increasing
concentrations of antibody and then analyzed by flow cytometry. The ratio between the Mean
Fluorescence Intensity values obtained with A20-hCD19 cells and A20 wt cells is reported; (b) Antibody
binding to erythrocytes from mouse (BALB/c) whole blood was determined by flow cytometry
and the results reported as the Mean Fluorescence Intensity values obtained with biAbs and the
corresponding mAbs; (c,d) To evaluate in vivo binding to RBC, BALB/c mice (n = 8/group) received
three intraperitoneal 400 μg doses of anti-human CD19 antibody, biAb1 or biAb2 every 2 days. (c) Blood
was collected 2 days after the last injection and RBC-bound antibody levels were determined by
flow cytometry. Histogram plots show mean fluorescence intensity values obtained with the three
antibodies tested; (d) Individual levels of RBC counts per mouse post antibody treatment; (e) Systemic
bioavailability of the biAbs was assessed by obtaining the plasma and determining the antibody levels
using a quantitative hCD19 ELISA assay. Normalized mean antibody titer +/− SD (standard deviation)
is reported. Statistical significance was determined using one way ANOVA (d) or t-test (e); p-value
* p < 0.05, ** p < 0.01; n.s., not significant.
We next assessed the binding of the CD47/CD19 biAbs to mouse red blood cells (RBC).
RBCs displayed 20,000–25,000 copies of CD47 per cell. Given their abundance (between 6 and 10 billion
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antibodies. To test binding to RBCs, antibodies were incubated with whole blood from BALB/c mice
followed by flow cytometry analysis. BiAb1 bound mouse RBC relatively well at high concentrations,
reaching binding levels comparable to anti-CD47 mAb2 at 100 μg/mL. In contrast, biAb2 showed
only minimal binding (Figure 3b). Binding to RBC was also assessed in vivo two days after three ip
injections of biAb at a dose of 20 mg/kg administered every other day. Consistent with the in vitro assay
results, in vivo RBC binding levels were significantly higher with biAb1 than with biAb2 (Figure 3c).
These results confirm once again the higher propensity of biAb1 to interact with the CD47 antigen
sink. As anti-CD47 mAbs induce cytopenia and anemia in nonclinical and clinical studies, we assessed
the effect of the two CD47/CD19 biAbs on RBC depletion. As shown on Figure 3d, RBCs declined
following treatment with an anti-CD47 mAb (i.e., CD47 mAb2), to a lesser extent with biAb1, but,
importantly, not with biAb2.
To assess how the ubiquitously expressed nature of CD47 affects biodistribution and
pharmacokinetics of the biAbs, we determined the levels of circulating antibody two days after
the last of three ip injections administered as described above. We observed a decreased bioavailability
in the blood of both biAbs as compared to a non-binding control IgG (anti-hCD19 mAb) (Figure 3e).
Consistent with the RBC binding results, biAb1 levels were significantly lower than biAb2 in circulation
(Figure 3e).
These findings highlight the fact that the CD47 antigen sink could be a major challenge not only for
monospecific anti-CD47 mAbs and SIRPα-Fc fusion proteins, but also for bispecific antibodies targeting
CD47, depending on the affinity of the anti-CD47 arm. However, as illustrated by the biAb2, with a
properly tuned affinity, negative effects of the CD47 antigen sink on bispecific drug pharmacology
and safety can be minimized without compromising the efficacy of TAA-mediated, tumor-directed
CD47 blockade.
3.5. CD47/CD19 biAb Induces Adaptive Antitumor Immunity
As it has been reported that CD47-SIRPα blockade enhances the T cell-dependent antitumor
response, we also studied the induction of adaptive immunity. Using our system, we observed that
biAb2 administered systemically was not only able to slow-down tumor progression (Figure 2b) but
also could provoke complete tumor regression in some animals and generate long-term survival
(Figure 4a), the latter suggesting creation of efficient tumor immunosurveillance. We hypothesized that
animals that rejected the primary hCD19-positive tumors may have developed immunological memory
against A20 tumor antigens other than the xenogeneic neo-antigen, hCD19. To test if indeed the
antitumor memory responses were associated with epitope spreading, mice with complete responses
were rechallenged with wild type A20 cells. In contrast to the control group (i.e., not treated with biAb
nor previously challenged with tumor), none of the previously treated and then rechallenged mice
developed tumors (Figure 4b), indicating the induction of long-lasting protective antitumor immunity
as well as a broadened antigen specificity.
To further define how tumor-directed blockade of CD47 resulted in enhanced adaptive immune
responses, an in vitro cross-priming system using hemagglutinin A (HA) CD8+ transgenic T cells was
established. The A20-hCD19 tumor cells were further transfected with HA (A20-hCD19-HA cells) to serve
as the target tumor cell, and macrophages derived from mouse bone marrow (BMDMs) were serving as
antigen-presenting cells. In the presence of biAb2, a substantially higher level of phagocytosis is observed
as compared to the higher affinity anti-hCD19 mAb (Figure 4c). Furthermore, biAb2 promoted higher
levels of T cell proliferation and cytokine production than with anti-hCD19 mAb-induced macrophages
(Figure 4d–f). From these data, we conclude that enhanced tumor cell phagocytosis and antigen
cross-presentation may contribute to in vivo efficacy of CD47-blocking biAbs. In any case, inhibition of
CD47 on tumor cells promoted tumor control in vivo, as biAb2 demonstrated superior efficacy compared
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(a) (b)
 
(c) (d) (e) (f) 
Figure 4. CD47/CD19 biAb promotes adaptive antitumor immunity. (a) Kaplan–Meier survival curves
of animals treated with biAb2 in the experiment presented in Figure 2b; (b) Mice that rejected the
A20-hCD19 primary tumor were rechallenged on the opposite flank with A20 wt cells and followed for
tumor growth. The average tumor volume compared to naïve mice control group (n = 7) is reported.
(c–f) biAb-mediated phagocytosis augments antigen cross-presentation and CD8+ T cell activation.
Results from a representative experiment are presented; (c) Phagocytosis of HA-expressing tumor cells
was assessed by incubating A20-hCD19-GFP-HA cells with bone marrow-derived macrophages from
BALB/c mice and 5 μg/mL of antibody overnight. Phagocytosis was determined by flow cytometry
and is expressed as the percentage of macrophages that ingested at least one target cell. The anti-human
CD19 mAb was tested for comparison. (d) CD8+ T cell activation was assessed using macrophages from
(c), co-cultured with cell tracer-labeled naive HA-specific TCR transgenic CD8+ T cells. The percentage
of proliferating T cells was determined after 48 h of co-culture. (e,f) Cytokine secretion associated
with T cell activation was assessed by quantifying the levels of IL-2 (e) and IFN-γ (f) released in the
supernatant upon T cell activation.
3.6. CD47/CD19 biAbs Enhance the Therapeutic Effect of Immune Checkpoint Blockade and Chemotherapy
PD-1/PD-L1 checkpoint inhibitors, while curative in some patients, have clinically demonstrated
the multifactorial primary and/or acquired resistance mechanisms that tumors use to thwart
immunosurveillance [38,39]. Thus, drug combinations aimed at overcoming these resistance factors,
are an area of intense clinical research. As our results demonstrate the ability to enhance antigen
presentation and endogenous T cell immunity, we hypothesized that tumor-directed blockade of CD47
with biAbs offer yet another means of attack. Indeed, CD47 blockers have been shown to increase
tumor control when combined with anti-PD-1/PD-L1 antibodies in preclinical models [13,15,16] and
CD47 expressed on tumor cells has recently been identified as a key agent of resistance to PD-1
immunotherapy in mice [20]. Thus, we next examined the efficacy of a combination therapy involving
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mAb or biAb2 single agent treatment was able to delay A20-hCD19 tumor growth, the combination
therapy was more potent (Figure 5a).
(a) (b)
(c) (d)
Figure 5. Combination therapies with anti-CD47 biAbs. (a) Combination of biAb2 and PD1/PD-L1
checkpoint blockade was assessed by engrafting BALB/c mice sc with A20-hCD19 cells and starting
treatment when the tumor size reached 100 mm3 (intra-peritoneal doses of 400 μg for biAb2, or 200 μg
doses for an anti-mouse PD-L1 antibody or a combination of the two antibodies on day 7, 9, 11, 13 and
15; n = 6 per group). (b,c) Combination of biAb2 and cyclophosphamide (CTX) was assessed by
engrafting BALB/c mice sc with A20-hCD19 cells and starting treatment when the tumor size reached
100 mm3 (a single dose of CTX, 60 mg/kg ip, on d6, or three intra-tumoral 100 μg doses of biAb1 on day
7, 9 and 12, or a combination of both; n = 10 per group) (b) Tumor growth is shown as average tumor
size per group +/− SEM. Statistical significance was determined using two-way ANOVA, p-value:
* p < 0.05, ** p < 0.01; n.s., not significant; (c) Kaplan–Meier curves of tumor-bearing mice; (d) Mice that
rejected the A20-hCD19 primary tumor were rechallenged on the opposite flank with A20-hCD19 cells
and followed for tumor growth. The average tumor volume compared to naïve mice control group
is reported.
We next studied the combination using cyclophosphamide (CTX). This chemotherapeutic agent
promotes antitumor immunity by mediating selective immunodepletion of regulatory T cells [40].
We used a sequential combination therapy protocol to test the effect of tumor-directed blockade of
CD47 in conjunction with CTX. A20-hCD19 tumors were allowed to grow to 100 mm3 and then the
mice were treated with a single ip dose of CTX followed by three intra-tumoral injections of biAb1.
The biAb, administered as monotherapy, was able to slow down tumor progression, whereas CTX
led to a rapid tumor regression and durable responses in 50% of the animals (Figure 5b,c). Strikingly,
the combination therapy allowed an even more potent effect, as 100% of the animals eliminated the
tumor (Figure 5b,c) and developed long-term protective immunity, as demonstrated by resistance to
tumor rechallenge (Figure 5d).
We used a second tumor type to confirm the antitumor efficacy of CD47-targeting biAbs.
The B16F10 mouse melanoma cells that were stably transfected with human CD19 antigen
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(ip) with biAb2. Similar to the results obtained with A20-hCD19 cells, we confirmed that binding of
biAb2 to tumor cells is predominantly driven by its high-affinity anti-hCD19 arm (Figure S6b). We also
demonstrated that tumor-directed blockade of CD47 with biAb2 administered systemically results in
tumor growth inhibition and prolonged survival. (Figure S6c,d).
In conclusion, our study demonstrates that tumor-directed blockade of CD47 with dual targeting
biAbs can inhibit tumor growth, promote tumor regression and induce durable antitumor memory
responses. Our results further support the concept that CD47 blockade promotes T cell-dependent
immunity via stimulating phagocytosis of tumor cells, antigen cross-presentation, and cytotoxic T
cell cross-priming. We also show that tumor-directed blockage of CD47 can be combined with other
therapeutic modalities, such as immune checkpoint inhibitors or chemotherapy, which should further
improve antitumor responses and lift the proportion of curative therapies to offer to cancer patients.
A key finding of this study is that using an in vivo system in which a CD47 antigen sink is present,
the affinity of the anti-CD47 arm is important not only for drug safety and pharmacokinetics, but
also for antitumor efficacy, in particular upon systemic administration. Therefore, the affinity of the
CD47-blocking arm needs to be carefully considered when designing biAb antibodies targeting human
CD47 for therapeutic intervention.
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Figure S1: Blockade of CD47-SIRPα interaction with anti-mouse CD47 mAbs. Binding of fluorescently labeled
recombinant mouse SIRPα to CD47 expressed on the surface of murine pre-B cell lymphoma L1.2 cells in the
presence of increasing concentrations of anti-mouse CD47 mAbs was assessed by FMAT and is represented as
Mean Fluorescence Intensity (MFI) ± S.D. of four replicates, Figure S2: Schematic representation of CD47/CD19
biAbs and the corresponding monovalent antibodies, Figure S3: biAb2-induced phagocytosis of A20-hCD19 cells,
Figure S4: CD47/CD19 bispecific antibody Fc region is required for efficient ADCP, Figure S5: Comparison of
in vivo efficacy of biAb2 and anti-CD19 monospecific antibodies, Figure S6. Antitumor efficacy of biAb2 in the
B16F10-hCD19 model, Table S1: Affinity of biAb1 and biAb2 antibody arms.
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Abstract: Antibiotic-resistant bacterial pathogens are increasingly implicated in hospital- and
community-acquired infections. Recent advances in monoclonal antibody (mAb) production and
engineering have led to renewed interest in the development of antibody-based therapies for
treatment of drug-resistant bacterial infections. Currently, there are three antibacterial mAb products
approved by the Food and Drug Administration (FDA) and at least nine mAbs are in clinical trials.
Antibacterial mAbs are typically developed to kill bacteria or to attenuate bacterial pathological
activity through neutralization of bacterial toxins and virulence factors. Antibodies exhibit distinct
pharmacological mechanisms from traditional antimicrobials and, hence, cross-resistance between
small molecule antimicrobials and antibacterial mAbs is unlikely. Additionally, the long biological
half-lives typically found for mAbs may allow convenient dosing and vaccine-like prophylaxis
from infection. However, the high affinity of mAbs and the involvement of the host immune
system in their pharmacological actions may lead to complex and nonlinear pharmacokinetics and
pharmacodynamics. In this review, we summarize the pharmacokinetics and pharmacodynamics
of the FDA-approved antibacterial mAbs and those are currently in clinical trials. Challenges in the
development of antibacterial mAbs are also discussed.
Keywords: bacterial infections; monoclonal antibodies; pharmacokinetics; pharmacodynamics
1. Introduction
The clinical application of antibodies for the treatment of infectious diseases was first
introduced in the form of serum therapy in early 1890s by Emil von Behring and Shibasaburo
Kitasato [1]. Serum therapy was then widely applied to treat infections caused by several bacterial
pathogens, including Corynebacterium diphtheria, Streptococcus pneumoniae, Neisseria meningitides,
Haemophilus influenzae, Group A Streptococcus, and Clostridium tetani [2]. Although serum therapy
became the standard-of-care for several infectious diseases in the pre-antibiotic era, treatment
with polyclonal antisera poses several drawbacks, including “serum sickness” or immune complex
hypersensitivity that can occur in 10–50% patients, lot-to-lot variation in efficacy, low content of specific
antibodies, and potential hazards in the transmission of infectious diseases [2–5]. In 1937, the discovery
of sulfonamides led to a boom in the development of antimicrobial chemotherapy [6], and the
significant advantages associated with antimicrobials, such as less toxicity and cost, higher efficacy,
and broad spectrum activity, resulted in the abandonment of serum therapy. Drug resistance,
which has been a concern from the onset of antibacterial chemotherapy, has become a major clinical
problem within the past few decades. It has been suggested that broad spectrum antimicrobial
activity contributes to the widespread development of resistant strains, and specific mechanisms of
resistance can either exist before, or emerge rapidly after, the clinical launch of new antibiotics [7].
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In 2004/5, pan-drug resistant strains (i.e., resistant to all antimicrobials currently approved by FDA) of
Acinetobacter and Pseudomonas were identified [7]. Unfortunately, as drug resistance has been increasing,
the rate of approval of new antibiotics has been decreasing. The number of new antibacterial drugs
approved has decreased from an average of five per year in the 1980s to less than one per year in the
2000s [7].
The discovery of hybridoma technology in 1975 and recent advances in monoclonal antibody
(mAb) engineering, which make production of unlimited amount of human mAbs possible [8,9],
have renewed interest in the development of antibacterial antibody therapies. Monoclonal antibodies
are widely used to treat immune deficiencies, cancers, multiple sclerosis, rheumatoid arthritis,
and psoriasis, but the application of mAbs for bacterial infections has progressed slowly. Currently,
there are only three mAbs approved by the FDA for use in the treatment of bacterial infections
(Table 1). All three mAbs are indicated as adjuvant therapies to antibiotics and do not have bactericidal
activity. They are directed against bacterial exotoxins and protect host cells from toxin-mediated
cytotoxicity through neutralization of exotoxin activities. As of December 2017, there are nine mAb
products in clinical trials (Table 2). Of these, six are ‘naked’ mAbs, two are mAb cocktails containing
two mAbs that bind to different targets (ASN100 and Shigamab), and one is an antibody-antibiotic
conjugate (DSTA4637S) that kills intracellular bacteria through the intracellular delivery of a potent
antibiotic. Of note, five of the nine mAb products in clinical testing bind to the bacterial cell surface
and have shown bactericidal activity in preclinical studies (DSTA4637S, 514G3, MEDI3902, Aerumab,
and Aerucin); the other four target exotoxins and protect against infections via toxin neutralization
(MEDI4893, ASN100, Salvecin, and Shigamab).
In this review, we discuss important considerations of mAb-based therapies for the
treatment of bacterial infections, including unique challenges, pharmacokinetic (PK) properties,
and pharmacodynamic (PD) mechanisms of action. The PK/PD characteristics of FDA-approved
antibacterial mAbs and those in clinical trial are also summarized.
2. Pharmacokinetic Considerations
All FDA-approved antibacterial mAbs and the majority of those in clinical trials are of the
immune gamma globulin (IgG) isotype. IgG is the predominant immunoglobulin isotype, comprising
approximately 80% of immunoglobulin in human serum. An intact IgG has a molecular weight
of ~150 kDa, with two antigen binding domains and a highly conserved crystallizable region (Fc)
that is responsible for binding to Fc gamma receptors (FcγRs) on immune cells and activating
Fc-mediated effector functions. IgG typically exhibits linear pharmacokinetics (i.e., area under
the drug concentration-time curve (AUC) is directly proportional to the dose) in healthy human
subjects, with small volumes of distribution (3–9 L), relatively slow clearance (8–12 mL/h), and long
half-lives (20–25 days) [10]. The long biological persistence of IgG is partially attributed to Brambell
receptor (FcRn) mediated salvage of IgG from lysosomal catabolism [11]. In contrast to the
pharmacokinetics of pooled endogenous IgG, therapeutic mAbs often demonstrate nonlinear PK
(i.e., AUC is not proportional to the dose), depending on the total body load of the pharmacological
target (i.e., the quantity of bacteria, in the case of antimicrobial mAb), the accessibility of the targets,
mAb-target affinity, and mAb doses. Key PK considerations for antibacterial mAbs are summarized
below, including a discussion of determinants of target mediated drug disposition (TMDD) and mAb
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2.1. Target Mediated Drug Disposition
Target mediated drug disposition describes the phenomenon where binding of a high affinity drug
to its pharmacological target affects the PK characteristics of the drug (i.e., kinetics of distribution and
clearance) [12]. At relatively low doses (compared to the amount of target), high affinity mAb-target
binding results in drug accumulation at the sites of action (i.e., target-expressing tissue or site of
infection), which may lead to a large apparent volume of distribution of the mAb. With increased
doses and increased mAb concentrations, the target sites become increasingly saturated, which may
decrease tissue to plasma mAb concentration ratios, decreasing the apparent volume of distribution.
Additionally, mAb-target binding may trigger receptor-mediated endocytosis, in which mAb-target
complexes are engulfed and degraded in lysosomes. This target-mediated elimination accelerates the
clearance of mAbs and thereby shortens their biological persistence and half-life. Due to the effect of
the drug in enhancing the elimination of the target, the volume of distribution and clearance of the
drug may decrease during the course of repeated dosing.
All marketed antibacterial mAbs and those in clinical trials were developed to kill bacteria
or attenuate bacterial pathological activity via antibody-mediated effector functions or toxin
neutralization (Tables 1 and 2). Antibody-toxin and antibody-bacteria complexes may be cleared by
phagocytic cells through Fc engagement with FcγRs, and via subsequent endocytosis and catabolism in
phagolysosomes. Thus, antibacterial mAbs may be expected to exhibit TMDD characteristics. However,
the pharmacokinetics of antibacterial mAbs have not been well evaluated to date. Obiltoxaximab,
a chimeric IgG1 targeting the protective antigen of Bacillus anthracis, showed ~2-fold faster clearances in
rabbits and monkeys challenged with B. anthracis spores compared to those in non-infected animals [13].
Similarly, a mAb directed against Staphylococcus aureus also demonstrated significantly increased
clearance (12.1–15.8 mL/day/kg) and decreased half-life (3.74–5.28 days) in S. aureus infected mice
compared to those in non-infected mice (4.69–5.19 mL/day/kg and 16.4–18.0 days, respectively) [14].
In contrast, pulmonary infection with Acinetobacter baumannii did not impact the PK of an anti-K2
capsule mAb in mouse blood, although a substantial accumulation of mAb (5.64–36.1 fold higher
amount) was observed in tissues (i.e., lung, liver, and spleen) with high bacterial load compared
to values found in non-infected mice [15]. Further investigations are needed, as TMDD results in
nonlinear PK, which impacts the design of efficacious dosing regimens, and contributes to potential
intra- and inter-patient PK variability (e.g., due to differences in bacterial burden and immune status).
2.2. Distribution of mAbs in Infected Tissues
The tissue disposition of anti-bacterial mAbs may be complex, involving extravasation of
mAb molecules from blood to tissue interstitial fluids, diffusion of the molecule in the interstitial
fluids to bacterial targets, binding to bacterial targets, and elimination of mAbs from tissue via
convective drainage through the lymphatics and via catabolism. Extravasation of IgG antibodies
is typically thought to be governed by both diffusion and convection (i.e., bulk movement of
molecules through paracellular pores in the vascular endothelium), but convection has been estimated
to contribute more than 98% of the total transport [16–18]. Bacterial invasion and dissemination
normally accompany disruption of the vascular endothelial integrity due to bacterial toxin-mediated
cytotoxicity. This vascular damage may lead to increased antibody extravasation within infected
tissues. Once bacterial cells seed in the tissue, rapid bacterial growth and release of exotoxins stimulate
immune responses, including recruitment of effector cells (i.e., lymphocytes, polymorphonuclear
leukocytes, and phagocytes) and massive release of cytokines and chemokines. These reactions on
one hand result in increased fluid infiltration and increased vascular permeability that facilitate mAb
extravasation; but, on the other hand, build up fluid pressure within tissue that hampers antibody
distribution (by decreasing the hydrostatic pressure gradient driving convective transport of mAb from
blood to tissue interstitial fluid) [19,20]. In addition, antibody-dependent phagocytosis accelerates the
elimination of mAbs (i.e., target-mediated elimination) in the tissue. Bacterial infections in visceral
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protect them from immune cells and mAbs. Furthermore, many pathogenic bacteria generate biofilms
that are comparatively inaccessible to antibodies, immune cells, and even small molecule antibiotics.
Another concern is that biofilms may mediate a near continuous release of virulence factors, such as
exopolysaccharides of Staphylococcus epidermis, that act as decoys to reduce mAb molecules reaching the
bacteria [21]. Therefore, formation of both abscesses and biofilms create barriers to mAb distribution,
and hence adversely affect the antibody-mediated clearance of bacteria.
3. Pharmacodynamic Mechanisms of Action
Antibacterial mAbs have been developed against a variety of bacterial cell surface targets
(i.e., proteins and polysaccharides) and soluble exotoxins (Tables 1 and 2). The potential
pharmacodynamic mechanism of action depends on the nature of the target, its role in
bacterial pathogenesis, and mAb isotype and structure (i.e., intact IgG mAb or IgG fragments,
immunoconjugates, bispecific antibodies, etc.). Anti-exotoxin mAbs typically attenuate bacterial
pathological activity via neutralization of exotoxins. Monoclonal antibodies targeting bacterial
surface epitopes are expected to increase bacterial clearance through enhancing antibody-dependent
phagocytosis, and/or complement-mediated bactericidal activity, or via immune system-independent
bacterial killing. In addition, there has been increasing interest in the development of
immunoconjugates and immunomodulatory mAbs that either carry potent antimicrobials or stimulate
exhausted immune effector functions to augment bactericidal activity.
3.1. Toxin Neutralization
Antibacterial mAbs that act through the mechanism of neutralization are typically directed against
exotoxins. mAb binding to soluble exotoxins leads to the formation of antibody-toxin complexes,
which are primarily cleared by the reticuloendothelial system. All three marketed antibacterial mAbs
achieve effects via toxin neutralization (Table 1). The efficacy of neutralizing mAbs has been shown to
be directly correlated with mAb binding affinity. Anti-protective antigen (PA) mAb with higher binding
affinity showed superior protection against anthrax lethal toxin challenge in macrophage cytotoxicity
assays and in a rat infection model, when compared to mAbs with relatively low affinities [22].
Additionally, antibody-FcγR engagement was found to be required for anti-PA mAb neutralization
activity, where mAb-mediated protection against anthrax infection was only shown in wild-type mice
but not FcγR-deficient mice [23]. However, FcγR engagement may not be required for all anti-toxin
mAb. For example, MAb166, an anti-PcrV (type III secretion injectisome) antibody, blocks the delivery
of Pseudomonas aeruginosa type III toxins to host cells [24]. A single dose of 10 μg of MAb166 Fab
fragments, which lack an Fc domain, was able to confer similar protection (≥80% survival) as intact
MAb166 against clinical isolates of P. aeruginosa in a mouse pneumonia infection model [24,25].
3.2. Opsonophagocytosis
Opsonophagocytosis has been considered as one of the key bactericidal mechanisms of the innate
immune system. Antibody-mediated opsonophagocytosis involves antibody binding to bacterial
surface antigens, followed by the engagement of FcγRs on the surface of professional phagocytes
(i.e., monocytes/macrophages, neutrophils and dendritic cells), which in turn trigger actin-myosin
driven endocytosis of antibody-bacteria complexes [26]. Phagosome vacuoles fuse with lysosomes,
which leads to formation of phagolysosomes where bacteria are catabolized. Antibody-dependent
phagocytosis is readily activated at the presence of phagocytes and antibody-bacteria complexes.
It has been estimated that a surface density of only 5.33–26.7 antibodies/μm2 (i.e., IgG density on
the surface of targeted particles) is required to trigger antibody-dependent phagocytosis [27]. In one
example of the significance of opsonophagocytosis for mAb treatment of bacterial infection, Russo et al.
developed a mAb 13D6 against K1 capsular polysaccharide of Acinetobacter baumannii, which showed
potent inhibitory effects on bacterial growth in a rat soft tissue infection model. Antibody-dependent
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3.3. Complement-Dependent Cytotoxicity
Antibody-dependent (i.e., classical) complement activation is another important bactericidal
mechanism of the innate immune system. Binding of antibodies on the bacterial surface enhances the
recruitment and binding of soluble complement factors, including C1q, to the Fc domain of the mAb,
which leads to the activation of the complement cascade (i.e., complement fixation), formation of the
membrane attack complex, thus leading to bacterial killing. Activation of the antibody-dependent
pathway requires interaction of C1q with at least two IgG molecules [29]. Based on the molecular size of
C1q, it is estimated that the surface density of IgG must be such that IgG molecules are separated by no
greater than ~40 nm to fix C1q [30]. In contrast, IgM is much more efficient in complement activation,
as a single IgM molecule is able to fix C1q [29]. An anti-keratin antibody IgM (3B4) directed against
Methicillin-resistant Staphylococcus aureus (MRSA) was generated by An et al. with strong binding to
MRSA and mannose-binding lectin (MBL), which in turn activated the classical and MBL complement
pathways and led to potent bactericidal activity [31]. Passive immunization with 3B4 significantly
decreased bacterial burden in organs and improved animal survival in a mouse bacteremia model [31].
3.4. Direct Bactericidal mAbs
In addition to the mechanisms of action discussed above, antibacterial mAbs showing direct
bactericidal activity have been occasionally identified. Binding of these mAbs may trigger lysis of
bacterial cells directly (i.e., without requirement for fixation of complement of engagement of other
components of the host immune system). For instance, LaRocca et al. developed an IgG1 mAb (CB2)
that targets outer surface protein B (OspB) of Borrelia burgdorferi for the treatment of Lyme disease [32].
CB2 exhibited complement-independent pore forming when bound to B. burgdorferi, which resulted in
osmotic lysis of bacterial cells. However, this bactericidal effect was not transferable to Escherichia coli
expressing recombinant OspB, suggesting a unique interaction between CB2 and B. burgdorferi [32].
The underlying mechanism of action is unclear, but it was found to be correlated with cholesterol
glycolipids in the B. burgdorferi outer membrane that exist as temperature-sensitive lipid raft-like
microdomains [33].
3.5. Immunoconjugates
The use of mAbs to deliver highly potent payloads has been successfully applied in cancer
treatment [34]. This strategy, on one hand, does not require the mAb itself to be protective; on the
other hand, it increases the half-life and specificity of the payload and, hence, decreases off-target
toxicity. However, application of this approach to bacterial infection is still in its infancy. In 2015,
Lehar and colleagues for the first time adapted the immunoconjugate strategy to antimicrobials and
developed a novel THIOMAB™ (Genentech, South San Francisco, CA, USA) antibody antibiotic
conjugate (AAC) against Staphylococcus aureus [35]. The antibody module opsonizes S. aureus and
mediates uptake into phagolysosomes, where a potent antibiotic payload is released, allowing
efficient killing of intracellular bacteria [35]. This AAC strategy demonstrated promising bactericidal
activity against vancomycin-resistant S. aureus, and it was especially efficacious for bacteria with
an intracellular life cycle [36]. Antibody-antibiotic conjugates may be expected to demonstrate
favorable pharmacokinetics (i.e., long half-lives), and decreased off-site toxicity. For example, the AAC
strategy ameliorated antibiotic-mediated disruption to the normal flora, and may decrease selective
pressure that enhances the development of cross resistance, due to the specificity provided by the
antibody carrier. The advantages provided by antibody conjugation may allow for reconsideration of
antimicrobials that failed in development due to unfavorable PK or toxicity.
Radioimmunoconjuates, which link radionuclides to mAbs, may allow targeted delivery
of bactericidal radiation to bacteria. As a proof-of-principle, Dadachova et al. developed a
radioimmunoconjugate with Bismuth-213 linked to a mAb (D11) targeting the pneumococcal capsular
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and in a mouse bacteremia model, without detectable hematological toxicity [37]. In addition,
radioimmunotherapy has also shown to confer protection against human immunodeficiency virus
(HIV) in severe combined immunodeficiency (SCID) mice, and to selectively kill HIV-infected
human T cells and human peripheral blood mononuclear cells in vitro [38]. These data suggest
that radioimmunoconjugates may provide protection in immunocompromised patients and may be
efficacious against infected host cells that express bacterial antigens on cell surfaces, which could be a
novel approach to clear latent intracellular bacteria.
3.6. Immunomodulatory mAbs
Immunomodulatory mAbs, such as T-cell engaging antibodies and antibodies targeting
programmed cell death protein 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 (CRLA-4),
have gained great success in the treatment of cancer. However, their application in bacterial infections
has not been well explored. Akin to cancer, chronic exposure of antigens to T-cells during persistent
infections leads to cellular exhaustion of effector functions [39]. Thus, immunomodulatory mAbs
theoretically may aid in the clearance of bacteria through stimulating the host immune system. Recently,
evidence from the literature supports the potential benefit of anti-PD-1 mAb for the treatment of
tuberculosis (TB) infection. PD-1 and its ligands (PD-L1 and PD-L2) were found to be significantly
decreased in CD4+ and CD8+ T cells in TB patients after standard-of-care therapy [40]. Treatment with
anti-PD-1 mAb has been shown to restore cytokine secretion and antigen responsiveness of T cells
isolated from TB patients ex vivo [41].
4. Challenges in the Development of mAbs for the Treatment of Bacterial Infections
Development of antibacterial mAbs has been progressing relatively slowly. Only three
antibacterial mAbs have been marketed in the United States (Table 1), and nine mAb products are
in Phase 1–2 clinical trials (Table 2). Although modest success in this area may be partly due to a
real or perceived lack of economic incentive to the pharmaceutical industry, limited development of
antibacterial mAbs may also relate to a host of scientific challenges. Some of the complexities include
difficulties in the selection of accessible and conserved bacterial targets, risk for antibody-dependent
enhancement of bacterial infection, and various bacterial countermeasures against antibodies.
4.1. Difficulties in Selection of Bacterial Targets
Antibacterial mAbs have been primarily developed to target either bacterial cell surface targets
or secreted exotoxins. Although anti-exotoxin antibodies have been successful, these mAbs only
attenuate bacterial pathological activity though neutralization of toxins, and are not expected to
provide bactericidal activities. Anti-exotoxin mAbs, therefore, are typically indicated for prophylaxis
or as adjunctive therapies to antibiotics. Antibacterial mAbs directed against bacterial surface epitopes
have primarily been developed for binding to outer membrane proteins (OMPs) or exopolysaccharides
(i.e., capsules or O-antigens of lipopolysaccharides) as shown in Table 2. OMPs are attractive
therapeutic targets for vaccination and passive immunization due to the high conservation of OMPs
among clinical isolates. Outer membrane protein A (OmpA)-like proteins, for instance, are conserved
across all sequenced clinical isolates with high protein homology in many Gram-negative bacteria such
as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii [42,43]. However, a concern
for mAbs targeting OMPs are reports that exopolysaccharides mask these conserved targets, impede
mAb binding, and hinder opsonization [44–48]. In contrast, exopolysaccharides are readily accessible
to antibody binding. Several of the mAbs in development are directed against exopolysaccharides,
such as DSTA4637S, MEDI3902, Aerumab, and Aerucin (Table 2). However, exopolysaccharide
epitopes are not typically conserved. Large numbers of capsular serotypes have been identified for
many bacterial pathogens. For example, at least 18 and 90 capsular serotypes have been described for
Staphylococcus aureus and Streptococcus pneumoniae, respectively [49,50]. A single mAb thus may only
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O11 of P. aeruginosa (Table 2) and, therefore, mAb cocktails that recognize different serotypes may be
required to confer meaningful antibacterial efficacy. In addition, exopolysaccharides may shed from
bacterial cells and act as decoys, which may reduce the amount of unbound antibody reaching the
bacterial surface. Capsular polysaccharides shed from Klebsiella pneumoniae, Streptococcus pneumoniae,
and P. aeruginosa have been shown to increase the resistance to antimicrobial peptides (e.g., polymyxin
B and neutrophil α-defensin 1) of an unencapsulated strains (i.e., 3-fold increase in minimum inhibitory
concentrations). Incubation with these antimicrobial peptides also stimulated the release of capsular
polysaccharide [51]. Shed capsular polysaccharides from A. baumannii appear to neutralize free
anti-capsule mAb molecules and may contribute to the lack of efficacy of mAb treatment in an
A. baumannii mouse pneumonia infection model [15].
4.2. Antibody-Dependent Enhancement of Infection
Although the role of immunoglobulin in host defense against invading microorganisms via
activation of effector cells and complement is undisputed, accumulating evidence supports that,
in some instances, antibody augments microorganism infection via assisting in their colonization and
invasion to host cells. Antibody-dependent enhancement (ADE) of infection was first discovered in
Murray Valley encephalitis virus by Hawkes [52], and it was found to also have relevance for other
viruses, such as Dengue virus, human immunodeficiency virus, Ebola virus, and Zika virus [53–57].
ADE of viral infection is mainly due to the intracellular viability of viruses, where binding with mAb
facilitates viral adherence and entry to host cells through interaction with Fc receptors or complement
receptors [58,59]. ADE of bacterial infection has been reported less frequently; however, striking
mechanisms have been identified. IgA1-dependent enhancement of pneumococcal adherence to
Detroit 562 pharyngeal epithelial cells found by Weiser et al. is a particular example. IgA1 protease
secreted by Streptococcus pneumoniae cleave the anti-capsule IgA1 mAb that is bound on the bacterial
exopolysaccharide. Positive charges on the IgA1 Fab fragments neutralize the negative charges
on the polysaccharide, which unmasks phosphorylcholine underneath the capsular polysaccharide,
thus enhancing S. pneumoniae binding to epithelial cells [60]. The increase in S. pneumoniae adherence
was found to be directly correlated with the isoelectric points of the IgA1 Fab fragments [60]. Recently,
antibodies obtained from persons with latent tuberculosis were found to be protective, whereas
antibodies obtained from those with active tuberculosis promote Mycobacterium tuberculosis infection
of human lung epithelial cells and promote bacterial replication in macrophages [61]. Additionally,
the activity of anti-M. tuberculosis mAbs (protective vs. non-protective) was shown to be correlated
with both antibody isotype and glycosylation patterns [62,63]. Monoclonal antibodies directed
against capsule epitopes of Acinetobacter baumannii, one of the three top priority pathogens listed
by World Health Organization, also demonstrated ADE of infection. Our laboratory had shown that
an anti-capsule mAb IgG3 enhances A. baumannii adherence/invasion to macrophages and human
lung epithelial cells through IgG engagement of FcγRs, and this ADE of infection leads to a significant
increase of animal mortality in a mouse pneumonia infection model [64].
4.3. Countermeasures against Antibacterial mAbs
Although antibacterial mAbs exploit pharmacological mechanisms that are distinct from
those of antimicrobials and hence cross-resistance with small-molecule antibiotics is unlikely,
host immunoglobulin has applied “selection pressure” to bacteria for millennia, which has led to the
evolution of a variety of bacterial defense mechanisms. Countermeasures against host immunoglobulin
may, in many cases, provide defense against therapeutic monoclonal antibacterial antibodies. Antibody
neutralizing proteins, for instance, protein A of S. aureus and protein G of Streptococcus, are membrane
proteins that bind antibody Fc domain and thus impede opsonophagocytosis and complement
activation [65–67]. Additionally, binding of serum IgG via the Fc region decorates the bacterial
surface, decreasing bacterial recognition by the immune system. Many bacteria also secrete proteinases
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for example, secrete IdeS (Immunoglobulin G-degrading enzyme of S. pyogenes) that specifically cleaves
the γ-chain of human IgG in the hinge region, and SpeB (Streptococcal erythrogenic toxin B) that has a
broad immunoglobulin-degrading activity toward IgG, IgA, IgM, IgD, and IgE [68,69]. Following IgG
cleavage, the resultant antibody fragments (e.g., Fab or F(ab’)2) may compete for binding with intact
antibodies and further impede antibody-mediated bactericidal activities [70]. Similar proteinases are
also found in S. aureus, P. aeruginosa, Streptococcus pneumoniae, and Haemophilus influenzae [71–74].
Antibody-based therapies that rely on antibody effector functions are likely to be affected by
these antibody neutralizing proteins and proteinases. Additionally, some bacteria can survive and
replicate inside phagocytes, which then turn into “Trojan horses” that contribute to the systemic
dissemination of bacteria and recurrence of infection. M. tuberculosis, for instance, inhibits fusion
of lysosomes with phagosomes in macrophages, which protects bacteria from killing mediated
by lysosomal constituents [75]. Rickettsia prowazekii escapes from phagosome vacuoles before
the phagosome-lysosome fusion, likely via phospholipase-mediated dissolution of phagosome
membrane [76]. S. aureus is resistant to killing by phagolysosomal catabolism through neutralization
of toxic oxygen radicals by released catalase, superoxide dismutase, and carotenoids [36,77,78]. Thus,
passive immunization that depends on opsonophagocytosis alone may be ineffective against these
bacteria, and antibody-antibiotic conjugates that release potent antibiotic molecules intracellularly
may be an effective strategy to kill these intracellular bacteria [35].
5. Currently Marketed mAbs for the Treatment of Bacterial Infections
5.1. Raxibacumab
Raxibacumab (Abthrax) is an anti-protective antigen (PA) mAb that has been approved for
the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis.
Raxibacumab is approved for use in combination with appropriate antibacterial drugs, and for
prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Raxibacumab binds free PA with a high affinity (equilibrium dissociation constant Kd = 2.78 nM),
which inhibits engagement of PA to its cellular receptors on macrophages. The antibody impedes
intracellular entry of anthrax lethal factor and edema factor, which contribute substantially to the
pathogenic effects of anthrax toxin [79,80]. Raxibacumab demonstrated linear PK in the dose range of
1–40 mg/kg following single IV doses in healthy human volunteers with a half-life of 20–22 days [81,82].
Co-administration with ciprofloxacin, a standard-of-care (SoC) antibiotic for B. anthracis bacteremia,
did not affect the PK of raxibacumab [82]. Likewise, raxibacumab did not alter the PK of ciprofloxacin.
Raxibacumab is the first biologic product that was developed and approved under the FDA
Animal Rule that may be applied when it is not ethical or feasible to conduct controlled clinical trials
in humans. The effectiveness of raxibacumab for treatment of inhalational anthrax thus is based
on efficacy studies in rabbits and monkeys. Treatment with raxibacumab was initiated when PA
was detected in serum (28–42 h) or when body temperature was sustained above baseline for 2 h
in animals after challenge with aerosolized B. anthracis spores. Significantly improved survival was
demonstrated in infected New Zealand White (NZW) rabbits and cynomolgus macaques (44% and
64% survival, respectively), when treated with 40 mg/kg raxibacumab compared to placebo groups
(0% survival) [82]. In addition, the combination of raxibacumab and levofloxacin provided significantly
enhanced protection (82% survival) compared to the antibiotic alone (65% survival) in B. anthracis
challenged NZW rabbits [83]. Based on the observed and simulated systemic exposure of raxibacumab
in animals versus humans, a single intravenous dose of 40 mg/kg was suggested to provide protection
in humans.
5.2. Obiltoxaximab
Obiltoxaximab (Anthim) is also an anti-PA mAb that was approved for the same indication
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close monitoring of individuals who receive obiltoxaximab is also required due to common adverse
reactions including hypersensitivity (10.6%, 34/320 healthy subjects) and anaphylaxis (0.9% cases)
observed in Phase 1 clinical trials [84]. Obiltoxaximab (Kd = 0.33 nM) protects against anthrax
toxin through inhibition of PA binding to cellular receptors on host cells [85]. Obiltoxaximab
demonstrated linear PK in dose range of 4–16 mg/kg following single IV administration in healthy
humans. Although obiltoxaximab PK has not been studied in infected patients [84], infection
of NZW rabbits and cynomolgus monkeys with B. anthracis led to significantly faster clearance
(17.0 mL/day/kg and 8.6 mL/day/kg) compared to values observed in non-infected animals (8.7 and
4.2 mL/day/kg, respectively) [13]. These data are suggestive of target-mediated elimination upon
binding of obiltoxaximab to PA; however, this hypothesis requires further investigation. The estimated
half-life and volume of distribution of obiltoxaximab in healthy volunteers was 17–23 days and
6.3–7.5 L, respectively [84]. Low titers (1:20–1:320) of anti-obiltoxaximab antibodies were detected
in eight subjects (2.5%) during phase 1 studies, but alterations in PK and toxicity profile were not
observed in these individuals [84]. Further, the PK of obiltoxaximab was not affected by concomitant
intravenous and oral doses of ciprofloxacin in healthy humans and vice versa [84].
Obiltoxaximab was also approved under the US FDA Animal Rule. Therapeutic efficacy of
obiltoxaximab was assessed in animals challenged with aerosolized B. anthracis spores. The mAb
was administered after animals exhibited clinical signs of systemic anthrax (i.e., presence of PA in
serum or sustained elevation of body temperature above baseline), and intravenous obiltoxaximab
at 16 mg/kg was able to significantly improve survival in NZW rabbits (62–93%) and cynomolgus
macaques (31–47%) compared to 0–6% survival in placebo groups [86]. In prophylaxis studies,
a single dose of obiltoxaximab (16 mg/kg) administered 24–72 h prior to B. anthracis infection
provided full protection (i.e., 100% survival) in cynomolgus macaques versus 10% survival in control
animals [13]. Furthermore, obiltoxaximab administered in combination with antibiotics such as
levofloxacin, ciprofloxacin, and doxycycline resulted in higher survival rates than the antibiotic alone
in B. anthracis infected animals [13].
5.3. Bezlotoxumab
Bezlotoxumab (Zinplava) is a human IgG1 that has been approved for use to reduce recurrence of
Clostridium difficile infection (CDI) in patients ≥18 years of age who are receiving antibacterial drugs
for CDI and are at high risk for CDI recurrence. Bezlotoxumab binds with high affinity (Kd < 1 nM)
to toxin B, a pivotal virulence factor of C. difficile. The mAb inhibits toxin B binding to host cells and
hence prevents toxin B-mediated inactivation of Rho GTPases and downstream signaling pathways in
cells [87]. The PK of bezlotoxumab was assessed in C. difficile-infected patients in Phase 3 clinical trials,
with estimated mean clearance, volume of distribution, and half-life of 0.317 L/day, 7.33 L, and 19 days,
respectively [88]. Recurrence of CDI (i.e., development of a new episode of C. difficile-associated
diarrhea following clinical cure of the presenting CDI episode) was significantly lower in patients
receiving 10 mg/kg bezlotoxumab with SoC (17.4% and 15.7%) than the subjects receiving placebo
with SoC therapy (27.6% and 25.7%) in two Phase 3 studies [89]. However, addition of bezlotoxumab
to SoC did not improve clinical cure rate in C. difficile-infected patients compared to the SoC group [89].
Thus bezlotoxumab is indicated only for prevention of recurrence of CDI, but not for treatment of CDI.
6. Antibacterial mAbs in Clinical Trials
In addition to the three marketed mAb products, there are nine mAbs that are currently being
investigated in clinical trials. Among the nine products listed in Table 2, five mAbs are developed
against Staphylococcus aureus, three are targeting Pseudomonas aeruginosa, and one is for Escherichia coli.
Released data from preclinical and clinical studies are summarized here to give a broad overview of
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6.1. MEDI4893
MEDI4893 is a human IgG1 mAb that specifically binds to and neutralizes alpha-toxin (AT) of
Staphylococcus aureus and hence inhibits AT-mediated cytotoxic activity toward host cells [90]. AT is a
33-kDa pore-forming toxin that forms heptameric pores in host cells membranes and results in cell
lysis [91]. Animal studies using isogenic AT negative mutants demonstrated that AT is a key virulence
factor in S. aureus infections including sepsis, skin and soft tissue infection, and pneumonia [91–93].
AT was found to be expressed in 83% clinical isolates worldwide, and 91% of the isolates encoded
AT subtypes that were neutralized by MEDI4893 [90]. In an acute pneumonia infection model,
MEDI4893 was shown to provide both prophylactic and therapeutic effects in immunocompetent and
immunocompromised mice. Further, sub-therapeutic MEDI4893 doses administered in combination
with sub-therapeutic doses of antibiotics (vancomycin or linezolid) provided significantly improved
survival rates compared to monotherapies [94,95]. In a recent phase 1 clinical trial, MEDI4893 exhibited
linear PK in the dose range of 225–5000 mg/subject. YTE mutations (amino acid substitutions
M252Y/S254T/T256E) in Fc region of the mAb, which increase binding affinity for FcRn, contribute to
its favorable clearance of 42–50 mL/day and extended half-life of 80–112 days [96].
6.2. ASN100
ASN100 is a mAb combination of two human IgG1, ASN-1 and ASN-2, which is in development
for the prevention of ventilator-associated S. aureus pneumonia (VASP). ASN-1 targets alpha-toxin
and four leukocidins including gamma hemolysins (HIgAB and HIgCB), Panton-Valentine leukocidin
(LukSF or PVL), and LukED. ASN-2 binds another leukocidin LukGH (LukAB) [97,98]. Leukocidins
are pore-forming toxins that typically lyse human phagocytic cells and thus play a key role in bacterial
evasion of the innate immune response [99–102]. Therefore, ASN100 binds six different toxin molecules
to protect against lysis of multiple human cells, including polymorphonuclear leukocytes, monocytes,
macrophages, red blood cells, T cells, epithelial, and endothelial cells. Among the five leukocidins,
HIgAB, HIgCB, and LukGH are highly conserved in S. aureus clinical isolates. LukED is expressed
in 50–75% isolates, while LukSF is only present in 5–10% isolates but is correlated with more severe
infections [99]. ASN-1 and ASN-2 exhibit linear serum PK over the dose range of 200–4000 mg/subject
either when administered alone or simultaneously in healthy human volunteers [103]. Estimated mean
clearance, volume of distribution, and half-life of ASN-1 are 0.256 L/day, 7.14 L, and 23.5 days. Values
for ASN-2 are 0.186 L/day, 6.45 L, and 26.7 days [103].
6.3. DSTA4637S
DSTA4637S is a THIOMAB™ (Genentech, South San Francisco, CA, USA) antibody antibiotic
conjugate (AAC) that is comprised of an anti-S. aureus THIOMAB™ (Genentech, South San Francisco,
CA, USA) antibody and a potent antibiotic, 4-dimethylamino piperidino-hydroxybenzoxazino
rifamycin (dmDNA31), linked through a protease cleavable valine-citrulline linker [35]. It has
been known for more than half-century that S. aureus can survive inside neutrophils and turn
them into “Trojan horses”, which assist in systemic bacterial dissemination and contribute to
recurrence of infection following antibacterial therapy [104]. DSTA4637A (a preclinical formulation
of DSTA4637S) demonstrated potent intracellular bactericidal activity against S. aureus both in vitro
and in a mouse bacteremia model [35]. The antibody module of the AAC specifically targets the
β-O-linked N-acetylglucosamine sugar modifications on cell wall teichoic acid residues of S. aureus
and is responsible for opsonization of bacteria. Once the opsonized bacteria are taken up into
phagolysosomes, proteases such as cathepsins cleave the linker and release the potent dmDNA31
antibiotic, which eradicates intracellular S. aureus [35]. Total concentrations of the DSTA4637A antibody
(TAb) and antibody-conjugated dmDNA31 (ac-dmDNA31) were consistent with linear plasma PK
over the dose range of 5–50 mg/kg in non-infected mice and 25–50 mg/kg in S. aureus bacteremia
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the efficacious dose range of 25–50 mg/kg, with mean clearance of 4.95 vs. 6.08 mL/day/kg, volume of
distribution of 94.9 vs. 119 mL/day/kg, and half-life of 14.3 vs. 13.9 days for TAb in non-infected and
infected mice, respectively [14]. PK data for DSTA4637S in human subjects have not been published.
6.4. Salvecin
Salvecin (AR-301) is a mAb developed as an adjunctive therapy to SoC antibiotics for
ventilator-associated S. aureus pneumonia [105]. It binds and neutralizes alpha-toxin and hence
prevents AT-mediated lysis of host cells. Phase 1/2a study results met their primary endpoints,
and showed that VASP patients who received Salvecin in combination with SoC antibiotics spent
shorter time under mechanical ventilation than patients treated with placebo plus antibiotics [106].
In addition, blood bacterial burden was consistently lower in Salvecin-treated patients compared to
the control group [106].
6.5. 514.G3
514G3 is a human mAb targeting Staphylococcus Protein A (SpA), a key virulence determinant
of S. aureus that is expressed in all clinical isolates [107]. SpA is present in the S. aureus cell wall
envelope and is released during bacterial growth [108]. SpA binds the Fc domain of human IgG and
protects S. aureus from antibody-dependent phagocytic killing [109,110]. Additionally, released SpA
triggers B cell superantigen activity through cross-linking of B cell receptors at VH3 domain [111,112].
514G3 displaces SpA-bound serum IgG on S. aureus surface and enhances opsonophagocytosis or other
mechanisms of immune clearance of bacteria [107]. In a pilot Phase 2 study in patients hospitalized
with S. aureus bacteremia, treatment with 40 mg/kg 514G3 led to 49% reduction in relative risk of
overall incidence of serious adverse events (SAEs) and 56% relative risk reduction in S. aureus related
SAEs compared to the placebo group [113]. More importantly, the duration of hospitalization was
reduced by 33% in 514G3 treated patients compared to patients who received placebo (8.6 ± 7 days vs.
12.7 ± 9 days, respectively) [113].
6.6. MEDI3902
MEDI3902 is a bispecific mAb that targets both type III secretion injectisome PcrV anchored on
bacterial cell wall and serotype-independent Psl exopolysaccharide of Pseudomonas aeruginosa [114].
PcrV is a critical component of the type III secretion system (T3SS) that delivers bacterial toxins and
effector molecules into host cells in order to initiate infection. Psl exopolysaccharide is important
for P. aeruginosa colonization/attachment to mammalian cells and formation of biofilms [115,116].
The majority of P. aeruginosa clinical isolates express Psl (89.8–91.2%) and PcrV (87.7–90.2%), and at
least one of the targets were identified in 97.3–100% of isolates [114]. While binding of MEDI3902
to PcrV inhibits T3SS-mediated cytotoxicity, targeting Psl prevents P. aeruginosa attachment to host
cells and enhances opsonophagocytic killing of bacteria. Intravenous administration of MEDI3902
(5 or 15 mg/kg) at 24 h before or 1 h after lethal P. aeruginosa challenge conferred 100% survival and
significant reductions on tissue bacterial burdens in acute pneumonia and bacteremia animal models
including mice, New Zealand rabbits, and pigs [114,117,118].
6.7. Aerumab
Aerumab (AR-101), previously known as panobacumab, is a human IgM mAb directed against
the O-antigen of P. aeruginosa lipopolysaccharide serotype O11, which accounts for ~20% of clinical
isolates. Aerumab is being developed as an adjunctive immunotherapy to SoC antibiotics for ventilator
associated pneumonia caused by P. aeruginosa [119,120]. Binding of Aerumab to P. aeruginosa leads
to enhanced bacterial clearance through either phagocytosis or complement-mediated bacterial
killing [120]. Aerumab demonstrated linear PK over the dose range of 0.1–4 mg/kg in healthy
human volunteers, with mean clearance of 0.039–0.120 L/h, volume of distribution of 4.75–5.47 L,
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following IV doses of 1.2 mg/kg, where estimated clearance, volume of distribution, and half-life
are 0.0579 L/h, 7.5 L, and 102 h, respectively [122]. Further, all 13 patients who received three doses
of 1.2 mg/kg Aerumab as an adjunctive therapy given every 72 h survived, with a mean clinical
resolution rate of 85% (11/13) in 8 days compared to a rate of 64% (9/14) in 18.5 days in patients who
did not receive the mAb [122,123].
6.8. Aerucin
As indicated above, Aerumab can only recognize ~20% of P. aeruginosa clinical isolates. Aerucin is
a second generation anti-P. aeruginosa mAb that binds to alginate (i.e., exopolysaccharide) in greater
than 90% of clinical isolates [124]. Aerucin is also developed as an adjunctive therapy to SoC antibiotics
for hospital-acquired and ventilator-associated pneumonia caused by P. aeruginosa, and binding
of Aerucin is also expected to augment the opsonophagocytic killing and complement-dependent
bactericidal activity against P. aeruginosa [124]. However, preclinical and clinical study results for
Aerucin have not been published.
6.9. Shigamab
Shiga toxin (Stx)-producing Escherichia coli (STEC) is the major cause of hemorrhagic colitis by
infectious agents in the United States. A serious consequence of STEC infection is hemolytic uremic
syndrome (HUS) that can lead to renal failure and death in 5–15% of infected children [125]. Treatments
for STEC infections are currently not available, and antibiotics may increase the risk of HUS [126].
Shigamab is a combination of two chimeric mabs, cαStx1 and cαStx2, which were developed to
neutralize Stx1 and Stx2, respectively. Stx1 and Stx2 are the two major types of shiga toxin that are
the key virulence factors contributing to the pathogenesis of HUS [127]. Treatment with 20 mg/kg of
Shigamab conferred 90% survival in mice challenged with lethal doses of Stx1 and Stx2, whereas cαStx1
or cαStx2 alone did not protect mice against infection [128]. In addition, infection with STEC strain
B2F1 in mice did not affect the PK of cαStx2 at 15 mg/kg [128]. Shigamab exhibited linear PK over the
dose range of 1–3 mg/kg, and cαStx1 was shown to have greater clearance (0.38 ± 0.16 mL/h/kg) and
shorter half-life (190 ± 140 h) than cαStx2 (0.20 ± 0.07 mL/h/kg and 261 ± 112 h, respectively) [129].
7. Conclusions
Pathogen-specific antibacterial mAbs have become an appealing therapeutic option due to
recent advances in mAb production and engineering technologies. Antibodies kill bacteria or
attenuate bacterial pathological activity via various mechanisms, including opsonophagocytosis,
complement-mediated bactericidal activity, antibody-dependent cellular cytotoxicity, and
neutralization of bacterial toxins. These pharmacodynamic mechanisms are distinct from those
of small-molecule antimicrobials and therefore, such mAbs provide an attractive therapeutic option for
antimicrobial resistant strains. The high specificity of mAbs may be expected to allow less disturbance
to normal flora and less selective pressure for cross-resistance. Extended half-lives of mAbs may allow
less frequent dosing and long-term prophylaxis. Antibacterial mAbs may also exhibit pharmacokinetic
properties such as target-mediated drug disposition due to opsonophagocytosis or formation of
antibody-toxin complexes, and there is some potential for complicated tissue distribution during the
course of bacterial infection. These possible complexities require further study. Though there are
only three mAbs marketed for prophylaxis or treatment of bacterial infection as of today, there is
promise for a more prominent future role for antibacterial mAbs in view of their many advantages
over traditional antimicrobials, and in view of the positive findings from clinical investigations of
several mAbs in development.
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Abstract: Human application of monoclonal antibodies (mAbs), enzymes, as well as contrast
media and many other particulate drugs and agents referred to as “nanomedicines”, can initiate
pseudoallergic hypersensitivity reactions, also known as infusion reactions. These may in part be
mediated by the activation of the complement system, a major humoral defense system of innate
immunity. In this review, we provide a brief outline of complement activation-related pseudoallergy
(CARPA) in general, and then focus on the reactions caused by mAb therapy. Because the alternative
pathway of complement activation may amplify such adverse reactions, we highlight the potential
use of complement factor H as an inhibitor of CARPA.
Keywords: CARPA; complement; complement activation; factor H; hypersensitivity; infusion
reaction; monoclonal antibody therapy; pseudoallergic reaction
1. Introduction: Monoclonal Antibodies and Hypersensitivity Reactions
Monoclonal antibodies (mAbs) are made by identical immune cells that are all clones of a unique
parent B cell, and are widely used both in basic research and the therapy of various diseases. For the
latter purpose, one of the main goals of scientists became to create “fully” human products to reduce the
side effects of humanized or chimeric therapeutic antibodies. These side effects include the induction
of hypersensitivity reactions (HSRs), also known as infusion reactions (IRs) [1]. A selected list of
anticancer and anti-inflammatory mAbs that cause such HSRs with various incidence and severity is
shown in Table 1 [2–6].
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HSRs have been traditionally categorized in four groups, from I to IV, according to Coombs
and Gell. This concept defined Type I reactions as IgE-mediated acute reactions, while the rest of
the categories included subacute or chronic immune changes triggered or mediated by IgG, immune
complexes, or lymphocytes [7]. However, it has increasingly been recognized that a substantial portion
of acute allergic reactions, whose symptoms fit in Coombs and Gell’s Type I category, are actually not
initiated or mediated by pre-existing IgE antibodies. These reactions are known to be “pseudoallergic”
or “anaphylactoid”. There are estimates that pseudoallergy may represent as high as 77% of all
immune-mediated immediate HSRs [8], implying hundreds of thousands of reactions and numerous
fatalities every year [9]. Many of these reactions involve the activation of the complement system,
an essential humoral arm of innate immunity. Complement activation-related pseudoallergy (CARPA)
is linked to adverse events evoked by several liposomal and micellar formulations, nanoparticles,
radiocontrast agents, and therapeutic antibodies [9].
Intravenous application of numerous drugs and medical agents, including therapeutic mAbs,
enzymes, radiocontrast media, and many other particulate drugs with physical size in the upper nano
(10−8–10−7 m) dimension (nanomedicines), can elicit HSRs with symptoms listed in Table 2.
Table 2. Symptoms of pseudoallergy. The most life-threatening symptoms are highlighted in
bold [10]. Reprinted from Molecular Immunology, Vol. 61, Szebeni J., Complement activation-related
pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals, Pages 163–173,








Angioedema Apnea Granulopenia Cyanosis Bloating Back pain Chills
Arrhythmia Bronchospasm Leukopenia Erythmea Cramping Chest pain Diaphoresis
Cardiogenic
shock
Coughing Lymphopenia Flushing Diarrhea Chest tightness Feeling ofwarmth
Edema Dyspnea Reboundleukocytosis Nasal congestion Metallic taste Confusion Fever
Hypertension Hoarsness Reboundgranulocytosis Rash Nausea Dizziness
Loss of
consciousness
Hypotension Hyperventillation Trombocytopenia Rhinitis Vomiting Feeling ofimminent death Rigors




distress Tearing Headache Wheezing





2. The Consequences of Complement Activation for the Activator and the Host
One of the major tasks of the complement system is to mark and dispose of potentially dangerous
particles, such as pathogenic microbes and altered host cells. This is achieved by targeted activation
on foreign surfaces as well as on modified host targets, such as apoptotic cells. The classical
pathway is activated by immunoglobulins bound to their target antigens, and the classical and lectin
complement pathways are activated upon the recognition of certain molecular patterns associated
with microbes or altered self, while the alternative pathway is activated constantly at a low rate and
in an indiscriminative manner [11]. The activation can result in the deposition of opsonic molecules
on the target cells or particles, thus labeling them for phagocytosis and, if not inhibited, allowing the
initiation of the terminal pathway that may generate lytic complexes in the target cell’s membrane.
The three pathways merge at the activation of the central C3 molecule, which is cleaved into the
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back to the alternative pathway because it is part of the enzyme complex that cleaves additional C3
molecules. Thus, the alternative pathway can amplify complement activation initiated by any of the
three pathways. Importantly, complement regulators expressed in body fluids and on cell surfaces
protect the host from bystander damage [11].
Complement activation by liposomes can easily be rationalized on the basis of their resemblance
to pathogenic viruses. In fact, both are phospholipid-coated vesicles in the same size range (60–200 nm),
with the difference being that liposomes do not express surface proteins as viruses do. In the case of
viruses, some of these surface proteins inhibit complement activation just as complement receptor
type 1 (CR1), decay accelerating factor (DAF), and membrane cofactor protein (MCP) do on the surface
of host blood cells and other cells. One may therefore conclude that liposomal nanomedicines activate
complement because the immune system considers them as pathogenic viruses, and liposomes do
not have a shield that protects them against complement attack [12]. The mechanism of complement
activation by smaller nanoparticles (d < 10 nm), such as PEGylated polyethylene-imine polymers (PEG
is polyethylene glycol) [13] or micelles formed from Cremophor EL (CrEL) and other polyethoxylated
surfactants (PS-80 and PS-20, also known as Tween-20 and Tween-80) [14] is more difficult to explain.
In those cases, complement activation may involve unconventional direct interaction with complement
proteins, or, as it was suggested for CrEL, prior interaction with plasma lipoproteins that can lead to
the formation of large(r) aggregates [9].
Furthermore, it is already shown in vitro that the aggregation of proteins during the preparation
of mAbs can induce the activation of human monocyte-derived dendritic cells as well as T cell
responses [15]. Complement activation is also possible in such conditions.
3. Therapeutic mAbs, Complement Activation, and CARPA
Antibodies are well known to activate the classical complement pathway upon binding to their
target antigen, which allows for the binding of C1q, the recognition molecule of the activation
initiator C1 complex, to the Fc part of the antibodies. Therapeutic mAbs may exploit this feature
and can be engineered to enhance the effectiveness of the treatment while circumventing certain
(e.g., Fc-receptor-mediated) adverse effects [16,17].
The role that complement plays in mAb therapy is exemplified well by the prototypic mAb
rituximab. Rituximab, a murine-human chimera type anti-CD20, has been used since 1997 in clinical
practice to treat malignant and autoimmune disorders related to the disfunction of B cells [18,19].
Besides the direct downregulation of CD20-related cell functions, both complement-dependent and
complement-independent immune reactions participate in the elimination of CD20 highly positive B
cells (Figure 1). Complement-dependent mechanisms include complement-dependent cytotoxicity
(CDC), initiated upon C1q binding, through the classical complement activation cascade [20], and
complement-enhanced antibody-dependent cell-mediated phagocytosis (ADCP). The most important
complement-independent mechanism is antibody-dependent cell-mediated cytotoxicity (ADCC),
which is performed mainly by natural killer (NK) cells (and macrophages). Programmed cell death
(PCD) seems to be less important in the case of rituximab, but it may have more prominent role in the
action of Type II-anti-CD20 antibodies, like tositumomab and GA101 [18,19]. However, it is likely that
the complement-activating capacity of rituximab is also responsible for the high frequency of CARPA
associated with this mAb [21].
Human IgG1 and IgG3 are particularly effective at fixing complement to the target cell surface,
and many of the currently approved therapeutic mAbs, like rituximab, are indeed of the IgG1
isotype. A variety of cell-based assays have demonstrated the ability of mAbs to recruit complement
components in vitro, but the efficiency of CDC to kill tumor cells in vivo is less clear, particularly for
solid tumors, in part because tumor cells themselves express membrane-bound complement regulators
as well as the soluble regulator factor H [22–24]. Since most of these mAbs work against cancer cells
with the help of complement activation, a clear distinction has to be made between complement
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hypersensitivity reaction related to complement activation in serum caused by the therapeutic antibody
itself. This means that the same mechanisms are involved in the beneficial effects and hypersensitivity.
Figure 1. Complement activation as an essential mechanism of the therapeutic action of rituximab,
an anti-CD20 antibody. Rituximab recognizes CD20 on the surface of pre- and mature B cells. After
binding, the complement activation cascade is initiated by the classical pathway leading to the cleavage
of C3 into C3a and C3b. C3b can cause complement-dependent cytotoxicity (CDC) by promoting
the assembly of the membrane attack complex (MAC), while complement receptors on phagocytic
cells, such as complement receptor type 3 (CR3) on macrophages, can mediate complement-enhanced
antibody-dependent cell-mediated phagocytosis (ADCP). Surface-bound rituximab can trigger natural
killer (NK) cells and macrophages by complement-independent mechanisms, via antibody-dependent
cell-mediated cytotoxicity (ADCC), ADCP and, to a lesser degree, the induction of programmed cell
death (PCD).
All currently available or publicly known mAbs can be considered to be potentially direct
immunogens, as their molecular size is large enough and their structure is different from endogenous
proteins. Despite current efforts to produce highly humanized or “human-like” mAbs, immunogenicity
is not yet totally eradicated. Treatment of human patients with mAbs can be associated with the
development of specific antibodies against these therapeutic antibodies (anti-drug antibodies, ADAs).
These neutralizing ADAs can block the biological activity of the drug either by binding directly to
the epitope(s) within their active site, or by steric hindrance due to binding to epitope(s) in close
proximity to the active site. The presence of neutralizing ADAs may not result in adverse clinical effect,
except that it decreases the efficacy of the therapeutic mAb, requiring its administration at higher
doses. Furthermore, the presence of specific ADAs against mAbs can be associated in some cases
with hypersensitivity reactions identical to the CARPA phenomenon delineated above for the case of
liposomes and other nano-pharmaceuticals. The rare anaphylactic reactions associated with mAbs








Antibodies 2018, 7, 14
True allergic reactions, which are mediated by anti-drug IgE, require prior exposure to the
mAb and, consequently, do not occur on the first infusion, except in rare cases where patients
have pre-existing antibodies that cross-react with the drug. However, pseudoallergic reactions
(IgE-independent reactions possibly mediated by direct immune cell and complement activation)
and cytokine release syndrome (CRS) both occur primarily on the first infusion of the drug,
although they can also occur on subsequent administrations. The symptoms of all three types of
immunologically-mediated infusion reactions (IRs) overlap, making it difficult to identify the cause
without additional laboratory work [26].
Rituximab and trastuzumab induce the highest incidence of IRs. In general, the incidence of
mAb-induced IRs varies from ~15–20% for cetuximab (including 3% more severe, grade 3, and life
threatening, grade 4 reactions) and 40% for trastuzumab first infusion (<1% grades 3–4) to 77% for
rituximab first infusion (10% grades 3–4). Even after the fourth infusion, 30% of cancer patients react
to rituximab, and the incidence of IRs remains 14% after the eighth infusion. Approximately 80% of
fatal reactions occur after the first rituximab infusion. The incidence of IRs to the humanized mAb
bevacizumab and the fully humanized panitumumab is significantly lower [27].
Thrombocytopenia, neutropenia, and anemia can occur in some patients treated with mAbs as part
of anticancer immunotherapy, but the mechanisms of these potentially severe side effects frequently
remain unexplored. Interestingly, these symptoms are also characteristic of liposome-induced CARPA.
Late-onset neutropenia, especially after rituximab treatment, has been examined in a growing number
of reports; however, with each of the three cytopenias seen during mAb therapy, it is frequently unclear
whether the depletion of cells is due to an immunological mechanism. Type III hypersensitivities, such
as serum sickness-like reactions and vasculitis, are also known to occur in response to mAbs. Some
pulmonary events, including mAb-induced lung diseases, are hypersensitivity reactions that result
from the interaction of the drug with the immune system and involve drug-specific antibodies or T
cells [2].
Although it remains to be shown in humans, it is hypothesized that mAbs could stimulate
anti-mAb IgGs bound to Fc-gamma-receptors on macrophages, basophils, and neutrophils,
triggering the release of platelet-activating factor, as shown in the mouse model of IgG-dependent
anaphylaxis [28]. In addition, the complement system could be activated by the formation of large
immune complexes, thereby generating anaphylatoxins (C3a and C5a). It is also important to point out
that patients with anti-infliximab IgGs are at increased risk of immediate HSRs compared with patients
without such antibodies [1]. Thus, in addition to the preferred complement activation induced by the
binding of therapeutic mAbs to their targets, complement activation can also arise as a consequence of
the binding of naturally forming ADAs against the therapeutic mAbs. The molecular background of
mAb-induced CARPA is yet to be studied in more detail.
4. Potential Role of Factor H in Mitigating Complement Activation
The use of natural or engineered complement inhibitors may represent an attractive way to prevent
CARPA-mediated HSRs. Early approaches used the complement-regulatory domains of the natural
complement inhibitor CR1 linked to a myristoyl group that mediated incorporation in liposomal
membranes [29]. A recent study suggested that factor H could be also employed to reduce or eliminate
complement activation triggered by liposomes, micelles, or therapeutic mAbs [30]. Factor H is the main
soluble inhibitor of the alternative pathway and the amplification loop of complement [31,32]. It was
shown that liposomal Amphotericin B, CrEL, and rituximab caused less complement activation in
serum in vitro when factor H was added to the serum in excess, as compared with the serum without
exogenous factor H [30]. Moreover, the artificial inhibitor, recombinant mini-factor H [33], which
unites the N-terminal complement-regulatory domains and the C-terminal host surface recognition
domains of the natural molecule, was even more effective in inhibiting such complement activation
compared with factor H [30]. These data suggest that factor H-based complement inhibition could be a








Antibodies 2018, 7, 14
5. Conclusions and Outlook
The prevention of IRs induced by mAbs can be addressed the same way as the prevention
of similar adverse reactions occurring upon nanomedicine treatments. The surface modification
of liposomes and other therapeutic proteins can lead to prevention of the aggregation of these
agents and reduction of immunogenicity and antigenicity. Recently, more and more antibodies and,
predominantly, antibody fragments designed for therapeutic purposes use the covalent attachment of
polyethylene glycol (PEG). PEGylation generally prolongs the half-life in the circulation and prevents
the immunogenicity of many liposomal drugs and mAb molecules [34]. However, in some cases
the generation of an IR event could be connected to the presence of PEGylation on the surfaces of
liposomes. The formation of anti-PEG IgMs against PEG molecules on liposomes are observed in
CARPA studies with animal models [35].
Another possible approach is the administration of complement inhibitors together with the
therapeutic agents to reduce the chance of a possible adverse reaction. Even though this could be a
good option as a prevention measure, most patients may not even need such an action if they are not
prone to IRs, and this approach would just elevate the costs of the therapies. The best scenario would
be to pre-screen each patient for proneness to any adverse reaction, using an in vitro test that could
predict from a blood sample if any CARPA event could arise during introduction of a therapeutic
agent, such as mAbs.
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